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Bacillus subtilis is a model Gram-positive GRAS organism sought after for its robust 
growth characteristics in inexpensive media, genetic tractability, and ability to secrete products 
into the extracellular environment. Although B. subtilis has gained widespread acceptance as an 
industrial workhorse for the production of low-cost enzymes, issues with protein degradation and 
misfolding, and plasmid instability have hindered its status as a recombinant protein expression 
host. Efforts aimed at resolving these issues have been partially successful, although strain 
development to this end has occurred on an insignificant scale relative to Escherichia coli. 
Accordingly, advanced genetic tools are needed to accelerate the progression of B. subtilis 
towards full industrial utility. The recently developed clustered regularly interspaced short 
palindromic repeat (CRISPR)-Cas9 (CRISPR-associated (protein) 9) system has revolutionized 
genetic manipulation and genome-scale interrogation of gene function across the spectrum of 
life. CRISPR-Cas9 systems have been developed for established industrial organisms such as E. 
coli and Saccharomyces cerevisiae, and are highly amenable to scalable strain construction. This 
thesis encompasses the development of a CRISPR-Cas9 toolkit for B. subtilis, and its application 
to strain engineering for the production of value-added biologicals. 
 We first developed and validated a CRISPR-Cas9 toolkit facilitating simplified genome 
editing and transcriptional interference in B. subtilis. To exploit the simplicity of the Cas9-
targeting synthetic guide RNA (gRNA), a novel gRNA transcription cassette was constructed 
that performed equally well compared with the native CRISPR RNA (crRNA)/trans-activating 
crRNA (tracrRNA) targeting system. To facilitate gRNA eviction and, in turn, continuous 
editing in the same background, the counter-selectable marker mazF was successfully employed. 
Multiplexing was subsequently evaluated and although efficiency was acceptable, it was deemed 
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too low to accommodate higher order multiplexing. Consequently, editing templates required for 
double-strand break (DSB) repair were evaluated to determine optimal homology length (HL) 
and appropriate format to enhance editing efficiency, and subsequent multiplexing under 
optimized conditions was highly efficient. Transcriptional interference, i.e. CRISPR interference 
(CRISPRi), was also demonstrated, resulting in high-level repression of gene expression 
comparable to that reported for CRISPR-Cas9 systems developed for other organisms.   
 Upon validating the CRISPR-Cas9 toolkit, we applied CRISPRi to enhance heterologous 
hyaluronic acid (HA) production in strains of B. subtilis via engineering of the cell membrane. 
Membrane cardiolipin (CL) levels were first enhanced in previously engineered HA-producing 
strains by overexpressing components of the CL biosynthesis pathway. CRISPRi was then 
applied to redistribute CL along the lateral membranes of CL-overproducing mutants via 
repression of the expression of the cell division initiator protein FtsZ, resulting in significant 
improvements to the HA titer and molecular weight (MW). Moreover, removal of 
phosphatidylethanolamine and neutral glycolipids from the membrane of HA-producing B. 
subtilis via inactivation of pssA and ugtP, respectively, has suggested the lipid dependence for 
functional expression of the hyaluronan synthase from Streptococcus equisimilis (SeHAS). 
 CRISPRi was also applied to reduce the expression of pfkA or zwf, whose respective gene 
products are enzymes at the branchpoints of glycolysis and the pentose phosphate pathway 
opposing cell wall biosynthesis, in HA-producing B. subtilis, leading to substantial 
improvements to the HA titer with a concomitant decrease in the MW. On the other hand, 
multiplexed repression of both pfkA and zwf expression resulted in significant increases to the 
HA titer and modest enhancements to the MW. Moreover, the addition of exogenous HA 
monomers, i.e. glucuronic acid (GlcUA) and N-acetyl-glucosamine (GlcNAc), to B. subtilis 
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cultures markedly improved the HA MW but decreased the HA titer, providing insights into the 
mechanism of HA biosynthesis by SeHAS in B. subtilis. 
 We also explored the application of hydrocarbons and perfluorocarbons as potential 
oxygen vectors to address the innate oxygen limitation associated with microbial cultures for HA 
production. Out of seven compounds evaluated in a preliminary screening, significant improvements 
to the HA titer and/or cell density were observed in cultures containing n-heptane, n-hexadecane, 
perfluoromethyldecalin, and perfluoro-1,3-dimethylcyclohexane. Adjustments to the vector 
concentration, timing of vector addition, and the agitation rate resulted in further enhancements to the 
HA titer, and the results suggest that certain vectors may alter the functional expression of SeHAS in 
B. subtilis, and that higher shear rates may be beneficial for HA production. 
 Finally, the capacity of the toolkit was fully assessed through a second case study in which B. 
subtilis strains were engineered for L-valine overproduction. The native L-valine biosynthetic 
pathway was engineered to relieve transcriptional and allosteric regulation in the presence of excess 
amino acids, leading to substantial improvements to the L-valine titer, compared to the wild-type 
strain. Further investigation revealed that pyruvate availability and competing amino acid 
biosynthesis limited L-valine overproduction in B. subtilis, and strain engineering to simultaneously 
resolve these bottlenecks resulted in an ~50-fold increase in the L-valine titer, relative to the wild-
type strain. Through this case study, recombination was identified as the step that limits toolkit 
performance, leading to the identification of potential strategies to overcome this limitation. 
 Collectively, we have developed a comprehensive and highly effective CRISPR-Cas9 
toolkit for B. subtilis, and have extensively demonstrated its utility for advanced strain 
engineering in biomanufacturing applications. Moreover, we have developed novel HA-
producing strains of B. subtilis that may be of industrial value, and have provided valuable 
insight into the application of oxygen vectors to mitigate oxygen limitation in microbial cultures 
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for HA production. Lastly, we have tested the limits of our toolkit through the construction of L-
valine-overproducing B. subtilis strains, resulting in a potentially industrially relevant production 
platform for this niche amino acid, and identification of the bottleneck limiting toolkit 
performance. Thus, it is anticipated that the CRISPR-Cas9 toolkit described herein will be an 
invaluable resource for scalable strain construction at the academic and industrial levels. 
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Chapter 1  
Introduction 
Industrial bioprocesses centered on microbial hosts often rely on the model organisms 
Escherichia coli and Bacillus subtilis due to their well characterized genomes, excellent growth 
characteristics in inexpensive media, and capacity for high-level protein production [1, 2]. As of 
2011, 66 out of 211 biopharmaceuticals receiving regulatory approval in the United States and 
European Union were produced in E. coli, while the remainder were expressed in eukaryotic cell 
lines [3]. These statistics reflect the continuing dependence on E. coli as the default prokaryotic 
expression host for recombinant therapeutic protein production, despite the fact that B. subtilis 
presents many advantages over its Gram-negative counterpart. B. subtilis is capable of growing 
on a wide range of carbon sources, can readily secrete proteins into the extracellular environment 
and has been granted a ‘Generally Recognized as Safe (GRAS)’ designation by the Food and 
Drug Administration (FDA), USA. In contrast, common industrial E. coli strains cannot 
metabolize cost-effective carbon sources such as sucrose [4], and cells must be disrupted and 
debris separated from the expressed protein, a limitation that is exacerbated by the release of 
endotoxins into the product [2]. In addition to possessing desirable traits for protein expression, 
B. subtilis is an ideal candidate for production of biopolymers and biofuels. High-level 
production of hyaluronic acid (HA), a valuable therapeutic biopolymer, has been achieved with 
B. subtilis in a minimal medium supplemented with sucrose [5], whereas comparatively low 
titers were obtained with E. coli using a rich medium supplemented with glucose and HA 
precursors [6]. Moreover, B. subtilis exhibits improved tolerance to butanol compared to E. coli 
and Saccharomyces cerevisiae [7].  
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 In addition to the potential cost savings associated with less expensive media components 
and simplified downstream product purification, and the ease of regulatory approval due to 
GRAS status, domesticated strains of B. subtilis are amenable to genetic manipulation. 
Commonly used auxotrophic strains develop a naturally competent state for DNA uptake and, in 
general, B. subtilis contains an efficient recombination system such that genome engineering is 
relatively straightforward [8]. However, the development of stable industrial strains is lagging 
behind the efforts applied to E. coli, such that certain issues continue to hamper protein 
expression in B. subtilis. Proteolytic degradation and protein misfolding, and limited availability 
of stable expression vectors have limited the acceptance of B. subtilis as a recombinant protein 
expression host [2, 9], relegating it to the production of low cost industrial enzymes (e.g. 
proteases and amylase) that are often naturally secreted [2, 10]. Furthermore, advanced genetic 
tools required for scalable strain development are lagging behind established industrial 
production hosts such as E. coli and S. cerevisiae [11, 12]. 
 Currently, markerless genome engineering strategies employed in B. subtilis rely on self-
evicting counter-selectable markers, e.g. mazF [13] and upp [14], and site specific recombination 
systems such as Cre/loxP [15] and FLP/FRT [16]. While these approaches are appropriate for 
lab-scale strain construction, they provide low editing efficiencies (in the case of counter-
selection alone) and/or are not conducive to multiplexing (i.e. editing multiple targets 
simultaneously), hindering their application to industrial strain construction.  CRISPR (clustered 
regularly interspaced palindromic repeats)-Cas (CRISPR-associated (proteins)) systems are 
adaptive prokaryotic viral defense mechanisms first described in E. coli in 1987 [17], although 
more than two decades passed before their function was demonstrated in vivo [18]. Identification 
of the minimal type II CRISPR-Cas9 system of Streptococcus pyogenes has significantly 
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expanded the capacity for genome editing in established industrial workhorses and genetically 
intractable organisms alike. CRISPR-Cas9 systems have been developed for E. coli [19, 20] and 
S. cerevisiae [21, 22], facilitating simple continuous (i.e. sequential) multiplexing in these 
organisms. In addition, the CRISPR-Cas9 system has been extended to transcriptional 
modulation (CRISPR interference; CRISPRi) through a catalytically inactive variant of Cas9 
(dCas9) [23]. 
This thesis investigates the development of a CRISPR-Cas9 toolkit for comprehensive 
genetic engineering of B. subtilis, and its application to strain construction for the production of 
value-added biologicals. The development of CRISPR-Cas9 systems for E. coli and S. cerevisiae 
has demonstrated the potential of this technology for industrial strain construction, and the 
performance of these systems serve as metrics for the evaluation of the toolkit. Once the 
functionality of the toolkit has been demonstrated, it will be utilized for advanced strain 
engineering through a case study of HA production to enhance the molecular weight (MW) and 
titer. As HA production in B. subtilis is an industrially important process and central theme of 
this investigation, the application of potential oxygen vectors to mitigate the inherent oxygen 
limitation observed in microbial HA production cultures will also be explored. Finally, the 
toolkit will be applied to a second case study of L-valine overproduction through advanced 
genome engineering strategies that will test the limits of toolkit performance, while resulting in 
the construction of potentially industrially useful L-valine-overproducing strains of B. subtilis. 
Collectively, the CRISPR-Cas9 toolkit should be an invaluable tool for the scalable construction 
of B. subtilis strains for biomanufacturing or academic studies of the complex regulatory 
architecture possessed by this model bacterium. Moreover, this investigation may result in the 
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generation of novel and industrially relevant strains of B. subtilis capable of high-level HA or L-
valine production.  
 
1.1 Research objectives 
The primary objectives of this research can be described as follows: 
1. Develop a CRISPR-Cas9 toolkit for comprehensive engineering of B. subtilis. This 
objective includes the design and construction of all necessary DNA elements and base 
strains required to implement CRISPR-Cas9 genome editing and CRISPRi in B. subtilis, 
and the evaluation of toolkit performance for single and multiplexed gene mutations and 
insertions, continuous editing, and transcriptional interference. 
2. Apply the toolkit to a case study of heterologous HA production in engineered B. subtilis. 
This objective includes the construction and evaluation of HA-producing control strains 
used to establish protocols for HA quantification and MW determination, and serve as a 
baseline with which to compare novel mutants. Employ CRISPRi to alter the distribution 
of cardiolipin (CL) in the cell membrane to improve the functional expression of the 
hyaluronan synthase of Streptococcus equisimilis (SeHAS), or to divert carbon flux from 
central metabolic pathways toward cell wall biosynthesis and, in turn, HA production 
with the ultimate goal of enhancing the HA titer and MW.  
3. Evaluate hydrocarbons and perfluorocarbons as potential oxygen vectors to enhance 
oxygen transfer in cultures of HA-producing B. subtilis. This objective includes a 
preliminary screening of three hydrocarbons and flour perfluorocarbons for their impact 
on culture performance, and the selection of two or three compounds for further 
characterization. Assess the effects of vector concentration and timing of addition, and 
5 
 
agitation rate on culture performance, and the influence of vectors on the overall mass 
transfer coefficient (kLa).  
4. Apply the toolkit to a case study of L-valine overproduction in engineered B. subtilis. 
Engineer the native L-valine biosynthetic pathway to relieve various levels of 
transcriptional and allosteric regulation resulting from the presence of excess amino 
acids. Investigate potential bottlenecks hindering L-valine overproduction, and 
combinatorial genome modifications to further improve L-valine overproduction. 
Establish the limitation(s) of the toolkit.  
 
1.2 Thesis organization 
This thesis is comprised of a literature review presented as Chapter 2, and five original 
research manuscripts corresponding to Chapters 3-7. Chapters 3, 4, and 6 have been published, 
Chapter 5 has been submitted for publication, and Chapter 7 is in preparation. 
 Chapter 2 provides a comprehensive summary of five subjects relevant to the 
development of this thesis: 1) the progress made toward developing B. subtilis as a 
biomanufacturing platform; 2) the development of the naturally competent state for DNA 
transformation, and markerless genome engineering strategies prior to the advent of CRISPR-
Cas9 technology; 3) the functionality of the CRISPR-Cas9 system, and its application to genome 
editing and transcriptional interference; 4) the function and lipid dependence of streptococcal 
hyaluronan synthase (HAS), and progress made toward engineering bacteria for heterologous 
HA production; and 5) the mechanisms by which oxygen vectors enhance mass transfer between 
gas and aqueous phases, and their application to real and simulated bacterial cultivations. 
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 Chapter 3 outlines the design, construction, and validation of the CRISPR-Cas9 toolkit. 
Upon construction of the toolkit components, the editing efficiencies of single gene mutations 
and insertions, and the capacity for continuous editing and multiplexing were evaluated. Editing 
template homology length size and type were subsequently investigated, leading to significant 
improvements to multiplexing efficiency, and transcriptional interference via dCas9 (i.e. 
CRISPRi) was demonstrated with high efficiency.   
 Chapter 4 details the construction and culture performance of HA-producing strains of B. 
subtilis in which the membrane CL content and spatial distribution have been altered to improve 
the functional expression of SeHAS. Significant improvements to the HA titer and MW were 
obtained, indicating that engineering of the cell membrane is an effective approach to enhance 
heterologous HA production in B. subtilis expressing HAS from group C streptococci.  
 Chapter 5 outlines the construction and culture performance of HA-producing strains of 
B. subtilis in which carbon flux was diverted from central metabolism into HA biosynthesis. 
CRISPRi was employed to reduce the expression of enzymes at the branch points of the pentose 
phosphate pathway (PPP) and glycolysis with cell wall biosynthesis to increase carbon flux 
through the HA biosynthetic pathway (i.e. an extension of cell wall biosynthesis). This metabolic 
engineering strategy resulted in significant improvements to the HA titer and modest 
enhancements to the MW.  
 Chapter 6 investigates hydrocarbons and perfluorocarbons as potential oxygen vectors to 
improve mass transfer in HA production cultures. After a preliminary screening of seven 
compounds, n-heptane, n-hexadecane, and perfluoromethyldecalin were selected for further 
characterization based on their relative cost and impact on culture performance. Manipulating 
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culture parameters led to further improvements to the HA titer, and provided insight into the 
effect of certain vectors on the functional expression of SeHAS.  
 Chapter 7 outlines the construction and culture performance of L-valine-overproducing 
strains of B. subtilis. The native L-valine biosynthetic pathway was engineered to relieve 
transcriptional and allosteric regulation in amino acid-containing medium, resulting in 
significantly improved L-valine production compared to the wild-type strain. Moreover, potential 
bottlenecks limiting L-valine overproduction in B. subtilis are identified, leading to markedly 
enhanced culture performance. 
 Lastly, Chapter 8 provides a summary of the work performed throughout the entirety of 
this thesis. Recommendations and potential avenues for future research are provided as a guide 
to further enhance toolkit performance, and improve the production capacity of HA-producing 














Chapter 2  
Literature review 
2.1 Developing B. subtilis as a biomanufacturing platform 
B. subtilis is a rod-shaped endospore-forming soil bacterium which has been extensively 
studied, leading to its status as the model Gram-positive organism [24]. The naturally competent 
state developed by domesticated strains, presence of an efficient recombination system, and 
development of replicating E. coli-B. subtilis shuttle vectors led to the early application of 
recombinant DNA technology in B. subtilis. However, issues with protein and plasmid instability 
have limited the use of B. subtilis to academic pursuits, or production of inexpensive industrial 
enzymes (most of which are endogenous or are native to other Bacillus species) [2, 10].  
 
2.1.1 Strategies for enhancing recombinant protein expression  
Much has been accomplished in addressing extracellular proteolysis in B. subtilis 
cultures. In an early study, the disruption of genes expressing extracellular neutral (nprE) and 
serine (aprE) proteases resulted in a 97% reduction in extracellular protease activity (strain 
DB104) relative to the parental strain (DB101), with the aprE mutation accounting for 61% of 
the reduction in activity [25]. Further efforts to reduce proteolysis in B. subtilis cultures resulted 
in strain WB800 (ΔnprE, ΔnprB, ΔaprE, Δepr, Δmpr, Δbpr, Δvpr, ΔwprA) which possesses less 
than 0.5% of the extracellular protease activity of DB101 [26]. However, mutation (or knockout; 
KO) of nprE and aprE resulted in a 5-fold increase in the extent of cell lysis in DB104 (relative 
to B. subtilis 168) upon entry to stationary phase [27] (combined mutations to nprB, epr, mpr, 
and bpr had a marginal effect on lysis), demonstrating that these proteases play a major role in 
regulating autolytic proteins. The severe cell lysis observed is a concern when expressing 
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recombinant proteins as intracellular proteases are released (along with other internal molecules), 
potentially causing product degradation and contamination.  
Protein misfolding (i.e. inclusion body formation) has been addressed in a few studies in 
which native molecular chaperones (i.e. the GroEL/ES complex and DnaK) were coexpressed 
with single chain antibody (SCA) fragments leading to marked improvements in expression of 
functional SCA fragments. Mutation of hrcA, encoding a common repressor of both the groES-
groEL and dnaK (grpE-dnaK-dnaJ-prmA-rsmE-mtaB) operons, and combined overexpression of 
the extracytoplasmic molecular chaperone prsA resulted in significant improvements to 
functional expression of both antidigoxin [28] and MH-1 (fibrin-specific monoclonal antibody) 
[26] SCA fragments in protease deficient strains (wprA mutation was required in the latter case). 
However, the resources invested in establishing B. subtilis as a recombinant protein expression 
host pale in comparison to the decades spent developing E. coli as the preeminent bacterium for 
protein expression [29]. 
 
2.1.2 The development of [conditionally] stable expression vectors  
The establishment of stable replicating vectors has been a significant challenge in B. 
subtilis. Segregational instability (i.e. the loss of the plasmid from the cell) and structural 
instability (i.e. rearrangements in the plasmid sequence) of replicating plasmids has been widely 
reported [30-33], and has been largely attributed to the mode of replication. The rolling circle 
method of replication entails nicking of the sense origin of replication (Sori) by a plasmid-
encoded replication protein, leaving a 3’–OH group used as a primer for leading strand synthesis 
[34]. The newly synthesized sense strand and parental antisense RNA (asRNA) strand form a 
double-strand DNA (dsDNA) replicate, leaving the displaced parental sense strand behind as a 
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single-strand DNA (ssDNA) intermediate [35]. The ssDNA intermediate poses several issues: 1) 
the asRNA ori (ASori) present on the displaced strand (required for conversion to dsDNA) is not 
entirely compatible between organisms potentially leading to accumulation of the ssDNA 
intermediate [32]; 2) recombination is strongly stimulated between direct repeats (DRs) as short 
as 9 base pairs (bp) in ssDNA intermediates (particularly when DRs flank inverted repeats) 
causing structural instability [30, 31]; and 3) the resulting unstable ssDNA structures lead to the 
accumulation of high MW linear DNA that impedes host fitness [30].  
The theta mode of replication entails melting of the parental plasmid strands and coupled 
continuous and discontinuous synthesis of the leading and lagging strands, respectively, such that 
ssDNA intermediates are avoided, and segregational and structural stability are significantly 
improved [34]. Theta-replicating vectors have been isolated from strains of B. subtilis [36-38], 
and one in particular (i.e. pBS72) has been used to construct the pHT E. coli-B. subtilis shuttle 
vector series for stable protein expression [9, 39]. Subsequent optimization of promoter elements 
led to pHT vectors which can facilitate protein expression levels reaching 30% of total cellular 
protein [40], which is still moderate compared to protein fractions obtained in E. coli (up to 50%) 
[41]. Unfortunately, the stability of theta-replicating vectors is dependent on the effect on host 
fitness imposed by the proteins expressed [42], which has also been observed by us when 
expressing recombinant proteins required for HA production. Accordingly, more effort is 
required to elucidate the complex regulatory architecture of this organism to enable inactivation 
or stimulation of stress responses that may affect genetic stability [43].  
 
2.2 Genetic manipulation in B. subtilis 
2.2.1 Transition to the naturally competent state 
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Most commonly used strains of B. subtilis are derivatives of strain 168, the first 
auxotrophic strain (unable to synthesize tryptophan) observed to be naturally competent [44]. 
The competent state develops in a fraction of the cell population (5-20%) at the end of 
exponential growth [8, 45] through a complex regulatory network initiated by the competence 
transcription factor ComK [45, 46]. During exponential growth, the repressor MecA binds to 
ComK inhibiting its activity. The competence quorum-sensing mechanism is activated late in 
exponential growth by a downshift in nutrient availability, inducing expression of the 
derepressor ComS [47, 48]. ComS binds to MecA, releasing ComK which results in upregulated 
expression of more than 100 genes [45, 46]. As many of these genes are not required for 
transformation, it was proposed that competence is only one aspect of the physiological state 
induced by ComK, which was speculated to be a global adaptation to stress (termed the K-state) 
enabling repair of cellular DNA and acquisition of new genetic elements to enhance cell fitness 
[45, 49]. Nonetheless, genes involved in the synthesis of DNA transport machinery (i.e. the 
comE, comF, and comG operons and comC), and those involved in DNA metabolism, repair and 
recombination (e.g. nucA, addAB and recA) are upregulated by ComK [45, 46, 50, 51]. 
 
2.2.2 DNA uptake and fate in the cytosol 
DNA transport begins with binding of dsDNA to the cell surface via ComEA and 
subsequent fragmentation by the endonuclease NucA [52]. DNA accessibility to ComEA relies 
on the pseudopilins ComGC (the major ComG pseuodpilin), ComGD, ComGE and ComGG 
which are believed to modify the cell wall (perhaps by opening channels) exposing ComEA [53]. 
ComGA is an ATPase required for assembly of the ComG pseudopilus (and binding of DNA to 
the cell), and prevents cell growth and division during competence prior to ComK depletion [54]. 
12 
 
In addition, ComC, a prepilin peptidase, and BdbD and BdbC (protein oxidoreductases) are 
required for ComG pseudopilus maturation [52].  Once bound by ComEA and fragmented by 
NucA, the dsDNA is converted to ssDNA by an unknown enzyme, and one strand is translocated 
into the cytosol (the other is degraded and released from the cell) through the ComEC membrane 
permease [55], a process mediated by the ATPase ComFA [56]. The DNA uptake machinery 
appears to be static, localizing at the cell poles, with the exception of ComEA which can 
colocalize with the stationary uptake apparatus or remain mobile [55]. It is believed that the 
mobility of ComEA enables DNA capture for later transport to the cytosol [55], although the 
static nature of the ComG pseudopilus required for DNA binding to ComEA complicates the 
matter. Another explanation for ComEA mobility is saturation of polar ComEA binding sites due 
to its abundance relative to other uptake proteins [54], or perhaps the ComG pseudopilus causes 
a global shift in cell wall structure to enable uniform DNA binding across the membrane for 
delayed transport to the cytosol. 
 Once ssDNA reaches the cytosol, ssDNA binding proteins (i.e. SsbA or SsbB) protect it 
from exonucleolytic degradation.  SsbA and SsbB perform similar functions in the recruitment of 
the primary recombination protein RecA to ssDNA via mediators RecO and DprA through 
independent pathways [57, 58]. DprA and RecO are important factors in homologous 
recombination (HR) as they facilitate RecA filamentation onto protein-coated ssDNA, modulate 
RecA-mediated strand exchange, and promote annealing of complementary DNA strands [57-
59]. It is believed that the path taken for HR depends largely on which protein (i.e. SbsA or 
SbsB) is bound to the incoming ssDNA [57], with DprA and RecO preferentially interacting with 
SsbB- and SsbA-bound ssDNA, respectively [57, 58]. SsbA and SsbB protect transformed 
ssDNA from degradation, remove DNA secondary structure, prevent unnecessary binding of 
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RecA to ssDNA, and enable DprA/RecO-mediated single-strand annealing (SSA) by RecA [58, 
60]. In vitro experiments indicate that RecA-ATP (ATP is a cofactor for RecA although dATP is 
preferred) will nucleate and polymerize onto naked ssDNA, albeit with low efficiency, and 
ultimately catalyze strand exchange [61]. However, SsbA-ssDNA and SsbB-ssDNA complexes 
are unavailable to RecA [60, 61], which requires either a RecO-ssDNA-SsbA or RecO-SsbA-
ssDNA-SsbB complex to efficiently carry out its functions [60]. The same concept applies to 
DprA except that it preferentially associates with SsbB, and either RecO or DprA can mediate 
RecA-ATP nucleation of the SsbA-ssDNA-SsbB complex [57].  
 
2.2.3 Transformation and markerless recombineering strategies  
The preferred method of DNA transformation in B. subtilis is via natural competence, 
although other methods are employed such as protoplast transformation, electroporation, 
transduction, and conjugation depending on strain compatibility. Transformation of genomic 
DNA (gDNA), a highly efficient process known as congression, is commonly performed to 
transfer genetic markers between isogenic strains, and is particularly useful for natural 
transformation of poorly transformable strains [8]. High efficiency transformation of B. subtilis 
for chromosomal integration (≥103 colony forming units [CFU] µg-1 DNA) has been reported 
using natural competence, for example [15, 62, 63], and artificially induced competence by 
overexpression of ComK [64], or coexpression of ComK and ComS [65]. Integration cassettes 
minimally consist of a selection marker flanked by two homology lengths (HL) corresponding to 
a target in the chromosome, facilitating HR by a double cross-over integration event. Single 
cross-over integration events also occur by a Campbell-like mechanism, however, these 
insertions are significantly less stable resulting in spontaneous chromosomal pop-out [66]. 
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Integration cassettes are often constructed as plasmids which replicate in E. coli (for cloning 
purposes) but not in B. subtilis, ensuring that transformation results in HR [8]. Transformation 
can also be achieved with PCR products, although efficiency is expectedly higher for linearized 
plasmids [64]. Transformation efficiency is highly dependent on HL size [15] and a minimum 
length of 400-500 bp is thought to be a requirement for double cross-over recombination to occur 
in B. subtilis [14].   
The flexibility afforded by markerless genome engineering strategies is essential for the 
development of laboratory and commercial strains. A common approach has been the application 
of counter-selectable markers, such as upp [14, 64], blaI [67] and mazF [13], flanked by short 
direct repeats (DR) to promote auto-eviction of the selection/counter-selection cassettes by 
single-crossover recombination. upp encodes a uracil-phosphoribosyltransferase, which converts 
uracil to UMP, and can also metabolize the toxic pyrimidine analog 5-fluorouracil (5FU) into 5-
fluoro-dUMP, a potent inhibitor of the thymidylate synthetase [14]. [14]. A cassette composed of 
upp and a selection marker (PhleoR, imparting phleomycin resistance) flanked by two DRs was 
cloned between HLs, yielding a HL5’-DR-upp-PhleoR-DR-HL3’ counter-selectable integration 
cassette (designated as upp-CS). In an upp null background, the upp-CS cassette was 
transformed into B. subtilis yielding a PhleoR, 5FU sensitive (5FUS) strain with the desired 
mutation. Subsequent growth in non-select (i.e. antibiotic-free) media for ~24 h enables 
automatic eviction of the upp-CS cassette, yielding PhleoS, 5FUR colonies (at low 5FU 
concentration, 10 µM) [14]. Similarly, the promoter of lysA, encoding a diaminopimelate 
decarboxylase needed for lysine synthesis in B. subtilis, was replaced with the blaP (encoding β-
lactamase) promoter (PblaP) from Bacillus licheniformis, and blaI (encoding the repressor of 
PblaP) was used as the counter-selectable marker (cells having lost the blaI-CS cassette were 
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selected on lysine deficient minimal media)  [67]. mazF, an endoribonuclease and part of the 
mazEF toxin-antitoxin module from E. coli, was applied as an inducible counter-selectable 
marker (i.e. cells having lost the mazF-CS cassette were resistant to the inducer) using the same 
approach [13], and has the distinct advantage of requiring no conditional genetic background. 
While these methods are simple to use, the editing efficiencies are relatively low (25-50% of 
counter-selected mutants lose the selection marker) and conditional genetic backgrounds are 
required in most cases. Site-specific recombination via the Cre/loxP [15] and FLP/FRT [16] 
systems has also been successfully applied to markerless recombineering in B. subtilis with a 
generally higher efficiency (~90%) than self-evicting counter-selection cassettes. The viral Cre 
recombinase catalyzes reciprocal site-specific recombination between two loxP sites in the 
absence of any host cofactors or accessory proteins, excising DNA sequences internal to the 
convergently oriented loxP sites [15]. A selection marker (e.g. SpcR, imparting spectinomycin 
resistance) flanked by mutant lox sites (lox71/lox66) was cloned between HLs yielding a HL5’-
lox77-SpcR-lox66-HL3’ cassette [15]. Chromosomally expressed Cre was induced to evict the 
SpcR cassette, leaving behind a poorly recognized double mutant lox72 site, which minimizes 
chromosomal instability in the presence of Cre. The FLP/FRT recombination system (S. 
cerevisiae) was applied in a similar manner [16], and while mutant FRT  sites have been 
established [68], they are often not applied due to the low frequency of unwanted recombination 
events [69]. Additionally, ssDNA recombineering mediated by the λ-Red phage β-recombinase 
of E. coli, for which the Cre/loxP system and counter-selectable hen egg white lysozyme (hewl) 
were used in combination to enhance marker eviction frequency, provided a high editing 
efficiency [70]. However, site-specific recombination systems are not particularly conducive to 
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multiplexing given the requirement for multiple selection (and potentially counter-selection) 
markers and the subsequent tedious screening needed to confirm their absence.  
 
2.3 CRISPR-Cas9 as a powerful tool for genome editing and transcriptional 
modulation 
CRISPRs were originally observed in E. coli and had been described as a series of short 
DRs separated by 32 bp inserts [17]. Early predictions were made about the possible role of 
CRISPR-Cas systems in DNA repair [71] or gene regulation [72]. However, subsequent studies 
revealed that spacer sequences matched those of viral genomes and plasmids, and that cas genes 
encode proteins with putative helicase and nuclease domains [73, 74], leading to the concept that 
CRISPR-Cas systems might be an adaptive defense mechanism in which asRNAs serve as record 
of prior invasions. Their function was demonstrated experimentally by bacteriophage challenge 
of a WT strain of Streptococcus thermophilus possessing CRISPR loci, resulting in phage-
resistant mutants in which additional spacers bearing complementarity to the invading phage 
DNA were acquired [18]. Type I, II, and III CRISPR-Cas systems have been identified (each 
containing multiple subsets), and are highly diverse in genetic structure (i.e. sequences of 
CRISPR repeats and cas genes, and cas operon arrangement) and mechanism (i.e. RNA 
processing, RNA-protein assembly, and targeting) [75], although the basic process of spacer 
acquisition to achieve immunity is conserved [76]. The type II CRISPR-Cas9 system derived 
from S. pyogenes has been extensively characterized and exploited for genetic engineering due to 
its simplicity relative to other identified CRISPR-Cas systems [77].  
 
2.3.1 Functionality of the CRISPR-Cas9 system 
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In the CRISPR-Cas9 system (as in other type II systems), CRISPR arrays (CRISPRa) 
containing target-specific protospacers flanked by short DRs are transcribed as immature 
CRISPR-targeting RNAs (pre-crRNAs). A trans-activating crRNA (tracrRNA) is also 
transcribed and forms a duplex with the pre-crRNA via complementarity to the DRs. To target 
Cas9, the pre-crRNA/tracrRNA duplex must be processed by host endoribonuclease RNase III 
[78], a process requiring Cas9 to presumably bind and position the duplex to enable cleavage 
[76].  Cas9 remains bound to the mature crRNA/tracrRNA duplex after cleavage by RNase III 
[79], yielding a catalytically active Cas9-RNA complex due to conformational changes in Cas9 
upon RNA binding [80] (apo-Cas9 will bind, but not cleave, DNA non-specifically [81]). In type 
I and II systems, site-specific binding and cleavage occur based on complementary base-pairing 
between the target and protospacer, and the presence of a recognition sequence adjacent to the 3’ 
end of the base pairing region known as the protospacer adjacent motif (PAM) [79]. The PAM 
site (NGG for S. pyogenes Cas9) is located on the non-targeting strand, i.e. the strand opposite to 
that which complements the protospacer, and is not included in the protospacer sequence. Cas9-
RNA target location occurs through random three-dimensional collisions with DNA, and 
targeting proceeds through binding of PAM sites and interrogation of adjacent DNA for 
protospacer complementarity [81].  A fully complementary 12 bp seed region at the 3’ end of the 
protospacer  is necessary for efficient Cas9-RNA binding and cleavage of the target [82], and 
mismatches in the two bp adjacent to the PAM site results in complete loss of Cas9-RNA activity 
[81]. Unwinding of the dsDNA target by Cas9-RNA begins at the PAM site and proceeds toward 
the distal end of the base pairing region [81]. Base pairing between the protospacer and target 
strand generates a RNA-DNA duplex, facilitating R-loop formation for Cas9 cleavage [83]. Cas9 
contains two nuclease domains responsible for cleavage of respective DNA stands: the HNH- 
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and RuvC-like domains cleave the target and non-target strands, respectively [79, 80]. The end 
result is a blunt-ended double-stranded break (DSB) in the target DNA three bp upstream of the 
PAM site (Figure 2.1). The high specificity of CRISPR-induced DSBs enables efficient selection 
of mutants that evade DNA cleavage via HR of exogenous donor DNA, or editing templates. 
More recently, the synthetic guide RNA (gRNA) comprised of a protospacer, a Cas9-binding 
hairpin (CBH) and a transcriptional terminator has been used in place of the native targeting 
crRNA/tracrRNA duplex, further simplifying application of the CRISPR-Cas9 system [79].  
 
Figure 2.1. DNA cleavage by Cas9 with the crRNA/tracrRNA duplex. Adapted from [77]. 
 
2.3.2 Application of the CRISPR-Cas9 system to genome editing 
The CRISPR-Cas9 system has been widely adopted for genome editing as Cas9 is the 
only Cas protein required for DNA targeting and cleavage (a common feature of type II 
systems), and Cas9 recognizes a short PAM sequence increasing the number of potential targets 
in a given genome. At around the same time, genome editing in human cell lines was reported in 
two independent studies [84, 85]. Using a human-codon optimized version of Cas9 (S. pyogenes) 
targeted by gRNAs, the activity of a chromosomally inserted inactive green fluorescent protein 
(GFP) was restored in human embryonic kidney cells (HEK293T) by HR of an exogenous 




demonstrated by targeting two sites (separated by 19 bp) in the AAVS1 locus, resulting in 
excision of the internal sequence and repair by nonhomologous end joining (NHEJ). In addition, 
an integration cassette containing functional GFP was delivered to the AAVS1 locus although 
efficiency was not reported. Similar observations were made in the other study, in which the 
functionality of a human-compatible version of Cas9 derived from S. thermophiles was also 
verified, although gRNA performance was inferior to the native crRNA/tracrRNA duplex [85]. 
At the same time, the CRISPR-Cas9 system was first applied to bacterial genome editing in 
Streptococcus pneumoniae and E. coli [82]. gDNA was isolated from S. pneumoniae strain crR6, 
which contains the heterologous CRISPR-Cas9 system from S. pyogenes that targets a sequence 
in bacteriophage ϕ8232.5 (S. pyogenes), and transformed by congression into two strains bearing 
either the intact viral target sequence (R68232.5), or the sequence carrying a mutation in the PAM 
site (R6370.1) inserted to the srtA locus. Unexpectedly [at the time], a small number of R68232.5 
mutants survived CRISPR-mediated cleavage by acquisition of the WT srtA gene by a double 
cross-over recombination event. In the same study, plasmids expressing Cas9 (pCas9) and the 
CRISPRa (pCRISPR) were used for ssDNA recombineering in E. coli strain HME63, which 
expresses the λ-Red γ, β and exo proteins, resulting in an editing efficiency of 65%. These were 
the first demonstrations that simultaneous transformation of CRISPR-Cas9 machinery and an 
editing template for DSB repair (or avoidance if HR happens first) could result in the selection of 
mutants with a desired mutation in the absence of a selectable marker. 
 Subsequent systems developed for E. coli and S. cerevisiae focused on enhancing 
continuous multiplexing capability for scalable strain construction. In a two plasmid system 
designed for E. coli, the λ-Red system, Cas9 (S. pyogenes) and an inducible gRNA targeting the 
pMB1 ori (pMB1-gRNA) were constructed in a vector containing a temperature sensitive ori 
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(pCas), while the gRNA(s) and editing template(s) were included in a second plasmid containing 
a pMB1 ori (pTargetT) [20]. High multiplexing efficiency was obtained for two KOs (maeA and 
maeB; 97%), although efficiency dropped markedly for three simultaneous mutations, likely due 
to the third target selected (cadA; discussed in section 4.1.7). High editing efficiency was also 
obtained for insertions up to 4.5 kb (75%). Elimination of the pTargetT vectors was 
accomplished by induction of the pMB1-gRNA and pCas was eliminated via growth at a non-
permissive temperature. However, inclusion of the editing templates in the pTargetT vectors 
limited the capacity of the system to three simultaneous KOs due to complications with cloning. 
A subsequent study employed a similar plasmid system except that editing templates were 
delivered as independent linear fragments [19]. High editing efficiencies were obtained for dual 
KOs (83%) with ssDNA, and single dsDNA insertions (or knock-ins; KI) up to 3 kb (≥59%). A 
system developed for S. cerevisiae made use of an ultrahigh copy vector to express all CRISPR-
Cas9 elements, including the editing template which was constructed as part of the CRISPRa 
[22]. High multiplexing efficiency was obtained (up to 100% depending on PAM site selection) 
for up to three targets, although four days of continuous growth was required to achieve 
acceptable efficiency. In addition, a counter-selectable marker was included in the single plasmid 
system, although the capacity of the system for continuous editing was not evaluated. Finally, a 
subsequent study employed gap repair, a form of in vivo HR in which plasmids are constructed 
by simultaneously transforming inserts bearing homology to a plasmid backbone (all linear 
components), for gRNA delivery, achieving multiplexing efficiencies of 64 and 27% for three 
and five KOs, respectively, in S. cerevisiae [21]. Moreover, a total of 11 genes were 
simultaneously inserted (via six editing templates) across three genomic loci (requiring nine 
recombination events) with an editing efficiency of 4.2%, resulting in a muconic acid producing 
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strain. Only one day of growth after transformation was required in this system, although editing 
template HLs were 10-fold longer than those used in the prior study in S. cerevisiae [22]. Cas9 
was chromosomally expressed and editing templates were transformed as individual fragments. 
Beyond the aforementioned work, the CRISPR-Cas9 system has proven an indispensable tool for 
simple and precise genome editing in bacteria [86-89], yeast [90] and higher eukaryotes, for 
example [91-94]. 
 


















E. coli plasmid gRNA  
92 / 1.3 
75 / 4.5  
97 / 2 




E. coli plasmid gRNA  
90 / 2 
59 / 3 
83a / 2 






plasmid crRNA\tracrRNA N/A 
87b / 3 






chromosome gRNAd 4.2 / 24e 
64 / 3 




a) KO performed with ssDNA; b) four days of cultivation required to obtain efficiency; c) six days of cultivation 
required to obtain efficiency; d) system not designed for continuous editing; e) six fragments inserted over three loci 
requiring nine simultaneous recombination events 
 
 
2.3.3 Application of CRISPRi to transcriptional modulation 
The utility of the CRISPR-Cas9 system extends beyond the capacity for chromosomal 
modification as an efficient means of metering transcription. A Cas9 variant (dCas9), exhibiting 
loss of endonucleolytic activity, through mutations to the HNH- and RuvC-like domains, while 
retaining DNA-binding capability (causing physical interruption of RNA polymerase) has 
recently been exploited as a transcriptional repressor, facilitating highly specific and reversible 
modulation of gene expression [23]. RNA-mediated regulatory mechanisms such as cis-acting 
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riboswitches [95], and asRNAs with [96, 97] or without [98, 99] recruiting motifs for proteins 
promoting hybridization have been successfully developed. While considerable transcriptional 
control can be achieved with these strategies, inherent complexities such as the requirement for 
upstream sequence modifications to the targeted gene, and extensive screening of endogenous 
regulatory RNAs and evaluation of synthetic constructs have limited their utility in tailoring gene 
expression. On the other hand, CRISPRi provides excellent transcriptional control, while being 
simple to implement and easily transferrable to any organism in which the CRISPR-Cas9 system 
is functional. CRISPRi was first demonstrated in E. coli using an inducible version of dCas9, 
resulting in up to 300-fold repression of the monomeric red fluorescent protein (mRFP) [23]. 
1000-fold repression was achieved when two gRNAs targeted the mRFP coding sequence 
simultaneously, and multiplexed repression of two reporters was demonstrated. gRNAs targeting 
the nontemplate DNA strand demonstrated effective gene silencing (or knock-down; KD), while 
those targeting the template strand provided marginal repression (repression via promoter 
targeting was strand independent). Additionally, modest repression levels were observed in the 
same study for HEK293 cells using human-compatible dCas9. Subsequent efforts to improve 
CRISPRi performance in mammalian cells focused on developing dCas9 fusions with repressive 
chromatin modifier domains (e.g. the Krüppel-associated box; KRAB), or transcription 
activators such as VP16 [100]. dCas9-KRAB fusions resulted in substantial improvements to 
repression levels, and transcriptional activation via dCas9-VP64 (four VP16 molecules) was also 
successful. Since these pioneering studies were published, CRISPRi has been successfully 
applied to genome-scale transcriptional repression [101] and activation [101, 102] for 




2.4 HA production in bacteria 
HA is a high-value biopolymer used in a broad range of applications such as abdominal, 
pelvic and opthalmic surgeries; viscosupplement injections for osteoarthritis treatment; and 
various health, food and cosmetic products [104, 105]. The current US market for HA is 
estimated to exceed $1 billion annually and is expected to increase quickly due to the escalating 
demand for viscosupplements and dermal fillers [105]. HA is a linear, unbranched 
polysaccharide composed of alternating N-acetyl-glucosamine (GlcNAc) and glucuronic acid 
(GlcUA) monomers, reaching up to 8 MDa in size [5]. High MW HA (>1.8 MDa) possesses an 
enhanced capacity to retain water, a desirable characteristic for biomedical applications [106]. 
Traditionally, HA was extracted from avian and mammalian sources, although microbial 
synthesis (primarily using Streptococcus sp.) has become increasingly common [5, 105]. 
Extraction from animal tissue is costly and the resulting products may cause allergic reactions or 
viral infections. Moreover, HA produced from Streptococcus sp. may contain exotoxins inherent 
to these pathogenic species [5]. Accordingly, the adoption of GRAS designated organisms to HA 
biomanufacturing processes is an attractive option. 
 
2.4.1 The function and phospholipid dependence of streptococcal hyaluronan synthases  
HA is naturally synthesized by certain pathogenic bacteria including Lancefield group A 
[107] and C [108] streptococci (Gram-positive), and Type A Pasteurella multocida (Gram-
negative) [109], in addition to many eukaryotes (and the odd virus). Streptococcal and eukaryotic 
HAS have been designated as Class I HAS as they are integral membrane proteins with similar 
predicted topology and contain a single glycosyltransferase 2 (GT2) family module [110]. In 
contrast, the P. multocida HAS (PmHAS) is a peripheral membrane protein containing two GT2 
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modules [111], and is the only Class II HAS identified to date [112]. The overall topology of the 
HAS from S. pyogenes (SpHAS) was deduced experimentally, and is proposed to contain four 
transmembrane domains, 2 membrane-associated regions and an intracellular catalytic domain 
[113]. Other Class I HAS topologies are expected to be similar based on comparative sequence 
analysis, although eukaryotic HAS (HAS1, HAS2 and HAS3) are predicted to contain two 
additional transmembrane domains [114]. Streptococcal HAS, like most other Class I HAS, 
alternately add uridine diphosphate (UDP)-GlcNAc and UDP-GlcUA to the reducing end of the 
growing HA chain, such that the UDP sugars are acceptors rather than donors [110]. The 
relatively small size and few transmembrane domains of Streptococcal HAS suggest that it could 
not facilitate pore formation for translocation of the growing HA chain [115]. This theory was 
supported by the observation that mutation of a component of an ABC transporter complex 
reduced HA capsule size in S. pyogenes, suggesting that additional proteins may assist 
translocation [116]. However, recent work showed that SeHAS could release a small fluorescent 
dye (Cascade Blue; CB) from inside liposomes, and that mutations to one of its transmembrane 
domains (which decreased enzyme activity and HA MW in an earlier study) resulted in reduced 
CB efflux [117] (a similar independent study released at the same time corroborated this 
observation [118]).  Furthermore, it was suggested that disruption of ABC transporters could 
lead to accumulation of cytoplasmic UDP, inhibiting HAS activity via substrate inhibition [117], 
and that CL may assist HAS in creating an internal pore-like passage for translocation [119]. 
Finally, pore formation is likely necessary to constrain the growing HA chain as it transiently 
dissociates from the HAS during each monomer addition cycle [117], considering that Class I 
HAS are strictly processive [115]. Accordingly, a single HAS protein appears to produce HA 
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autonomously, a process requiring as many as seven different functions to initiate and elongate 
the HA chain, and subsequently extrude it across the membrane [115]. 
 The dependence of SpHAS activity on its orientation with CL was first demonstrated 
when the activity of solubilized SpHAS recovered from membrane preparations was recovered 
upon treatment with CL [120]. More than a decade passed before active SpHAS and SeHAS 
were observed to be ~23 kDa larger than the purified enzymes, both of which were inactive 
(~47.8 kDa each) [119]. Based on the estimated size difference, it was proposed that ~16 CL 
molecules must interact with a single SpHAS or SeHAS protein, and that loss of even a single 
molecule can cause enzyme inactivation. Subsequent work demonstrated that other anionic 
phospholipids could stimulate SpHAS and SeHAS activity, albeit less effectively than CL, and 
that respective enzymes responded very differently to each compound [121]. For example 
(comparisons are relative to pure HAS), phosphatidylserine increased SpHAS activity 2.5-fold 
while increasing SeHAS activity 6-fold, while phosphatidic acid slightly inhibited SpHAS and 
provided similar stimulation to SeHAS activity as phosphatidylserine. Furthermore, bovine CL 
was shown to stimulate HAS activity more effectively than E. coli CL (1.3- and 2-fold for 
SpHAS and SeHAS, respectively), demonstrating that the composition of CL fatty acyl chains 
(four in total) is also important. Later investigations confirmed that tetraoleoyl-CL, containing 
unsaturated 18:1(Δ9) oleoyl chains, stimulates SeHAS activity considerably (1.5-fold increase 
relative to bovine CL), and that saturated CL chains do not stimulate SeHAS activity [122, 123].  
 
2.4.2 Metabolic engineering for HA production 
While a considerable amount of effort has been applied to developing bioprocesses for 
endogenous HA production via exotoxin-free strains of group C streptococci  [105], this review 
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focuses on production of HA in recombinant strains which are non-native producers, although a 
few highlights are provided for the sake of comparison. Through optimization of media 
components, a titer of 7 g/L and MW of 5.9 MDa was achieved in a non-hemolytic, 
hyaluronidase-negative (an enzyme degrading HA) strain of Streptococcus (Streptococcus sp. 
ID9102) obtained through chemical mutagenesis [124]. Similar titers (6-7 g/L) and MW of 3.2 
MDa were achieved using a non-hemolytic, hyaluronidase-negative S. equisimilis strain (KFCC 
10830; also obtained with mutagenesis), through optimization of culture conditions [125]. 
Production of HA in a recombinant host was first demonstrated in B. subtilis [5], leading to the 
exploration of heterologous HA production in several other bacteria. As both Streptococcus sp. 
and B. subtilis are Gram-positive, HA biosynthesis pathways can be readily adapted to achieve 
production in B. subtilis (Figure 2.2) [5]. HA production is a metabolically demanding process 
requiring 2 mol of glucose, 5 mol of nucleoside triphosphates and 1 mol acetyl-coA for every 
polymer subunit (i.e. -GlcUA-GlcNAc-) synthesized [5]. HA-producing streptococci have 
evolved a dedicated expression system to address this issue, which entails expression of has 
genes to maintain suitable precursor flux during HA capsule formation. In addition to hasA 
(encoding HAS), S. pyogenes expresses hasB (tuaD), encoding a UDP-glucose 6-dehydrogenase, 
and hasC (gtaB), encoding a UTP-glucose-1-P uridylyltransferase [126], while S. equisimilis also 
expresses hasD (gcaD), encoding a UDP-GlcNAc pyrophosphorylase (B. subtilis homologues 
are in parentheses) [5]. For heterologous production of HA in B. subtilis, SeHAS was expressed 
due to its enhanced rate of polymerization relative to SpHAS [108], and an extra copy of tuaD 
was constitutively expressed as the expression of native tuaD is repressed in the presence of 
phosphates [127], a common component of B. subtilis media formulations. Accordingly, 
constitutive coexpression of seHas and tuaD resulted in significant HA production in B. subtilis, 
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and expression of gtaB or gcaD provided moderate enhancements to the titer which was in the 
multi-gram per liter range (MW of 1.1-1.2 MDa; all genes expressed chromosomally) [5]. A 
subsequent study reported that coexpression of hasA and tuaD led to an improved HA titer 
compared to coexpression of hasA and hasB (has genes from group C Streptococcus sp.) in B. 
subtilis [128]. In addition, coexpression of vhb, encoding bacterial hemoglobin from Vitreoscilla 
(VHb), provided a further 1.8-fold increase in the HA titer. Finally, chromosomal expression of 
the Class II HAS from P. multocida (pmHas), in combination with tuaD and gtaB expressed 
from a plasmid, resulted in high HA titers (up to 6.8 g/L) and MWs (up to 5.4 MDa) [129]. MW 
was observed to decline between 36 h and 48 h which was observed in the initial study based on 
the drop in relative viscosity with time [5]. Finally, the coexpression of szHas (encoding HAS 
from S. zooepidemicus; SzHAS), tuaD, gtaB, glmS (encoding L-glutamine-D-fructose-6-
phosphate amidotransferase; GlmS), glmM (encoding phosphoglucosamine mutase; GlmM), and 
gcaD improved the HA titer by ~30% (2.8 g/L) in shake flask cultures, compared to the 
coexpression of only szHas and tuaD, or szHas and gcaD, without improving the MW [130]. In 
the same study, reducing the expression of pfkA (encoding 6-phosphofructokinase; PfkA), via 
replacement of the native ATG start codon with TTG, further increased the HA titer by 18% (3.2 
g/L).  
HA production has also been investigated in the Gram-positive bacterium Lactococcus 
lactis, leading to the same observation that GlcUA availability was limiting synthesis [131]. 
Plasmid-based expression of hasA (has genes from group C Streptococcus sp.) alone resulted in 
a very low HA titer (80 mg/L), while coexpression of hasB increased the titer 8-fold (shake 
flasks). A subsequent study exploiting L. lactis reported that coexpression of hasC (has genes 




Figure 2.2. HA biosynthetic pathway in B. subtilis. TuaD, UDP-glucose 6-dehydrogenase; 
HasA, hyaluronan synthase; Pgi, glucose-6-P isomerase; PgcA, phosphoglucomutase; GlmS, 
glutamine-fructose-6-P amidotransferase; GtaB, UTP-glucose-1-P uridylyltransferase; GlmM, 
phosphoglucosamine mutase; GcaD, UDP-GlcNAc pyrophosphorylase. Adapted from [5]. 
 
 
coexpression of hasA and hasB without hasC (all genes were expressed from the same plasmid 
used in the previous study) [132]. The HA titer and MW reached 1.8 g/L and 2.8 MDa, 
respectively, in a batch stirred-tank reactor (STR) cultivation. HA production in Streptomyces 
albulus has also been demonstrated, although due to the high GC content of its genome, it was 
necessary to codon-optimize seHas and replace Lys residues flanking the transmembrane 
domains with Arg residues, resulting in hasAm [133]. Plasmid-based expression of hasAm and 
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endogenous udgA (hasB), glmU (hasD) and gtaB (hasC) resulted in a titer of 6.2 g/L and MW of 
2.2 MDa in a batch STR cultivation (coexpression of only hasAm and udgA reduced the titer). 
The desirable HA production characteristics observed for S. albulus were attributed to the 
enhanced ATP pools generated during native polylysine production. Gram-negative bacteria 
have also been exploited as HA production platforms. Expression of plasmid-borne spHas and E. 
coli homologues ugD (hasB) and galF (hasC) led to a very low titer (48 mg/L). Replacement of 
spHas with codon-optimized seHas increased the titer to 160 mg/L, while removing galF from 
the operon, surprisingly, increased the titer to 196 mg/L in shake flask cultures (MW of 0.5 
MDa) [134]. Furthermore, as observed in all Gram-positive species, GlcUA was the limiting 
factor for HA production in E. coli such that exclusion of ugD led to no appreciable HA being 
produced. Significantly improved HA production was achieved with E. coli by expressing 
pmHas and the E. coli K5 homologue kfiD (hasB). The titer reached 2.7 g/L in fed-batch cultures 
and could be increased to 3.7 g/L with GlcNAc supplementation (MW of 1.5 MDa) [6]. The 
authors of the aforementioned study originally designed the expression system used in E. coli for 
HA production in Agrobacterium sp., and the HA titer and MW reached 220 mg/L and 2.2 MDa, 
respectively, in shake flask cultures of Agrobacterium sp., although GlcNAc supplementation 
was necessary [135]. Based on the results summarized here (and personal experience), it appears 
that mating Gram-negative and Gram-positive organisms with corresponding HAS is ideal to 
promote productivity and strain stability. We observed that PmHAS is not stable in B. subtilis, 
even when expressed as a chromosomal insert from promoters of varying strength, such that a 





Table 2.2. Summary of strain characteristics and heterologous HA production in cultures of 















N/A 1.2 STR [5] 




1.8 N/A flask [128] 









L. lactis Class I 
plasmid 
(hasA-hasB) 
0.64 N/A flask [131] 




1.8 2.8 STR [132] 




6.2 2.2 STR [133] 
E. coli Class I 
plasmid 
(hasA-hasB) 
0.2 0.5 flask [134] 
E. coli Class II 
plasmid 
(hasA-hasB) 






0.22e 2.2 flask [135] 
a) expressed from plasmid; b) after 36 h cultivation; c) after 48 h cultivation; d) enzyme 
modified as described in text; e) GlcNAc supplementation required 
 
 
2.5 Oxygen vectors 
Oxygen vectors are water-immiscible compounds possessing a greater capacity to dissolve 
oxygen compared to water. Hydrocarbons [136-139], perfluorocarbons [140-142], vegetable oil 
[143], and silicone oil [139, 144] can enhance oxygen transfer in microbial cultivations, while 
insoluble polymers such as silicone rubber [139, 145], nylon [145], glass beads [145], Hytrel [139], 
Kraton [139], Desmopan [139, 144], and Elvax [144] are examples of solid oxygen vectors. 
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2.5.1 Mechanism of oxygen transfer in microbial cultures 
In the context of a system containing a dispersed phase (liquid vector), continuous phase  
 (aqueous media), gas phase (air) and suspended bacterial cells, there are five possible pathways 
for oxygen transfer from gas bubbles to bacterial cells (Figure 2.3). Liquid vectors are often 
categorized based on their propensity to form droplets (non-spreading) or films (spreading) when  
 
Figure 2.3. Oxygen transfer in microbial cultures containing oxygen vectors. A) Possible 
pathways for oxygen transfer from a gas bubble to a bacterial cell in an aqueous medium 
containing an oxygen vector. B) Profile of oxygen transfer in a cultivation medium containing a 
spreading oxygen vector. a2 and a3 represent the gas-vector and vector-water interfacial areas. 




contacting an aqueous phase. The spreading coefficient (SVW) is used to predict the behavior of 
liquid vectors in aqueous media [146, 147]: 
𝑆𝑉𝑊 = 𝜎𝑊𝐺 − (𝜎𝑉𝐺 + 𝜎𝑉𝑊)      (2.1) 
Where σij is the interfacial tension between the (V)ector, (W)ater and (G)as phases. Positive 
values of SVW indicate that a liquid vector will spread as a thin film over gas bubbles, while 
negative spreading coefficients (SVW < 0) typically result in the formation of discrete droplets 
[148]. For spreading liquid vectors, the most likely pathway of oxygen transfer is parallel 
transfer (i.e. simultaneous gas-water and gas-vector oxygen transfer) [138, 146]. However, mass 
transfer in series (i.e. gas-vector-water or gas-water-vector oxygen transfer) was determined to 
be the most significant pathway in vector-water systems [147], and the significantly higher kL 
values for gas-vector compared to gas-water oxygen transfer for spreading vectors (and highly 
similar kL for vector-water and gas-water) indicate that mass transfer occurs in series by the gas-
vector-water pathway (then taken up by the bacterial cells) [146]. In addition, the significantly 
reduced γ between gas and vector relative to gas and the aqueous phase favors gas-vector transfer 
by reducing the local free energy [149]. ‘Coalescence’ of gas bubbles and vector (n-dodecane or 
forane) droplets has been observed in a static aqueous system [146], confirming that gas-vector 
mass transfer is a likely scenario. Gas-vector coalescence has also been observed in dynamic 
experiments in which toluene, n-dodecane or refined petrol were injected into a water stream 
containing a fixed number of stationary gas bubbles [150]. The formation of gas-vector 





2)   (2.2) 
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Where Rb, Rc and Rd represent the radii of the gas bubble, gas-vector complex and vector droplet, 
respectively. If the vector droplet is much smaller than the gas bubble (which can be achieved 
mechanically), then Rc ~ Rb, and the following condition of the bubble-to-droplet size ratio 
















  (for S* < 0)   (2.3) 
Where * indicates properties of a mutually saturated system. For S* > 0, gas-vector coalescence 
would be favorable for any size ratio [150]. One additional criterion must be met to attain vector 
film formation over droplet separation, in addition to Equation 2.3, which is the minimum vector 
film thickness (2-10 nm) [151]. 
 
2.5.2 Oxygen storage in hydrocarbons and perfluorocarbons 
While hydrocarbons have been used extensively as oxygen vectors in bacterial cultivation 
(simulated or otherwise) [137-139, 146, 152-156], perfluorocarbons show considerable promise 
as next generation oxygen vectors due to substantially higher oxygen solubilities, lower γ  and 
biocompatibility [157]. The enhanced solubility of oxygen in perfluorocarbons can be attributed 
to their intermolecular arrangement, rather than F-O electrostatic interactions, as confirmed by 
several studies of paramagnetic relaxation induced by the presence of oxygen in 
perfluorocarbons and hydrocarbons. The longitudinal relaxation time (T1) corresponds to the 
process of establishing (or re-establishing) the normal Gaussian population distribution of α and 
β spin states in a magnetic field [158]. Nuclear relaxation arises from a dipolar interaction 
between the electron spins of oxygen and spins of the solvent nuclei (either F or C in this case) 
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0 = 𝑞𝑥𝑥𝐺      (2.4) 
Where 𝑇1
0 is the relaxation time of the pure solvent and qx is the relaxation coefficient [159, 160]. 
perfluorocarbons consistently present lower qx values compared to their parent hydrocarbons 
(e.g., 60 and 40 s-1 for benzene and perfluorobenzene, respectively), such that an inverse 
(roughly linear) relationship between qx and oxygen solubility exists [159, 161]. Relaxation rates 
(LHS of Equation 2.4) in hydrocarbon systems can be attributed to a continuous translational 
diffusion of oxygen through the network of hydrocarbon molecules. Conversely, a discontinuous 
diffusion model of oxygen molecules in perfluorocarbons has been proposed, in which a network 
of solvent molecules would enclose a cavity in which an oxygen molecule is temporarily trapped 
prior to migrating into an adjacent cavity [159, 161]. The relatively large size of fluorine atoms 
in perfluorocarbons (compared to hydrogen atoms in hydrocarbons) causing irregular molecular 
arrangements and, in turn, opening large cavities for oxygen entrapment, is a reasonable picture 
of the action of perfluorocarbons in dissolving large quantities of gaseous molecules given the 
lower boiling points and higher viscosities of perfluorocarbons versus hydrocarbons [161].  
 
2.5.3 Solid vectors 
Enhanced oxygen transfer rates (OTR) via solid vectors is thought to occur through 1) 
increased turbulence at the gas-water interface through particle-stagnant film collision (reduced 
gas bubble size via mechanical disruption will also occur), and/or 2) the shuttling effect which 
entails particles saturated with oxygen at the gas-water interface moving into the bulk liquid 
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where the oxygen is desorbed (regenerating the particle for subsequent transfer) [139, 162]. The 




− 1) × 100%     (2.5) 
While certain solid vectors possess high affinities for oxygen, they often provide lower values of 
EF than those with significantly lower (in some cases negligible) affinity. The equilibrium 
concentration of oxygen in the combined liquid phase (𝐶𝑚𝑖𝑥
∗ ) was used to evaluate enhancements 








     (2.6) 
Where fi is the volume fraction of respective phases, Cg is the concentration of gaseous oxygen 
and Kij represents the partitioning coefficients between respective phases. Kraton™ and 
Desmopan™ provided increases of 220% and 175%, respectively, to the concentration gradient 
available for mass transfer (based on relative 𝐶𝑚𝑖𝑥
∗  values), while respective EF values for 
Kraton™ and Desmopan™ were 23% and 171% [139]. Similarly, glass beads (Doxygen<1x10
-15 
cm2/s) and nylon 6,6 (Doxygen=1.6x10
-9 cm2/s) provided significant enhancements to the kLa, 
while silicone rubber (Doxygen=3.4x10
-5 cm2/s) and a styrene-butadiene copolymer 
(Doxygen=1.4x10
-6 cm2/s) caused a reduction to the kLa in a STR [163]. The reduced kLa values 
were likely due to an increase in the time needed to reach oxygen saturation in the bulk liquid in 
the presence of silicone rubber (i.e. the vector was absorbing the oxygen), as the OTR in this 
dispersed system was significantly higher compared to that without vector. Accordingly, the 
work completed to date demonstrates that the selection of solid vectors is a complex process for 
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which the oxygen affinity of a given material is only one consideration (and will not guarantee a 
higher OTR as is evident from the performance of Kraton™).  
 
2.5.4 Enhancements to oxygen transfer 
The effect of oxygen vectors on a in gas-vector-water systems is poorly understood. It 
has been reported that small increases in a arise from the prevention of gas bubble coalescence 
for low fV values (dispersed toluene), while a decreases as fV increases further due to reduced 
turbulence [164, 165] (dispersed n-dodecane, n-heptane and 1-octanol decreased a as fV increased 
without achieving a maxima in ref [37]). Conversely, a 15% decrease in the bubble Sauter mean 
diameter was observed for a n-dodecane dispersed system for fV = 0.23 (also corresponding to 
the maximum kLa), representing a proportional increase in a [146]. Increasing fV further resulted 
in a reduction in the kLa, suggesting that a similar reduction in a may have resulted from 
exceeding the optimal fV value (which was not observed in ref [37]). Conversely, dispersed FC-
40 (a perfluorocarbon) had no significant effect on a for fV up to 0.15, although the OTR steadily 
increased with fV up to a value of 0.4 [147]. It is, therefore, evident that no consensus exists on 
the effects of liquid vectors on a, and further investigation is required to understand this 
phenomena. The effect of solid vectors on a has not been studied in detail, however, an increase 
in a is expected due to direct mechanical bubble breakage [139]. 
 As discussed for solid vectors, the kLa may not fully represent the utility of an oxygen 
vector for enhancing oxygen availability in bacterial cultivations, as the initial loading of the 
vector may extend the time required to reach saturation in the bulk liquid. Moreover, reports of 
the effect of the dispersed phase on the kLa are at times inconsistent, as is the case with 
estimation of a. For example, n-dodecane was reported to enhance kLa slightly up to fV ~ 0.01 
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after which a decline was observed [165], while the kLa increased ~3-fold at fV = 0.23 (a linear 
increase was observed up to fV = 0.23, followed by a sharp decline) in an earlier study [146]. 
Furthermore, another study found that n-dodecane reduced the kLa in a fV-independent manner, 
while dispersed n-hexadecane provided enhancements to the kLa  [166]. The results of the latter 
study are particularly confusing given that for both hydrocarbons SVW < 0, SVW,hexadecane is 3.6-fold 
lower than SVW,dodecane, and that dispersed beading hydrocarbons typically provide a reduction or 
no changes in the kLa [148]. For hydrocarbons of SVW > 0, the kLa initially decreases quickly for 
low fV and then gradually approaches the baseline value (i.e. that observed without the vector) 
[165, 167, 168]. It was hypothesized that the initial decrease in the kLa resulted from increased 
liquid phase resistance due to accumulation of surface active contaminants at the gas-water 
interface, and that gas bubble size decreased with increasing vector concentration (γ is reduced 
which, in turn, increases a and the kLa) as the system approached the fV at which phase inversion 
occurs [167, 168].  
 
2.5.5 Application to bacterial cultivation 
Oxygen vectors have been applied successfully to bacterial cultivations for the 
production of biopolymers, recombinant proteins and antibiotics. The HA titer and MW were 
increased by ~50% and 200%, respectively, in S. zooepidemicus cultures in which 0.5% v/v n-
hexadecane was added at the time of inoculation [152]. In the same study, n-dodecane (1% v/v) 
led to increased biomass (relative to cultivation with n-hexadecane), but negligible 
improvements to titer (although MW increased by 100%). In an earlier study, the use of a 
perfluorocarbon (i.e. perfluorodecalin) in S. zooepidemicus cultures resulted in an improved HA 
titer (32%), although MW was not assessed [140]. Titers were slightly higher when using 
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dispersed perfluorodecalin compared to a three phase agitation strategy in which the agitation 
speed in a STR was increased from 200 to 600 rpm, and the MW may have been enhanced due to 
reduced shear stress. Dispersed n-heptane (0.3% v/v) provided an ~25% increase to titer and 
MW of poly(γ-glutamic acid) (PGA) produced in B. subtilis [153]. In the same study, the use of 
n-dodecane as vector decreased the PGA titer and MW substantially, and the significant 
difference in culture performance was attributed to a low NADH/NAD+ ratio and ATP levels 
when n-dodecane was applied. The application of n-hexane (1% v/v) and n-dodecane (0.5% v/v) 
as oxygen vectors resulted in respective 12% and 27% increases in the titer of ε-poly-lysine 
produced in cultures of Streptomyces albulus, while, surprisingly, oleic acid as dispersed phase 
(0.2% v/v) provided only a 7% increase in titer (n-hexane and oleic acid are spreading vectors, 
while n-dodecane beads) [154]. Finally, the actinorhodin (antibiotic and pigment) titer doubled in 
cultures of Streptomyces coelicolor when using dispersed perfluorodecalin (10% v/v), while 
biomass was reduced proportionally [142]. The increase in culture performance was attributed to 
the substantial improvements to the oxygen uptake rate (OUR) and kLa (3- to 4-fold for both) 












Chapter 3  




Genetic engineering strategies aimed at converting common microbes to productive cell 
factories are becoming increasingly common [11]. Strain construction entails metabolic design of 
biosynthetic pathways and genetic manipulations. To enhance productivity, key genes for 
heightened expression are introduced via plasmid transformation or genomic integration (knock-
in; KI), while divergent pathways are eliminated via gene disruption (i.e. KO) [169]. However, 
certain genes, particularly those associated with central metabolism or core aspects of physiology 
(e.g. membrane integrity, ATP generation, etc.), cannot be completely inactivated, otherwise host 
viability can be compromised. In such cases, reducing expression levels of the key genes (i.e. 
KD) may ultimately prove effective [98].  
While engineering microbial genomes is challenging, recent application of CRISPRs and 
their Cas proteins has dramatically altered the course of genomic engineering across the 
spectrum of life. CRISPR arrays are part of an adaptive prokaryotic viral defense system, and 
contain target-specific protospacers that are expressed as crRNAs [170]. crRNAs direct Cas 
nucleases to DNA targets based on the presence of a PAM specific to the Cas protein [171, 172] 
and protospacer homology. In type II systems such as CRISPR-Cas9 from S. pyogenes, a 
tracrRNA is required for processing a pre-crRNA into a functional crRNA [78]. More recently, 
the synthetic gRNA, comprised of a protospacer, CBH, and transcriptional terminator, has been 
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used for targeting, further simplifying application of the CRISPR-Cas9 system [79]. The 
CRISPR-induced DSBs enable selection of mutants that evade DNA cleavage via recombination 
of exogenous editing templates. Accordingly, the CRISPR-Cas9 system has proven an 
indispensable tool for genome editing in bacteria [19, 20, 82, 86-89, 173-179], yeast [21, 22] and 
higher eukaryotes [84, 91-93]. 
In addition to genome editing, the CRISPR-Cas9 system can be applied to reversibly 
regulating gene transcription, known as CRISPRi for which a Cas9 variant (dead Cas9; dCas9), 
exhibiting loss of endonucleolytic activity while retaining DNA-binding capability, acts as a 
transcriptional repressor [23, 180]. While various RNA-mediated regulatory mechanisms, such 
as cis-acting riboswitches [95] and asRNAs with [96, 97] or without [98, 99] recruiting motifs 
for proteins promoting hybridization, have been developed for tailoring gene expression, 
inherent complexities exist in the application of these technologies. The use of cis-acting 
riboswitches requires upstream sequence modifications to the targeted gene [95], limiting their 
practical utility for metabolic engineering and genetic screening. Similarly, the design of 
recruiting scaffolds for synthetic asRNAs entails extensive screening of endogenous regulatory 
RNAs and evaluation of synthetic constructs [96, 97], while off target effects may also be a 
concern when applying asRNAs [98]. On the other hand, CRISPRi provides excellent 
transcriptional control and is simple to implement in many organisms. The CRISPR-dCas9 
system has been applied to genome-scale transcriptional repression [101] and activation [101, 
102] for interrogation of gene function in human cell lines as well as to genetic and metabolic 




B. subtilis is a model Gram-positive organism sought after for its capacity in high-level 
production of biopolymers [5], metabolites [184], and recombinant proteins [185]. In contrast to 
E. coli, B. subtilis has received a GRAS designation, readily secretes products into the 
extracellular medium, and can metabolize nearly any carbon source, making it an attractive 
biomanufacturing platform [185]. While B. subtilis is an ideal organism for industrial 
application, available genetic tools are lagging behind popular production hosts such as E. coli 
and S. cerevisiae [11, 12]. Because markerless genome engineering is essential for the 
development of commercial B. subtilis strains, a common approach has been the application of 
counter-selectable markers, such as upp [14, 186], blaI [67] and mazF [13], flanked by short 
direct repeats (DR) for auto-eviction of the selection cassettes by single-crossover 
recombination. While these methods are simple to use, the editing efficiencies are relatively low, 
conditional genetic backgrounds are required in some cases, and cloning of integration constructs 
(i.e. integration vectors or PCR-amplified integration cassettes) can be complicated and/or time 
consuming. Moreover, multiplexing is not practical as the number of available selection and 
counter-selection markers is limited, exposure to multiple antibiotics is not preferable (i.e. may 
compromise cell physiology), and counter-selection will become increasingly difficult (i.e. less 
efficient or more time consuming) as the number of simultaneous targets increases. On the other 
hand, site-specific recombination via the Cre/loxP [15] and FLP/FRT [16] systems has also been 
applied to markerless recombineering in B. subtilis with a generally higher efficiency than 
counter-selection methods. Additionally, ssDNA recombineering mediated by the λ-Red phage 
β-recombinase provides a high editing efficiency [70]. However, these systems are not 
particularly conducive to multiplexing either given the requirement for multiple selection (and 
potentially counter-selection) markers and subsequent tedious screening.  
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In this study, we developed a CRISPR-Cas9 toolkit for comprehensive engineering of B. 
subtilis to overcome major limitations associated with existing genome engineering technologies 
(e.g. low editing efficiency, tedious cloning, and limited multiplexing capability). While 
CRISPR-Cas9 offers potential solutions to these technical issues in E. coli and S. cerevisiae [21, 
22, 82, 86], the protocols include multicopy plasmids which must be removed from the cell. In 
that regard, an ideal CRISPR-Cas9 system should facilitate multiple mutations, either in series or 
simultaneously, while imposing minimal physiological impact to the host. Our approach not only 
simplifies construction of genetic elements required for CRISPR-Cas9-mediated genome editing 
and transcriptional interference in B. subtilis, but also obviates reliance on potentially unstable 
multicopy plasmids and subsequent plasmid curing. We demonstrated high editing efficacy of 
our novel gRNA transcription and delivery system based on a simple counter-selection procedure 
with the capacity for successive genomic manipulations, including site-specific mutations for 
gene inactivation, and gene insertions. The effects of editing template characteristics and PAM 
site sensitivity were also investigated to increase editing efficiency. Finally, we expand our 
toolkit for transcriptional repression of gene expression using dCas9 with our gRNA delivery 
system. The developed toolkit will advance technologies in engineering of B. subtilis to achieve 
its full potential as a biomanufacturing platform. 
 
3.2 Materials and methods 
3.2.1 Bacterial strains, primers and plasmids 
The B. subtilis strains used in this study are listed in Table S3.1. E. coli HI-Control™ 
10G chemically competent cells (Lucigen; Wisconsin, USA) were prepared as electrocompetent 
cells as described previously [187] and used as host for plasmid construction. B. subtilis and E. 
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coli strains were maintained as glycerol stocks at -80 °C. Primers (Table S3.1) were synthesized 
by Integrated DNA Technologies (IDT; Iowa, USA). Plasmids pIEFBPR (ECE195), pDG1731 
(ECE119) and pAX01 (ECE137) were obtained from the Bacillus Genetic Stock Center (BGSC;  
Columbus, Ohio). pCRISPR and pCas9 were gifts from Luciano Marraffini (Addgene plasmids # 
42875 and 42876, respectively), and pgRNA-bacteria and pdCas9-bacteria were gifts from 
Stanley Qi (Addgene plasmid # 44251 and 44249, respectively).  
 
3.2.2 Plasmid and editing template construction 
DNA manipulation was performed using standard cloning techniques [187], and DNA 
sequencing was conducted by The Centre for Applied Genomics (TCAG; Ontario, Canada). We 
previously identified the thrC locus as a recombination ‘hot spot’ in the genome of B. subtilis, 
making it a potential site for integration of gRNA transcription cassettes. To construct the gRNA 
delivery vector, we began by amplifying the thrC 5’- and 3’- homology lengths (HLs) from 
plasmid pDG1731 [188] with primers P3.1/P3.2 and P3.3/P3.4, respectively, followed by 
insertion in place of the corresponding bpr HL-5’ and HL-3’ of pIEFBPR [13] using the 
respective SbfI/NheI and XmaI/SpeI restriction sites, yielding pAW001-2. Subsequently, the 
ampicillin resistance marker (AmpR) in pAW001-2 was replaced with an erythromycin cassette 
(ErmR). To do this, the ColE1 replicon was amplified from pIEFBPR with primers P3.5/P3.6, the 
ErmR cassette was amplified from pAX01 [189] with primers P3.7/P3.8, and the two fragments 
were spliced via Splicing by Overlap Extension (SOE)-PCR (this process will be subsequently 
referred to as splicing), followed by insertion of the spliced fragment into pAW001-2 using the 
SacI/NgoMIV restriction sites, resulting in pAW002-2. 
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Potentially due to leaky transcription from the spac promoter (Pspac), the transformation 
efficiencies of pIEFBPR and pAW002-2 in B. subtilis were unacceptably low. Accordingly, the 
tightly regulated xylA/R promoter cassette from Bacillus megaterium (PxylA, Bm) was amplified 
from pAX01 with primers P3.9/P3.10 (--/MfeI), mazF was amplified from pIEFBPR with 
primers P3.11/P3.12 (BamHI/--), and the two fragments were spliced. The resulting PxylA, 
Bm::mazF cassette replaced the Pspac::mazF cassette in BamHI/EcoRI digested pAW002-2, 
yielding pAW003-2. Though transformation efficiency was improved in B. subtilis, propagation 
of pAW003-2 was difficult in E. coli, prompting us to identify another inducible promoter to 
drive mazF. The araE/R promoter system from B. subtilis (ParaE) was chosen as it is very tightly 
repressed in the presence of glucose due to the presence of the catabolite repression element 
(CRE) upstream of the araE open reading frame (ORF) [190]. The ParaE cassette was amplified 
with primers P3.13/P3.14 from 1A751 genomic DNA (gDNA) and was spliced with mazF as 
previously described. The resulting ParaE::mazF cassette was used to replace the Pspac::mazF 
cassette in pAW002-2 using the BamHI/EcoRI restriction sites, resulting in plasmid pAW004-2, 
a vector found to be stable in E. coli while providing significantly enhanced transformation 
efficiency in B. subtilis relative to pAW002-2.  
The xylA promoter (PxylA) from B. subtilis was used to drive transcription of gRNAs. To 
do this, PxylA was amplified with primers P3.15/P3.16 from 1A751 gDNA, replacing the 6 base 
pairs (bp) between the -10 and +2 regions of PxylA with a SphI restriction site. The resulting 
promoter, PxylA.SphI+1 (Figure 3.1A), was inserted in place of the direct repeat (DR) adjacent to the 
thrC HL-5’ of pAW004-2 using the NheI/BamHI restriction sites, yielding pAW005-2 (Figure 
3.1B). The gRNA cassettes ugtP-gRNA.P395T, amyE-gRNA.P25NT, amyE-gRNA.P330T, 
amyE-gRNA.P636T, amyE-gRNA.P1344T, and seHas-gRNA.P394T, were amplified from 
45 
 
pgRNA-bacteria [23] with respective forward primers P3.17-P3.22 containing unique 
protospacers, and a common reverse primer P3.23. Each gRNA cassette was inserted 
downstream of PxylA.SphI+1 in pAW005-2 using SphI/BamHI restriction sites to obtain single-
gRNA delivery vectors (Figure 3.1B). To generate the native CRISPR array (CRISPRa) for ugtP 
disruption (ugtP-CRISPRa.P395T), the empty CRISPRa was amplified from pCRISPR [82] with 
primers P3.24/P3.25 and inserted in place of the DR adjacent to the thrC HL-5’ of pAW004-2 
using the NheI/BamHI restriction sites, yielding pAW012-2. Oligonucleotides P3.26/P3.27 were 
then annealed and ligated into BsaI digested pAW012-2 as previously described [82], resulting in 
pAW013-2. The lacA locus was chosen for genomic integration of cas9. To do this, pAW016-2 
(Figure 3.1C) was constructed by removing the PxylA, Bm cassette from pAX01 by SacI digestion 
and self-ligation, and then inserting the cas9-tracrRNA cassette amplified from pCas9 [82] with 
primers P3.34/P3.35 using the XbaI restriction sites. The orientation of the cas9-tracrRNA 
cassette was confirmed by DNA sequencing. 
To construct the multi-gRNA delivery vector, the BamHI restriction site downstream of 
mazF was replaced with a NcoI restriction site, and the BglII restriction site upstream of mazF 
was removed and a new BglII restriction site was inserted between the NheI restriction site and 
PxylA.SphI+1 in pAW006-2 (Figure 3.2), to facilitate Biobrick cloning of gRNA transcription 
cassettes. This was accomplished by amplifying the PxylA.SphI+1::ugtP-gRNA.P395T cassette and 
mazF from pAW006-2 with primers P3.28/P3.29 (NheI/--) and P3.30/P3.31 (--/BamHI), 
respectively, followed by splicing of the two fragments to generate a PxylA.SphI+1::ugtP-
gRNA.P395T-mazF cassette. The PxylA.SphI+1::ugtP-gRNA.P395T-mazF cassette was 
subsequently inserted into NheI/BglII digested pAW005-2, yielding pAW014-2, and the 




Figure 3.1. Schematic representation of the PxylA.SphI+1 gRNA transcription cassette, and the 
single-gRNA and Cas9 delivery vectors. A) Sequences of the native promoter PxylA of B. subtilis 
and PxylA.SphI+1 are provided. The 6 bp between the -10 and +2 regions of PxylA were replaced with 
a SphI restriction site enabling protospacer (represented as PS in the figure) exchange without 
the need for inverse PCR. A unique protospacer is introduced as an overhang in the forward 
primer amplifying the CBH and terminator (represented as ter in the figure) as a single fragment, 
and the resulting gRNA cassette is inserted downstream of PxylA.SphI+1 in the single-gRNA 
delivery vector. The -35 and -10 regions are in bold font, the +1 is in dark bold font and the SphI 
restriction site is underlined. B) PxylA.SphI+1 was inserted into pAW004-2 removing the DR 
adjacent to the thrC HL-5’, yielding pAW005-2. gRNA cassettes were inserted between the SphI 
and BamHI restriction sites of pAW005-2, generating respective single-gRNA delivery vectors. 
Transformation of a linearized single-gRNA delivery vector results in integration of the 
combined PxylA.SphI+1::gRNA-ParaE::mazF-Spc
R (gRNA*) cassette at the thrC locus. The gRNA* 
cassette is subsequently evicted by transformation of the thrC editing template, followed by 
arabinose selection to induce mazF expression, and screening for spectinomycin sensitivity. C) 
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The PxylA, Bm cassette was removed from pAX01 and the cas9-tracrRNA cassette inserted, 
yielding pAW016-2. Transformation of linearized pAW016-2 results in integration of the 
combined cas9-tracrRNA-ErmR (Cas9*) cassette at the lacA locus.  
 
 
Figure 3.2. Schematic representation of the construction of the multi-gRNA delivery vector. The 
BamHI restriction site was replaced with a NcoI restriction site, and the BglII restriction site 
moved between the NheI restriction site and PxylA.SphI+1 in pAW006-2 (top) to facilitate Biobrick 
cloning, yielding pAW014-2 (bottom). The PxylA.SphI+1::amyE-gRNA.P636T cassette was inserted 
between the NheI/BglII restriction sites of pAW014-2, resulting in pAW015-2. In general, a 
single-gRNA delivery vector is generated from pAW005-2, and the gRNA transcription cassette 
is amplified, digested with NheI\BamHI and inserted into the NheI/BglII digested multi-gRNA 
delivery vector. If a single-gRNA delivery vector is not required, PxylA.SphI+1 and the gRNA 
cassette can be spliced and cloned directly into the multi-gRNA delivery vector (protospacer is 
represented as PS and terminator as ter in the figure). 
 
arrangement, the first gRNA cassette to be inserted into the multi-gRNA delivery vector is 
amplified with a forward primer introducing the unique protospacer and reverse primer P3.32 
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from pgRNA-bacteria (or any plasmid containing a gRNA), and cloned into pAW014-2 using the 
SphI/NcoI restriction sites. Each additional gRNA is cloned into pAW005-2, generating single-
gRNA delivery vectors from which the corresponding gRNA transcription cassettes are 
amplified with primers P3.28/P3.33 (NheI/BamHI) and sequentially inserted into the NheI/BglII 
digested multi-gRNA delivery vector. All gRNA delivery vectors were linearized via SacI 
digestion prior to transformation into B. Subtilis. To enable continuous genome editing (a 
procedure which is summarized in Figure 3.3), 1A751 was first transformed with BseYI-
linearized pAW016-2, resulting in strain AW001-2, which constitutively expresses Cas9 from 
the lacA locus. Continuous editing is then performed by transforming AW001-2 (or its 
derivatives) with a single- or multi-gRNA delivery vector, integrating the combined 
PxylA.SphI+1::gRNA-ParaE::mazF-Spc
R cassette (gRNA*) at the thrC locus, and an editing 
template(s) introducing the desired mutation(s). Cells containing the desired mutation(s) evade 
the CRISPR-Cas9-mediated chromosomal DSB(s) [as elimination of the PAM site(s) occurs in 
edited gDNA], and the mutation(s) is verified with genetic screening and sequencing. The 
gRNA* cassette is subsequently removed via transformation of the thrC editing template, 
restoring the integration site for the next round of editing.  
To construct the gRNA delivery vector for dCas9 targeting, the wprA HL-5’ was 
amplified with primers P3.36/P3.37, and PxylA.SphI+1 with P3.38/P3.39 from 1A751 gDNA, and the 
two fragments were spliced, followed by insertion of the spliced fragment in place of the thrC 
HL-5’ in pAW004-2 using the SbfI/NcoI restriction sites. The vector was completed by 
amplifying the wprA HL-3’ with primers P3.40/P3.41 from 1A751 gDNA, followed by insertion 
in place of the thrC HL-3’ using the AscI/AgeI restriction sites, resulting in pAW017-2. The 




Figure 3.3. Continuous editing with the CRISPR-Cas9 toolkit. The combined cas9-tracrRNA-
ErmR (Cas9*) cassette was integrated into the lacA locus of 1A751 via transformation with 
pAW016-2, generating strain AW001-2, which constitutively expresses Cas9. A linearized 
single- or multi-gRNA delivery vector, and the editing template(s) [represented as ET in the 
figure], are transformed into AW001-2 (or one of its derivatives), resulting in integration of the 
combined PxylA.SphI+1::gRNA-ParaE::mazF-Spc
R (gRNA*) cassette at the thrC locus, and 
introduction of the desired mutation(s) via integration of the editing template (s). Cells 
containing the desired mutation(s) evade the CRISPR-Cas9-mediated chromosomal DSB(s) due 
to the elimination of the PAM site(s) in the edited gDNA. The resulting mutant is resistant to 
spectinomycin and sensitive to arabinose induction of mazF expression. After the desired 
mutation(s) is verified, the gRNA* cassette is evicted by transformation of the thrC editing 
template to arabinose resistance and spectinomycin sensitivity, restoring the native thrC locus. 
The mutant is now ready for the next round of editing using the same procedure. Refer to Figures 





Figure 3.4. Schematic representation of the gRNA delivery vector for integration of dCas9-
targeting gRNA transcription cassettes, and the dCas9 delivery vector. A) The wprA HL-5’ and 
PxylA.SphI+1 were spliced and inserted in place of the thrC HL-5’ of pAW004-2 preserving the 
adjacent DR, and the thrC HL-3’ was replaced with the wprA HL-3’, generating pAW017-2. 
lacZ-gRNA.P28NT was inserted between the SphI and NcoI restriction sites of pAW017-2, 
yielding pAW018-2. Transformation of linearized pAW018-2 results in integration of the 
PxylA.SphI+1::lacZ-gRNA.P28NT (gRNA
ǂ) cassette, and the combined ParaE::mazF-Spc
R (CS) 
cassette at the wprA locus. The CS cassette is auto-evicted via single-crossover recombination 
between the flanking DRs. B) dcas9 was inserted downstream of PxylA, Bm in pAX01 yielding 
pAW019-2. Transformation of linearized pAW019-2 results in integration of the combined PxylA, 
Bm::dcas9-Erm
R (dCas9*) cassette at the lacA locus (protospacer is represented as PS and 
terminator as ter in the figure). 
 
for compatibility purposes based on intended future applications for CRISPRi in other areas of 
research conducted by our group. The lacZ-gRNA.P28NT cassette was amplified from pgRNA- 
bacteria with primers P3.42/P3.32 and cloned into pAW017-2 using the SphI/NcoI restriction 
sites, yielding pAW018-2 (Figure 3.4A). pAW018-2 was linearized via SacI digestion prior to 
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transformation into B. Subtilis. Similar to cas9, the lacA locus was selected for genomic 
integration of the xylose-inducible dCas9 cassette. To do this, pAW019-2 (Figure 3.4B) 
wasconstructed by amplifying dcas9 from pdCas9-bacteria [23] with primers P3.43/P3.44 
(SpeI/BglII), followed by insertion into SpeI/BamHI digested pAX01. To enable transcriptional 
interference via dCas9 (a procedure which is summarized in Figure 3.5), AW009 was 
transformed with BseYI-linearized pAW019-2, yielding strain AW014-2, which expresses 
xylose-inducible dCas9 from the lacA locus. Note that the HA-producing strain AW009 was 
selected as the host for CRISPRi demonstration to accommodate our research in strain 
engineering for enhanced HA production in B. subtilis, and any strain possessing an intact lacA 
locus (e.g. 1A751) can be used in place of AW009. AW014-2 was then transformed with 
pAW018-2, resulting in integration of the PxylA.SphI+1::lacZ-gRNA.P28NT cassette and the 
combined ParaE::mazF-Spc
R (CS) cassette at the wprA locus. The CS cassette was subsequently 
auto-evicted via single-crossover recombination between the flanking DRs [13], yielding strain 
AW015-2, which transcribes lacZ-gRNA.P28NT from the wprA locus. Subsequent genomic 
integration of an inducible copy of lacZ from E. coli at the ugtP locus was performed to assess 
CRISPRi. To do this, AW015-2 was transformed with pAW016, a vector previously constructed 
in our lab for genomic integration of isopropyl β-D-thiogalactopyranoside (IPTG)-inducible lacZ 
at the ugtP locus, yielding strain AW016-2 (note that this part is not shown in Figure 3.5). The 
gRNA directs dCas9 to the target (i.e. lacZ) based on the presence of a PAM site and adjacent 
seed region complementary to the protospacer, and the dCas9-gRNA complex remains bound to 
the target, blocking transcription by RNA polymerase (RNAP). 
For the ugtP KO, PAM site ugtP.P395T was selected, where the number in the 




Figure 3.5. Implementing CRISPRi with the CRISPR-Cas9 toolkit. The combined PxylA, 
Bm::dcas9-Erm
R (dCas9*) cassette was integrated into the lacA locus of strain AW009 via 
transformation with pAW019-2, yielding strain AW014-2, which expresses xylose-inducible 
dCas9 [note that any strain possessing an intact lacA locus (e.g. 1A751) can be used in place of 
AW009]. AW014-2 was then transformed with pAW018-2, resulting in integration of the 
PxylA.SphI+1::lacZ-gRNA.P28NT (gRNA
ǂ) cassette, and the combined ParaE::mazF-Spc
R (CS) 
cassette, at the wprA locus (the resulting mutant was spectinomycin resistant and arabinose 
sensitive). The CS cassette was subsequently auto-evicted via single-crossover recombination 
between the flanking DRs (black rectangles), yielding strain AW015-2 (spectinomycin sensitive 
and arabinose resistant), which transcribes lacZ-gRNA.P28NT from the wprA locus [subsequent 
integration of IPTG-inducible lacZ (E. coli) at the ugtP locus was performed to assess CRISPRi, 
and is not shown in Figure 3.5]. The gRNA directs dCas9 to the target based on the presence of a 
PAM site and adjacent seed region complementary to the protospacer, and the dCas9-gRNA 
complex remains bound to the target, blocking transcription by RNA polymerase (RNAP). Refer 





beginning of the ugtP ORF (i.e. CGG, where the cytosine is the 395th bp in the ORF), and base-
pairing occurs with the template (T) strand (or the non-template (NT) strand for other PAM 
sites). The full length ugtP editing template was generated by splicing the two 1,337 bp and 
1,332 bp HLs (flanking a 12 bp mutation region; Figure 3.6A) amplified with primers 
P3.45/P3.46 and P3.47/P3.48, respectively, from 1A751 gDNA. The ugtP editing templates of 
HLs 100, 300, 500, 750 and 1,000 bp (Figure 3.6A) were amplified with primers P3.49/P3.50, 
P3.51/P3.52, P3.53/P3.54, P3.55/P3.56 and P3.57/P3.58, respectively, from the full length ugtP 
editing template, and, therefore, preserved the original 12 bp mutation region. The full length 
amyE editing template (amyE.P636T) was constructed by splicing the two 1,368 bp and 1,335 bp 
HLs (flanking a 15 bp mutation region; Figure 3.6B) amplified with primers P3.67/P3.68 and 
P3.69/P3.70, respectively, from 1A751 gDNA. The full length amyE editing template was 
inserted into pJET1.2/blunt using the CloneJET PCR Cloning Kit (ThermoFisher Scientific; 
Massachusetts, USA) as per the manufacturer’s instructions, yielding pAW022-2 which was 
linearized via BsaI digestion prior to transformation into B. subtilis as an editing template. The 
1,000 bp HL amyE editing template (amyE.P636T) was amplified from the full length amyE 
editing template with primers P3.71/P3.72 preserving the original 15 bp mutation region. The 
amyE editing templates for PAM sites amyE.P25NT (primers P3.73/P3.74 and P3.75/P3.76), 
amyE.P330T (primers P3.77/P3.78 and P3.79/P3.80) and amyE.P1344T (primers P3.81/P3.82 
and P3.83/P3.84) were constructed in the same way as the full length amyE editing template 
(amyE.P636T), except that only 1,000 bp HLs flanked 11 bp (amyE.P330T) or 12 bp 
(amyE.P25NT and amyE.P1344T) mutation regions (Figure 3.6B). Editing templates introduced 
premature stop codons and restriction sites in place of PAM sites and adjacent nucleotides. 
Alternatively, the HA operon (i.e. Pgrac::seHas:tuaD) flanked by the amyE HL-5’ and HL-3’ was 
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also used as the editing template for evading the DSB associated with PAM site amyE.P636T, 
resulting in KI of the HA operon at the amyE locus. To construct this editing template, the partial 
HA operon KI cassette, containing the 759 bp amyE HL-3’ and 2,909 bp Pgrac::seHas:tuaD HA 
operon, was amplified from pAW008, a vector previously constructed in our lab, with primers 
P3.59/P3.60, and inserted into pJET1.2/blunt, yielding an intermediate vector. To complete the 
HA operon KI cassette, the 738 bp amyE HL-5’ was amplified from 1A751 gDNA with primers 
P3.61/P3.62 and inserted into the intermediate vector using the NcoI/NheI restriction sites, 
yielding pAW020-2. pAW020-2 was linearized via ScaI digestion prior to transformation into B. 
subtilis as an editing template. The seHas editing template (seHas.P394T) was constructed by 
splicing the two 1,303 bp and 1,338 bp HLs (flanking a 15 bp mutation region; Figure 3.6C) 
amplified with primers P3.63/P3.64 and P3.65/P3.66, respectively, from pAW020-2. The seHas 
editing template was inserted into pJET1.2/blunt to enhance transformation efficiency of the 
poorly transformable HA-producing strain AW005-2, and the resulting plasmid was pAW021-2. 
pAW021-2 was linearized via ScaI digestion prior to transformation into B. subtilis as an editing 
template. The thrC editing template used to evict gRNA transcription cassettes was generated as 
a 2,876 bp PCR product (i.e. 1,452 bp and 1,306 bp fragments flanking the deleted 118 bp region 
of thrC) amplified with primers P3.85/P3.86 from 1A751 gDNA.   
 
3.2.3 Competent cell preparation and transformation 
Transformation of B. subtilis was performed using a standard protocol for natural 
competence [8]. SpC media contained the following: (NH4)2SO4, 1.67 g/L; K2HPO4, 11.64 g/L; 
KH2PO4, 5.0 g/L; trisodium citrate dihydrate, 833 mg/L; glucose, 4.17 g/L; MgSO4∙7H2O, 151 




Figure 3.6. Unaltered sequences and mutation regions of editing templates for ugtP, seHas and 
amyE KOs, and schematic representation of the KI of the HA biosynthetic operon at the amyE 
locus. (A) The native (ugtP) and modified (editing template) sequences of the mutation region 
for ugtP KO at ugtP.P395T are capitalized, and the adjacent 20 bp of flanking homology are in 
lowercase font. In the native sequence, the PAM site is underlined and the two bp between which 
the DSB occurs are in bold font. The BspHI restriction site is italicized in the modified sequence, 
and a summary of HLs analyzed during editing template HL optimization are shown (editing 
template is represented as ET in the figure). (B) The native (amyE) and modified (editing 
template) sequences of the mutation regions for amyE KO at amyE.P25NT, amyE.P330T, 
amyE.P636T and amyE.P1344T are capitalized, and the adjacent 18-21 bp of flanking homology 
are in lowercase font. In the native sequences, PAM sites are underlined and the two bp between 
which the DSBs occur are in bold font. The XhoI (amyE.P25NT and amyE.P330T), ScaI 
(amyE.P636T) and BamHI (amyE.P1344T) restriction sites are italicized in the modified 
sequences. (C) The unaltered (seHas) and modified (editing template) sequences of the mutation 
region for seHas KO at seHas.P394T are capitalized, and the adjacent 18 bp of flanking 
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homology are in lowercase font. In the unaltered sequence, the PAM site is underlined and the 
two bp between which the chromosomal DSB occurs are in bold font.  
 
mg/L. SpII media contained the following: (NH4)2SO4, 1.67 g/L; K2HPO4, 11.64 g/L; KH2PO4, 
5.0 g/L; trisodium citrate dihydrate, 833 mg/L; glucose, 4.17 g/L; MgSO4∙7H2O, 725 mg/L; yeast 
extract, 858 mg/L; casamino acids, 86 mg/L; Arg, 3.78 g/L; His, 189 mg/L; Trp, 24 mg/L; 
CaCl2, 48 mg/L. To improve transformation efficiency, the following modifications were made 
to the cited protocol: i) yeast extract was increased by 30% in SpC (2.17 g/L) and SpII (1.12 g/L) 
media, ii) glycerol was removed from the resuspension media, and iii) cells were resuspended in 
1/40 of the initial volume of SpII media (the cited protocol specifies 1/10 of the initial volume).  
B. subtilis strains were plated on non-select lysogeny broth (LB) containing 5 g/L NaCl, 5 g/L 
yeast extract and 10 g/L tryptone, and incubated overnight (O/N). Pre-warmed SpC media was 
inoculated by cell patches from the O/N plate to OD600 0.5-0.7. Seventy five min after the 
logarithmic growth phase ended, cultured cells were then diluted 100-fold in pre-warmed SpII 
media, and incubated for 110 min before harvesting. Two µg of gRNA delivery vector and 2 µg 
of each editing template were used per transformation (400 µL total volume), and transformed 
cells were incubated for 80 min [260 revolutions per min (rpm)], and then plated on LB agar 
containing 12 g/L glucose (LBG) and 85 µg/mL spectinomycin to select recombinants. All 
cultivation steps were conducted at 37 °C and 300 rpm unless otherwise indicated, and all 
experiments were performed in triplicate. To remove the gRNA transcription cassettes by 
transformation of the thrC editing template, cells were transformed with 1.5 µg of the thrC 
editing template, plated on LB agar containing 20 g/L arabinose (LBA) to select recombinants, 




R cassette after transformation of pAW018-2, cells were grown for ~20 h in non-
select LB at 37 °C and 260 rpm, plated on LBA and screened for spectinomycin sensitivity.  
 
3.2.4 HA production, purification and analysis 
To assess HA production, AW005-2 was plated on non-select LB and grown O/N at 37 
°C. A single colony was used to inoculate 25 mL non-select LB, and the culture was grown for 
~14 h at 37 °C and 280 rpm. The culture was then used to inoculate 20 mL pre-warmed non-
select cultivation media (4% v/v) of the following composition: (NH4)2SO4, 1 g; K2HPO4∙3H2O, 
9.15 g; KH2PO4, 3 g; trisodium citrate∙ 2H2O, 1 g; yeast extract, 10 g; casamino acids, 2.5 g; 
CaCl2, 5.5 mg; FeCl2∙ 6H2O, 13.5 mg; MnCl2∙ 4H2O, 1 mg; ZnCl2, 1.7 mg; CuCl2∙ 2H2O, 0.43 
mg; CoCl2∙ 6H2O, 0.6 mg; Na2MoO4∙ 2H2O, 0.6 mg. Glucose or sucrose was used as primary 
carbon source (20 g/L), and the cultures were grown at 37 °C and 280 rpm in triplicate. Samples 
were diluted two-fold in phosphate buffered saline, and HA was purified with cetylpyridinium 
chloride as previously described [128]. HA titer was determined using the modified carbazole 
assay [191], and molecular weight (MW) was analyzed via agarose gel electrophoresis [192] 
with slight modifications. 2 µg of purified HA was loaded per well, and gels stained O/N in 
0.005% Stains-All (50% v/v ethanol) were destained for ~8 h  in 20% v/v ethanol, followed by 
destaining for ~16 h in 10% v/v ethanol. Gels were then photobleached for 20 min on a LED 
light box, and scanned with an Epson Perfection V600 Photo scanner (Epson; Nagano, Japan). 
Scanned images were analyzed using ImageJ [193], and data analysis was performed as 
previously described [192]. All samples were analyzed in duplicate. 
 
3.2.5 Sample preparation and evaluation of β-galactosidase activity 
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To assess transcriptional interference of lacZ, a single colony was used to inoculate 25 
mL LB (85 µg/mL spectinomycin) and the seed culture was incubated for ~14 h at 37 °C and 
280 rpm. 0.5 mL of the seed culture was transferred into 50 mL LB containing 85 µg/mL 
spectinomycin, 1 mM IPTG for induction of lacZ, and 1.2 % (w/v) xylose for induction of 
dCas9, and grown to OD600 of ~1.6. To obtain cell extract, cells in the amount of 30 OD600-units 
(defined as the product of cell density in OD600 and sample volume in mL) were centrifuged at 
10,000g for 10 min at room temperature. The cell pellet was resuspended in 1.5 mL Z-buffer and 
sonicated intermittently (0.5/0.5 s on/off) for 4 min in an ice water environment with a Sonicator 
3000 ultrasonic liquid processor and microtip (Misonix; New York, USA). The raw cell extract 
was then used to determine β-galactosidase activity as previously described [194]. All 
experiments were performed in triplicate. 
 
3.2.6 Real-time quantitative reverse transcription PCR (qRT-PCR)  
For RNA isolation, cells were grown as described in the preceding section. Total RNA 
was prepared using the High Pure RNA Isolation Kit (Roche Diagnostics; Basel, Switzerland) as 
per the manufacturer’s instructions. cDNAs were synthesized using the High-Capacity cDNA 
Reverse Transcription Kit (ThermoFisher Scientific; Massachusetts, USA). Sequence specific 
primers were used for reverse transcription of the lacZ (P3.88) mRNA and internal control rpsJ 
(P3.90) mRNA, encoding the 30S ribosomal protein S10, at a final concentration of 1 µM. 100 
ng of total RNA and 20 units of Murine RNase Inhibitor (New England Biolabs (NEB); 
Massachusetts, USA) were used per 20 µL reaction. Real-time qRT-PCR was carried out using 
the Power SYBR® Green PCR Master Mix (ThermoFisher Scientific; Massachusetts, USA) in 
an Applied Biosystems StepOnePlus™ System as per the manufacturers’ instructions. Sequence 
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specific primers were used for amplification of lacZ (P3.87/P3.88) and rpsJ (P3.89/P3.90). Data 
analysis to quantify relative expression between cultures with or without induction of dCas9 was 
performed as previously described [195]. All experiments were performed in triplicate. 
 
3.3 Results 
3.3.1 Design and evaluation of the PxylA.SphI+1 gRNA transcription cassette 
Compared to the native pre-crRNA/tracrRNA duplex, the chimeric gRNA has been 
preferred for CRISPR-Cas9-mediated genome editing and transcriptional interference [19, 20, 
23, 84, 101-103, 196] since its introduction. We first developed a gRNA transcription cassette 
facilitating simple replacement of the protospacer without the requirement for inverse PCR, 
which is a procedure often employed to replace the existing protospacer [23, 197]. Given the 
requirement for a precise 5’ end to the protospacer [197], we chose the native promoter PxylA for 
its considerable strength and annotated transcriptional start site [198]. To facilitate insertion of 
the gRNA transcription cassette, we introduced a SphI restriction site between the -10 and +2 
regions of PxylA, yielding PxylA.SphI+1 (Figure 3.1A). This arrangement allowed the addition of a 
unique protospacer as an overhang in the forward primer amplifying the combined CBH-
terminator fragment, generating a gRNA cassette that can be inserted downstream of PxylA.SphI+1 
using restriction/ligation cloning. To construct the base B. subtilis strain for evaluation of 
CRISPR-Cas9 toolkit components, we transformed pAW016-2 into 1A751, resulting in AW001-
2, which constitutively expressed cas9 and transcribed the tracrRNA from the lacA locus. On the 
other hand, the gRNA transcription cassette(s) was integrated into the thrC locus of the B. 
subtilis genome to ensure gRNA stability and to allow simple eviction of the cassette with a 
subsequent integration event using the thrC editing template once the CRISPR-Cas9-mediated 
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mutation was complete. Also, mazF was included in the gRNA delivery vectors for genomic co-
integration with the gRNA transcription cassette as it is an effective counter-selectable marker in 
B. subtilis [13]. To assess the vector design, we chose to KO ugtP (encoding a UDP-glucose 
diacylglyceroltransferase) since the mutation causes a distinct morphological change. For 
comparison purposes, AW001-2 was transformed with either pAW006-2 (transcribing a gRNA 
targeting ugtP.P395T) or pAW013-2 (transcribing a CRISPR array targeting ugtP.P395T), and 
the full length ugtP editing template, generating AW002-2 and AW003-2, respectively. The 
editing efficiency was evaluated via phenotypical screening, followed by colony PCR, 
subsequent BspHI digestion (Figure 3.7A), and sequencing of selected colonies. Similar editing 
efficiencies were observed when transforming pAW006-2 (79%) and pAW013-2 (82%) (Figure 
3.7B), suggesting functional promoter activity of PxylA.SphI+1. Nevertheless, the transformation 
efficiency remained low at less than 20 CFU µg-1 editing template. We then modified the 
competence protocol to increase transformation efficiency as described in M&M. 
 
3.3.2 Continuous editing for gene KI and KOs 
With the modified transformation protocol, we exploited the capacity of our toolkit for 
continuous editing. We first conducted genomic insertion of the HA operon (Pgrac::seHas:tuaD) 
into the amyE locus (amyE.P636T). HA is a linear, unbranched polysaccharide composed of 
alternating GlcNAc and GlcUA residues, reaching up to 8 MDa in size [5]. The hyaluronan 
synthase (HasA) autonomously synthesizes HA from UDP-GlcNAc and UDP-GlcUA [115], 
which are precursors for cell wall synthesis in B. subtilis. As a result, HasA is the only 
heterologous enzyme required to produce HA in this organism [5]. UDP-GlcUA availability has 
been shown to limit HA production in B. subtilis, such that constitutive expression of the UDP-
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glucose 6-dehydrogenase is required to achieve high-level production [5]. Pgrac is a strong hybrid 
promoter developed for B. subtilis [39], whereas seHas and tuaD encode the HasA from 
Streptococcus equisimilis [108] and native UDP-glucose 6-dehydrogenase [TuaD] [5], 
respectively. HA was chosen for demonstration for the following reasons. First, it is a high-value 
therapeutic biopolymer and only two genes (i.e. seHas and tuaD, or equivalent homologues) 
need to be expressed in B. subtilis to achieve significant production. Additionally, HA-producing 
strains have a prominent and observable mucoid phenotype [5], facilitating evaluation of editing 
efficiency. AW001-2 was transformed with pAW009-2 (transcribing a gRNA targeting 
amyE.P636T) and pAW020-2 (as an editing template), resulting in a mucoid strain (AW004-2) 
upon successful KI. The high KI efficiency for the HA operon (69%; Figure 3.7C) was attributed 
to the enhanced transformation which led to a 5-fold increase in the number of successful 
mutants relative to the initial ugtP KO demonstration. To prepare for the next round of editing, 
AW004-2 was transformed to be arabinose-resistant with the thrC editing template (refer to 
Figure 3.3 for continuous editing procedure), producing AW005-2. Eviction of the combined 
PxylA.SphI+1::amyE-gRNA.P636T-ParaE::mazF-Spc
R cassette was confirmed by screening for 
spectinomycin sensitivity. The efficiency of mazF counter-selection was, however, low (6%), 
compared to the initial demonstration [13], due to the significant reduction (~30-fold) in 
transformation efficiency observed for HA-encapsulated strains (data not shown). For the next 
round of editing, seHas was mutated by transformation of AW005-2 with pAW011-2 
(transcribing a gRNA targeting seHas.P394T) and pAW021-2 (as an editing template), 
abolishing HA production and the mucoid phenotype in the resulting strain (AW006-2). The 
seHas editing efficiency was also low (Figure 3.7C), owing to transformation interference from 




Figure 3.7. Assessment of the PxylA.SphI+1 gRNA transcription cassette, and continuous editing 
with the CRISPR-Cas9 toolkit. A) Colony PCR screening of ugtP, seHas and amyE KOs, and KI 
of the HA operon. To screen for the ugtP KO (ugtP.P395T), primers P3.45/P3.138 amplified a 
1,817 bp product, and successful recombination of the editing template generated products of 
1,344 bp and 473 bp upon BspHI digestion. To screen for the seHas KO (seHas.P394T), primers 
P3.139/P3.140 amplified a 1,284 bp product, and successful recombination of the editing 
template generated products of 407 bp and 877 bp upon SacI digestion. To screen for the KI of 
the HA operon (amyE.P636T), primers P3.141/P3.143 amplified a 1,559 bp product upon 
successful recombination of the editing template (no product is observed in the absence of 
recombination). To screen for the amyE KO (amyE.P636T), primers P3.142/P3.143 amplified a 
2,286 bp product, and successful recombination of the editing template generated products of 
690 bp and 1,596 bp upon ScaI digestion. Lane 1: marker; lanes 2 and 3: modified (2) and 
unmodified (3) colonies screened for the ugtP KO; lanes 4 and 5: modified (4) and unmodified 
(5) colonies screened for the KI of the HA operon; lanes 6 and 7: modified (6) and unmodified 
(7) colonies screened for the seHas KO; lanes 8 and 9: modified (8) and unmodified (9) colonies 
screened for the amyE KO. Images of multiple agarose gels have been spliced together for the 
purpose of condensing the data presented. B) The PxylA.SphI+1 gRNA transcription cassette was 
assessed in a parallel comparison with the native CRISPRa by transforming AW001-2 with 
either pAW006-2 (transcribing a gRNA targeting ugtP.P395T) or pAW013-2 (transcribing a 
CRISPRa targeting ugtP.P395T), and the full length ugtP editing template to KO ugtP. Editing 
efficiency was evaluated via phenotypical screening and colony PCR (and subsequent BspHI 
digestion). Transformation efficiency is defined as the total number of colony forming units 
(CFU) containing the desired mutation generated per µg of editing template DNA (represented as 
ET in the figure). Standard deviations (SD) of experiments performed in triplicate are shown. C) 
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The capacity of the toolkit for continuous editing was evaluated by introducing three successive 
mutations into the same background. First, the HA operon (Pgrac::seHas:tuaD) was inserted into 
the amyE locus (amyE.P636T) of AW001-2 via transformation of pAW009-2 and pAW020-2, 
resulting in mucoid strain AW004-2. KI efficiency was evaluated via phenotypical screening 
followed by colony PCR. The combined PxylA.SphI+1::amyE-gRNA.P636T-ParaE::mazF-Spc
R 
cassette was evicted from AW004-2 by transformation of the thrC editing template to arabinose 
resistance (and spectinomycin sensitivity), resulting in AW005-2. Next, seHas was mutated (at 
seHas.P394T) in AW005-2 via transformation of pAW011-2 and pAW021-2, resulting in 
AW006-2, a strain exhibiting the WT morphology. Editing efficiency was evaluated by 
phenotypical screening, followed by colony PCR (and subsequent SacI digestion). The combined 
PxylA.SphI+1::seHas-gRNA.P394T-ParaE::mazF-Spc
R cassette was evicted from AW006-2 as 
previously described, yielding AW007-2. Finally, ugtP was mutated (at ugtP.P395T) in AW007-
2 via transformation of pAW006-2 and the full length ugtP editing template. Editing efficiency 
was evaluated by phenotypical screening, followed by colony PCR (and subsequent BspHI 
digestion). SD of experiments performed in triplicate are shown.  
 
gRNA.P394T-ParaE::mazF-Spc
R cassette using the same counter-selection procedure, yielding 
AW007-2, and subsequently mutated ugtP by transformation of AW007-2 with the full length 
ugtP editing template and pAW006-2 (transcribing a gRNA targeting ugtP.P395T), generating 
AW008-2. The mazF counter-selection efficiency was significantly higher when generating 
AW007-2 (31%) compared to AW005-2 (6%), supporting the conclusion that poor 
transformability led to low editing efficiency. The high editing efficiency for the ugtP KO (99%; 
Figure 3.7C) represented a substantial improvement over the initial ugtP KO demonstration 
(79%; Figure 3.7B) and this observation coincides with the 276-fold increase in transformation 
efficiency obtained with the enhanced competence protocol (4.0 × 103 CFU µg-1 editing template 
vs. 14.5 CFU µg-1 editing template). Note that the KI efficiency of the HA operon was 
comparable to that of single gene insertions reported in E. coli [20]. Also, the ugtP editing 
efficiency was in line with systems developed for E. coli [19, 20] and S. cerevisiae [21, 22], all 
of which rely on multicopy vectors to deliver CRISPR-Cas9 machinery. 
 We assessed the capacity of AW005-2 to produce high MW HA using glucose or sucrose 




Figure 3.8. Cultivation of AW005-2 for HA production. A) Cell density, B) HA titer and C) HA 
MW. SD of experiments performed in triplicate are shown in Panels A and B, and SD of 
duplicate samples are shown in Panel C. 
 
carbon source (OD600 ~8 after 8 h; Figure 3.8A), and were similar to those of our HA-producing 
strains constructed using traditional cloning techniques (data not shown). The HA titer was 
slightly higher for the 8 h cultivation sample with sucrose (717 ± 99 mg/L) as the carbon source, 
compared to glucose (530 ± 139 mg/L; Figure 3.8B), although sucrose metabolism generally led 
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to a significantly higher MW (1.67 ± 0.05 MDa and 1.15 ± 0.09 MDa for sucrose and glucose, 
respectively) (Figure 3.8C). Moreover, a higher maximum MW was obtained (2.1 ± 0.22 MDa 
and 1.60 ± 0.07 MDa for sucrose and glucose, respectively), and the MW peaked later (and 
declined to a lesser extent) for the sucrose cultivation. The MW observed during cultivation on 
either carbon source compares favorably to a previous report of HA production in B. subtilis [5], 
and both HA titer and MW were similar to those obtained with our HA-producing strains 
developed through conventional cloning. The titers obtained with AW005-2 also compared 
favorably to the titer reported for a similar strain of B. subtilis over the same cultivation period 
[128]. A significantly longer cultivation was required to achieve a similar titer, and MW was not 
assessed in the aforementioned study. In addition, the titer and MW of HA produced by AW005-
2 was similar to those obtained with strains of B. subtilis overexpressing additional enzymes of 
the HA biosynthetic pathway (i.e. GtaB, GlmM, GlmS and GlmU), in combination with HasA 
and TuaD [130]. Accordingly, it appears that chromosomal expression of Cas9 does not hinder 
HA production, and this feature is critical for the toolkit to be applied to industrial strain 
development. Finally, the HA titer increased by extending the cultivation, although a 
concomitant decrease in MW was observed. Declining MW during extended cultures of HA-
producing strains of B. subtilis has been reported [5, 129]. 
 
3.3.3 Application of the CRISPR-Cas9 toolkit to multiplexing 
For simultaneous editing of B. subtilis genomic targets, we constructed a multi-gRNA 
delivery vector to accommodate multiple gRNAs using the Biobrick assembly approach [199]. 
Each gRNA transcription cassette can be transferred from its respective single-gRNA delivery 
vector to the multi-gRNA delivery vector or by direct cloning of the spliced PxylA.SphI+1 and 
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gRNA cassette as described in M&M. To assess multiplexing capability, the PxylA.SphI+1::amyE-
gRNA.P636T cassette was inserted into pAW014-2 using NheI and BglII restriction sites, 
yielding pAW015-2, to enable simultaneous KO of ugtP and amyE. AW001-2 was transformed 
with pAW015-2 (transcribing two gRNAs targeting ugtP.P395T and amyE.P636T) and the full 
length ugtP and amyE editing templates which each contain ~1,330 bp HLs. Colonies were first 
assessed for the ugtP null phenotype, after which ugtP mutant and non- mutant colonies were 
screened for α-amylase (encoded by amyE) deficiency via iodine staining. Colonies from each of 
the phenotype subsets (i.e. ugtP+/amyE+, ΔugtP/amyE+, ugtP+/ΔamyE and ΔugtP/ΔamyE) were 
screened via colony PCR and subsequent BspHI (ugtP) or ScaI (amyE) digestion, and selected 
colonies were sequenced. While simultaneous KO of ugtP and amyE was successful, the 
multiplexing efficiency was only 36% (Figure 3.9A), owing to a much lower editing efficiency 
for amyE compared to ugtP (38 and 86%, respectively). Hence, several genome editing factors 
potentially limiting multiplexing efficiency, specifically editing template type (i.e. PCR product 
vs. linearized plasmid), HL size, and PAM site sensitivity, were investigated. 
 
3.3.4 Effect of editing template type 
Due to the distinctively low amyE editing efficiency and given that transformation 
efficiencies for PCR products are expectedly lower compared to linearized plasmids [186], the 
amyE single KO was evaluated by transforming AW001-2 with pAW009-2 (transcribing a 
gRNA targeting amyE.P636T), and the full length amyE editing template (as a PCR product 
editing template) or pAW022-2 (as a plasmid editing template). While the amyE editing 
efficiency was significantly higher as a single KO (93%; Figure 3.9B), the transformation 
efficiency (2.69 × 102 CFU µg-1 editing template) was low. On the other hand, the use of 
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pAW022-2 as an editing template increased transformation efficiency by nearly six-fold (1.55 
×103 CFU µg-1 editing template) and, in turn, editing efficiency (100%; Figure 3.9B) compared 
to the full length amyE editing template.  
 
3.3.5 Effect of HL size 
The optimal HL was determined by targeting ugtP as it was perceived to be a 
recombination ‘hot spot’ based on generally high editing and transformation efficiencies. Editing 
templates containing 100, 300, 500, 750 and 1,000 bp HLs were constructed from the full length 
ugtP editing template such that the same mutation region was flanked by the specified HL 
(Figure 3.6A). Various editing templates were transformed with pAW006-2 (transcribing a 
gRNA targeting ugtP.P395T) into AW007-2. The editing efficiency remained high for HLs 
between 500 and 1,000 bp (>97%; Figure 3.9C), but decreased dramatically when HL was 
reduced to 300 bp. No transformants were obtained for 100 bp HL. Our results are consistent 
with earlier reports suggesting that 400-500 bp HLs are sufficient for acceptable transformation 
efficiency of linear DNA in B. subtilis [15]. The optimal HL was determined to be 1,000 bp, for 
which editing efficiency reached ~100%.  
 
3.3.6 PAM site sensitivity  
To further improve amyE editing efficiency, we assessed three PAM sites in the amyE 
ORF, in addition to the original PAM site (amyE.P636T). The PAM sites were selected based on 
the purine content of the last four bp of the 3’ end of the protospacer [min. 75%] [196], and the 
location relative to the initial PAM site. P25NT was the first available site in the ORF; P330T 
was approximately half the distance from P25NT to P636T; P1344T was approximately half the 
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distance from P636T to the stop codon. Due to the moderate GC content of the B. subtilis 
genome (43.5%), all protospacers were 40-55% GC, and the targeting strand was not considered 
a priority due to a modest effect on gRNA efficacy [196]. AW001-2 was transformed with 
pAW007-2 (transcribing a gRNA targeting amyE.P25NT), pAW008-2 (transcribing a gRNA 
targeting amyE.P330T), pAW009-2 (transcribing a gRNA targeting amyE.P636T) or pAW010-2 
(transcribing a gRNA targeting amyE.P1344T), using the optimized editing template HL of 
1,000 bp. Editing efficiency was evaluated via iodine staining, followed by colony PCR and 
subsequent digestion with XhoI (amyE.P25NT and amyE.P330T), ScaI (amyE.P636T) or BamHI 
(amyE.P1344T) [Figure 3.9E]. The editing efficiencies for the first three PAM sites from the 
start codon were similar (87, 85 and 91%, respectively; Figure 3.9D) with amyE.P636T being 
targeted most effectively, suggesting minimal bias for the targeted strand. The observation of the 
low editing efficiency when targeting P1344T (23%) is consisent with the previous report that 
editing efficiency can vary dramatically between PAM sites in a single gene [22].  
 
3.3.7 Enhanced multiplexing efficiency under optimized conditions 
To enhance the multiplexing capacity of the toolkit, we re-explored the double KO of 
amyE and ugtP (by targeting ugtP.P395T and amyE.P636T) under the optimized conditions for 
editing template and amyE PAM site. Two editing template combinations were evaluated: 1) 
PCR products containing 1,000 bp HLs (amyE and ugtP), and 2) PCR product containing 1,000 
bp HLs (ugtP) and pAW022-2 (amyE). AW001-2 was transformed with pAW015-2 (transcribing 
two gRNAs targeting ugtP.P395T and amyE.P636T) and either editing template combination 1 




Figure 3.9. Application of the CRISPR-Cas9 toolkit to multiplexing. A) The preliminary 
evaluation of multiplexing efficiency was performed by simultaneously mutating ugtP and amyE 
via transformation of AW001-2 with pAW015-2, and the full length ugtP (ugtP.P395T) and 
amyE (amyE.P636T) editing templates. Mutants were first screened for the ugtP null phenotype, 
followed by iodine staining of mutant and WT colonies to evaluate amyE editing efficiency. 
Colonies from each of the phenotype subsets (i.e. ugtP+/amyE+, ΔugtP/amyE+, ugtP+/ΔamyE and 
ΔugtP/ΔamyE) were screened via colony PCR, and subsequent BspHI (ugtP) or ScaI (amyE) 
digestion. Transformation efficiency is defined as the total number of CFU containing the 
desired mutation generated per µg of editing template DNA (represented as ET in the figure). SD 
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of experiments performed in triplicate are shown. B) amyE was evaluated as a single KO (at 
amyE.P636T) by transforming AW001-2 with either the full length amyE editing template or 
linearized pAW022-2, and pAW009-2. Editing efficiency was evaluated via iodine staining, 
followed by colony PCR and subsequent ScaI digestion. SD of experiments performed in 
triplicate are shown. C) Editing template HL was optimized using ugtP as a KO target 
(ugtP.P395T). Editing templates containing HLs of 100, 300, 500, 750 and 1,000 bp (in addition 
to the full length ugtP editing template) were assessed by transforming AW007-2 with pAW006-
2 and the corresponding editing templates. Editing efficiency was evaluated by phenotypical 
screening, followed by colony PCR (and subsequent BspHI digestion). SD of experiments 
performed in triplicate are shown. D) PAM site sensitivity analysis for amyE. Three PAM sites 
in the amyE ORF were evaluated (amyE.P25NT, amyE.P330T and amyE.P1344T), in addition to 
amyE.P636T, using the optimized editing template HL of 1,000 bp. AW001-2 was transformed 
with pAW007-2 (amyE.P25NT), pAW008-2 (amyE.P330T), pAW009-2 (amyE.P636T) or 
pAW010-2 (amyE.P1344T), and the corresponding editing templates. Editing efficiency was 
evaluated via iodine staining, followed by colony PCR and subsequent XhoI (amyE.P25NT and 
amyE.P330T), ScaI (amyE.P636T) or BamHI (amyE.P1344T) digestion. SD of experiments 
performed in triplicate are shown. E) Colony PCR screening of amyE KOs at amyE.P25NT, 
amyE.P330T, amyE.P636T or amyE.P1344T. To screen for the amyE KO at amyE.P25NT, 
primers P77/P80 amplified a 2,001 bp product, and successful recombination of the editing 
template generated products of 685 bp and 1,316 bp upon XhoI digestion. To screen for the 
amyE KO at amyE.P330T, primers P3.67/P3.76 amplified a 1,772 bp product, and successful 
recombination of the editing template generated products of 703 bp and 1,069 bp upon XhoI 
digestion. To screen for the amyE KO at amyE.P636T, primers P3.142/P3.143 amplified a 2,286 
bp product, and successful recombination of the editing template generated products of 690 bp 
and 1,596 bp upon ScaI digestion. To screen for the amyE KO at amyE.P1344T, primers 
P3.142/P3.143 amplified a 2,286 bp product, and successful recombination of the editing 
template generated products of 1,396 bp and 890 bp upon BamHI digestion. Lane 1: marker; 
lanes 2 and 3: modified (2) and unmodified (3) colonies screened for the amyE KO at 
amyE.P25NT; lanes 4 and 5: modified (4) and unmodified (5) colonies screened for the amyE 
KO at amyE.P330T; lanes 6 and 7: modified (6) and unmodified (7) colonies screened for the 
amyE KO at amyE.P636T; lanes 8 and 9: modified (8) and unmodified (9) colonies screened for 
the amyE KO at amyE.P1344T. Images of multiple agarose gels have been spliced together for 
the purpose of condensing the data presented. F) Enhanced multiplexing using editing template 
combination 1. ugtP and amyE were simultaneously mutated by transforming AW001-2 with 
pAW015-2, and the 1,000 bp HL ugtP (ugtP.P395T) and amyE (amyE.P636T) editing templates. 
Editing efficiency was evaluated as described for Panel A, and SD of experiments performed in 
triplicate are shown. G) Enhanced multiplexing using editing template combination 2. ugtP and 
amyE were simultaneously mutated by transforming AW001-2 with pAW015-2, and the 1,000 
bp HL ugtP (ugtP.P395T) editing template and pAW022-2 (amyE.P636T). Editing efficiency 
was evaluated in the same way as for editing template combination 1. SD of experiments 
performed in triplicate are shown. 
 
combination 1 resulted in an improved editing efficiency for both the amyE KO (45%) and the 
double KO (45%), although a substantial reduction was observed for the ugtP KO (46%; Figure 
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3.9F). On the other hand, using editing template combination 2 led to drastic improvements in 
editing efficiency for both the amyE KO (86%) and the double KO (85%), with a similarly high 
efficiency for the ugtP KO (85%; Figure 3.9G). The high multiplexing efficiency observed for 
editing template combination 2 was similar to reports of the double editing efficiency with 
ssDNA as an editing template (83%) [19], but somewhat lower compared to the editing with a 
dsDNA editing template [97%] [20] in E. coli. These results suggest that our CRISPR-Cas9 
toolkit can achieve high multiplexing efficiency in B. subtilis, even when challenging targets 
(such as amyE) are chosen. 
 
3.3.8 Extension of the CRISPR-Cas9 toolkit to transcriptional interference 
To exploit the full utility of the toolkit, we extended our existing CRISPR-Cas9 platform 
from genome editing to CRISPRi for transcriptional interference. The lacZ gene was used as a 
reporter to assess repression at the level of transcription and protein expression in AW016-2. To 
construct AW016-2, we began by transforming AW009 with pAW019-2, yielding strain 
AW014-2, which expresses xylose-inducible dCas9 from the lacA locus. AW014-2 was then 
transformed with pAW018-2, followed by auto-eviction of the CS cassette (Figure 3.4A), 
yielding strain AW015-2, in which a gRNA targeting lacZ.P28NT was transcribed from the 
wprA locus. Finally, IPTG-inducible lacZ was integrated into the ugtP locus of AW015-2 via 
transformation of pAW016, generating strain AW016-2. Cultures of AW016-2 in which dCas9 
expression was induced with xylose were compared with uninduced cultures to assess CRISPRi 
efficiency. Nearly 8-fold reduction in both lacZ  mRNA and β-galactosidase activity was 
observed in AW016-2 upon induction of dCas9 (Figure 3.10), demonstrating the efficacy of our 




Figure 3.10. Evaluation of CRISPRi-mediated repression of lacZ expression at the level of 
transcription and protein expression. AW016-2 was grown in LB supplemented with 85 µg/mL 
spectinomycin, 1 mM IPTG to induce lacZ expression, and 1.2% (w/v) xylose to induce dCas9 
expression (xylose+) or without xylose (xylose-). rpsJ, encoding the 30S ribosomal protein S10, 
served as an internal control for analysis of transcriptional repression via real-time qRT-PCR. β-
galactosidase activity was evaluated using the Miller assay to assess repression at the level of 
protein expression. Relative transcription (i.e. relative to transcription of rpsJ) and protein 
expression were normalized to the values obtained from cultures in which dCas9 expression was 
not induced (xylose-). SD of experiments performed in triplicate are shown. 
 
3.4 Discussion 
Recent advent of the CRISPR-Cas9 system has significantly increased the capacity for 
genome editing and transcriptional modulation in a selection of organisms [19, 21, 84, 88, 92, 
94]. B. subtilis shows considerable promise as an established industrial workhorse [24, 200], 
such that a CRISPR-Cas9 toolkit is essential to its progression towards full industrial utility. 
Traditional methods employed in B. subtilis such as auto-evicting counter-selectable markers and 
site-specific recombination suffer from low editing efficiency [13, 67] and/or limited capacity for 
multiplexing. Furthermore, existing technologies for transcriptional metering require extensive 
characterization or sequence modification prior to deployment, making their adoption 
cumbersome and time-consuming [95-99]. Here we propose an effective and scalable CRISPR-
Cas9 toolkit for comprehensive engineering of B. subtilis, including targeted single gene KO and 
KI, continuous genome editing, multiplexing and targeted transcriptional repression. We 
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employed chromosomal maintenance of CRISPR-Cas9 machinery for several reasons: i) 
Multicopy plasmids are potentially unstable, an issue that is of particular concern in B. subtilis 
[30-32]; ii) Multicopy plasmids can impose a fitness burden on the host, particularly when 
selection is required to maintain them; iii) CRISPR-Cas systems naturally exist in many bacteria, 
and presumably do not impede cell viability in this context; iv) The transformation efficiency of 
monomeric plasmids obtained from traditional cloning procedures is typically low in B. subtilis 
[8, 201]; and v) Plasmids must be cured from the engineered cell. 
For the development of the counter-selectable gRNA delivery vectors, we tested two 
promoters for inducible mazF expression, in addition to Pspac, whose leaky nature presumably 
resulted in low transformation efficiency in B. subtilis. The resulting vector (pAW003-2) based 
on the use of PxylA, Bm, a stronger and more tightly controlled promoter [189], was difficult to 
maintain in E. coli. The reduced viability of the E. coli strain carrying pAW003-2 could not be 
resolved, even by replacing mazF with mazE, encoding the antitoxin of MazF (MazE). On the 
other hand, the use of ParaE resulted in a vector (pAW004-2) that was stable in E. coli and 
effectively transformed into B. subtilis. The presence of the native CRE between ParaE and the 
ribosome binding site (RBS) of mazF provides additional regulation of transcription in the 
presence of glucose, and this feature is desirable given the strong dependence of toolkit 
performance on transformation efficiency (as subsequently discussed). To exploit the simplicity 
of the CRISPR-Cas9 system, we developed a gRNA transcription cassette using a modified 
version of the native promoter PxylA, i.e. PxylA.SphI+1, facilitating the construction of gRNA delivery 
vectors. The transcriptional start site (+1) of PxylA was determined to be 4-6 bp downstream of the 
-10 region [198], while that of the similar PxylA, Bm was found to be located 6 bp downstream of 
the -10 region [202]. Accordingly, a single mismatch at the 5’ end of the gRNA (i.e. the 6th bp of 
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the SphI restriction site; Figure 3.1A) appears to have a negligible effect on Cas9 targeting given 
high editing efficiencies and transcriptional repression observed in general. 
As the CRISPR-Cas9 mechanism involves at least two simultaneous recombination 
events [i.e. integration of gRNA(s) and editing template(s)], effective transformation becomes 
critical. Our enhanced competence protocol significantly improved DNA transformation into B. 
subtilis, leading to high editing efficiencies with our CRISPR-Cas9 toolkit. Using the improved 
protocol, the transformation efficiency for the ugtP KO with the 1,000 bp HL editing template 
(8.87 × 103 CFU µg-1 editing template; Figure 3.9C) exceeds that of a recent report of enhanced 
transformation efficiency of individual dsDNA PCR products (~4.0 × 103 CFU µg-1 dsDNA) and 
is similar to efficiency reported for linearized plasmid (~1.0 × 104 CFU µg-1 plasmid) via 
induction of the master competence regulator ComK [186]. Our toolkit also provided high 
editing efficiencies for both a multi-gene KI and a single-gene KO over sequential rounds of 
editing using the counter-selectable marker mazF. While our toolkit is not necessarily a 
convenient option to replace existing technologies for single KIs and KOs, it is more efficient for 
continuous genome engineering in B. subtilis. Using successive knock-outs as an example, this 
procedure would entail two rounds of restriction/ligation cloning to replace the HLs of an 
existing vector, or using an advanced cloning technique (e.g. Gibson assembly) to fuse various 
DNA fragments, (i.e. the plasmid backbone, the 5’-HL, the selection and counter-selection 
markers, and the 3’-HL). These methods are either time consuming or resulting in unwanted 
mutations. The situation becomes more complicated for conventional cloning when mutations 
are introduced into the targeted ORF. This will require that either 1) the DRs of the integration 
vector be redesigned such that the single-crossover event between them needed to excise the 
selection and counter-selection markers results in the introduction of the desired mutation, or 2) 
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an editing template be designed to replace the selection and counter-selection markers with the 
desired mutation. Another option would be to construct an integration cassette using multiple 
rounds of SOE-PCR, which can be unreliable due to large DNA sizes [203]. On the other hand, 
our toolkit requires only a single restriction/ligation step to insert the new gRNA (102 bp) into 
the gRNA delivery vector, and a single round of SOE-PCR to generate the editing template 
(which can be as small as 1 kb). Furthermore, our toolkit requires no additional effort to 
introduce specific mutations, beyond designing the mutation region of the editing template to 
introduce the desired mutation, and, if necessary, an additional silent mutation to remove the 
PAM site [94].  
The improved editing efficiency observed for the ugtP KO compared to the KI of the HA 
operon (Figure 3.7C) was expected given that increasing insertion size has been shown to 
correlate with decreasing editing efficiency in CRISPR-Cas9 systems [19, 86]. Moreover, the 
reduced recombination frequency of the HA operon KI cassette could have been exacerbated by 
an excessive metabolic burden associated with HA synthesis, which is an energy and carbon 
intensive process directly competing with central metabolism and cell wall synthesis [5]. This 
conclusion was supported by our observation of a few transformants with the KI of the HA 
operon but showing no mucoid phenotype, implying that expression of functional seHas and/or 
tuaD can be inactivated. In addition to the expected reduction in recombination frequency 
associated with large insertions, recombination may occur less effectively at certain genomic 
loci. Considering that the number of escapers were similar between the KI of the HA operon (at 
amyE.P636T), the ugtP KO and the single amyE KOs (except at amyE.P1344T), discrepancies in 
transformation and editing efficiencies at the amyE and ugtP loci (Figures 3.7C, 3.8B and 3.8D) 
could have been influenced by different recombination frequencies at these sites. Interestingly, 
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our KI efficiency for the 2,909 bp HA operon (69%) exceeds that reported for a 3,000 bp 
CRISPR-Cas9-mediated insertion in E. coli [59%] [19]. This comparison corroborates the 
efficacy of our toolkit for large chromosomal insertions given the insertion location of amyE 
appears to be a difficult recombination site and the inserted operon imparts a significant 
metabolic burden on the host. Finally, chromosomal expression of Cas9 appeared to have a 
minimal effect on cell viability given that the specific growth rates and final cell densities were 
similar between 1A751 and AW001-2 (data not shown), and Cas9 was stably maintained in the 
chromosome across three sequential rounds of editing. 
The low efficiency of the initial multiplexing trial (36%) suggests that amyE is a difficult 
recombination target. As previously discussed, the similar number of escapers observed when 
targeting amyE and ugtP suggests that CRISPR-Cas9-mediated cleavage was not the limiting 
factor for the low amyE editing efficiency. Various factors limiting the editing efficiency were 
systematically evaluated to enhance the performance of our toolkit when targeting difficult sites. 
Our results for the ugtP KO (Figure 3.9C) support the previous conclusion that 400-500 bp HLs 
are sufficient to achieve an acceptable transformation efficiency of linear DNA in B. subtilis 
[15]. Decline in transformation efficiency for increasing homology beyond an optimal length has 
been reported elsewhere [204], and was attributed to the reduced number of plasmids 
transformed at larger HLs (based on an equivalent quantity of DNA per transformation). A stark 
decline in CRISPR-Cas9 editing efficiency in S. cerevisiae was also observed upon increasing 
the editing template HL from 50 to 60 bp, and sequence-specific features of the longer editing 
template causing premature termination of the hybrid editing template-crRNA transcript were the 
proposed cause [22].  
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Targeting amyE.P25NT, amyE.P330T and amyE.P636T resulted in comparable 
transformation and editing efficiencies, with amyE.P636T being targeted most effectively 
(Figure 3.9D). Small discrepancies in the number of escapers were observed, suggesting that 
Cas9 accessibility to the amyE locus was not limiting the editing efficiency. On the other hand, it 
has been perceived that certain PAM sites are less susceptible to CRISPR-Cas9-mediated DSBs 
since the editing efficiency can vary substantially between PAM sites in a single gene [22]. The 
poor editing efficiency when targeting amyE.P1344T supports this theory, although gRNA 
sequence characteristics can also affect targeting efficacy [196]. With the critical design 
parameters (except targeting strand for which minimal bias appears to exist) in mind [196], the 
underlying problem in gRNA design may be associated with potential secondary structures 
formed in vivo. Several secondary structures are generally possible for each gRNA sequence 
such that unwanted secondary structures may form, reducing the binding capacity (or frequency 
of binding) of Cas9 to the gRNA.  
The multiplexing efficiency of our toolkit reached 85% through optimization of various 
editing template parameters and PAM sites (Figure 3.9G). A high multiplexing efficiency (up to 
97%) was reported for the double KO of maeA and maeB in E. coli, although the multiplexing 
capacity was limited by the inclusion of gRNA transcription cassettes and editing templates in a 
single plasmid [20]. A CRISPR-Cas9 system recently developed for S. cerevisiae provided a 
high multiplexing efficiency for three targets (up to 87%), however, a long period of cultivation 
after transformation was required, significantly increasing the duration of a single round of 
editing [22]. In contrast to these systems and other improved methods for use in E. coli [19] and 
S. cerevisiae [21], our toolkit provides comparably high multiplexing efficiencies via CRISPR-
Cas9 elements maintained in the chromosome. Our approach is more similar to the chromosomal 
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arrangement of CRISPR-Cas systems in native hosts, and takes advantage of the simplicity of the 
gRNA for Cas9 targeting.  
The extension of our toolkit to CRISPRi provides an effective strategy for transcriptional 
modulation in B. subtilis. We demonstrate that expressing dCas9 and transcribing gRNAs 
chromosomally is sufficient to achieve efficient transcriptional repression in B. subtilis, which is 
likely the case in E. coli and many other bacterial species [197]. This is an attractive aspect of 
our approach due to potential plasmid instability [30-32], which is a greater concern when 
applying CRISPRi as dCas9 and gRNA transcription cassettes must be stably maintained in the 
cell. The extent of repression achieved with our toolkit is comparable to that obtained with 
existing asRNA protocols. Repression levels as high as 90% were obtained using an asRNA 
targeting buk mRNA (encoding the butyrate kinase) in Clostridium acetobutylicum [98]. 
However, significant repression of the acetate kinase (encoded by ack) was observed in the same 
strain, owing to the large degree of homology between buk and ack, demonstrating the potential 
for off target effects when applying asRNA strategies. Similar repression of DsRed2 expression 
was observed in E. coli using an asRNA containing an Hfq-recruiting scaffold to enhance 
hybridization, although the assessment of multiple scaffold sequences from endogenous asRNAs 
was necessary to achieve maximum repression [96]. Higher repression levels (>98%) were 
obtained in E. coli with 5’-cis sequences inserted upstream of the RBS (to which the sequences 
were complementary) of a green fluorescent protein, blocking recognition of the RBS by the 30S 
ribosomal subunit via a stem-loop structure [95]. Repression could be deactivated with a trans-
activating RNA, although application of this strategy requires upstream sequence modification of 
the target gene, making it tedious to apply, particularly for multiplexing. A significant level of 
repression of β-galactosidase expression via CRISPRi was reported in E. coli, in which dCas9 
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and a lacZ-targeting gRNA were maintained in plasmids [23]. In the same study, up to 300-fold 
repression of expression of a monomeric red fluorescent protein (mRFP) was observed, which is 
similar to the CRISPR-dCas9-mediated RFP repression levels achieved in Corynebacterium 
glutamicum [182]. The differences in repression efficiency observed between β-galactosidase 
and RFP suggests that certain targets may be more susceptible to CRISPRi. Varying degrees of 
repression between different targets has also been observed in mycobacteria when applying 
CRISPRi, although the differences were less dramatic [183]. To allow targeting of multiple 
genes for multiplexing or targeting multiple sites in the same gene for enhanced repression, a 
multi-gRNA delivery vector was also constructed to enable auto-eviction of the ParaE::mazF-
SpcR cassette, while the multi-gRNA array is retained in the chromosome, using the same 
approach as outlined for pAW014-2 (Figure 3.2). Finally, the repression level can be adjusted by 
tuning gRNA design parameters established previously [23], rather than adjusting xylose 
concentration for inducing dCas9 expression [197]. For example, mismatches introduced in bp 8-
12 of the protospacer (relative to the 3’ end) cause a dramatic reduction in repression, while 
mismatches in bp 13-20 have a less significant effect on repression efficiency [the first 7 bp of 
the protospacer should not be altered] [23]. Moreover, the repression level is inversely 









Chapter 4  




HA is naturally synthesized by certain pathogenic strains of bacteria, such as Lancefield 
group A [107] and C [108] streptococci, and Type A P. multocida [109], as a means of evading 
the host immune response [111]. HAS autonomously synthesizes HA from UDP-GlcNAc and 
UDP-GlcUA, and is classified as either a Class I or II HAS based on topology (i.e. 
transmembrane and peripheral membrane proteins for Class I and II HAS, respectively) and the 
number of glycosyltransferase 2 family modules present (i.e. one and two modules for Class I 
and II HAS, respectively). The relatively small size and few transmembrane domains of 
streptococcal HAS suggest that they cannot facilitate pore formation for translocation of the 
growing HA chain [115]. This theory was supported by the observation that mutation of a 
component of an ABC transporter complex reduced HA capsule size in S. pyogenes, suggesting 
that additional proteins may assist translocation [116]. However, recent work showed that 
SeHAS could mediate the release of the small fluorescent dye Cascade Blue from inside 
liposomes, and that mutations, which decreased HAS activity and HA MW in an earlier study, in 
one of its transmembrane domains resulted in reduced Cascade Blue efflux [117, 205]. Similarly, 
purified SeHAS, reconstituted into E. coli-derived or synthetic proteoliposomes, synthesized and 
translocated high MW HA into the vesicle lumen, requiring only exogenous UDP-GlcUA and 
UDP-GlcNAc [118]. These observations, along with the demonstration of HA production in a 
variety of bacteria heterologously expressing HAS [5, 6, 131, 133], indicate that a single HAS 
81 
 
protein produces HA autonomously via a process requiring as many as seven different functions 
to initiate and elongate the HA chain, and extrude it across the membrane [115].  
CL is the least abundant phospholipid present in the membrane of growing B. subtilis 
cells as a dimer of the essential and abundant anionic phospholipid phosphatidylglycerol (PG) 
[206, 207]. PG is synthesized from cytosine diphosphate (CDP)-diacylglycerol by 
phosphatidylglycerophosphate synthase (PgsA; encoded by pgsA), and CL is subsequently 
produced from PG by the major CL synthase (ClsA; encoded by clsA) [206]. ClsA localizes at 
the septal region of the B. subtilis membrane in a FtsZ-dependent manner (Note that FtsZ 
initiates cell division.), presumably to assist in the assembly of the cell division machinery [208]. 
FtsZ depletion potentially results in dispersion of ClsA along the lateral membrane and, in turn, 
spatially coupled dispersion of CL [209]. The dependence of Class I HAS activity on its 
orientation with CL was first observed when the activity of the solubilized HAS of S. pyogenes 
(SpHAS) was recovered upon treatment with CL [120]. Active SpHAS and SeHAS were 
observed to be ~23 kDa larger than the purified enzymes, both of which were inactive [119]. 
Furthermore, the activity of purified SpHAS was not significantly enhanced by other lipids in 
vitro, and although the in vitro activity of purified SeHAS was stimulated by phosphatidic acid 
(PA) and phosphatidylserine, CL provided the greatest enhancements to SeHAS activity [121]. 
Therefore, it was proposed that ~16 CL molecules interact with a single SpHAS or SeHAS 
protein, and that loss of even a single molecule can cause enzyme inactivation. Accordingly, CL 
may assist HAS in creating an internal pore-like passage for HA translocation [119], which is 
similar to the function of CL proposed for several mitochondrial membrane proteins that lack 
transport capability in its absence [210]. In addition, interactions between CL and HA may add 
to the net retention force that keeps the HA-UDP/HAS complex together during polymerization 
until a sufficient opposing [release] force exceeds the net retention force, resulting in the release 
(and cessation of growth) of the growing HA chain [121, 211].   
82 
 
While membrane engineering for enhanced biological production is a challenging 
strategy with increasing applications in bacteria [29, 212], the approach is unpopular for B. 
subtilis. A documented study focused on the alteration of the lipid composition of the B. subtilis 
membrane, leading to enhanced secretion of the industrially important enzyme α-amylase [213]. 
Mutation of clsA or pssA, encoding phosphatidylserine synthase (PssA), significantly increased 
extracellular amylase production, presumably through creating a more negative membrane 
charge density [213]. In this study, we engineered the cell membrane of an HA-producing strain 
of B. subtilis to increase the functional expression of heterologously expressed SeHAS and, in 
turn, improve HA production. The membrane CL content was increased by overexpressing pgsA 
and clsA, resulting in significant improvements to the HA titer and MW. To further enhance the 
functional expression of SeHAS, we then altered the distribution of CL in the membrane by 
reducing the expression of ftsZ via CRISPRi using our recently developed CRISPR-Cas9 toolkit 
for B. subtilis [214]. The reduced ftsZ expression led to partial redistribution of CL along the 
lateral membrane and, as a result, improved HA titers and MWs in shake flask cultures. We also 
assessed the efficacy of increasing dCas9 expression to modulate targeted gene expression. The 
results of this study have shed new light on the lipid dependence for functional expression of 
streptococcal Class I HAS in B. subtilis.  
 
4.2 Materials and Methods 
4.2.1 Bacterial strains, primers and plasmids 
The B. subtilis strains used in this study are listed in Table S4.1. E. coli HI-Control™ 
10G chemically competent cells were prepared to be electrocompetent as described previously 
[187] and used as host for molecular cloning and plasmid construction. B. subtilis and E. coli 
strains were maintained as glycerol stocks stored at -80 °C. Primers (Table S4.1) were 




4.2.2 Plasmid construction and transformation 
DNA manipulation was performed using standard molecular cloning techniques [187], 
and DNA sequencing was conducted by The Centre for Applied Genomics. To construct an 
expression cassette in which pgsA and clsA were driven by the strong promoter Pgrac, pgsA and 
clsA were amplified with respective primers P4.122/P4.123 and P4.124/P4.125 from 1A751 
gDNA, and the two fragments were spliced. The spliced fragment was then inserted into 
BamHI/SpeI-digested pAW005, yielding pAW001-4. pAW005 is a pHT01 [215] derivative 
containing a multiple cloning site (MCS) comprised of BamHI-AatII-SbfI-AscI and SpeI-
NgoMIV-NotI-AsiSI-AgeI-XmaI restriction sites flanking promoter Pgrac.max, a modified version 
of Pgrac (i.e. promoter P01) [40]. The MCS was synthesized by Bio Basic (Ontario, Canada) and 
the sequence is provided in Table S4.1. Pgrac.max contains the upstream promoter element (UP) of 
promoter P64, the -35 region of promoter P71, the -15 region of promoter P57, the native -10 
region, and a T-C substitution at the +3 site [40]. pAW005 was constructed by amplifying the 
synthesized MCS with primers P4.126/P4.127, followed by insertion into BamHI/XmaI-digested 
pHT01. The Pgrac::pgsA:clsA cassette, including the partial MCS and trpA terminator from E. 
coli, was amplified with primers P4.128/P4.129 from pAW001-4, and the thrC 5’- homology 
length (HL-5’) was amplified with primers P4.130/P4.131 from 1A751 gDNA, and the two 
fragments were spliced, generating a thrC HL-5’-Pgrac::pgsA:clsA cassette. This cassette was 
inserted into SbfI/NheI-digested pAW004-2 [214], yielding pAW002-4. Plasmid pAW003-4 is 
similar to pAW002-4 but contains promoter Pgrac.UPmod, i.e. promoter P61 which is a weaker 
derivative of promoter Pgrac, in place of promoter Pgrac. It was constructed from pAW001-4 in the 
same way as pAW002-4, except that primers P4.132 and P4.133 were used in place of primers 
P4.128 and P4.131, respectively. The gRNA cassettes ftsZ-gRNA.P79NT, ftsZ-
gRNA.P79NT(10A-G), ftsZ-gRNA.P79NT(15C-U), ftsZ-gRNA.P244NT, ftsZ-
84 
 
gRNA.P244NT(15C-A), and ftsZ-gRNA.P533NT were amplified with respective forward 
primers P4.134-P4.139 and a common reverse primer P4.32 from pgRNA-bacteria [23], and 
inserted into SphI/NcoI-digested pAW017-2 [214] to obtain respective gRNA delivery vectors 
pAW004-4, pAW005-4, pAW006-4, pAW007-4, pAW008-4, and pAW009-4. All gRNA 
delivery vectors were linearized with SacI prior to transformation. To construct the integration 
vector for mutation of pssA, the pssA HL-5’ and HL-3’ were amplified from 1A751 gDNA with 
respective primers P4.140/P4.141 and P4.142/P4.143, followed by sequential insertion in place 
of the corresponding thrC HL-5’ and HL-3’ of pAW004-2 using the respective SbfI/NheI and 
AscI/AgeI restriction sites, yielding pAW010-4. pAW011-4, an integration vector for mutation 
of ugtP, was constructed in the same way as pAW010-4, except the ugtP HL-5’ and HL-3’ were 
amplified with primers P4.144/P4.145 and P4.146/P4.147. Competent cell preparation and 
transformation, and eviction of the ParaE::mazF-Spc
R cassette after transformation of counter-
selectable integration vectors were performed as previously described [214]. 
 
4.2.3 HA production, purification and analysis 
HA production medium and seed culture preparation have been described previously (see 
section 3.2.4) [214], with some modifications. An overnight culture was used to inoculate flasks 
containing 25 mL prewarmed nonselect cultivation medium (20 g/L glucose) to an initial cell 
density of ~ 0.1 OD600. Purification of HA and analysis of HA titer and MW were also 
performed as previously outlined (see section 3.2.4) [214]. 
 
4.2.4 Fluorescence microscopy 
B. subtilis strains were grown to mid-exponential growth phase prior to the addition of 
10-N-nonyl-acridine orange (NAO; ThermoFisher Scientific; Massachusetts, USA) in semi-
defined medium with the following composition: (NH4)2SO4, 0.83 g/L; K2HPO4, 5.82 g/L; 
85 
 
KH2PO4, 2.5 g/L; trisodium citrate dihydrate, 417 mg/L; glucose, 4.17 g/L; MgSO4∙7H2O, 151 
mg/L; yeast extract, 1.67 g/L; casamino acids, 208 mg/L; Arg, 7.5 g/L; His, 383 mg/L; Trp, 48 
mg/L. B. subtilis strains were plated on non-select lysogeny broth (LB) agar containing 5 g/L 
NaCl, 5 g/L yeast extract, 10 g/L tryptone, and 15 g/L agar, and incubated overnight at 37 °C. 
Pre-warmed medium (24 mL) was inoculated with cell patches from the overnight plate to OD600 
0.1-0.2, and cultured cells were grown to OD600 0.3-0.5, at which time NAO was added to a final 
concentration of 1 µM. Cultures containing NAO were incubated in the dark at room temperature 
and 260 rpm for 25 min. The stained cells were then washed once in phosphate buffered saline 
(PBS; NaCl, 8 g/L; KCl, 0.2 g/L; Na2HPO4, 1.44 g/L; KH2PO4, 0.24 g/L) and resuspended in 
ProLong™ Live Antifade Reagent (ThermoFisher Scientific; Massachusetts, USA) diluted 25-
fold from the stock concentration. The stained cells were then mounted on object slides covered 
with agarose pads (1% wt/v in PBS). Fluorescence images were viewed using an Axio Imager 
D1 microscope and an AxioCam MRm camera (Carl Zeiss; Oberkochen, Germany). Green and 
red fluorescence from NAO was detected using standard filters, and exposure times were 
automatically set to less than 0.8 s. Captured images were processed using ImageJ [193]. 
 
4.3 Results 
4.3.1 Derivation of HA-producing strains of B. subtilis 
Significant HA production can be achieved in strains of B. subtilis coexpressing only 
HAS and TuaD  [5, 128, 216], for which the expression is repressed in the presence of excess 
phosphate [127]. Accordingly, an HA-producing control strain was constructed by transforming 
B. subtilis 168 with NdeI-linearized pAW008 [214], a vector previously constructed for the 
integration of a Pgrac::seHas:tuaD cassette at the amyE locus (Figure 4.1), yielding strain AW006 
with a prominent mucoid phenotype characteristic of HA production in B. subtilis [5]. However, 
for unknown reasons, AW006 formed a segregated population with the majority of cells being 
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reverted to the wild-type phenotype upon strain revival. Such genetic instability was also an 
issue for AW007, an HA-producing 1A786 derivative constructed in the same manner as 
AW006. Consequently, 1A751 was selected as the production host due to its superior genetic 
stability based on the persistence of the mucoid phenotype of the HA-producing strain AW008, 
i.e. 1A751 transformed with NdeI-linearized pAW008. We then assessed HA production in 
shake flask cultures of AW008 as the control for comparison with other mutants. The cell density 
and HA titer reached OD600 4.2 (Figure 4.2A) and 0.48 g/L (Figure 4.2B), respectively, after 10 
h, while the MW peaked at 1.95 MDa at 8 h (Figure 4.2C). Decreasing MW with prolonged 
cultivation time has been reported for HA-producing strains of B. subtilis [5, 214], and, 
therefore, the cultivations were terminated at 10 h in light of declining MW. The HA titer 
compared favorably to a previous report of a similar HA-producing strain of B. subtilis [128], as 
did the peak MW [5, 216]. In each case, B. subtilis 168 or its derivatives were used to coexpress 
SeHAS or SzHAS, and TuaD [5, 128, 216]. The improved culture performance of AW008 
relative to similar HA-producing B. subtilis mutants may result, in part, from the promoter 
driving expression of SeHAS and TuaD. Specifically, the grac promoter (Pgrac) was reported to 
be 30 times stronger than the commonly employed promoter PxylA, Bm [40], which was used to 
drive the expression of SzHAS in the aforementioned study [216]. Medium composition may 
also be related to culture performance as minimal medium was used for HA production in some 
studies [5, 128], resulting in lower MWs compared to cultivation in complex medium based on 
our observations (data not published). 
 
4.3.2 Increased membrane CL content enhances HA production 
Given the dependence of HAS activity on its orientation with CL in the membrane, we 
sought to assess the effects of increased membrane CL content on HA production. Accordingly, 




Figure 4.1. Genomic engineering strategies to enhance HA production in B. subtilis. The 
combined Pgrac::seHas:tuaD-Neo
R (HA*) cassette was integrated into the amyE locus of 1A751 
via transformation with pAW008, yielding strain AW008, which synthesizes HA. AW008 was 
then transformed with pAW002-4, resulting in integration of the Pgrac::pgsA:clsA (CL
ǂ) cassette, 
and the combined ParaE::mazF-Spc
R (CS) cassette, at the thrC locus (the resulting mutant was 
spectinomycin resistant and arabinose sensitive). The CS cassette was subsequently auto-evicted 
via single-crossover recombination between the flanking direct repeats (black rectangles), 
yielding strain AW001-4 (spectinomycin sensitive and arabinose resistant), which overproduces 
CL. To generate strains in which expression of ftsZ was repressed, AW008 was first transformed 
with pAW019-2, resulting in integration of the combined PxylA, Bm::dcas9-Erm
R (dCas9+) cassette 
at the lacA locus, yielding strain AW002-4, which expresses xylose-inducible dCas9. AW002-4 
was then transformed with either pAW002-4 or pAW003-4, resulting in integration of the 
Pgrac::pgsA:clsA and Pgrac.UPmod::pgsA:clsA (CL
ǂ) cassettes, respectively, and the CS cassette, at 
the thrC locus. The CS cassettes were subsequently auto-evicted, yielding respective strains 
AW003-4 and AW007-4, which both overproduce CL (AW003-4 produces more CL than 
AW007-4). AW003-4 was then transformed with pAW006-4, resulting in integration of the 
PxylA.SphI+1::ftsZ-gRNA.P79NT(15C-U) (gRNA
ǂ) cassette, and the CS cassette, at the wprA locus. 
The CS cassette was subsequently auto-evicted, yielding strain AW004-4, which transcribes ftsZ-
gRNA.P79NT(15C-U). AW007-4 was transformed with either pAW006-4, pAW007-4, 
pAW008-4, or pAW009-4, resulting in integration of the PxylA.SphI+1::ftsZ-gRNA.P79NT(15C-U), 
PxylA.SphI+1::ftsZ-gRNA.P244NT, PxylA.SphI+1::ftsZ-gRNA.P244NT(15C-A), and PxylA.SphI+1::ftsZ-
gRNA.P533NT (gRNAǂ) cassettes, respectively, and the CS cassette, at the wprA locus. The CS 
cassettes were subsequently auto-evicted, yielding respective strains AW008-4, AW009-4, 
AW010-4, and AW011-4, which transcribe ftsZ-gRNA.P79NT(15C-U), ftsZ-gRNA.P244NT, 
ftsZ-gRNA.P244NT(15C-A), and ftsZ-gRNA.P533NT, respectively. The gRNAs direct dCas9 to 
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the target (i.e. ftsZ) based on the presence of a PAM site and adjacent seed region 
complementary to the protospacer, and the dCas9-gRNA complex remains bound to the target, 
partially blocking transcription of ftsZ by RNA polymerase (RNAP). §The dCas9+ cassette was 
chromosomally integrated prior to the CLǂ cassette in strains in which ftsZ expression was 
repressed. 
 
constructed by transforming AW008 with SacI-linearized pAW002-4, resulting in strain 
AW001-4, which constitutively expressed pgsA and clsA (regulated by promoter Pgrac) from the 
thrC locus (Figure 4.1). Compared to the control strain AW008, the HA titer increased by 32%  
 (0.63 g/L) for strain AW001-4 after 10 h of cultivation (Figure 4.2B). Moreover, the peak MW 
was higher (2.06 MDa) and declined to a lesser extent between 8 and 10 h of cultivation (Figure 
4.2C), such that the MW of HA produced in cultures of AW001-4 after 10 h was comparable to 
the peak MW in cultures of AW008. An 83% increase in the final cell density, i.e. OD600 7.7 for 
AW001-4 vs. 4.2 for AW008 (Figure 4.2A), was also observed, and the improved cell growth 
may partially explain the increased HA titer in cultures of AW001-4. We qualitatively assessed 
the CL levels in the membranes of our engineered strains using the CL-specific fluorescent dye 
NAO [208, 209]. Binding of NAO to CL results in the dimerization of NAO monomers, causing 
a shift in the emitted fluorescence peak of the monomer from green (at 525 nm) to red (at 640 
nm) due to the metachromatic effect [208]. Red fluorescence was observed to co-localize with 
green fluorescence at the poles and septa of all strains analyzed, as exemplified in Figures 4.3A-
C, in which green (Figure 4.3A) and red (Figure 4.3B) fluorescence emitted from NAO-stained 
AW008 co-localized in Figure 4.3C (i.e. an image generated by merging Figures 4.3A and 4.3B).  
The increased amount of CL in the membrane of AW001-4 was clearly visible (Figure 4.3D) 
based on the significantly higher fluorescence observed at the poles and septa of the cells, 




Figure 4.2. Time profiles of A) cell density, B) HA titer, and C) HA MW in cultures of AW008, 
AW001-4, AW004-4, and AW005-4. SD of experiments performed in triplicate are shown in 
Panels A and B, and SD of duplicate samples are shown in Panel C. 
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4.3.3 Redistributing CL in the membrane further enhances HA production 
The localization of CL at the poles and septal regions of the B. subtilis cell membrane 
during exponential growth presumably facilitates cell division through the formation of non-
bilayer structures in the presence of divalent cations, such as Ca2+ or Mg2+ [208, 210]. Given that 
SeHAS is a foreign protein to B. subtilis with no known homologue, it should not interact with  
other cellular machinery that may restrict its localization and distribution in the membrane. Also, 
as the intended function of Class I HAS in streptococci is to encapsulate the entire cell to prevent 
recognition by the host immune response [122], SeHAS may be distributed throughout the 
membrane of B. subtilis. We hypothesized that a narrow distribution of CL in the B. subtilis cell 
membrane could reduce its interaction with SeHAS, such that altering the distribution of CL may 
increase its availability to SeHAS, thereby enhancing the functional expression of the enzyme. 
Accordingly, we sought to tune the expression of ftsZ to redistribute CL along the lateral 
membrane in AW001-4. Recently, we developed a CRISPR-Cas9 toolkit enabling both genome 
editing and transcriptional interference in B. subtilis [214]. To apply CRISPRi for the purpose of 
modulating ftsZ expression, AW008 was transformed with BseYI-linearized pAW019-2 [214],  
yielding strain AW002-4 in which xylose-inducible dCas9 was expressed from the lacA locus 
(Figure 4.1). AW002-4 was subsequently transformed with SacI-linearized pAW002-4, 
generating strain AW003-4 which is a CL-overproducing strain suitable for evaluation of various 
gRNAs targeting ftsZ. Six ftsZ-targeting gRNAs were designed to cover the range of relative 
repression efficiency by manipulating gRNA design parameters previously described [23, 197]. 
Mismatches introduced in base pairs (bp) 8-12 of the protospacer (relative to the 3’-end) cause a 
dramatic reduction in repression efficiency, while mismatches in bp 13-20 have a reduced effect 
on repression efficiency (Note that the first 7 bp should not be altered.) [23, 197]. Moreover, 
repression levels are roughly inversely proportional to the distance between the selected PAM 
site and the start codon of the target ORF [23, 197]. We chose PAM sites P79NT, P244NT, and 
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P533NT, which correspond to relative distances of 0.06, 0.21, and 0.46, respectively, from the 
start codon (Note that the first bp of the start codon and last bp of the stop codon correspond to 
relative distances of 0 and 1, respectively.). Based on proximity to the start codon alone, the 
relative repression efficiency afforded by targeting PAM sites P79NT, P244NT, and P533NT 
were estimated to be 1, 0.8, and 0.4, respectively [23]. Mismatches were introduced in the 
protospacer at position 10 and 15 to further reduce the relative repression efficiency by ~75% 
and ~30%, respectively. We assumed that the effects of PAM site selection and mismatches 
introduced in the protospacer were multiplicative when estimating the overall relative repression 
efficiency. For example, the relative repression efficiency of ftsZ expression resulting from 
transcription of ftsZ-gRNA.P244NT(15C-A) was estimated to be 0.8 × 0.7 = 0.56. Table 4.1 
summarizes various ftsZ-targeting gRNAs with their corresponding protospacer sequence and 
estimated relative repression efficiency.  
 
Table 4.1. ftsZ-targeting gRNAs and their respective protospacer sequence and estimated 
relative repression efficiency 
gRNA protospacer sequence^ 
Relative repression 
efficiency 
ftsZ-gRNA.P79NT ATTTTCAATCATTCGGTTAA 1 
ftsZ-gRNA.P79NT(10A-G) ATTTTCAATCGTTCGGTTAA 0.25 
ftsZ-gRNA.P79NT(15C-U) ATTTTTAATCATTCGGTTAA 0.7 
ftsZ-gRNA.P244NT CTGCTCTTTGCTTTCTTCAG 0.8 
ftsZ-gRNA.P244NT(15C-A) CTGCTATTTGCTTTCTTCAG 0.56 
ftsZ-gRNA.P533NT TCGCGGAATGCTTCAAGCAT 0.4 
^mismatches are underlined 
 
Of the six gRNA delivery vectors constructed, only pAW006-4, containing ftsZ-
gRNA.P79NT(15C-U), could be stably transformed into AW003-4 as the resulting strain 
AW004-4 maintained the mucoid phenotype upon revival from a glycerol stock. Interestingly, 
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AW004-4 produced 65% and 25% more HA than AW008 and AW001-4, respectively, after 10 h 
cultivation (0.79 g/L; Figure 4.2B), while the peak MW of 2.17 MDa obtained at 8 h was a 
moderate improvement relative to either strain (Figure 4.2C). However, the MW decreased 
substantially to 1.49 MDa after 10 h, resulting in a lower overall MW than AW008 or AW001-4. 
Note that the growth profile of AW004-4 was nearly identical to that of AW001-4, with the final  
cell density reaching OD600 7.8 (Figure 4.2A). Fluorescence microscopy revealed a moderate 
reduction in the fluorescence intensity of CL domains in the membrane of AW004-4 (Figure 
4.3E), compared to AW001-4 (Figure 4.3D), indicating that partial redistribution of CL along the 
lateral membrane of AW004-4 had occurred, presumably due to reduced ftsZ expression. 
Furthermore, a moderate degree of filamentation was observed for AW004-4 (Figure 4.3E).  
We then examined the effect of dCas9 expression on HA production using cultures of 
AW004-4 induced with xylose under different concentrations. No significant change in the HA 
titer, MW or cell growth was observed except at the highest xylose concentration of 1% wt/v, 
which resulted in decreases to the titer and cell density after 10 h (Figure 4.4). These 
observations may be explained by a visible increase in filamentation in cultures induced with 1% 
wt/v xylose, resulting in large aggregate formation in the flasks, skewing cell density 
measurements, and potentially disrupting the extracellular release of HA. The results suggest that 
tailoring transcriptional repression via CRISPRi by adjusting dCas9 expression may be 
ineffective [197], while manipulating the protospacer sequence and PAM site selection may 
provide more control over repression efficiency.  
 
4.3.4 Targeting ftsZ for CL redistribution is sensitive to CL or ClsA levels in the membrane  
To separate the effects of reduced ftsZ expression and increased membrane CL content on 
HA production as well as to determine if the poor transformability of gRNA delivery vectors 




Figure 4.3. Representative images of strains of B. subtilis stained with NAO obtained with 
fluorescence microscopy. Panels A and B display green and red fluorescence emitted by AW008, 
respectively, and Panels C (AW008), D (AW001-4), E (AW004-4), F (AW007-4), G (AW009-
4), H (AW010-4), and I (AW011-4) are merged images of green and red fluorescence emitted by 
respective strains. The single arrow indicates localization of CL at the septal region of the cell 
membrane, and the double arrows indicate localization of CL at the pole in Panel A. NAO was 
added to cultures during mid-exponential growth phase to a final concentration of 1 µM, 
followed by incubation in the dark at room temperature and 260 rpm for 25 min. Stained cells 
were then washed once in PBS and resuspended in ProLong™ Live Antifade Reagent diluted 25-





Figure 4.4. Time profiles of A) cell density, B) HA titer, and C) HA MW in cultures of AW004-





transformed with pAW006-4 and pAW007-4, which could not be transformed into AW003-4, 
yielding genetically stable strains AW005-4 and AW006-4, respectively. The observation that 
AW002-4, but not AW003-4, could be transformed with pAW007-4 suggests that the impact of 
reduced ftsZ expression on cell physiology was related with the level of CL (or ClsA) in the 
membrane. Accordingly, AW002-4 was transformed with SacI-linearized pAW003-4, generating 
strain AW007-4 containing a Pgrac.UPmod::pgsA:clsA cassette at the thrC locus (Figure 4.1). 
Promoter Pgrac.UPmod is a weaker derivative of promoter Pgrac with the relative promoter strength 
of ~0.5 [40], and fluorescence microscopy confirmed the reduced CL levels in the membrane of 
AW007-4 (Figure 4.3F), compared to AW001-4 (Figure 4.3D). AW007-4 was subsequently 
transformed with pAW006-4, pAW007-4, pAW008-4, and pAW009-4, yielding genetically 
stable strains AW008-4, AW009-4, AW010-4, and AW011-4, respectively, with the mucoid 
phenotype upon revival from glycerol stocks (Note that pAW004-4 and pAW005-4 could not be 
transformed into AW007-4.). The enhanced transformability of AW007-4 associated with gRNA 
delivery vectors containing ftsZ-targeting gRNAs confirmed that the sensitivity of strains of B. 
subtilis to reduced ftsZ expression was dependent on membrane CL (or ClsA) levels. Our results 
are consistent with the previous observation that the distribution of ClsA in the membrane is 
dependent on FtsZ or some other component(s) of the cell division machinery [209].  
Upon transformation of AW003-4 and AW007-4 with pAW006-4, distinct changes in 
morphology were observed for the resulting strains AW004-4 and AW008-4. AW004-4 formed 
small colonies surrounded by a clear HA capsule for which the thickness could be visually 
distinguished from the edge of the colony. As expected, the colonies had a stringy texture 
associated with cell filamentation resulting from reduced ftsZ expression [209]. On the other 
hand, AW008-4, with a lower CL level than AW004-4, formed large colonies and more 
resembled the parent strain, suggesting that the effects of repression of ftsZ expression on cell 
physiology are related to CL levels in the membrane. In addition, AW010-4 formed relatively 
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large colonies (though not as large as AW004-4) with a less stringy texture (but more stringy 
than AW008-4) compared to AW004-4. AW009-4 and AW011-4 formed very small translucent 
colonies for which the HA capsule could not be distinguished from the colony, as was the case 
for AW004-4, and the colonies had a more stringy texture than AW004-4. Fluorescence 
microscopy revealed a significant degree of CL redistribution along the lateral membrane of 
AW009-4 (Figure 4.3G) and AW011-4 (Figure 4.3I), while the membrane CL distribution in 
AW010-4 (Figure 4.3H) was less drastically altered. Similarly, extensive filamentation of 
AW009-4 (Figure 4.3G) and AW011-4 (Figure 4.3I) occurred, while AW010-4 (Figure 4.3H) 
retained a morphology similar to that of AW007-4 (Figure 4.3F). Based on the results of 
fluorescence microscopy, cell morphology, and the transformation efficiencies associated with 
various gRNA delivery vectors, the highest relative repression efficiency of ftsZ expression 
resulted from transcription of ftsZ-gRNA.P244NT, followed by ftsZ-gRNA.P533NT, ftsZ-
gRNA.P244NT(15C-A), and ftsZ-gRNA.P79NT(15C-U), in the order of declining repression 
efficiency.   
Mutants transcribing ftsZ-targeting gRNAs derived from AW002-4 (i.e. AW005-4) and 
AW007-4 (i.e. AW008-4, AW009-4, AW010-4, and AW011-4) were further evaluated for HA 
production in shake flask cultures. AW005-4 produced 204% and 85% more HA than AW008 
and AW004-4, respectively, with the titer reaching 1.46 g/L after 10 h (Figure 4.2B). While the 
peak MW was only 1.67 MDa after 8 h in cultures of AW005-4 (Figure 4.2C), the MW did not 
decline substantially afterwards, and was slightly higher than the MW of HA produced in 
cultures of AW004-4 after 10 h (Figure 4.2C). The culture performance of AW004-4 (Figures 
4.2A-C) and AW008-4 (Figures 4.5A-C) was similar, with the MW of HA and cell density of 
AW008-4 being slightly lower. Notably, AW011-4 produced 1.25 g/L of HA after only 8 h 





Figure 4.5. Time profiles of A) cell density, B) HA titer, and C) HA MW in cultures of AW008, 
AW007-4, AW008-4, and AW009-4, AW010-4, and AW011-4. SD of experiments performed in 




HA synthesis is an intricate process performed by Class I or II HAS, with the former 
being a relatively small integral membrane protein which requires precisely coordinated lipid 
molecules to autonomously polymerize and extrude the growing HA chain. Here, we have shown 
that engineering of the cell membrane can enhance heterologous HA production in B. subtilis  
expressing SeHAS. Given that the activity of streptococcal Class I HAS is restored upon 
reconstitution of the purified enzyme with CL in vitro [120, 121], it is plausible that the presence 
and distribution of CL in the cell membrane can critically affect HA synthesis and even 
secretion. However, the results of a prior study in S. pyogenes [217] and ours suggest that the 
lipid dependence of streptococcal Class I HAS in vitro may be less flexible than its lipid 
dependence in vivo.  
 Microbial cultivation has become the dominant method of industrial HA production in 
recent years [105]. Group C streptococci (e.g. S. zooepidemicus) are the most commonly 
employed production hosts, due to their capability to produce HA of MWs up to 5.9 MDa, with 
titers reaching 7 g/L [124, 218]. However, the production of exotoxins, poor growth 
characteristics and extensive nutritional requirements, and lack of genetic tractability [5, 219] 
prompted exploration of alternate microbial HA production platforms. L. lactis is a promising 
candidate for industrial HA production as it has been granted GRAS status, tools are available 
for its genetic manipulation, and it has produced HA titers of up to 1.8 g/L in batch cultivations 
[132]. While the nutritional requirements of L. lactis are simple, its slow growth rate can 
potentially result in higher biomanufacturing costs. High-level heterologous HA production has 
also been achieved in S. albulus, which can generate significant quantities of ATP required for 
the natural production of ε-poly-L-lysine [133]. As a result, an HA titer of 6.2 g/L was obtained 
in a fed-batch cultivation, which is comparable to that obtained in streptococcal cultivations. 
However, the application of S. albulus to biomanufacturing may be limited by slow growth, 
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relatively difficult genetic manipulation, problems expressing HAS, and lack of GRAS status 
[133]. Heterologous HA production has also been achieved with some success in the yeast 
Pichia pastoris [220]. While highly amenable to genetic manipulation and commonly employed 
for recombinant protein expression [221], P. pastoris grows slowly and its HA production 
capacity is poor compared to bacteria (up to 1.7 g/L HA produced after 48 h fed-batch 
cultivation) [220]. E. coli has also been used as a host for heterologous HA production, 
generating titers of up to 3.8 g/L with GlcNAc supplementation [6]. While E. coli is the preferred 
industrial bacterium for biomanufacturing for well-known reasons, its use is still hampered by 
endotoxin contamination of its products [222]. Of all the non-native hosts used for heterologous 
HA production to date, B. subtilis may show the most promise. We have obtained a HA titer of 
3.5 g/L in a 10 h batch cultivation of AW008 (data not shown), and fed-batch cultivation has led 
to titers exceeding 7 g/L [5]. High production capacity coupled with easy genetic manipulation, 
excellent growth on simple media, and GRAS status, make B. subtilis an ideal choice for 
industrial HA production. However, B. subtilis, like all other heterologous producers of HA 
investigated to date, produce lower MW HA than group C streptococci. Accordingly, improving 
the MW of heterologously produced HA is currently the major challenge to be addressed with 
advanced strain engineering strategies. 
The significant increase in the amount of CL in AW001-4 (Figure 4.3D), compared with 
AW008 (Figure 4.3C), was associated with the increased levels of pgsA and clsA. The relative 
membrane CL levels between AW001-4 (Figure 4.3D) and AW007-4 (Figure 4.3F) appeared to 
be less significant given that the strength of promoter Pgrac is only twice that of promoter 
Pgrac.UPmod [40]. On the other hand, the enhanced transformability of gRNA delivery vectors 
containing ftsZ-targeting gRNAs in AW007-4, compared to AW003-4, suggests that membrane 
CL levels may be significantly different between the two strains. Comparison of the culture 
performance of both AW001-4 and AW007-4 to AW008 shows that moderation of the 
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membrane CL content (based on the use of different promoters driving the expression of pgsA 
and clsA) may provide similar improvements to cell density, while resulting in a higher titer and 
lower MW of HA for AW007-4. This suggests that a higher amount of CL in the membrane may 
have increased the functional expression of SeHAS, although the increased CL synthesis may 
have simultaneously diminished the carbon flux available for HA production. The addition of CL 
to purified SeHAS or SpHAS resulted in the highest enzyme activity in vitro, compared to the 
addition of other lipids [120, 121], and exogenous CL was shown to enhance the activity of both 
enzymes in the membrane fractions of E. coli cells, suggesting that the ratio of CL to HAS was 
not high enough to maximize the activity of heterologously expressed HAS [119]. It was 
revealed that controlling chain length and polymerizing activity are independent functions of 
SeHAS that are not coupled to one another [211], although CL may play dual roles in chain 
elongation. CL may assist HAS in the formation of pores in the cell membrane through which 
the growing HA chain is translocated [119], and its interaction with HA may contribute to the net 
force required to retain the chain as it is extended . Accordingly, increased CL availability in the 
cell membrane of HA-producing B. subtilis could enable more of the total expressed enzyme per 
cell to achieve higher activity (i.e. higher polymerization rate) and improved functionality with 
regard to the retention and translocation of the growing HA chain, resulting in the improved 
functional expression of SeHAS. This may partially explain the improved culture performance of 
AW001-4, compared to AW008, although the lower specific HA titer (Figure 4.6) indicates that 
overproduction of CL competed with HA synthesis for glucose. This point is supported by the 
nearly identical specific HA titers in cultures of AW007-4 and AW008 (Figure 4.6), and the 
similar final cell densities observed in cultures of AW001-4 (Figure 4.2A) and AW007-4 (Figure 
4.5A), such that further increasing CL production in AW001-4, compared to AW007-4, reduced 
the HA titer without affecting biomass accumulation. Accordingly, optimizing the expression of 




Figure 4.6. Time profiles of the specific HA titer in cultures of AW008, AW001-4, AW004-4, 
AW005-4, AW007-4, AW008-4, and AW009-4, AW010-4, and AW011-4. SD of experiments 
performed in triplicate are shown. 
 
subtilis. Deletion of cls, encoding the sole CL synthase, in Streptococcus mutans significantly 
increased the doubling time and reduced the final cell density in acidic medium, relative to the 
parent strain, while growth characteristics were identical between both strains in neutral medium 
[223]. CL has also been implicated in the adaptive response of B. subtilis to conditions of high 
salinity [224]. The poor oxygen mass transfer and lack of pH control in shake flask cultures can 
result in their acidification as the culture progresses, such that the initial pH in our cultivations 
(i.e. pH 7) would have declined by the end of the cultivation. The enhanced cell growth in 
cultures of AW001-4, compared to AW008, suggests that increasing the amount of CL in the B. 
subtilis membrane may improve the acid-adaptive response. However, we observed that the 
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exponential growth rates of both AW008 and AW001-4 declined by ~30%, while the respective 
final cell densities increased and decreased by 10% and 24% in medium titrated to pH 6 (data not 
shown). Furthermore, AW001-4 did not grow, while the logarithmic growth rate and final cell 
density of AW008 did not change (although the length of the lag phase increased by 60%) as the 
initial pH of the medium was further reduced to 5.7. Accordingly, the improved growth of 
AW001-4, compared to AW008, does not appear to be related to an improved acid-adaptive 
response. Further investigation is required to elucidate the mechanism(s) through which cell 
physiology was improved upon increasing the membrane CL level. As HA is a growth-
associated product [225], the increased HA titers in cultures of CL-overproducing strains can be 
explained, in part, by their improved growth, which is evident from the similar specific HA titers 
observed in cultures of AW007-4 and AW008 (Figure 4.6). 
While higher cell densities were achieved in cultivation medium with strains in which 
expression of ftsZ was repressed, relative to AW008, the opposite behavior was observed for 
cultures with LB medium, i.e. the final cell density of overnight LB cultures of AW008 were 
higher in each case (data not shown). The improved growth of these strains in cultivation 
medium may have resulted from the presence of divalent metals, which have been shown to 
enhance self-assembly of high MW FtsZ oligomers in vitro [226]. Moreover, Z-ring formation is 
coupled to pyruvate levels via the E1α subunit of pyruvate dehydrogenase [227], such that 
cultivation medium containing glucose may enhance FtsZ polymerization relative to LB which 
lacks a preferred carbon source. The relatively small amount and narrow spatial distribution of 
CL in the cell membrane of B. subtilis may result in CL levels which are not sufficient to 
maximize the functional expression of SeHAS, which was observed in E. coli heterologously 
expressing streptococcal Class I HAS [119]. Note that CL localizes at the poles and septal 
regions of the cell membrane in both E. coli and B. subtilis [208, 228]. Thus, the functional 
expression of SeHAS may be improved by redistributing CL along the lateral membrane, which 
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may partially explain the increased MW and HA titers observed in cultures of certain strains in 
which expression of ftsZ is repressed. The redistribution of natural CL without carbon being 
siphoned away from HA production to accommodate CL overproduction, may partially explain 
the significantly improved HA titer obtained in cultures of AW005-4, relative to all other strains. 
However, the reduced peak MW of HA produced in cultures of AW005-4, compared to AW008, 
was unexpected, given that AW004-4 and strains derived from AW007-4 in which ftsZ 
expression was repressed, produced HA of an equivalent or higher peak MW compared to their 
respective parent strains. Moreover, the significantly increased specific HA titer in cultures of 
AW005-4, compared to AW008 (Figure 4.6), may indicate that more glucose was available for 
HA synthesis due to the reduced expression of FtsZ. Taken together, the increased specific HA 
titer and reduction in MW in cultures of AW005-4, compared to AW008, suggest that improved 
carbon flux through the HA biosynthetic pathway, rather than the enhanced functional 
expression of SeHAS, had a greater impact on the culture performance of AW005-4. In general, 
an increase in the specific HA titer was observed in cultures of strains in which expression of 
ftsZ was repressed, compared to their respective parent strains, which could be partially 
attributed to increased carbon availability for HA synthesis due to reduced FtsZ expression, 
and/or reduced biomass accumulation in the case of AW008-4 and AW010-4. The improved HA 
titer in cultures of AW011-4, compared to AW008-4 and AW010-4 (Figure 4.5B), suggests that 
the repression of ftsZ expression was conducive to HA production in B. subtilis. On the other 
hand, a further increase in repression efficiency may reduce the HA titer, as observed in cultures 
of AW009-4 (Figure 4.5B), without significantly affecting the MW. The results suggest that a 
delicate balance between the CL level and distribution in the cell membrane of B. subtilis 
appears to be critical for optimization of culture performance for heterologous HA production.  
 The improvements to the MW of HA produced by most engineered B. subtilis strains 
possessing CL-enriched membranes in this study was modest. This is not entirely surprising 
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given that a cls (encoding CL synthase) deficient S. pyogenes mutant retained the full ability to 
produce the HA capsule, relative to the parent strain which constitutively produced HA due to a 
mutation of the transcriptional regulator CovR [217]. Moreover, the titer and MW of HA 
produced by strains of B. subtilis expressing only SeHAS and TuaD were comparable to those 
based on streptococcal cultivations [5], in spite of the relatively small amount of CL naturally 
present in the B. subtilis membrane. Similarly, heterologous HA production was achieved in a 
variety of bacterial hosts expressing Class I HAS from group C streptococci without alterations 
to the host membrane [131, 133, 134]. Accordingly, it appears that alternate lipids may suffice to 
assist bacterial Class I HAS in HA synthesis. The B. subtilis membrane is composed mainly of 
PG (the only essential lipid) and phosphatidylethanolamine (PE), in addition to a large amount of 
neutral glycolipids (GL) [206]. The dependence of SeHAS activity on PG could not be assessed 
in vivo in B. subtilis as pgsA mutants are not viable [229]. However, PG was observed to have no 
stimulatory effect on the activity of purified SeHAS in vitro [121]. To determine if either of the 
other major lipids present in the B. subtilis membrane, i.e. PE and GL, were critical in 
maintaining the activity of SeHAS, we respectively mutated pssA (encoding PssA, an enzyme for 
synthesizing phosphatidylserine, which is subsequently converted to PE) and ugtP (encoding 
UDP-glucose diacylglyceroltransferase; UgtP, an enzyme involved in the conversion of PA  to 
GL [206]) in AW008 via transformation of respective plasmids pAW010-4 and pAW011-4, 
generating respective mutant strains AW012-4 and AW013-4. The HA titers obtained in cultures 
of AW012-4 and AW013-4 were not significantly different from that obtained in cultures of 
AW008 (data not shown). The fact that PE deficiency did not significantly alter HA production 
in B. subtilis was not surprising, given that PE marginally enhanced the activity of purified 
SeHAS in vitro [121], and that, like CL, PE localizes at the septal regions of the membrane in B. 
subtilis [209]. On the other hand, UgtP is involved in the synthesis of diglucosyldiacylglycerol, 
the membrane anchor for lipoteichoic acids [206, 230], and in the coupling of nutrient 
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availability to cell division by potentially inhibiting Z ring formation in nutrient rich conditions 
[231], such that its mutation results in pronounced growth defects [206, 230]. Regardless of the 
physiological defects arising from UgtP deficiency, AW013-4 reached a similar cell density to 
AW008 with a comparable HA titer, suggesting that SeHAS might not preferentially coordinate 
with GL. Based on our results and the previous observation of HA synthesis in cls-deficient S. 
pyogenes whose membrane is composed primarily of CL, PG, and GL [217], PG may satisfy the 
lipid requirements of streptococcal Class I HAS in vivo. Our results also suggest that HA 
synthesis in B. subtilis is a robust process potentially insensitive to major physiological 
perturbations in the host. 
 The estimated relative repression efficiencies of ftsZ-targeting gRNAs did not agree well 
with our experimental observations, particularly in terms of transformability, morphology, and 
microscopy analysis. For example, ftsZ-gRNA.P79NT(10A-G) was expected to provide the 
lowest degree of repression of ftsZ expression, but it appeared to show a high level of repression 
relative to four of the other five gRNAs tested, and the nature of the substitution may be 
associated with the observed high level of repression. On the other hand, ftsZ-
gRNA.P79NT(15C-U) resulted in the lowest level of repression of ftsZ expression while it was 
anticipated to provide a high repression level of 0.7. A recent investigation of the kinetics of 
dCas9 binding to off-target sequences indicated that the apparent association rates for targets in 
which A-G mismatches had been introduced outside of the seed region (Note that the seed region 
includes the first seven bp adjacent to the PAM site.) were typically high [232]. Substitution of 
an A with a G residue could potentially result in a G-T wobble base pair (in which hydrogen 
bonds link N1 of G with O2 of T and O6 of G with N3 of T) which can be accommodated in 
biologically active dsDNA [233]. A poly(T) signal and/or more stable hairpin structure in the 
protospacer of ftsZ-gRNA.P79NT(15C-U) may have led to low repression of ftsZ expression in 
AW004-4 and AW008-4. The protospacer of ftsZ-gRNA.P79NT is expected to form a minimally 
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stable hairpin structure (ΔG = -2.46 kcal/mole), although substitution of the C with a U residue at 
position 15 for ftsZ-gRNA.P79NT(15C-U) may result in the formation of a more stable hairpin 
structure (ΔG = -4.07 kcal/mole). While the poly(T) signal is a distinguishing characteristic of 
rho-independent terminators in bacteria, its presence alone is typically not sufficient to achieve 
efficient transcription termination [234, 235], as is the case in eukaryotes [236]. Accordingly, it 
is likely that hairpin formation in the protospacer may disrupt base pairing between the gRNA 
and the DNA target. Evidently, tuning repression efficiency by introducing mismatches in the 
protospacer of gRNAs when applying CRISPRi is a complicated and trial-and-error process, 
given the availability of a meticulous gRNA design protocol. On the other hand, the selection of 
PAM sites based on their proximity to the beginning of the target ORF may provide more control 






Chapter 5  
Metabolic engineering to enhance heterologous production of HA in B. subtilis 
 
5.1 Introduction 
In light of significant advances in the areas of synthetic biology, metabolic engineering, 
and molecular biology, strain engineering to enhance target metabolite production has become 
increasingly common [11]. The standard approach begins with the rational design of a 
biosynthetic pathway to generate the desired product. Heightened expression of key genes, in 
parallel with inactivation of genes in competing pathways, aims to direct carbon flux toward 
target metabolite formation [237]. However, complete inactivation of certain essential genes 
associated with central metabolism or core aspects of physiology (e.g. ATP generation, cell 
division, etc.) may not be feasible, such that reducing expression levels of these genes, while 
maintaining cell physiology, may ultimately prove more effective [98]. Prior efforts to produce 
HA in B. subtilis have primarily involved overexpressing genes comprising the HA biosynthetic 
pathway (Figure 5.1). Initially, it was shown that UDP-GlcUA is limiting for HA biosynthesis, 
such that coexpression of tuaD and seHas was critical for high-level HA production [5]. 
Coexpression of additional native enzymes involved in cell wall biosynthesis, i.e. GtaB and 
GcaD, moderately improved HA production. On the other hand, coexpression of szHas, tuaD, 
and vhb, significantly improved HA production, presumably due to increased ATP production 
resulting from vhb expression [128]. Recently, the coexpression of szHas, tuaD, gtaB, glmS, 
glmM, and gcaD improved the HA titer by ~30%, compared to the coexpression of only szHas 
and tuaD, or szHas and gcaD, without improving the MW, while simply downregulating the 
expression of pfkA, via replacement of the native ATG start codon with TTG, moderately 
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improved HA production [130]. Moreover, the carbon source used to produce HA in B. subtilis 
can affect the MW [238], and modifying the CL content and distribution in the cell membrane 
can improve both the titer and MW [239]. Collectively, the results from prior studies of HA 
production in B. subtilis suggest that coexpressing key genes from the HA biosynthetic pathway 
results in diminishing returns on the titer and MW, while metabolic engineering strategies, such 
as enhancing ATP generation or reducing glycolytic flux, have a greater impact on culture 
performance by reducing the burden on cellular resources.  
Heterologous HA production directly competes with central metabolism and cell wall 
synthesis, making it particularly challenging to manipulate with metabolic engineering strategies. 
In B. subtilis, glucose-6-P enters the branch point between the PPP, glycolysis, and the synthesis 
of cell wall components (Figure 5.1). Glucose-6-phosphate 1-dehydrogenase (Zwf; encoded by 
zwf) converts glucose-6-P to 6-phosphogluconolactone to initiate the oxidative branch of the 
PPP. In opposing directions, phosphoglucomutase (PgcA; encoded by pgcA) and Glucose-6-P 
isomerase (Pgi; encoded by pgi) convert glucose-6-P to glucose-1-P and fructose-6-P, 
respectively. Glucose-1-P feeds into the synthesis of cell wall components (e.g. teichoic and 
teichuronic acids), and fructose-6-P will enter glycolysis upon conversion to fructose-1,6-
bisphosphate by PfkA, or be converted to glucosamine-6-P, an intermediate in the synthesis of 
peptidoglycan and other cell wall constituents, by GlmS. Streptococcal Class I HAS alternately 
adds UDP-GlcNAc and UDP-GlcUA, intermediates in the synthesis of cell wall components 
respectively derived from glucosamine-6-P and glucose-1-P, to the reducing end of the growing 
HA chain [110]. Presumably, shifting carbon flux from central metabolism toward cell wall 
synthesis may improve HA production though cell physiology may be affected. In fact, 
inactivation of pfkA was lethal to B. subtilis [229, 240], and inactivation of zwf led to significant 
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carbon flux rerouting into glycolysis [240]. Accordingly, repression of pfkA and/or zwf 
expression may be an effective approach to redirect carbon flux from glycolysis and the PPP, 
respectively, toward cell wall biosynthesis and, ultimately, HA biosynthesis with minimum 
impact to cell physiology.  
In this study, we engineered the metabolism of a HA-producing strain of B. subtilis to 
redirect more carbon flux from the PPP and glycolysis into HA biosynthesis. An improved base 
strain AW002-3 was first developed for more effective HA production than our previous 
engineered strain AW008 [239]. The base strain was also less sensitive to catabolite repression 
when expressing genes from a xylose-inducible promoter due to the genomic integration of 
constitutively expressed araE, encoding the broad specificity transporter of L-arabinose and D-
xylose (AraE). Microbial strain engineering has recently advanced at an unprecedented rate due  
to the widespread adoption of the CRISPR-Cas9 system, an effective biotool for genome editing 
and transcriptional interference [241, 242]. To redirect carbon flux from the PPP and glycolysis 
into HA biosynthesis, we repressed the expression of zwf and pfkA, respectively, via CRISPRi 
using our recently developed CRISPR-Cas9 toolkit for B. subtilis [238]. While, compared to the 
control strain, lower cell densities were obtained potentially due to a reduced carbon flux into the 
PPP or glycolysis, the volumetric HA titers generally maintained significantly higher or, at least, 
similar levels, resulting in substantial improvements to the specific HA titers. However, in most 
cases, the MW of HA was negatively affected. On the other hand, multiplexed repression of both 
pfkA and zwf expression resulted in substantial improvements to both the HA titer and MW. 
Moreover, the addition of exogenous GlcUA and GlcNAc markedly increased the MW but 
decreased the titer of HA, providing further evidence that chain elongation and polymerizing 




Figure 5.1. The HA biosynthetic pathway in B. subtilis. Pink arrows: upregulated in all strains. 
Green arrows: upregulated in certain strains. Blue arrows: potential targets for upregulation. Red 
arrows: downregulated in certain strains. Orange arrows: potential targets for downregulation. 
Enzymes listed by category: TuaD, UDP-glucose 6-dehydrogenase; HasA, hyaluronan synthase; 
PgcA, phosphoglucomutase; GlmS, glutamine-fructose-6-P amidotransferase; Pgi, glucose-6-P 
isomerase; GtaB, UTP-glucose-1-P uridylyltransferase; GlmM, phosphoglucosamine mutase; 
GcaD, UDP-GlcNAc pyrophosphorylase; Zwf, glucose-6-P 1-dehydrogenase; PfkA, 6-
phosphofructokinase; TagE, UDP-glucose:polyglycerol phosphate glucosyltransferase; TagO,  
UDP-GlcNAc:undecaprenyl-P N-acetylglucosaminyl-1-P transferase; MnaA, UDP-N-
acetylmannosamine (ManNAc) 2-epimerase; MurAA, UDP-GlcNAc 1-carboxyvinyltransferase; 
MurAB, UDP-GlcNAc 1-carboxyvinyltransferase; SacP, phosphotransferase system sucrose-
specific transporter; SacA, Sucrose-6-P hydrolase; GmuE, fructokinase. 
111 
 
our study clearly demonstrates that simultaneously maximizing the titer and MW of HA 
produced in B. subtilis is a challenging task. 
 
5.2 Materials and Methods 
5.2.1 Bacterial strains, primers and plasmids 
The B. subtilis strains used in this study are listed in Table S5.1. E. coli HI-Control™ 
10G chemically competent cells were prepared as electrocompetent cells as described previously 
[187] and used as host for plasmid construction. B. subtilis and E. coli strains were maintained as 
glycerol stocks at -80 °C. Primers (Table S5.1) were synthesized by Integrated DNA 
Technologies. 
 
5.2.2 Plasmid construction  
DNA manipulation was performed using standard cloning techniques [187], and DNA 
sequencing was conducted by The Centre for Applied Genomics. To construct pAW009, 
promoter Pgrac.UPmod (i.e. promoter P61), a weaker derivative of promoter Pgrac (i.e. promoter P01) 
for which the relative promoter strength is ~0.5 [40], was amplified from pHT01 [215] with 
primers P5.97/P5.98, and inserted into SalI/BamHI digested pAW008 [238]. Transformation of 
pAW009 into B. subtilis results in the integration of a Pgrac.UPmod::seHas:tuaD cassette at the 
amyE locus (Figure 5.2). To construct the expression cassette in which araE, encoding the broad 
specificity transporter of L-arabinose and D-xylose (AraE) [243], was driven by promoter 
Pgrac.UPmod from the vpr locus, Pgrac.UPmod was amplified with primers P5.114/P5.115 from pHT01, 
araE was amplified with primers P5.116/P5.117 from 1A751 gDNA, and the two fragments 




Figure 5.2. Genomic engineering strategies to enhance HA production in B. subtilis. B. subtilis 
1A751 was transformed with pAW009, yielding strain AW009, which synthesizes HA.AW009 
was subsequently transformed with pAW019-2, yielding strain AW014-2, which expresses 
xylose-inducible dCas9. AW014-2 was then transformed with pAW002-3, and the combined 
ParaE::mazF-Spc
R (CS) cassette was subsequently auto-evicted via single-crossover 
recombination between the flanking direct repeats (black rectangles), yielding strain AW002-3, 
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which constitutively expresses araE to enhance xylose uptake. To generate strains in which 
expression of pfkA was repressed, AW002-3 was transformed with various gRNA delivery 
vectors containing pfkA-targeting gRNAs. Similarly, to generate strains in which expression of 
zwf was repressed, AW002-3 was transformed with various gRNA delivery vectors containing 
zwf-targeting gRNAs. To generate strains in which expression of both pfkA and zwf were 
repressed, AW002-3 was transformed with pAW017-3 or pAW018-3, resulting in respective 
strains AW018-3 and AW019-3 that transcribe both pfkA- and zwf-targeting gRNAs. The gRNAs 
direct dCas9 to pfkA and/or zwf based on the presence of a PAM site and adjacent seed region 
complementary to the protospacer, and the dCas9-gRNA complex remains bound to the target, 
partially blocking transcription of pfkA and/or zwf by RNA polymerase (RNAP).  
 
amplified with primers P5.118/P5.119 and spliced with the Pgrac.UPmod::araE cassette, yielding a 
vpr HL-5’-Pgrac.UPmod::araE cassette, which was subsequently inserted into SbfI/AsiSI-digested 
pAW002-4 [239]. To complete the vector, the vpr HL-3’ was amplified with primers 
P5.120/P5.121 from 1A751 gDNA and inserted in place of the thrC HL-3’, yielding pAW001-3. 
To construct pAW002-3, promoter Pgrac.ΔUP was amplified with primers P5.150/P5.151 from 
pAW009 and inserted into AvrII/SphI-digested pAW001-3. Pgrac.ΔUP (i.e. promoter P70) is a 
weaker derivative of Pgrac for which the relative promoter strength is ~0.1 [40].  
The gRNA cassettes pfkA-gRNA.P41NT, pfkA-gRNA.P41NT(10C-A), pfkA-
gRNA.P41NT(15U-C), pfkA-gRNA.P315NT(10G-A), pfkA-gRNA.P315NT(15U-G), pfkA-
gRNA.P610NT(10G-A), and pfkA-gRNA.P610NT(15U-C) were amplified with respective 
forward primers P5.107-P5.113 and common reverse primer P5.32 from pgRNA-bacteria [23], 
and inserted into SphI/NcoI-digested pAW017-2 [238] to obtain respective gRNA delivery 
vectors pAW003-3, pAW004-3, pAW005-3, pAW006-3, pAW007-3, pAW008-3, and pAW009-
3. The gRNA cassettes zwf-gRNA.P92NT, zwf-gRNA.P92NT(10U-G), zwf-gRNA.P92NT(15C-
A), zwf-gRNA.P603NT, zwf-gRNA.P603NT(10U-C), and zwf-gRNA.P603NT(15G-U) were 
amplified with respective forward primers P5.152-P5.157 and common reverse primer P5.32 
from pgRNA-bacteria, and inserted into SphI/NcoI-digested pAW017-2 to obtain respective 
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gRNA delivery vectors pAW010-3, pAW011-3, pAW012-3, pAW013-3, pAW014-3, and 
pAW015-3. To construct the multi-gRNA delivery vector, the BglII and BamHI restriction sites 
upstream and downstream of mazF, respectively, were removed, and a new BglII restriction site 
was inserted between the NheI restriction site and promoter PxylA.SphI+1 in pAW017-2 to facilitate 
Biobrick cloning of gRNA transcription cassettes as previously described [238]. This was 
accomplished by amplifying the PxylA.SphI+1-DR cassette and mazF from pAW017-2 with primers 
P5.28/P5.158 (NheI/--) and P5.159/P5.31 (--/BamHI), respectively, followed by splicing of the 
two fragments to generate a PxylA.SphI+1-DR-mazF cassette, which was subsequently inserted into 
NheI/BglII digested pAW017-2, generating pAW016-3. The previously amplified zwf-
gRNA.P603NT(10U-C) cassette was then inserted into SphI/NcoI-digested pAW016-3. To 
complete the respective dual gRNA delivery vectors pAW017-3 and pAW018-3, the 
PxylA.SphI+1::pfkA-gRNA.P41NT and PxylA.SphI+1::pfkA-gRNA.P41NT(10C-A) cassettes were 
amplified with primers P5.28/P5.33 (NheI/BamHI), and inserted into the NheI/BglII-digested 
derivative of pAW016-3 containing zwf-gRNA.P603NT(10U-C). All gRNA delivery vectors 
were linearized with SacI prior to transformation into B. subtilis.  
To construct an expression cassette in which pgcA was driven by promoter Pgrac from the 
thrC locus, the thrC HL-5’-Pgrac cassette was amplified with primers P5.160/P5.161 from 
pAW002-4, pgcA was amplified with primers P5.162/P5.163 from 1A751 gDNA, and the two 
fragments were spliced, generating a thrC HL-5’-Pgrac::pgcA cassette, which was subsequently 
inserted into SbfI/AsiSI digested pAW002-4, yielding pAW019-3. Similarly, to construct an 
expression cassette in which glmS was driven by promoter Pgrac from the thrC locus, the thrC 
HL-5’-Pgrac cassette was amplified with primers P5.160/P5.164 from pAW002-4, glmS was 
amplified with primers P5.165/P5.166 from 1A751 gDNA, and the two fragments were spliced, 
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generating a thrC HL-5’-Pgrac::glmS cassette, which was subsequently inserted into SbfI/AsiSI 
digested pAW002-4, yielding pAW020-3. Finally, to construct an expression cassette in which 
pgcA and glmS were driven by promoter Pgrac from the thrC locus, glmS was amplified with 
primers P5.167/P5.166 from 1A751 gDNA, and was subsequently inserted into ClaI/AsiSI 
digested pAW019-3, yielding pAW021-3. 
 
5.2.3 Competent cell preparation and transformation 
Transformation of B. subtilis was performed using a standard protocol for natural 
competence [8]. SpC medium contained the following (per L): (NH4)2SO4, 1.67 g; K2HPO4, 
11.64 g; KH2PO4, 5.0 g; trisodium citrate dihydrate, 833 mg; glucose, 4.17 g; MgSO4∙7H2O, 151 
mg; yeast extract, 1.67 g; casamino acids, 208 mg; Arg, 7.5 g; His, 383 mg; Trp, 48 mg. SpII 
medium contained the following (per L): (NH4)2SO4, 1.67 g; K2HPO4, 11.64 g; KH2PO4, 5.0 g; 
trisodium citrate dihydrate, 833 mg; glucose, 4.17 g; MgSO4∙7H2O, 725 mg; yeast extract, 858 
mg; casamino acids, 86 mg; Arg, 3.78 g; His, 189 mg; Trp, 24 mg; CaCl2, 48 mg. B. subtilis 
strains were plated on non-select lysogeny broth (LB) agar containing 5 g/L NaCl, 5 g/L yeast 
extract, 10 g/L tryptone, and 15 g/L agar, and incubated overnight. Pre-warmed SpC medium 
was inoculated by cell patches from the overnight plate to OD600 0.5-0.7. Seventy five min after 
the logarithmic growth phase ended, cultured cells were then diluted 100-fold in pre-warmed 
SpII medium, and incubated for 110 min before harvesting. Transformed cells were incubated 
for 80 min at 260 rpm, and then plated on LBG containing 85 µg/mL spectinomycin to select 
recombinants. To facilitate auto-eviction of the ParaE::mazF-Spc
R cassette after transformation of 
counter-selectable integration vectors, cells were grown for ~20 h in non-select LB at 37 °C and 
260 rpm, plated on LB agar containing 20 g/L arabinose (LBA), and screened for spectinomycin 
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sensitivity. All cultivation steps were conducted at 37 °C and 300 rpm unless otherwise 
indicated.  
 
5.2.4 HA production, purification and analysis 
HA production was assessed as previously described [238] with minor modifications. B. 
subtilis strains were plated on non-select LB and grown overnight at 37 °C. A single colony was 
used to inoculate 25 mL non-select LB, and the culture was grown for ~13 h at 37 °C and 280 
rpm. The culture was then used to inoculate 20 mL pre-warmed non-select cultivation medium 
(4% v/v) of the following composition (per L): sucrose, 20 g; (NH4)2SO4, 1 g; K2HPO4∙3H2O, 
9.15 g; KH2PO4, 3 g; trisodium citrate∙ 2H2O, 1 g; yeast extract, 10 g; casamino acids, 2.5 g; 
CaCl2, 5.5 mg; FeCl2∙ 6H2O, 13.5 mg; MnCl2∙ 4H2O, 1 mg; ZnCl2, 1.7 mg; CuCl2∙ 2H2O, 0.43 
mg; CoCl2∙ 6H2O, 0.6 mg; Na2MoO4∙ 2H2O, 0.6 mg. Cultures were grown at 37 °C and 280 rpm, 
and were induced with xylose (0.75% wt/v) 1.5 h after inoculation. Samples were diluted 
appropriately in PBS (NaCl, 8 g/L; KCl, 0.2 g/L; Na2HPO4, 1.44 g/L; KH2PO4, 0.24 g/L), and 
HA was purified with cetylpyridinium chloride as previously described [128]. HA titers were 
determined using the modified carbazole assay [191], and MW was analyzed via agarose gel 
electrophoresis [192] with slight modifications. 2 µg of purified HA was loaded per well, and 
gels stained O/N in 0.005% Stains-All (50% v/v ethanol) were destained for ~8 h  in 20% v/v 
ethanol, followed by destaining for ~16 h in 10% v/v ethanol. Gels were then photobleached for 
20 min on a LED light box, and scanned with an Epson Perfection V600 Photo scanner (Nagano, 
Japan). Scanned images were analyzed using ImageJ [244], and data analysis was performed as 





5.3.1 Strain engineering of B. subtilis as a base strain for improved HA production 
We previously constructed a B. subtilis strain capable of high-level production of high 
MW HA, i.e. AW008, in which coexpression of seHas and tuaD was driven by the strong 
promoter Pgrac [239]. We also observed that reducing the strength of the promoter driving CL 
overproduction in an AW008 derivative, in which the membrane CL content was artificially 
enhanced, improved the HA titer by 30% with a slight reduction in the MW [239]. This 
prompted us to examine the effects of seHas and tuaD expression on HA production via 
construction of strain AW009, in which coexpression of both genes was driven by the promoter 
Pgrac.UPmod, a derivative of Pgrac with a relative promoter strength of ~0.5 [40]. AW009 was 
constructed via transformation of B. subtilis 1A751 with NdeI-linearized pAW009 (Figure 5.2). 
Similar to AW008, AW009 presented a mucoid phenotype, a characteristic for HA production in 
B. subtilis [5], and was genetically stable based on the persistence of the mucoid phenotype upon 
repetitive revival. AW009 produced approximately twice as much HA as AW008 (0.97 g/L vs. 
0.48 g/L; Figure 5.3A) after 10 h of shake flask cultivation, while the MW slightly declined by 
12% (Figure 5.3B). Moreover, the cell density of the AW009 culture at 10 h was 45% higher 
than that of AW008 (Figure 5.3C). The improved cell growth of AW009, compared to AW008, 
may have contributed to the enhanced HA production as HA is a growth-associated product 
[225]. UDP-GlcNAc is the limiting substrate for HA biosynthesis in S. zooepidemicus, such that 
expression of hasD (a gcaD homologue) and/or hasE (a pgi homologue) improved the MW of 
HA, relative to the wild-type strain [245]. Accordingly, the slight MW reduction in AW009 may 




Figure 5.3. Time profiles of A) HA titer, B) HA MW, and C) cell density in cultures of AW008 
and AW009. AW008 and AW009 each coexpress seHas and tuaD, under control of the 
constitutive promoters Pgrac and Pgrac.UPmod, respectively, from the amyE locus. Cultivation 
conditions were the same as those described in M&M, except that glucose was the primary 
carbon source (20 g/L), the culture volume was 25 mL, and the inoculum size was 2% v/v. SD of 
experiments performed in triplicate are shown in Panels A and C, and SD of duplicate samples 
are shown in Panel B. 
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GlcUA as the limiting substrate in B. subtilis. With a better overall culture performance, AW009 
was selected as the host for metabolic engineering via CRISPRi to enhance HA production. To 
conduct CRISPRi, AW009 was transformed with pAW019-2, generating AW014-2 which 
expressed xylose-inducible dCas9 from the lacA locus (Figure 5.2) [238].  
 The araE gene encodes a broad specificity transporter of L-arabinose, D-xylose and other 
sugars [243]. Expression of araE is not induced by xylose and is subject to CcpA-mediated 
catabolite repression via a CRE upstream of the ORF of araE [190, 246]. Given that the major 
carbon source for HA cultivation was sucrose (which can catabolically repress araE expression) 
and dCas9 expression was driven by the xylose-inducible promoter PxylA, Bm [238], we opted to 
integrate constitutively expressed CRE-free araE into the vpr locus of AW014-2 to enhance 
xylose uptake for induction of dCas9 expression. To achieve this, AW014-2 was transformed 
with SacI-linearized pAW001-3, generating AW001-3. However, AW001-3 had a specific 
growth rate of approximately half that of the parent strain, indicating that expression of araE 
from Pgrac.UPmod significantly impacted cell growth. We hypothesized that such physiological 
burden was associated with the promoter strength and, therefore, replaced Pgrac.UPmod (with a 
relative promoter strength of ~0.5) with Pgrac.ΔUP (with a relative promoter strength of ~0.1). To 
do this, we transformed AW014-2 with SacI-linearized pAW002-3, yielding AW002-3 (Figure 
5.2), a strain with a specific growth rate similar to that of the parent strain.  
To evaluate this approach for enhancing xylose uptake, we transformed AW002-3 with 
pAW018-2 [238], generating AW003-3, a strain that transcribed lacZ-gRNA.P28NT (a gRNA 
targeting the lacZ ORF of E. coli) from the wprA locus. After counter-selection to evict the 
ParaE::mazF-Spc
R cassette, AW003-3 was subsequently transformed with pAW016 [238], 
generating AW004-3, a strain that expressed IPTG-inducible lacZ from the ugtP locus. AW004-
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3 and AW016-2 [238], an equivalent strain to AW004-3 but without constitutively expressed 
araE, were assessed for the repression efficiency of lacZ expression in cultivation medium 
containing 2% wt/v sucrose and IPTG, in the presence or absence of xylose, as previously 
described [238]. The specific β-galactosidase activities of uninduced cultures of AW004-3 and 
AW016-2 were 8.1-fold and 6.5-fold, respectively, that of the xylose-induced cultures of the 
corresponding strains (data not shown), implying less catabolite repression in AW004-3. 
Moreover, the 8.1-fold difference in the specific β-galactosidase activity between uninduced and 
xylose-induced AW004-3 grown in sucrose-containing medium compared favorably to the 7.7-
fold difference in the specific β-galactosidase activity between uninduced and xylose-induced 
AW016-2 grown in LB (containing no sucrose) [238], suggesting that catabolite repression effect 
was insignificant in both cultures. 
 
5.3.2 Repression of pfkA expression increases the HA titer but decreases the MW 
Overexpressing genes in the HA biosynthetic pathway has been extensively explored for 
heterologous HA production in B. subtilis. As UDP-GlcUA is the limiting substrate in 
phosphate-rich medium, coexpression of hasA and tuaD is necessary to enhance HA production 
[5]. However, the expression of additional genes in the HA biosynthetic pathway resulted in 
modest gains in the HA titer, while having essentially no effect on the MW [5, 130]. 
Accordingly, we imposed a more dramatic shift in carbon flux away from central metabolism 
toward HA biosynthesis. We engineered B. subtilis by reducing pfkA expression to siphon 
fructose-6-P directly from glycolysis using our recently developed CRISPR-Cas9 toolkit [238]. 
We previously showed that introducing mismatches in the protospacer sequence (i.e. gRNA 
base-pairing region) of dCas9-targeting gRNAs and/or PAM site selection based on the relative 
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distance from the start codon could effectively alter repression efficiency when applying 
CRISPRi in B. subtilis [239]. Thus, this strategy was applied in the design of seven pfkA-
targeting gRNAs covering a range of relative repression efficiency. Single mismatches in base 
pairs (bp) 8-12 of the protospacer sequence (relative to the 3’-end) of gRNAs cause a dramatic 
(~75%) reduction in repression efficiency, while single mismatches in bp 13-20 cause a slight 
(~30%) reduction in repression efficiency (Note that the first 7 bp should not be altered as single 
mismatches in this region almost eliminate the repression efficiency.) [23, 197]. Moreover, 
repression levels are roughly inversely proportional to the distance between the selected PAM 
site and the start codon of the target ORF [23, 197]. We chose PAM sites P41NT, P315NT, and 
P610NT, which correspond to relative distances of 0.04, 0.33, and 0.64, respectively, from the 
start codon (Note that the first bp of the start codon and last bp of the stop codon correspond to 
relative distances of 0 and 1, respectively.). Based on proximity to the start codon alone, the 
relative repression efficiency afforded by targeting PAM sites P41NT, P315NT, and P610NT 
were estimated to be 1.0, 0.5, and 0.3, respectively [23]. Single mismatches were introduced in 
the protospacer sequence of gRNAs at position 10 and 15 to further reduce the relative 
repression efficiency by ~75% and ~30%, respectively. We assumed that the effects of PAM site 
selection and mismatches introduced in the protospacer sequence of gRNAs were multiplicative 
when estimating the overall relative repression efficiency. For example, the relative repression 
efficiency of pfkA expression resulting from transcription of pfkA-gRNA.P41NT(10C-A) was 
estimated to be 1.0 × 0.25 = 0.25. Table 5.1 summarizes various pfkA-targeting gRNAs with 
their corresponding protospacer sequence and estimated relative repression efficiency. 




Table 5.1. pfkA- and zwf-targeting gRNAs and their respective protospacer sequence and 
estimated relative repression efficiency 




pfkA   
pfkA-gRNA.P41NT CGAACTGCTGCGTTCATTCC 1.0 
pfkA-gRNA.P41NT(10C-A) CGAACTGCTGAGTTCATTCC 0.25 
pfkA-gRNA.P41NT(15U-C) CGAACCGCTGCGTTCATTCC 0.7 
pfkA-gRNA.P315NT(10G-A) TAATTTTTTCACACCCATAT 0.13 
pfkA-gRNA.P315NT(15U-G) TAATTGTTTCGCACCCATAT 0.35 
pfkA-gRNA.P610NT(10G-A) GTTCGTGGCCACGTTTTAAG 0.08 
pfkA-gRNA.P610NT(15U-C) GTTCGCGGCCGCGTTTTAAG 0.21 
zwf   
zwf-gRNA.P92NT TTTGTCCGTTTTGATATAAA 1.0 
zwf-gRNA.P92NT(10U-G) TTTGTCCGTTGTGATATAAA 0.25 
zwf-gRNA.P92NT(15C-A) TTTGTACGTTTTGATATAAA 0.7 
zwf-gRNA.P603NT ATGTAGCGGTTTGTCCAAAG 0.55 
zwf-gRNA.P603NT(10U-C) ATGTAGCGGTCTGTCCAAAG 0.14 
zwf-gRNA.P603NT(15G-U) ATGTATCGGTTTGTCCAAAG 0.39 
^mismatches are underlined 
To reduce pfkA expression with various repression efficiencies in HA-producing B. subtilis, 
AW002-3 was respectively transformed with SacI-linearized pAW003-3, pAW004-3, pAW005-
3, pAW006-3, pAW007-3, pAW008-3, and pAW009-3, generating corresponding strains 
AW005-3, AW006-3, AW007-3, AW008-3, AW009-3, AW010-3, and AW011-3. All pfkA-
repressed strains produced more HA than the control strain AW009 under shake flask cultivation 
(Figure 5.4A). In particular, AW005-3, AW006-3, and AW007-3, which all transcribe gRNAs 
targeting P41NT, had HA titers ~50% higher than that of AW009 after 10 h. However, the peak 




Figure 5.4. Time profiles of A) HA titer, B) HA MW, and C) cell density in cultures of AW009, 
AW005-3 (transcribing pfkA-gRNA.P41NT), AW006-3 (transcribing pfkA-gRNA.P41NT(10C-
A)), AW007-3 (transcribing pfkA-gRNA.P41NT(15U-C)), AW008-3 (transcribing pfkA-
gRNA.P315NT(10G-A)), AW009-3 (transcribing pfkA-gRNA.P315NT(15U-G)), AW010-3 
(transcribing pfkA-gRNA.P610NT(10G-A)), and AW011-3 (transcribing pfkA-
gRNA.P610NT(15U-C)). All strains transcribing pfkA-targeting gRNAs are derivatives of 
AW002-3, which expresses xylose-inducible dCas9 with constitutively expressed araE to 




AW009 (Figure 5.4B), with the exception of AW008-3, for which the final MW was slightly 
higher (1.71 MDa vs. 1.54 MDa; Figure 5.4B). As expected, the final cell density of pfkA- 
repressed strains was significantly lower than AW009 (Figure 5.4C), with the exception of 
AW008-3, for which the final cell density was slightly higher (7.9 OD600 vs. 7.45 OD600; Figure 
5.4C). As a result, the specific HA titers in cultures of AW005-3, AW006-3, and AW007-3 were 
116%, 98%, and 86% respectively higher than that of AW009 (0.146 g/L/OD600), suggesting that 
the dissimilated carbon flux was redirected from biomass accumulation to HA biosynthesis upon 
pfkA repression. 
 
5.3.3 Repression of zwf expression can affect HA production 
As the PPP is another central metabolic pathway potentially competing with the HA 
biosynthetic pathway for the dissimilated carbon flux, we extended our metabolic engineering 
strategy for carbon flux redirection by reducing zwf expression. We chose two PAM sites P92NT 
and P603NT, which correspond to relative distances of 0.06 and 0.41, respectively, from the start 
codon of the zwf ORF. Based on proximity to the start codon alone, the relative repression 
efficiency afforded by targeting PAM sites P92NT and P603NT were estimated to be 1.0 and 
0.55, respectively. Single mismatches were introduced in the protospacer sequence of gRNAs at 
position 10 and 15 to further reduce the relative repression efficiency. Table 5.1 summarizes 
various zwf-targeting gRNAs with their corresponding protospacer sequences and estimated 
relative repression efficiencies.  
To reduce zwf expression with various repression efficiencies in HA-producing B. 
subtilis, AW002-3 was respectively transformed with SacI-linearized pAW010-3, pAW011-3, 
pAW012-3, pAW013-3, pAW014-3, and pAW015-3, generating corresponding strains AW012-
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3, AW013-3, AW014-3, AW015-3, AW016-3, and AW017-3. Culture performance for HA 
production for these zwf-repressed strains varied considerably, with the HA titers of AW012-3, 
AW014-3, AW015-3, and AW016-3 being 33%, 44%, 26%, and 74% respectively higher than 
that of AW009 after 8 h, while those of AW013-3 and AW017-3 were lower (Figure 5.5A). 
However, HA production for AW012-3, AW014-3, AW015-3, and AW016-3 did not persist 
much between 8 h and 10 h, such that the final HA titers of these strains were similar to that of 
AW009. Moreover, the peak MW of HA produced by all zwf-repressed strains was somewhat 
lower compared to AW009, although the final MW of HA produced by AW014-3 (1.64 MDa) 
and AW017-3 (1.77 MDa) was higher (Figure 5.5B). Also, the growth of zwf-repressed strains 
varied considerably. Cultures of AW012-3, AW013-3, and AW016-3 reached substantially lower 
final cell densities compared to AW009, while the final cell density in cultures of AW014-3 was 
a bit higher (Figure 5.5C). Accordingly, the specific HA titers in cultures of AW014-3 and 
AW016-3 were respectively equal to and 131% higher than that of AW009.  
 
5.3.4 Multiplexed repression of pfkA and zwf expression further improves the HA titer and 
restores the MW 
We next evaluated the effect of multiplexed repression of pfkA and zwf expression on HA 
production. Given the significant improvements to the volumetric HA titer and, in particular, the 
specific HA titer in cultures of AW005-3, AW006-3, and AW016-3 compared to AW009, we 
selected pfkA-gRNA.P41NT or pfkA-gRNA.P41NT(10C-A) to be co-transcribed with zwf-
gRNA.P603NT(10U-C) for gene repression in the newly derived strains. Accordingly, AW002-3 
was respectively transformed with SacI-linearized pAW017-3 and pAW018-3, generating 




Figure 5.5. Time profiles of A) HA titer, B) HA MW, and C) cell density in cultures of AW009, 
AW012-3 (transcribing zwf-gRNA.P92NT), AW013-3 (transcribing zwf-gRNA.P92NT(10U-G)), 
AW014-3 (transcribing zwf-gRNA.P92NT(15C-A)), AW015-3 (transcribing zwf-
gRNA.P603NT), AW016-3 (transcribing zwf-gRNA.P603NT(10U-C)), and AW017-3 
(transcribing zwf-gRNA.P603NT(15G-U)). All strains transcribing zwf-targeting gRNAs are 
derivatives of AW002-3, which expresses xylose-inducible dCas9 with constitutively expressed 
araE to enhance xylose uptake. SD of experiments performed in duplicate are shown in Panels 
A, B, and C. 
127 
 
AW019-3 reached 2.16 g/L and 2.26 g/L after 10 h (Figure 5.6A), respectively, representing 
98% and 108% increases compared to AW009. Importantly, the peak MW of HA produced by 
either strain was slightly higher, while the final MW in cultures of AW018-3 and AW019-3 was 
equal to and 14% higher, respectively, compared to AW009 (Figure 5.6B). Surprisingly, the final 
cell density in cultures of AW018-3 (i.e. a strain with multiplexed repression of pfkA and zwf) 
was 53% and 88% higher, compared to AW005-3 and AW016-3 (i.e. strains with single 
repression of pfkA or zwf), respectively, and was slightly higher compared to AW009 (Figure 
5.6C). Similarly, the final cell density in cultures of AW019-3 (i.e. a strain with multiplexed 
repression of pfkA and zwf) was 16% and 63% higher compared to AW006-3 and AW016-3 (i.e. 
strains with single repression of pfkA or zwf), respectively, although was slightly lower compared 
to AW009. Accordingly, the specific HA titers in cultures of AW018-3 and AW019-3 were 92% 
and 131% higher after 10 h cultivation, compared to AW009. The results suggest that proper 
modulation of repression of pfkA and zwf expression could significantly enhance HA production 
without negatively affecting the MW of produced HA. 
 
5.4 Discussion 
HA biosynthesis is a metabolically demanding process, requiring 2 mol glucose, 3 mol 
ATP, 2 mol UTP, and 1 mol acetyl-CoA to generate 1 mol of the HA disaccharide. The major 
substrates for HA biosynthesis, i.e. nucleotide sugars UDP-GlcUA and UDP-GlcNAc, are also 
required for cell wall biosynthesis. Hence, HA biosynthesis directly competes with the PPP and 
glycolysis for glucose-6-P and fructose-6-P, respectively. However, heterologous HA production 
in B. subtilis often does not significantly alter the cell growth profile based on our observations 




Figure 5.6. Time profiles of A) HA titer, B) HA MW, and C) cell density in cultures of AW009, 
AW005-3 (transcribing pfkA-gRNA.P41NT), AW006-3 (transcribing pfkA-gRNA.P41NT(10C-
A)), AW016-3 (transcribing zwf-gRNA.P603NT(10U-C)), AW018-3 (transcribing pfkA-
gRNA.P41NT and zwf-gRNA.P603NT(10U-C)), and AW019-3 (transcribing pfkA-
gRNA.P41NT(10C-A) and zwf-gRNA.P603NT(10U-C)). All strains transcribing pfkA- and/or 
zwf-targeting gRNAs are derivatives of AW002-3, which expresses xylose-inducible dCas9 with 
constitutively expressed araE to enhance xylose uptake.SD of experiments performed in 
triplicate are shown in Panels A and C, and SD of duplicate samples are shown in Panel B. 
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can exist between central metabolism and biosynthesis of HA and cell wall. Accordingly, 
overexpressing enzymes involved in HA biosynthesis may be futile, particularly if substrate 
availability is the limiting factor due to strict carbon flux partitioning in the HA-producing host. 
In this study, we redirected carbon flux from central metabolism, i.e. the PPP and  
glycolysis, toward HA biosynthesis by repressing expression of zwf and/or pfkA, which encode 
branch point enzymes driving dissimilated carbon into the respective pathways. Significant 
improvements to the HA titer were obtained in cultures of all seven AW002-3 derivatives 
transcribing pfkA-targeting gRNAs covering a range of relative repression efficiency (Figure 
5.4A). Note that pfkA is an essential gene in B. subtilis [229, 240] that cannot be knocked out, 
and repression of pfkA expression should reduce glycolytic carbon flux. Our results are 
consistent with a previous study in which attenuated pfkA expression via start codon replacement 
improved the HA titer in B. subtilis [130]. However, the increase in the HA titer was 
accompanied by a decrease in the MW (Figure 5.4B). HA biosynthesis is limited by insufficient 
UDP-GlcNAc levels in S. zooepidemicus [245], such that overexpression of hasE and hasD (i.e. 
respective homologues of pgi and gcaD encoding enzymes involved in UDP-GlcNAc synthesis) 
[245], or addition of exogenous GlcNAc [247] dramatically improved the MW. A similar 
substrate imbalance could exist with UDP-GlcUA being the limiting substrate for HA 
biosynthesis in B. subtilis under our cultivation conditions (i.e. using a medium with a high 
phosphate content), potentially causing premature termination of the growing HA polymer [245]. 
Theoretically, overexpression of tuaD should at least partially resolve the natural imbalance 
between UDP-GlcUA and UDP-GlcNAc. However, we suspected that the reduced expression of 
pfkA might have increased the conversion of fructose-6-P to glucosamine-6-P via GlmS and, 
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therefore, increased the carbon flux through the UDP-GlcNAc branch of the HA biosynthetic 
pathway, resulting in an imbalance between substrate levels and a reduction in the MW.  
To test this hypothesis, we supplemented cultures of AW006-3 with either GlcUA or 
GlcNAc at a concentration of 0.4 g/L or 0.8 g/L. Interestingly, the addition of GlcUA and 
GlcNAc to 0.4 g/L reduced the final HA titer by 31% and 55%, respectively, compared to 
cultures without exogenous GlcUA and GlcNAc, while increasing the concentration of each 
substrate to 0.8 g/L led to respective 18% and 24% increases in the final HA titer, compared to 
the corresponding cultures with a concentration of 0.4 g/L (Figure 5.7A). Moreover, the addition 
of 0.4 g/L GlcUA resulted in a 35% increase in the peak MW (2.19 MDa; at 8 h), compared to 
the peak MW (1.62 MDa; at 6 h) of the control culture lacking exogenous supplementation 
(Figure 5.7B). The effect on MW was even more pronounced in the culture supplemented with 
0.4 g/L GlcNAc, and the peak MW reached 2.62 MDa at 10 h, representing a 62% increase 
compared to the control culture (Figure 5.7B). A further increase in the concentration of either 
substrate to 0.8 g/L had a marginal effect on the MW, compared to the corresponding culture 
with a concentration of 0.4 g/L (Figure 5.7B). The decrease in the HA titer without cell growth 
being negatively affected upon the addition of exogenous GlcUA or GlcNAc may suggest that 
imbalanced substrate levels occurred even at the lowest concentration of 0.4 g/L. The activity of 
membrane-bound SeHAS was observed to decrease with increasing UDP-GlcUA concentration, 
particularly when the ratio of UDP-GlcUA to UDP-GlcNAc was significantly higher than 1:1 
[248]. While a proposed decline in the activity of SeHAS may seem counterintuitive given the 
large increase in the MW observed upon the addition of either GlcUA or GlcNAc, note that the 
polymerizing activity (affecting HA titer) and control of chain length (affecting HA MW) are 




Figure 5.7. Time profiles of A) HA titer, B) HA MW, and C) cell density in cultures of AW006-
3, an AW002-3 derivative transcribing pfkA-gRNA.P41NT(10C-A), supplemented with GlcUA 
or GlcNAc at a concentration of 0.4 g/L or 0.8 g/L. SD of experiments performed in triplicate are 




other hand, in the presence of excess UDP-GlcUA or UDP-GlcNAc, chain elongation might stall 
temporarily as the excess substrate transiently occupies the binding site of the other substrate as a 
competitive inhibitor [248], but the chain is retained until the appropriate substrate is available 
for synthesis and chain elongation to commence. An alternate explanation might be that 
supplementing cultures with GlcNAc altered the rate of synthesis of UDP-GlcNAc. GlcNAc is 
simultaneously transported into the cell and phosphorylated to yield GlcNAc-6-P by the GlcNAc 
specific phosphotransferase system transporter NagP, and GlcNAc-6-P is subsequently converted 
to glucosamine-6-P by GlcNAc-6-P deacetylase (i.e. NagA) [249]. Glucosamine-6-P inhibits 
expression of glmS by associating with its 5’-untranslated region (UTR), resulting in self-
cleavage of the 5’-UTR by the glmS ribozyme, and subsequent targeting of the glmS mRNA for 
degradation [250]. Accordingly, the addition of exogenous GlcNAc in cultures of AW006-3 may 
disrupt the dissimilated carbon flux into the UDP-GlcNAc branch of the HA biosynthetic 
pathway and, therefore, increase the ratio of UDP-GlcUA to UDP-GlcNAc, resulting in 
decreased HA titers and increased MWs. We have previously observed that increased HA titers 
in cultures of B. subtilis are often accompanied by a decrease in the MW [239], and the yield on 
glucose and MW of HA produced in S. zooepidemicus were not correlated [245]. In any case, 
further investigation is required to elucidate the effects of overall carbon flux into the HA 
biosynthetic pathway and the UDP-GlcNAc/UDP-GlcUA ratio on the titer and MW of HA 
produced in B. subtilis. 
 The culture performance of zwf-repressed strains varied considerably. Mutation of zwf 
resulted in increased glycolytic flux in B. subtilis grown on glucose, albeit with a lower biomass 
yield [240]. This is consistent with our results as the final cell density of all zwf-repressed strains 
except AW014-3 was lower compared to AW009 (Figure 5.5C). Clearly, the majority of carbon 
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diverted from the PPP either entered glycolysis or another pathway other than HA biosynthesis 
given that the HA titers were not necessarily increased in these zwf-repressed strains (Figure 
5.5A). In this context, improving HA production may not be possible without reducing pfkA 
expression, particularly when the primary carbon source is sucrose with half of the dissimilated 
carbon naturally bypassing Zwf. By simultaneously repressing the expression of both pfkA and 
zwf in AW018-3 and AW019-3, we obtained significant increases in the HA titer (Figure 5.6A) 
and modest enhancements to the MW relative to AW009 (Figure 5.6B), indicating a significantly 
higher and more balanced carbon flux through the UDP-GlcUA and UDP-GlcNAc branches for 
HA biosynthesis. Note that the high degree of reversibility for the interconversion of glucose-6-P 
and fructose-6-P by Pgi is well documented [251, 252], potentially leading to more balanced flux 
distribution at these two nodes toward UDP-GlcUA and UDP-GlcNAc, respectively, in AW018-
3 and AW019-3.  
 A common approach to improve microbial HA production has been to overexpress genes 
in either branch of the HA biosynthetic pathway to upregulate the level of the limiting substrate 
(i.e. UDP-GlcUA or UDP-GlcNAc), but this strategy often yields modest returns on the HA titer 
and MW [5, 130]. To this end, we also evaluated the effects of overexpressing pgcA, glmS, or 
both genes on HA biosynthesis by transforming AW009 respectively with pAW019-3, pAW020-
3, and pAW021-3, generating corresponding strains AW020-3, AW021-3, and AW022-3. The 
titers and MWs of HA produced in cultures of AW020-3, AW021-3, and AW022-3 were highly 
similar to those obtained in cultures of AW009 (data not shown), confirming the deficiency of 
this metabolic approach.  
In addition to pfkA and zwf, we also targeted additional essential genes of interest for 
transcriptional interference, i.e. tagO, encoding UDP-GlcNAc-undecaprenyl-phosphate N-
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acetylglucosaminephosphotransferase (TagO) that converts UDP-GlcNAc to N-acetyl-
glucosaminyldiphospho-ditrans,octacis-undecaprenol during teichoic acid synthesis, and murAA, 
encoding UDP-GlcNAc 1-carboxyvinyltransferase (MurAA) that converts UDP-GlcNAc to 
UDP-GlcNAc-enolpyruvate during UDP-N-acetylmuramoyl-pentapeptide (i.e. cell wall) 
synthesis (Figure 5.1) [229]. However, preliminary attempts to reduce the expression of tagO 
and murAA via CRISPRi in AW002-3 resulted in poor growth and genetic instability, as certain 
derived B. subtilis strains lost the mucoid phenotype for HA-production (data not shown). 
Accordingly, future attempts to repress expression of these genes may employ very low levels of 
repression. 
 While the feasibility of repressing the expression levels of pfkA and zwf for enhanced HA 
production has been demonstrated, there appears to be no correlation between the repression 
efficiencies and culture performance. For example, the HA titer, MW, and cell density profiles in 
cultures of AW005-3, AW006-3, and AW007-3 were quite similar, even though the respective 
gRNAs in AW006-3 and AW007-3, i.e. pfkA-gRNA.P41NT(10C-A) and pfkA-
gRNA.P41NT(15U-C), contained single mismatches in their protospacers and, thus, should have 
significantly lowered repression efficiency compared to pfkA-gRNA.P41NT in AW005-3 for 
which the protospacer was unaltered. Moreover, AW009-3 achieved a significantly lower cell 
density compared to AW005-3, although the gRNA in AW009-3, i.e. pfkA-gRNA.P315NT(15U-
G), targeted dCas9 to a PAM site significantly further from the start codon of the pfkA ORF, 
compared to pfkA-gRNA.P41NT, and contained a single mismatch in the protospacer. Similarly, 
the HA titers and MWs were similar in cultures of AW012-3 and AW013-3 while transcription 
of zwf-gRNA.P92NT(10U-G) in AW013-3 should reduce the repression efficiency of zwf 
expression by ~75%, relative to the transcription of zwf-gRNA.P92NT in AW012-3. 
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Accordingly, anticipating the effects of altered repression efficiency for the expression of genes 
in the central metabolic pathways may not be practical, such that the design of multiple gRNAs 
for a single target is deemed necessary to realize the true impact of its repression on target 
metabolite production. Nevertheless, our results stress the importance of balancing intracellular 
substrate levels of UDP-GlcUA and UDP-GlcNAc for high-level production of high-MW HA in 





Chapter 6  
Application of hydrocarbon and perfluorocarbon oxygen vectors to enhance 
heterologous production of HA in engineered B. subtilis 
 
6.1 Introduction 
Industrial bioprocesses based on microbial platforms are typically aerobic and utilize aqueous 
growth medium containing salts and other nutrients [253]. Oxygen is sparingly soluble in aqueous 
solutions, a limitation that is exacerbated by factors such as salinity and culture viscosity [254, 255]. 
High-cell-density cultures are highly viscous, and, therefore, the diffusivity of oxygen becomes 
limited, causing a steep decline in dissolved oxygen (DO) levels [253, 255]. The increase in culture 
viscosity is more severe in bioprocesses in which high molecular weight (MW) biopolymers are 
secreted into the extracellular environment. For example, a substantial increase in viscosity (up to 
500-fold) is observed as HA titers exceed 5 g/L in microbial cultivations [5]. The DO concentration 
is an intrinsic factor influencing HA synthesis due to a high demand of ATP for HA-producing cells 
[5, 225]. Oxygen transfer in microbial cultivations can be improved by increasing agitation and 
aeration rates, and, if necessary, pure oxygen supplementation. However, shearing due to high 
agitation and aeration rates may reduce the quality (i.e. MW) of HA [136, 152, 256], and 
supplementing pure oxygen can be detrimental to microorganisms as exposure to reactive oxygen 
species such as H2O2, O2
-, and OH can result in DNA instability, and protein and lipid denaturation 
[257]. Moreover, recombinant protein expression may be hampered by excessive DO levels due to 
misfolding, loss of activity, and protease degradation [258, 259]. Consequently, alternate methods to 
improve oxygen transfer in microbial cultivations for HA production are of significant interest, and 
using oxygen vectors is one of them.  
Oxygen vectors are water-immiscible compounds possessing a greater capacity to dissolve 
oxygen compared to water. Hydrocarbons [136-139], perfluorocarbons [140-142], vegetable oil 
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[143], and silicone oil [139, 144] can enhance oxygen transfer in microbial cultivations, while 
insoluble polymers such as silicone rubber [139, 145], nylon [145], glass beads [145], Hytrel [139], 
Kraton [139], Desmopan [139, 144], and Elvax [144] have also been investigated as oxygen vectors. 
Oxygen vectors can enhance oxygen transfer by 1) creating large local concentration gradients in the 
bulk aqueous phase by shuttling oxygen-rich vector droplets from the gas-liquid interface to the bulk 
liquid; 2) reducing surface tension at the air-water interface, resulting in reduced bubble coalescence 
and, in turn, smaller bubble diameter and increased interfacial area for oxygen transfer; and 3) 
colliding with and breaking air bubbles, in turn, reducing bubble diameter [144, 260]. Oxygen 
vectors are categorized based on their propensity to form discrete droplets (i.e. non-spreading) or 
films which spread over gas bubbles (i.e. spreading) in an aqueous phase, and the means by which 
they affect oxygen transfer may be dictated by their tendency to spread or lack thereof [148]. The 
selection of an appropriate oxygen vector can potentially reduce operating costs associated with 
power consumption from high agitation rates, compressed air delivery, and supplemental oxygen, 
and can reduce oxidative damage to the producing cell and target metabolite or protein, while also 
minimizing foaming during high-cell-density cultivations [139, 257, 261]. 
The application of hydrocarbon and perfluorocarbon oxygen vectors to microbial cultivations 
for HA production has been investigated, albeit to a limited extent. The addition of n-dodecane [262] 
and n-hexadecane [152] to S. zooepidemicus cultivations resulted in improvements to both the HA 
titer and MW, while perfluorodecalin also increased the HA titer in S. zooepidemicus cultivations 
relative to a three-stage agitation operation in which the agitation speed was increased in a step-wise 
manner [140]. However, these studies investigated only a few compounds as potential oxygen 
vectors, and no data is currently available on the application of oxygen vectors to heterologous HA 
production in common microbial hosts. In this study, we evaluated three hydrocarbons (i.e. n-
heptane, n-hexadecane, and 2,2,4-trimethylpentane) and four perfluorocarbons (i.e. n-
perfluorooctane, perfluorodecalin, perfluoromethyldecalin, and perfluoro-1,3-dimethylcyclohexane) 
as potential oxygen vectors to enhance heterologous HA production in an engineered strain of B. 
subtilis with a significantly higher HA producing capacity than our previously reported strain [239]. 
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Significant improvements to the HA titer and/or cell density were observed in cultures containing n-
heptane, n-hexadecane, perfluoromethyldecalin, and perfluoro-1,3-dimethylcyclohexane, although 
the MW was marginally affected. We then manipulated the vector concentration and timing of 
addition, resulting in further improvements to the culture performance. Assessment of oxygen 
transfer via measuring the overall oxygen mass transfer coefficient kLa revealed that, regardless of 
spreading characteristics, hydrocarbon vectors slightly reduced kLa over the low vector 
concentrations employed in this study, while perfluoromethyldecalin enhanced oxygen transfer. We 
also investigated culture performance at higher agitation rates, and observed that the addition of n-
hexadecane or perfluoromethyldecalin further enhanced the HA titer and cell density, although the 
MW was somewhat reduced when n-hexadecane was present, suggesting that functional expression 
of hyaluronan synthase (HAS) may be affected by n-hexadecane exposure in B. subtilis. Moreover, 
our results indicate that higher shear rates may somehow drive more carbon flux through the HA 
biosynthetic pathway without negatively affecting the MW.   
 
6.2 Materials and methods 
6.2.1 Bacterial Strains and plasmid construction  
E. coli HI-Control™ 10G chemically competent cells were prepared as electrocompetent 
cells as described previously [187] and used as host for plasmid construction. Strain 1A751 is a 
derivative of B. subtilis 168 (i.e. B. subtilis 168 his nprR2 nprE18 ΔaprA3 ΔeglS102 ΔbglT bglSRV) 
that has proven to be an effective host for heterologous HA production [128, 239, 263]. B. subtilis 
and E. coli strains were maintained as glycerol stocks at -80 °C. To construct the genomic integration 
vector pAW009,  promoter Pgrac.UPmod was amplified from pHT01 [215] with primers 
Pgrac.UPmod,SalI.f (5’-cagattgagtcgacggatcactagaaaattttttatcttatcacttgaaattgg-3’) and 
Pgrac.UPmod.BamHI.r (5’-gcacttgaggatccttcctcctttaattggg-3’), followed by insertion into 
SalI/BamHI-digested pAW008 [263] as shown in Figure S6.1 (restriction sites are underlined in the 
primer sequences). Pgrac.UPmod (i.e. promoter P61) is a weaker derivative of promoter Pgrac (i.e. 
promoter P01) that contains a modified upstream promoter element (UP) that reduces the relative 
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promoter strength by approximately half [40] [Note that the modified UP was introduced with primer 
Pgrac.UPmod,SalI.f and the modified sequence is in bold font.]. Transformation of pAW009 into B. 
subtilis results in the integration of a Pgrac.UPmod::seHas:tuaD expression cassette at the amyE locus as 
shown in Figure S6.1 [tuaD encodes native UDP-glucose-6 dehydrogenase (TuaD) and seHas 
encodes hyaluronan synthase from S. equisimilis (SeHAS)]. Competent cell preparation and 
transformation of pAW009 was performed as previously described [263]. 
 
6.2.2 Cultivation medium and conditions 
  B. subtilis strains were plated on non-select LB agar (NaCl, 5 g/L; yeast extract, 5 g/L; 
tryptone, 10 g/L; agar, 15 g/L), and grown overnight at 37 °C. Shake flask cultures to compare 
HA production in AW008 and AW009 were performed as previously described (see section 
4.2.3) [239]. To prepare the seed cultures for bioreactor cultivations, a single colony was used to 
inoculate 25 mL prewarmed non-select LB, and grown for ~8 h at 37 °C and 280 rpm to generate 
the starter culture. The starter culture was subsequently diluted 100-fold into 100 mL prewarmed 
non-select LB, and grown for ~13 h at 37 °C and 280 rpm to generate the seed culture. 
Cultivations were performed in a New Brunswick™ BioFlo® 115 bioreactor (Hamburg, 
Germany) under the following conditions: 0.7 L working volume (1.3 L vessel), 2 volume per 
volume per minute (vvm) [i.e. 1.4 L/min] air, 300 rpm, 37 °C, pH 7 (3 M NH4OH). The non-
select cultivation medium was of the following composition (per L): sucrose, 30 g; (NH4)2SO4, 1 
g; K2HPO4∙3H2O, 9.15 g; KH2PO4, 3 g; trisodium citrate∙ 2H2O, 1 g; yeast extract, 10 g; CaCl2, 
5.5 mg; FeCl2∙ 6H2O, 13.5 mg; MnCl2∙ 4H2O, 1 mg; ZnCl2, 1.7 mg; CuCl2∙ 2H2O, 0.43 mg; 
CoCl2∙ 6H2O, 0.6 mg; Na2MoO4∙ 2H2O, 0.6 mg. The bioreactor was inoculated with 10% volume 
per volume (v/v) of the seed culture. HA purification and analysis was performed as previously 




6.2.3 Determination of kLa 
Experiments to determine kLa were performed under the same cultivation conditions described 
above without the inoculum. Measurements of kLa were performed using the dynamic “gas out-gas in” 
method, and the probe response time was neglected due to the relatively low kLa values obtained under 




) = −𝑘𝐿𝑎(𝑡 − 𝑡0)     (6.1) 
where DO* is the saturation reading of the probe. ANOVA was performed to determine the significance 
between kLa measurements, and the results of the analysis are presented in Table S6.1. 
 
6.2.4 Oxygen vectors  
n-heptane (>99%), n-hexadecane (>99%), n-perfluorooctane (98%), perfluorodecalin (95%), 
and perfluoro-1,3-dimethylcyclohexane (80%) were obtained from MilliporeSigma (MO). 
Perfluoromethyldecalin (80%), a mixture of perfluoro-1-methyldecalin and perfluoro-2-
methyldecalin, was also obtained from MilliporeSigma. n-Heptane (>99%) was obtained from J.T. 
Baker (NJ). The physical properties of oxygen vectors used in this study are provided in Table 6.1.  
 
6.2.5 Side metabolite analysis 
The titers of the side metabolites lactate, acetate, and 2,3-butanediol (2,3-BDO) were 
analyzed via high-performance liquid chromatography (HPLC). The system consists of a Shimadzu 
(Kyoto, Japan) LC-10AT solvent delivery unit, Shimadzu RID-10A refractive index detector, 
Shimadzu CTO-20A column oven, and an Aminex HPX-87H chromatographic column (Bio-Rad 
Laboratories, CA). The column temperature was maintained at 65°C, and the flow rate of the mobile 
phase (i.e. 5 mM H2SO4) was 0.6 mL/min. Signal acquisition and data processing was performed 
with Clarity Lite (DataApex, Prague, Czech Republic). 
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Table 6.1. Physical properties of oxygen vectors used in Chapter 6 measured at 25 °C and 
atmospheric pressure unless otherwise indicated. 
Compound 
Molecular  
















3.0 0.77 287 8.2 [265, 266] 
n-heptane C7H16 
(linear) 
0.39 0.68 98.4 10.8 [267, 268] 
2,2,4-trimethylpentane C8H18 
(branched) 











6.47 1.95 137-160 12.7 [273, 274] 
perfluorodecalin C10F18 
(bicyclic) 
5.41 1.91 142 13.9b [271, 275] 
n-perfluorooctane C8F18 
(linear) 
1.26 1.77 103 14.0c [275, 276] 
*Expressed as the fold increase in oxygen solubility relative to water. Measured at 16 °Ca, 38 
°Cb, and 36 °Cc 
 
6.3 Results 
6.3.1 Preliminary evaluation of potential oxygen vectors 
Three hydrocarbons and four perfluorocarbons were evaluated for their effects on HA 
production in batch cultivations of strain AW009 in a bench-scale STR. Potential oxygen vectors 
were selected based on their volatility (i.e. a minimum normal boiling point of ~100 °C) and relative 
oxygen solubility (i.e. at least 8-fold higher than water). Compounds such as n-heptane, n-
hexadecane, and perfluorodecalin were preferred as they had been successfully applied to either 
microbial HA production [140, 152] or biopolymer production in B. subtilis [153]. In the preliminary 
evaluation, each compound was added to the cultivation medium at a concentration of 1% v/v 2 h 
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after inoculation. A relatively low agitation rate at 300 rpm was used to minimize potential HA 
degradation resulting from polymer shearing [136].  
 AW009 produced 992 mg/L of HA after 12 h (Figure 6.1A) with a peak MW of 1.2 MDa at 8 
h, (Figure 6.1B), and final cell density of OD600 12.8 (Figure 6.1C). The DO fell below 5% saturation 
after 4 h where it remained for the rest of the cultivation (Figure 6.1D). The addition of n-hexadecane 
resulted in a 34% increase to the final HA titer (1327 mg/L; Figure 6.1A), although the MW was not 
significantly affected (Figure 6.1B). Note that ANOVA was performed on all measurements of the 
HA titer, MW, and cell density for all data sets presented herein, and a summary of the results of the 
analysis is presented in Table S6.1 of the Supplementary Materials. Moreover, the cell growth rate 
was improved such that the final cell density (OD600 13.3) was obtained at 10 h, compared to 12 h 
with no vector (Figure 6.1C). Notably, n-hexadecane was the only compound tested that provided a 
substantial increase in DO levels, which remained above 10% saturation throughout the cultivation 
(Figure 6.1D). While the addition of n-heptane did not markedly affect the volumetric HA titer, it did 
improve the specific HA titer by 26%, i.e. 97.6 mg/(L∙OD600) for n-heptane compared to 77.5 
mg/(L∙OD600) with no vector. Moreover, the addition of n-heptane prolonged the oxygen limitation 
by 1 h compared to the cultivation with no vector (Figure 6.1D).  
Two of the four perfluorocarbons tested, i.e. perfluoro-1,3-dimethylcyclohexane and 
perfluoromethyldecalin, significantly improved culture performance. The addition of perfluoro-1,3-
dimethylcyclohexane and perfluoromethyldecalin resulted in 50% (1490 mg/L) and 49% (1481 
mg/L) increases to the final HA titer (Figure 6.1A), respectively, although the MW was not 
significantly affected (Figure 6.1B). Moreover, the respective final cell densities increased by 16% 
(OD600 14.8) and 11% (OD600 14.2) relative to the cultivation with no vector (Figure 6.1C) although 
DO levels were marginally improved (Figure 6.1D). Conversely, the addition of n-perfluorooctane 
resulted in a 23% decrease to the HA titer (761 mg/L; Figure 6.1A), and an 11% decrease in the final 
cell density (OD600 11.4; Figure 6.1C). The specific HA titer was highest for the cultivation with 
perfluoromethyldecalin (104.7 mg/(L∙OD600)), compared to all other vectors, and was 35% higher 




Figure 6.1. Time profiles of A) HA titer, B) HA MW, C) cell density, and D) DO in cultures of 
AW009 with no vector, or in which n-hexadecane, n-heptane, 2,2,4-trimethylpentane, perfluoro-
1,3-dimethylcyclohexane, perfluoromethyldecalin, perfluorodecalin, or n-perfluorooctane was 
added 2 h after inoculation at a final concentration of 1% v/v. SD of duplicate samples shown in 
Panels A, B, and C. 
 
1,3-dimethylcyclohexane, the oxygen vectors were added at the time of seed culture inoculation. 
However, the addition of 2,2,4-trimethylpentane and perfluoromethyldecalin at the time of 
inoculation completely inhibited growth, such that in subsequent experiments all vectors were added 
2 h after inoculation when the exponential growth phase was reached. This bioprocessing strategy 
was developed based on the prior observation that 2,2,4-trimethylpentane is toxic to E. coli in the 
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stationary phase, but is not during exponential growth [277]. Adding n-hexadecane at the time of 
inoculation resulted in a 30% increase in the final HA titer (1731 mg/L; Figure 6.2A), a 14% increase 
in the final MW (1.14 MDa; Figure 6.2B), and a 22% increase in the final cell density (OD600 16.1; 
Figure 6.2C), although DO levels were lower between 5 h and 8 h (Figure 6.2D), compared to the 
addition of n-hexadecane at 2 h. The addition of perfluoro-1,3-dimethylcyclohexane at the time of 
inoculation did not significantly increase the final HA titer or MW, although the titer after 10 h was 
similar to the final titer when the vector was added at 2 h (Figure 6.2A). Moreover, the final cell 
density increased by 15% (OD600 17; Figure 6.2C), although the DO profiles were not significantly 
different (Figure 6.2D).  
 
6.3.2 Vector concentration affects HA production 
Based on the results from the preliminary evaluation, n-hexadecane provided the greatest 
enhancements to DO levels and HA production. Accordingly, we attempted to further improve 
culture performance by manipulating the n-hexadecane concentration. Reducing the n-hexadecane 
concentration to 0.5% v/v increased the final HA titer by 20% (1596 mg/L; Figure 6.3A), without 
significantly affecting the MW (Figure 6.3B). The final cell density also increased by 22% (OD600 
17.4; Figure 6.3C), which may be attributed, in part, to the increase in DO levels after 6 h (Figure 
6.3D). Our results are similar to an earlier report of enhanced HA production in batch cultures of S. 
zooepidemicus upon the addition of n-hexadecane to 0.5% v/v, which maximized kLa [152]. In 
contrast, adding n-hexadecane to 1% v/v was found to be optimal for PGA production in B. subtilis 
[153]. The application of n-heptane as an oxygen vector to enhance PGA production in cultures of B. 
subtilis resulted in greater improvements to both the titer and MW, compared to cultures 
supplemented with n-hexadecane, and the optimal concentration of n-heptane (0.3% v/v) was 
significantly lower compared to n-hexadecane (1% v/v) [153]. On the other hand, we obtained 
significantly higher HA titers with n-hexadecane compared to n-heptane (Figure 6.1A), albeit with a 
slight reduction in MW (Figure 6.1B). Given that our preliminary evaluation was conducted with a 




Figure 6.2. Time profiles of A) HA titer, B) HA MW, C) cell density, and D) DO in cultures of 
AW009 in which n-hexadecane or perfluoro-1,3-dimethylcyclohexane was added at the time of 
inoculation (0 h) or 2 h after inoculation at a final concentration of 1% v/v. SD of duplicate 
samples shown in Panels A, B, and C. 
 
concentration might improve culture performance. Reducing the n-heptane concentration to 0.4% v/v 
resulted in a substantially higher HA titer after 10 h cultivation (1123 mg/L), compared to the 
cultivations containing either 1% v/v n-heptane (672 mg/L) or no vector (599 mg/L; Figure 6.4A). 
However, the final HA titer (Figure 6.4A) and MW profile (Figure 6.4B) were not significantly 
improved by reducing the n-heptane concentration. The DO levels declined quickly prior to the 




Figure 6.3. Time profiles of A) HA titer, B) HA MW, C) cell density, and D) DO in cultures of 
AW009 with no vector, or in which n-hexadecane was added 2 h after inoculation at a final 




rescued upon adding n-heptane, before dropping to approximately 0% saturation at around 3 h 
(Figure 6.4D). Similarly, the addition of 0.4% v/v n-heptane did not delay oxygen limitation, 
compared to the cultivation with no vector, such that in both cultivations the DO level fell below 5% 
saturation after approximately 4 h (Figure 6.4D). This is in contrast to the cultivation containing 1%  
v/v n-heptane in which oxygen limitation was postponed by approximately 1 h. 
 Due to the high specific HA titer observed in the cultivation containing 




Figure 6.4. Time profiles of A) HA titer, B) HA MW, C) cell density, and D) DO in cultures of 
AW009 with no vector, or in which n-heptane was added 2 h after inoculation at a final 
concentration of 0.2%, 0.4%, or 1% v/v. SD of duplicate samples shown in Panels A, B, and C. 
 
further evaluated the effect of perfluoromethyldecalin concentration on HA production. Reducing the 
perfluoromethyldecalin concentration to 0.5% v/v resulted in culture performance similar to the 
cultivation with no vector (Figure 6.5). Moreover, further increasing the perfluoromethyldecalin  
concentration to 2% v/v did not significantly improve the culture performance compared to 1% v/v 
(Figure 6.5). In spite of the delay in reaching oxygen limitation by 2 h upon adding 
perfluoromethyldecalin to 3% v/v, the final HA titer and cell density were not improved, compared to 
2% v/v, and the MW declined potentially due to an increase in viscosity with increasing 





Figure 6.5. Time profiles of A) HA titer, B) HA MW, C) cell density, and D) DO in cultures of 
AW009 with no vector, or in which perfluoromethyldecalin was added 2 h after inoculation at a 
final concentration of 0.5%, 1%, 2%, or 3% v/v. SD of duplicate samples shown in Panels A, B, 
and C. 
 
6.3.3 The effect of oxygen vectors on oxygen mass transfer 
In an attempt to understand how oxygen vectors can enhance HA production in B. subtilis, 
we assessed oxygen mass transfer in our cultivation system. The addition of 0.25% v/v n-hexadecane 
resulted in a modest decrease in kLa, although increasing the concentration to 2% v/v had essentially 
no further effect on kLa (Figure 6.6A). The magnitude and trend of our kLa estimates with increasing 
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n-hexadecane concentration are consistent with previous work in which kLa decreased modestly for 
concentrations up to 2.5% v/v during the operation at 288 rpm and 1 vvm air-purging [152]. In 
contrast to our results, an initial increase in kLa was observed at low n-hexadecane concentrations 
(i.e. < 2.5% v/v), followed by a decline in kLa at higher n-hexadecane concentrations until phase 
inversion occurred (i.e. the culture becomes a continuous phase when the vector concentration is high 
enough) [278]. However, the latter study employed surface aeration in a STR operated at 1000 rpm 
such that direct comparison of results is difficult. As was the case for n-hexadecane, the addition of 
n-heptane at 0.2% v/v resulted in a modest decrease to kLa, and increasing the concentration to 1% 
v/v did not appreciably affect kLa (Figure 6.6B). In contrast to our results, the addition of n-heptane 
at 0.1% v/v in a STR operated at 300 rpm and 0.5 vvm resulted in a 15% increase in kLa, and 
increasing the n-heptane concentration to 5% v/v increased kLa by 175% [279]. On the other hand, 
simultaneously increasing the agitation and aeration rates to 400 rpm and 1 vvm, respectively, 
resulted in an initial 50% reduction in kLa for n-heptane concentrations up to 1% v/v, followed by a 
gradual increase in kLa with a further increase in the n-heptane concentration [279]. Accordingly, the 
effect of n-heptane on kLa in aerated STRs appears to vary considerably with agitation and aeration 
rates, such that our observation of a slight reduction in kLa was considered reasonable. Finally, n-
heptane can dramatically increase kLa in bubble column reactors as both vector concentration and 
superficial gas velocity are increased [280]. In general, non-spreading hydrocarbons (e.g. n-
hexadecane) negatively or hardly affect kLa [148], although at lower vector concentrations kLa may 
increase due to the shuttling effect, through which vector droplets briefly contact the air bubble 
surface and subsequently transfer oxygen to the bulk aqueous phase [139, 279]. Alternatively, 
spreading hydrocarbons (e.g. n-heptane) generally induce an initial decrease in kLa at low 
concentrations, followed by a gradual increase in kLa with increasing concentration [165, 167, 168, 
279]. It was hypothesized that the initial decrease in kLa resulted from increased liquid phase 
resistance due to the accumulation of surface active contaminants at the gas-water interface, and that 





Figure 6.6. kLa determined for different concentrations of A) n-hexadecane, B) n-heptane, and 
C) perfluoromethyldecalin. Experimental conditions described in M&M. SD of three 
experiments shown. 
 
phase inversion [167, 168]. An alternate/complementary explanation is that the vector film forming 
around air bubbles becomes unstable with increasing thickness as the vector concentration increases, 
resulting in the release of oxygen-rich droplets into the bulk aqueous phase [279].  
While n-hexadecane and n-heptane slightly reduced kLa, perfluoromethyldecalin had the 
opposite effect such that kLa increased with increasing concentration up to 2% v/v, resulting in a 
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maximum increase of 35% in kLa compared to the control with no vector (Figure 6.6C). While kLa 
measurements for perfluoromethyldecalin are not available in the literature, perfluorodecalin, a 
structurally similar vector, was observed to increase kLa in a STR at concentrations up to 20% v/v, 
using the same agitation rate and lower aeration (1.1 vvm) compared to our study, resulting in a 
maximum increase of ~70% in kLa [281]. Similarly, the addition of perfluorodecalin to 5% v/v 
provided a slight increase in kLa in a STR operated at 300 rpm and 0.5 vvm air-purging, while 
increasing the concentration to 10% v/v resulted in a 40% increase in kLa [282]. The addition of 
forane F66E, an unsaturated perfluorocarbon, to Aerobacter aerogenes cultures operated at 400 rpm 
and 0.21 vvm air-purging, increased kLa for concentrations up to 23% v/v, resulting in a maximum 
increase of ~250% in kLa [141]. Accordingly, a consensus seems to exist regarding the positive 
influence of perfluorocarbons on oxygen transfer in biological cultivation systems, and this is in line 
with our observations.  
 
6.4 Discussion  
Simultaneously achieving a high MW and titer in cultivations for HA production is a 
challenging task. Generally, it requires a high carbon flux through both branches of the HA 
biosynthetic pathway to ensure a sufficient and balanced monomer supply of UDP-GlcNAc and 
UDP-GlcUA [245]. Moreover, an adequate supply of oxygen is essential to generate the substantial 
amount of ATP consumed during HA biosynthesis, and this is particularly challenging due to the 
rapid increase in culture viscosity with increasing HA titer [5, 140]. To further complicate matters, 
the functional expression of HAS to maximize HA production is dependent on its specific orientation 
with certain lipids in the cell membrane  [123, 239]. Here we have shown that hydrocarbon and 
perfluorocarbon oxygen vectors can significantly increase the HA titer in B. subtilis cultures. 
However, certain vectors may reduce the efficacy with which streptococcal Class I HAS can extend 
the growing HA chain, compromising the MW of the produced HA in B. subtilis. 
 Maintaining the DO above a critical level of ~5% saturation was essential to maximize the 
HA yield in S. zooepidemicus cultivations [225], and this is expected given that three mol ATP are 
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required to produce one mol HA disaccharide [5]. While evidence exists to suggest that B. subtilis is 
a facultative anaerobe which uses nitrate as an electron acceptor [283, 284], our attempts to grow 
1A751 anaerobically were unsuccessful (unpublished data), indicating that this strain may require a 
more oxygenic condition to achieve optimal growth. In our study, only supplementation of n-
hexadecane resulted in DO levels that exceeded 5% saturation throughout the cultivation. 
Nonetheless, supplementation of n-hexadecane, n-heptane, perfluoro-1,3,-dimethylcyclohexane, and 
perfluoromethyldecalin resulted in improvements to the HA titer. To gain further insight into the 
improved culture performance upon the addition of n-hexadecane, we analyzed the side metabolite 
distribution in cultures with no vector or 0.5% v/v n-hexadecane. No ethanol or succinate was 
detected in cultures with or without n-hexadecane, and lactate (Figure 6.7A) and acetate (Figure 
6.7B) accumulation were not significantly different between cultures as determined by ANOVA 
(Table S6.1). Conversely, the 2,3-BDO titer was 2-fold higher in cultures with no vector compared to 
those with n-hexadecane, i.e. 5385 mg/L with no vector compared to 2694 mg/L for n-hexadecane 
(Figure 6.7C). Exogenous supplementation of 2,3-BDO at a concentration of 10 g/L significantly 
reduced the PGA titer in B. subtilis cultures [285], such that 2,3-BDO accumulation in cultures with 
no vector may have negatively affected HA production in our study. Moreover, reduced carbon flux 
toward 2,3-BDO production due to improved aerobicity may, in part, explain the improved HA titers 
in cultures containing n-hexadecane compared to those with no vector. Interestingly, the HA titer was 
lower in cultures containing 1% v/v n-hexadecane, compared to 1% v/v perfluoro-1,3,-
dimethylcyclohexane or perfluoromethyldecalin, in spite of significantly higher DO levels when n-
hexadecane was present. Manipulation of the n-hexadecane concentration led to further increases to 
the DO level, particularly between 6 and 12 h, although the final HA titer was not significantly  
higher than that obtained in cultivations containing perfluoro-1,3-dimethylcyclohexane or 
perfluoromethyldecalin. As a result, we cultivated AW009 under a higher agitation rate of 600 rpm 
with or without n-hexadecane to investigate the individual effects of increased DO levels and n-
hexadecane addition. The HA titer increased by 245% (3423 mg/L; Figure 6.8A) after 10 h and the 




Figure 6.7. Time profiles of A) lactate titer, B) acetate titer, and C) 2,3-BDO titer in cultures of 
AW009 with no vector, or in which n-hexadecane was added 2 h after inoculation at a final 
concentration of 0.5% v/v. SD of duplicate samples shown in Panels A, B, and C. 
 
300 to 600 rpm with no vector. Cultivation with 0.5% v/v n-hexadecane at 600 rpm further increased 
the HA titer by 30% (4,462 mg/L; Figure 6.8A), although the MW was 12% lower (1.71 MDa; 




Figure 6.8. Time profiles of A) HA titer, B) HA MW, C) cell density, and D) DO in cultures of 
AW009. Experimental conditions: no vector and 600 rpm; 0.5% v/v n-hexadecane and 600 rpm; 
1% v/v perfluoromethyldecalin and 600 rpm; or no vector, 300 rpm, and supplemental oxygen to 
maintain the DO concentration at 20 ± 5% saturation. Oxygen vectors were added 2 h after 
inoculation. SD of duplicate samples shown in Panels A, B, and C. 
 
final cell density was improved upon the addition of n-hexadecane, i.e. OD600 27 for 0.5% v/v n-
hexadecane vs. OD600 22.1 for the control with no vector (Figure 6.8C), although the DO profiles 
were not much different (Figure 6.8D). Moreover, increasing the n-hexadecane concentration to 1%  
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v/v during cultivation at 600 rpm reduced the MW by an additional 30%, compared to 0.5% v/v n-
hexadecane, although DO levels were markedly increased and the final cell density was slightly 
higher (data not shown).  
While our results show that n-hexadecane does not impede cell growth in the concentration 
range up to 2% v/v, the effects of n-hexadecane on HA production may be somewhat polar in nature. 
Streptococcal HAS is an integral membrane protein for autonomous HA synthesis, which is a process 
requiring as many as seven different functions for initiation, elongation, and secretion of the HA 
chain [115]. The relatively small size and few transmembrane domains of streptococcal HAS suggest 
that they cannot facilitate pore formation for translocation of the growing HA chain [115], and CL or 
other lipids may assist HAS in creating an internal pore for HA translocation [119, 239]. Moreover, 
interactions between CL and HA may add to the net retention force that keeps the HA-UDP/HAS 
complex together during polymerization until a sufficient opposing force exceeds the net retention 
force, resulting in the release of the growing HA chain [121, 211]. The use of n-hexadecane as an 
oxygen vector resulted in significant increases to the HA titer in this work, and in a prior study in 
which HA was produced in the native production host S. zooepidemicus [152]. Accordingly, the 
enhanced HA production upon supplementation of n-hexadecane may not be associated with the 
catalytic activities of HAS, but the increased ATP generation resulting from increased oxygen 
transfer [133]. On the other hand, the lower MW of HA produced in cultures containing n-
hexadecane suggests premature release of the HA chain. Longer alkanes such as n- hexadecane can 
align parallel to the acyl chains in the lipid bilayer, and, therefore, affect acyl chain packing and tilt, 
resulting in a reduction in the projected area occupied per lipid molecule and an overall increase in 
the degree of ordering of the lipid bilayer [286, 287]. In our study, penetration of n-hexadecane 
through the cell membrane may result in the reordering of lipid acyl chains in the lipid bilayer, in 
turn, altering their interaction with SeHAS. As a result, the HA-binding regions that retain  
and coordinate translocation of the growing HA chain, and the pore-like structure through which the 
chain is extruded may be altered, resulting in lower MW HA.  
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In addition to the reordering of lipids in the bilayer, exposure to organic solvents can alter the 
fatty acid and lipid composition of the cell membrane. For example, insertion of long chain alcohols 
(>C5) into a lipid bilayer can increase membrane fluidity [288, 289], and an increase in the 
abundance of saturated fatty acids has been observed in the cell membrane of E. coli upon exposure 
to C5-C8 alcohols [290]. Conversely, exposure to ethanol resulted in an increase in unsaturated fatty 
acids, presumably to compensate for a reduction in membrane fluidity in E. coli [290]. Moreover, an 
increase in either saturated or unsaturated fatty acids has been reported for E. coli exposed to a 
number of other organic solvents [291]. In some cases, the shift in cellular fatty acid composition 
coincided with changes in the ratio of the major lipids PG and phosphatidylethanolamine, while 
certain solvents caused a dramatic increase in the CL content [291]. Considering that the functional 
expression of HAS is dependent on its orientation with certain lipids in the cell membrane (i.e. a 
strong preference for CL has been observed in vitro) [121], it is possible that alterations to the lipid 
content of the cell membrane of AW009 via exposure to various oxygen vectors could modulate the 
functional expression of SeHAS. Furthermore, the composition of CL acyl chains affected SeHAS 
activity in vitro [122, 123], such that a shift in acyl chain composition of lipids in the cell membrane 
may also affect the functional expression of SeHAS and, in turn, HA production. 
The spreading coefficient (Svw) is an indicator of the spreading characteristics of a given 
compound, and spreading behavior is anticipated when Svw > 0 [141]. While measurements of Svw 
tend to vary, there is agreement that Svw decreases with increasing size and branching or methylation 
of the molecule [292-294]. n-Heptane is reportedly a spreading vector [278, 292], while n-
hexadecane may be a spreading [278] or non-spreading [293] vector. Given the significant molecular 
size difference between the two vectors, n-heptane is more prone to spreading than n-hexadecane, 
such that oxygen transfer was more likely to improve upon the addition of n-hexadecane at the low 
concentrations employed in our study. However, our estimates of kLa suggest that the specific rate of 
oxygen transfer was nearly identical at the respective optimal concentration of each vector, i.e. 21.8 
h-1 for 0.5% v/v n-hexadecane (Figure 6.6A) vs. 22 h-1 for 0.4% v/v n-heptane (Figure 6.6B), both of 
which are slightly lower than kLa with no vector (22.9 h
-1; Figure 6.6). The reduced kLa in the 
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presence of n-hexadecane could be due to an increased time needed to reach oxygen saturation in the 
bulk liquid, and this was observed during the application of silicone rubber, a compound with a high 
affinity for oxygen, as a solid oxygen vector [145]. In any case, the specific rate of oxygen transfer is 
not the sole determinant of culture performance for HA production, given that the HA titers and cell 
densities were higher in cultures containing the optimal concentration of n-hexadecane, compared to 
perfluoromethyldecalin, at both 300 rpm and 600 rpm. Furthermore, the relative affinities for oxygen 
between vectors do not correspond to culture performance, as the respective oxygen solubilities of n-
heptane and perfluoromethyldecalin are ~80% and 100% higher than n-hexadecane [268, 274]. 
Consequently, alternate factors specific to cell physiology may contribute to the net effects of oxygen 
vectors on culture performance, and this is underlined by the observation that adding n-hexadecane to 
cultures in different growth phases, i.e. stationary at 0 h and exponential at 2 h, has a dramatic effect 
on culture performance (Figure 6.2). As previously mentioned, longer alkanes such as n-hexadecane 
can align parallel to the acyl chains in the lipid bilayer, affecting acyl chain packing and tilt for an 
overall increase in the ordering of the lipid bilayer [286, 287]. On the other hand, the interactions 
between smaller alkanes (e.g. n-heptane) and acyl chains disturb the interactions between acyl chains 
and, in turn, reduce the ordering of the lipid bilayer [286]. The net effect on the structure of the lipid 
bilayer of AW009 may partially explain the difference in culture performance, which seems to be 
largely dependent on cell growth, based on the highly similar specific HA titers of 91.7 mg/(L∙OD600) 
and 93.9 mg/(L∙OD600) obtained in cultivations containing optimal concentrations of n-hexadecane 
and n-heptane, respectively. In the case of perfluorocarbons, membrane uptake of them is slow 
compared to hydrocarbons due to their relatively high lipophobicity [295], such that partitioning of 
perfluoromethyldecalin into the lipid bilayer may be less extensive compared to hydrocarbon vectors. 
Accordingly, increased oxygen transfer may be the most significant factor enhancing culture 
performance with the presence of perfluoromethyldecalin and perfluoro-1,3-dimethylcyclohexane.  
Evidence suggests that excessive shear stress due to high agitation rates can be detrimental to 
the MW of HA produced in S. zooepidemicus cultures [136, 152, 256]. The MW increased from 1.69 
MDa to 2.01 MDa as the agitation rate increased from 150 rpm to 450 rpm, while at 700 rpm the 
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MW declined to 1.84 MDa [136]. However, the DO was not held constant during respective 
experiments at different agitation rates, and it was hypothesized that the lower OTR at 150 rpm 
negatively affected the MW [136]. Similarly, we observed a 58% increase in the MW of HA 
produced by AW009 as the agitation rate increased from 300 rpm to 600 rpm. To distinguish 
between the effects of shear stress and enhanced oxygen transfer, AW009 was cultivated at 300 rpm 
with supplemental oxygen to maintain the DO concentration at 20 ± 5% saturation (with no vector) 
to ensure operation above the critical DO level. The peak MW was within 3% (1.88 MDa; Figure 
6.8B) and the final cell density was 9% higher (OD600 24; Figure 6.8C), although the titer was 37% 
lower (2141 mg/L; Figure 6.8A) compared to the cultivation at 600 rpm with no vector. Based on 
these observations, it appears that a higher shear rate is not detrimental to the MW of HA produced 
by B. subtilis in batch cultivations operated up to 600 rpm and, in fact, may be beneficial in 
maximizing the HA titer. Maximum growth rates corresponding to optimal agitation rates have been 
observed in cultures of various microorganisms [296, 297], although the maximum growth rate also 
corresponded to a maximum OUR in Brevibacterium flavum [297]. In our study, oxygen uptake is 
not limiting in cultivations operated at 300 rpm with supplemental oxygen, suggesting that either a 
higher shear rate improved flux through the HA biosynthetic pathway, or excess DO levels were 
detrimental to the functional expression of SeHAS or carbon flux for HA production. An increase in 
the specific growth rate, cell density, and expression of certain extracellular enzymes was observed 
with increasing shear rates in B. subtilis cultures [298], indicating that a higher agitation rate could 
contribute to the higher growth rate and increased HA synthesis observed during operation at 600 
rpm with no vector. On the other hand, excess DO can reduce the yields of certain recombinant 
proteins via oxidation of Met and Cys residues [257], resulting in misfolding, loss of activity, and 
protease degradation [258, 259]. Throughout much of the cultivation in our study, pure oxygen was 
needed to maintain the desired DO level. However, the peak MW of HA did not decrease when 
operating at 300 rpm with supplemental oxygen. While the functional expression of SeHAS could 
still be affected by pure oxygen feeding, the control of chain length and polymerizing activity are 
independent functions of SeHAS that are not coupled to one another [211]. Accordingly, further 
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investigation is required to elucidate the effects of shear stress and DO levels in cultivations of HA-
producing B. subtilis. In addition, our results suggest that operating at agitation rates in excess of 300 
rpm can enhance the MW and HA titer, and that oxygen vectors can further enhance culture 
performance under these conditions.   
Few reports exist on the application of oxygen vectors to microbial HA production or 
biopolymer production in B. subtilis. The application of 0.5% v/v n-hexadecane to cultivations of S. 
zooepidemicus for HA production resulted in a similar increase to the HA titer as observed in our 
work [152]. However, the highest reported MW of 15.4 MDa in the cited study is far in excess of any 
reported MWs to date, such that comparison of MW data may be not be reasonable. n-Dodecane has 
also been applied to cultivations of S. zooepidemicus for enhanced HA production [262]. The 
addition of 5% v/v n-dodecane resulted in a 25% increase in the HA titer, although the maximum 
increase in MW of 46% was obtained at a concentration of 3% v/v n-dodecane, with the peak MW 
reaching 1.9 MDa [262]. Perfluorodecalin has also been used to enhance HA production in cultures 
of S. zooepidemicus, although the MW was not assessed [140]. The addition of perfluorodecalin to 
3% v/v resulted in a 32% improvement to the HA titer, compared to a three phase agitation strategy 
in which the agitation speed was increased from 200 rpm to 600 rpm, and a further increase in the 
perfluorodecalin concentration reduced DO levels presumably due to an increase in culture viscosity 
[140]. While the application of oxygen vectors to cultivations of S. zooepidemicus result in relative 
increases in the HA titer similar to our cultivations with B. subtilis, the improvements to the MW 
suggest that the functional expression of native HAS may be less sensitive to perturbations that may 
affect cell membrane ordering and fluidity. n-Heptane and n-hexadecane have also been applied as 
oxygen vectors to PGA production in cultures of B. subtilis [153], resulting in respective increases in 
the titer of 25% and 20%, as well as respective increases in the MWs of 25% and 20%. PgsB and 
PgsC, which are the capsular PGA synthetase and capsular PGA amide ligase/translocase subunit, 
respectively, polymerize PGA, which is presumably translocated out of the cell by CapA and PgsE 
(whose respective functions have not been formally elucidated) with assistance from PgsC [299]. 
Accordingly, at least four proteins are involved in the synthesis and translocation of PGA in B. 
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subtilis, and this is in contrast to HA production for which a single enzyme (i.e. HAS) is responsible 
[115]. Due to the autonomous functionality of SeHAS, which is dependent on its orientation with 
lipids in the cell membrane [119, 239], reordering or alteration of lipids in the cell membrane may 
have a more pronounced impact on the functional expression of SeHAS, but not the elaborate PGA-
producing enzyme complex. This potentially results in markedly different effects on the MW of 
























Chapter 7  
Metabolic engineering of B. subtilis for L-valine overproduction 
 
7.1 Introduction 
As one of the three branched-chain amino acids (BCAAs), L-valine is an essential 
nutrient for humans and animals, and is used in infusion solutions and human dietary 
supplements [300], commercial feed in the swine and poultry industries [301], and as a precursor 
for herbicide and antibiotic synthesis [301]. The extraction of L-valine, and most other amino 
acids, from protein hydrolysate has been replaced by microbial production and/or enzymatic 
synthesis [302]. To date, E. coli [303-305] and C. glutamicum [306-310] have been extensively 
engineered for microbial L-valine overproduction. E. coli is an endotoxin-producing bacterium 
[2] and, thus, is not an ideal production host for use in the pharmaceutical and food industries. 
On the other hand, C. glutamicum has been granted GRAS status and has been used for the large-
scale production of a selection of amino acids [311]. However, genetic manipulation of C. 
glutamicum remains cumbersome due to the absence of an efficient recombination system [312], 
and engineered strains typically contain replicating plasmids that require antibiotic selection and 
may be unstable in the host cell. While C. glutamicum is currently the preferred workhorse for 
industrial amino acid production, other microorganisms may be promising candidates in this 
arena. B. subtilis is a genetically tractable model Gram-positive bacterium, grows rapidly in 
simple medium, has been granted GRAS status [1], and, therefore, can be an ideal host for L-
valine production. Moreover, a comprehensive CRISPR-Cas9 toolkit was recently developed for 
B. subtilis, enabling efficient multiplexing of gene mutations and transcriptional repression 
[263], such that scalable strain construction can now be achieved in this organism. B. subtilis 
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serves as a biomanufacturing platform for the commercial production of enzymes [2], HA [105], 
and surfactants [313], and is capable of high-level isobutanol production [314], with which the L-
valine biosynthetic pathway shares the common precursor 2-ketoisovalerate.  
 Like many important biomolecules, BCAAs are derived from pyruvate and their 
biosynthesis is controlled at the transcriptional level through a complex regulatory cascade in B. 
subtilis. Pyruvate is first converted to 2-acetolactate by an acetohydroxy-acid synthase (AHAS) 
composed of regulatory (i.e. IlvH, encoded by ilvH) and catalytic (i.e. IlvB, encoded by ilvB) 
subunits, or by acetolactate synthase (ALS) encoded by alsS (AlsS), as an intermediate of L-
valine biosynthesis (Figure 7.1). In parallel, IlvBH can convert 2-ketobutyrate (derived from L-
threonine) and pyruvate to 2-aceto-2-hydroxybutyrate as an intermediate of L-isoleucine 
biosynthesis (Figure 7.1). On the other hand, AlsS appears to be a dedicated ALS as it 
presumably cannot facilitate L-isoleucine synthesis [315], which is a common characteristic of 
several such bacterial enzymes that convert pyruvate to 2-acetolactate as a precursor to acetoin 
production [315, 316]. 2-acetolactate and 2-aceto-2-hydroxybutyrate are respectively converted 
to 2,3-dihydroxyisovalerate and 2,3-dihydroxy-3-methylpentanoate by acetohydroxy-acid 
isomeroreductase (i.e. IlvC, encoded by ilvC), followed by their conversion to 2-ketoisovalerate 
and 3-methyl-2-oxopentanoate, respectively, by dihydroxy-acid dehydratase (i.e. IlvD, encoded 
by ilvD) (Note that 2-ketoisovalerate is also an intermediate of L-leucine and pantothenate 
synthesis.). Finally, 2-ketoisovalerate and 3-methyl-2-oxopentanoate are converted to L-valine 
and L-isoleucine, respectively, by one of two BCAA aminotransferases, i.e. YbgE (encoded by 
ybgE) and YwaA (encoded by ywaA), either of which can also convert 4-methyl-2-
oxopentanoate to L-leucine (Figure 7.1).   




Figure 7.1. The L-valine biosynthetic pathway in B. subtilis. Green arrows represent reactions 
catalyzed by enzymes whose expression was upregulated, and red arrows represent reactions 
catalyzed by enzymes that were inactivated. AlsS, acetolactate synthase; BcaP, BCAA permease; 
Bcd, BCAA dehydrogenase; IlvA, L-threonine dehydratase; IlvB, acetohydroxy-acid synthase 
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catalytic subunit; IlvC, acetohydroxy-acid isomeroreductase; IlvD, dihydroxy-acid dehydratase; 
IlvH*, engineered acetohydroxy-acid synthase regulatory subunit; LeuA, 2-isopropylmalate 
synthase; PdhABCD, pyruvate dehydrogenase complex; YbgE, BCAA aminotransferase; YwaA; 
BCAA aminotransferase. 
 
operons: 1) ilvBHC-leuABCD (leuABCD encodes 2-isopropylmalate synthase, 3-isopropylmalate 
dehydrogenase, and 2-isopropylmalate dehydratase large and small subunits, respectively); 2) 
ilvA (encoding L-threonine dehydratase); 3) ilvD; 4) ybgE; and 5) ywaA [317]. Operons 1-5 are 
repressed under amino acid-rich conditions by the activity of the transcriptional regulator CodY 
in B. subtilis [318-320], and L-valine and L-isoleucine are positive effectors of CodY such that 
BCAA biosynthesis is negatively autoregulated at relatively low BCAA concentrations [319]. 
Specifically, expression of the ilvBHC-leuABCD (ilv-leu) operon is repressed through the 
interaction of CodY with two high-affinity (i.e. CodY-I and CodY-II) and two low-affinity (i.e. 
CodY-III and CodY-IV) binding sites, while the CodY binding sites regulating the expression of 
ilvA, ilvD, ybgE, and ywaA have not been formally elucidated [318]. CodY-I, CodY-II, CodY-III, 
and CodY-IV are located at base pairs (bp) -42/-32, -84/-52, -154/-107, and -168/-185, 
respectively, relative to the transcriptional start site of promoter Pilv-leu [321, 322]. CodY-II 
partially overlaps a CRE (located at bp -96/-82) that, in combination with an upstream CRE site 
(located at bp -128/-110) that overlaps CodY-III, can facilitate catabolite activation of Pilv-leu by 
the transcriptional regulator carbon catabolite protein A (CcpA) complexed with P-Ser-histidine-
containing phosphocarrier (HPr) protein  [321]. CodY outcompetes the CcpA-P-Ser-HPr 
complex under amino acid-rich conditions, nearly abolishing catabolite activation of Pilv-leu. 
Moreover, catabolite activation of Pilv-leu by the CcpA-P-Ser-HPr complex is also negatively 
regulated by the nitrogen sensing transcriptional regulator TnrA, which binds to the TnrA box 
located at bp -209/-193, presumably inducing DNA bending to enable interaction between TnrA 
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and the CcpA-P-Ser-HPr complex [321, 323]. Finally, a T-box located at bp +115/+361 serves as 
a transcription termination signal unless it is bound by uncharged tRNALeu, providing additional 
transcriptional regulation of the ilv-leu operon in the presence of excess L-leucine [324]. The 
alsSD operon is expressed during anaerobic fermentative growth, or under aerobic conditions as 
cells enter the stationary phase or during exponential growth under high glucose concentrations 
[315, 325]. The transcriptional regulator AlsR, encoded by alsR, activates transcription of alsSD 
from promoter Pals in response to the accumulation of its presumed inducer, acetate, via binding 
of AlsR tetramers to the regulatory and activator binding sites located at bp -78/-58 and -41/-26, 
respectively, relative to the transcriptional start site of Pals, and alsR is transcribed divergently 
from alsSD from the promoter adjacent  to Pals, i.e. PalsR [325]. In addition, the transcriptional 
repressor Rex may repress transcription from Pals in response to low NADH levels via a putative 
Rex binding site that has not been formally identified [326].  
Once L-valine has been synthesized in B. subtilis, it can be utilized for protein synthesis, 
secreted from the cell, or converted back to 2-ketoisovalerate as an intermediate in the synthesis 
of branched-chain fatty acids, the major acyl constituents of the cell membrane [327]. The 
contribution of permeases BcaP, BraB, and BrnQ to BCAA uptake have been investigated, and 
BcaP, encoded by bcaP, appears to be the most efficient permease for the uptake of L-valine and 
L-isoleucine [328], such that it may be the most effective transporter of excess L-valine out of B. 
subtilis. The expression of bcaP is strongly repressed by CodY in amino acid-rich medium via 
binding sites CodY-I, located at bp -61/-31, and CodY-II, located at bp +65/+93, relative to the 
transcriptional start site of PbcaP [329]. The conversion of L-valine to 2-ketoisovalerate as the first 
step of the L-valine degradation pathway is potentially catalyzed by YbgE, YwaA, or Bcd (i.e. 
BCAA dehydrogenase, encoded by bcd). Relatively small decreases in CodY activity can 
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significantly increase the expression of bcd and ywaA, compared to the expression of ybgE, 
which occurs when CodY is almost completely inactive [320]. Speculation has been made that 
the coexpression of YwaA and Bcd when CodY is largely active may indicate that both enzymes 
primarily convert BCAAs to their corresponding branched-chain keto acids (BCKAs), while 
YbgE converts BCKAs to BCAAs upon nutrient limitation [320]. However, the mutation of bcd 
completely abolished the growth of B. subtilis when L-valine and L-isoleucine were supplied as 
the sole nitrogen source [327], suggesting that YwaA does not naturally play a role in BCAA 
catabolism.  
 While B. subtilis has been employed extensively in biomanufacturing as previously 
outlined, it is not commonly used as a host for amino acid production. In this study, we 
engineered the metabolism of B. subtilis for L-valine overproduction using our recently 
developed CRISPR-Cas9 toolkit [263]. The L-valine titer was increased by >14-fold, compared 
to the wild-type strain, by replacing the Pilv-leu promoter and its regulatory elements, engineering 
IlvH to reduce L-valine feedback inhibition, chromosomally overexpressing ilvD, ybgE, and 
ywaA, and mutating bcd. Further investigation revealed that pyruvate availability was severely 
limiting L-valine overproduction in our engineered strains, which was overcome by mutating 
pdhA, encoding the E1α subunit (PdhA) of the pyruvate dehydrogenase complex (PdhABCD), 
resulting in a significant increase in the L-valine titer. Moreover, inactivation of the L-leucine 
and L-isoleucine biosynthetic pathways via mutation of leuA and ilvA, respectively, in the ΔpdhA 
background further improved L-valine overproduction, resulting in a titer of 4.61 g/L after 24 h 
in shake flask cultures. Interestingly, the L-valine titer reached 3.6 g/L after 24 h in shake flask 
cultures of a ΔpdhA ΔleuA ΔilvA mutant expressing native ilvH, indicating that L-valine 
feedback inhibition of IlvBH is minimal in B. subtilis.  
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7.2 Materials and Methods 
7.2.1 Bacterial strains, primers, and plasmids 
The B. subtilis strains used in this study are listed in Table S7.1. E. coli HI-Control™ 
10G chemically competent cells were prepared as electrocompetent cells as described previously 
[187] and used as host for plasmid construction. B. subtilis and E. coli strains were maintained as 
glycerol stocks at -80 °C. Primers (Table S7.1) were synthesized by Integrated DNA 
Technologies. Plasmid pAX01 (ECE137) was obtained from the Bacillus Genetic Stock Center, 
and pgRNA-bacteria was a gift from Stanley Qi (Addgene plasmid # 44251). 
 
7.2.2 Plasmid and editing template construction  
DNA manipulation was performed using standard cloning techniques [187], and DNA 
sequencing was conducted by The Centre for Applied Genomics. To construct a genomic 
integration vector for the xylose-inducible expression of comK and comS from the bpr locus, 
PxylA, Bm was amplified from pAX01 [330] with primers P7.1/P7.2, comK was amplified from 
1A751 gDNA with primers P7.3/P7.4, and the two fragments were spliced. The bpr 5’- 
homology length (HL) was then amplified from 1A751 gDNA with primers P7.5/P7.6, and was 
spliced with the PxylA, Bm::comK cassette, and the resulting bpr HL-5’- PxylA, Bm::comK cassette 
was inserted into SbfI/NheI-digested pAW004-2 [263]. To complete the vector, the bpr HL-3’ 
was amplified with primers P7.7/P7.8 from 1A751 gDNA and inserted in place of the thrC HL-
3’, yielding pAW001-5. comS was subsequently amplified from 1A751 gDNA with primers 
P7.9/P7.10 and inserted into NheI/NotI-digested pAW001-5, resulting in plasmid pAW002-5.  
 To construct a triple gRNA delivery vector for the simultaneous replacement of promoter 
Pilv-leu, and mutation of bcd and leuA, the Pgrac::ilvBHC-gRNA cassette was first amplified from 
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pgRNA-bacteria [23] with primers P7.11/P7.12, and inserted into SphI/NcoI-digested pAW014-2 
[263], resulting in plasmid pAW003-5. The PxylA.SphI+1 cassette was subsequently amplified from 
pAW014-2 with primers P7.13/P7.14 (NheI/--), the bcd-gRNA.P585T cassette was amplified 
from pgRNA-bacteria with primers P7.15/P7.16 (--/BamHI), and the two fragments were 
spliced. The resulting PxylA.SphI+1::bcd-gRNA.P585T cassette was inserted into NheI/BglII-
digested pAW003-5, yielding the dual gRNA delivery vector pAW004-5. Finally, the PxylA.SphI+1 
cassette was amplified from pAW014-2 with primers P7.13/P7.17 (NheI/--), the leuA-
gRNA.P764NT cassette was amplified from pgRNA-bacteria with primers P7.18/P7.16 (--
/BamHI), and the two fragments were spliced. The resulting PxylA.SphI+1::leuA-gRNA.P764NT 
cassette was inserted into NheI/BglII-digested pAW004-5, yielding plasmid pAW005-5. To 
construct a dual gRNA delivery vector for the simultaneous insertion of Pgrac::ybgE:ywaA and 
Pgrac::ilvD cassettes at the amyE and wprA loci, respectively, amyE-gRNA.P636T was amplified 
from pgRNA-bacteria with primers P7.19/P7.12 and inserted into SphI/NcoI-digested pAW014-
2, resulting in plasmid pAW006-5. The PxylA.SphI+1 cassette was subsequently amplified from 
pAW014-2 with primers P7.13/P7.20 (NheI/--), the wprA-gRNA.P1419T cassette was amplified 
from pgRNA-bacteria with primers P7.21/P7.16 (--/BamHI), and the two fragments were 
spliced. The resulting PxylA.SphI+1::wprA-gRNA.P1419T cassette was inserted into NheI/BglII-
digested pAW006-5, yielding plasmid pAW007-5. To construct a dual gRNA delivery vector for 
the simultaneous mutation of ilvB and replacement of Pals, the PxylA.SphI+1 cassette was amplified 
from pAW014-2 with primers P7.13/P7.22 (NheI/--), the Pgrac.UPmod::als-gRNA cassette was 
amplified from pgRNA-bacteria with primers P7.23/P7.12 (--/NcoI), and the two fragments were 
spliced. The resulting PxylA.SphI+1::Pgrac.UPmod::als-gRNA cassette was inserted into NheI/NcoI-
digested pAW014-2, yielding plasmid pAW008-5. The PxylA.SphI+1 cassette was subsequently 
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amplified from pAW014-2 with primers P7.13/P7.24 (NheI/--), the ilvB-gRNA.P1101NT 
cassette was amplified from pgRNA-bacteria with primers P7.25/P7.16 (--/BamHI), and the two 
fragments were spliced. The resulting PxylA.SphI+1::ilvB-gRNA.P1101NT cassette was inserted into 
NheI/BglII-digested pAW008-5, yielding plasmid pAW009-5. To construct a dual gRNA 
delivery vector for simultaneous mutation of leuA and ilvA, the PxylA.SphI+1 cassette was amplified 
from pAW014-2 with primers P7.13/P7.26 (NheI/--), the ilvA-gRNA.P581NT cassette was 
amplified from pgRNA-bacteria with primers P7.27/P7.16 (--/BamHI), and the two fragments 
were spliced. The resulting PxylA.SphI+1::ilvA-gRNA.P581NT cassette was inserted into 
NheI/BglII-digested pAW005-5, yielding plasmid pAW010-5. To construct a dual gRNA 
delivery vector for the simultaneous replacement of promoter PbcaP and mutation of sigF, the 
PxylA.SphI+1 cassette was amplified from pAW014-2 with primers P7.13/P7.28 (NheI/--), the 
Pgrac.UPmod::bcaP-gRNA cassette was amplified from pgRNA-bacteria with primers P7.29/P7.12 
(--/NcoI), and the two fragments were spliced. The resulting PxylA.SphI+1::Pgrac.UPmod::bcaP-gRNA 
cassette was inserted into NheI/NcoI-digested pAW014-2, yielding plasmid pAW011-5. The 
PxylA.SphI+1 cassette was subsequently amplified from pAW014-2 with primers P7.13/P7.30 
(NheI/--), the sigF-gRNA.P371T cassette was amplified from pgRNA-bacteria with primers 
P7.31/P7.16 (--/BamHI), and the two fragments were spliced. The resulting PxylA.SphI+1::sigF-
gRNA.P371T cassette was inserted into NheI/BglII-digested pAW011-5, yielding plasmid 
pAW012-5. To construct the single gRNA delivery vector pAW013-5, the ilvH-gRNA.P40T 
cassette was amplified from pgRNA-bacteria with primers P7.32/P7.12 and inserted into 
SphI/NcoI-digested pAW014-2. Similarly, the PxylA.SphI+1 cassette was amplified from pAW014-2 
with primers P7.13/P7.33 (NheI/--), the alsD-gRNA.P99T cassette was amplified from pgRNA-
bacteria with primers P7.34/P7.12 (--/NcoI), and the two fragments were spliced. The resulting 
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PxylA.SphI+1::alsD-gRNA.P99T cassette was inserted into NheI/NcoI-digested pAW014-2, yielding 
plasmid pAW014-5. Plasmids pAW015-5 and pAW016-5 were constructed in the same manner 
as pAW014-5, except that primers P7.35 and P7.36, and P7.30 and P7.31 were used in place of 
primers P7.33 and P7.34 to generate the respective PxylA.SphI+1::pdhA-gRNA.P116T and 
PxylA.SphI+1::sigF-gRNA.P371T cassettes.  
 The Pgrac::ilvBHC editing template for replacement of Pilv-leu with promoter Pgrac, i.e. 
plasmid pAW017-5, was constructed by amplifying the 808 bp and 765 bp HLs from 1A751 
gDNA with respective primers P7.37/P7.38 and P7.39/P7.40, promoter Pgrac (with an upstream 
SphI restriction site) from pAW008 [263] with primers P7.41/P7.42, and the plasmid backbone 
from pAW020-2 [263] with primers P7.43/P7.44, followed by assembly of the four fragments 
via the NEBuilder® HiFi DNA Assembly Master Mix (New England Biolabs; MA) as per the 
manufacturer’s instructions. The mut.bcd.P585T editing template for mutation of bcd, i.e. 
plasmid pAW018-5, was constructed by amplifying the 782 bp and 764 bp HLs (flanking an in-
frame BssHII restriction site followed by two stop codons) from 1A751 gDNA with respective 
primers P7.45/P7.46 and P7.47/P7.48, and the plasmid backbone from pAW020-2 with primers 
P7.49/P7.50, followed by assembly of the three fragments. The mut.leuA.P764NT editing 
template for mutation of leuA, i.e. plasmid pAW019-5, was constructed by amplifying the 762 bp 
and 739 bp HLs (flanking an in-frame BssHII restriction site followed by two stop codons) from 
1A751 gDNA with respective primers P7.51/P7.52 and P7.53/P7.54, and the plasmid backbone 
from pAW020-2 with primers P7.55/P7.56, followed by assembly of the three fragments. The 
Pgrac::ybgE:ywaA ΔamyE editing template for insertion of the Pgrac::ybgE:ywaA expression 
cassette at the amyE locus, i.e. plasmid pAW020-5, was constructed by amplifying the combined 
amyE HL-5’-backbone-amyE HL-3’-Pgrac fragment from pAW020-2 with primers P7.57/P7.58, 
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ybgE and ywaA from 1A751 gDNA with respective primers P7.59/P7.60 and P7.61/P7.62, 
followed by assembly of the three fragments. The Pgrac::ilvD ΔwprA editing template for 
insertion of the Pgrac::ilvD expression cassette at the wprA locus, i.e. plasmid pAW021-5, was 
constructed by amplifying the wprA HL-5’ and HL-3’ from 1A751 gDNA with respective 
primers P7.63/P7.64 and P7.65/P7.66, Pgrac from pAW008 with primers P7.67/P7.68, ilvD from 
1A751 gDNA with primers P7.69/P7.70, and the plasmid backbone from pAW020-2 with 
primers P7.71/P7.72, followed by assembly of the five fragments. The 
IlvH(N11A,G14D,N17F,N29H) editing template for engineering of IlvH to relieve L-valine 
feedback inhibition, i.e. plasmid pAW022-5, was constructed by amplifying the 808 bp and 774 
bp HLs from 1A751 gDNA with respective primers P7.73/P7.74 and P7.75/P7.76, followed by 
splicing of the two fragments and subsequent insertion into pJET1.2/blunt using the CloneJET 
PCR Cloning Kit (ThermoFisher Scientific; MA) as per the manufacturer’s instructions. The 
specified point mutations were introduced using primers P7.74 and P7.75, and a BssHII 
restriction site was introduced into the ilvH ORF as a result of the N11A mutation. The 
Pgrac.UPmod::als editing template for replacement of the als promoter with promoter Pgrac.UPmod, i.e. 
plasmid pAW023-5, was constructed by amplifying the 775 bp and 798 bp HLs from 1A751 
gDNA with respective primers P7.77/P7.78 and P7.79/P7.80, Pgrac.UPmod (with an upstream XhoI 
restriction site) from pAW003-4 [239] with primers P7.81/P7.82, and the plasmid backbone from 
pAW020-2 with primers P7.83/P7.84, followed by assembly of the four fragments. The PmtlA::als 
editing template for replacement of the als promoter with promoter PmtlA, i.e. plasmid pAW024-
5, was constructed by amplifying the combined HL-3’-backbone-HL-5’ fragment from 
pAW023-5 with primers P7.85/P7.86, PmtlA from 1A751 gDNA with primers P7.87/P7.88, 
followed by assembly of the two fragments. The mut.ilvB.P1101NT editing template for 
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mutation of ilvB, i.e. plasmid pAW025-5, was constructed by amplifying the 769 bp and 773 bp 
HLs (flanking an in-frame NheI restriction site preceded by two stop codons) from 1A751 gDNA 
with respective primers P7.89/P7.90 and P7.91/P7.92, and the plasmid backbone from pAW020-
2 with primers P7.93/P7.94, followed by assembly of the three fragments. The mut.ilvA.P581NT 
editing template for mutation of ilvA, i.e. plasmid pAW026-5, was constructed by amplifying the 
740 bp and 787 bp HLs (flanking an in-frame BssHII restriction site preceded by two stop 
codons) from 1A751 gDNA with respective primers P7.95/P7.96 and P7.97/P7.98, and the 
plasmid backbone from pAW020-2 with primers P7.99/P7.100, followed by assembly of the 
three fragments. The mut.alsD.P99T editing template for mutation of alsD, i.e. plasmid 
pAW027-5, was constructed by amplifying the 771 bp and 764 bp HLs (flanking an in-frame 
BseYI restriction site between two stop codons) from 1A751 gDNA with respective primers 
P7.101/P7.102 and P7.103/P7.104, and the plasmid backbone from pAW020-2 with primers 
P7.105/P7.106, followed by assembly of the three fragments. The Pgrac.UPmod::bcaP editing 
template for replacement of the bcaP promoter with Pgrac.UPmod, i.e. plasmid pAW028-5, was 
constructed by amplifying the 763 bp and 776 bp HLs from 1A751 gDNA with respective 
primers P7.107/P7.108 and P7.109/P7.110, Pgrac.UPmod (with an upstream XhoI restriction site) 
from pAW003-4 with primers P7.111/P7.112, and the plasmid backbone from pAW020-2 with 
primers P7.113/P7.114, followed by assembly of the four fragments. The mut.sigF.P371T 
editing template for mutation of sigF, i.e. plasmid pAW029-5, was constructed by amplifying the 
773 bp and 763 bp HLs (flanking an in-frame AvrII restriction site between two stop codons) 
from 1A751 gDNA with respective primers P7.115/P7.116 and P7.117/P7.118, and the plasmid 
backbone from pAW020-2 with primers P7.119/P7.120, followed by assembly of the three 
fragments. The mut.pdhA.P116T editing template for mutation of pdhA, i.e. plasmid pAW030-5, 
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was constructed by amplifying the 806 bp and 795 bp HLs (flanking an in-frame XbaI restriction 
site followed by two stop codons) from 1A751 gDNA with respective primers P7.121/P7.122 
and P7.123/P7.124, and the plasmid backbone from pAW020-2 with primers P7.125/P7.126, 
followed by assembly of the three fragments. Finally, the thrC editing template for removal of 
gRNA transcription cassettes from the thrC locus, i.e. pAW031-5, was constructed by 
amplifying a 2876 bp fragment consisting of 1452 bp and 1306 bp HLs flanking the deleted 118 
bp region of the thrC ORF from 1A751 gDNA with primers P7.127/P7.128, followed by 
insertion into pJET1.2/blunt. 
 
7.2.3 Competent cell preparation and transformation 
Preparation and transformation of naturally competent B. subtilis was performed as 
previously described [263]. To prepare artificially supercompetent strains, cells were plated on 
non-select LB agar containing (per L) 5 g NaCl, 5 g yeast extract, 10 g tryptone, and 15 g agar, 
and incubated overnight at 37 °C. Pre-warmed LB medium (20 mL) containing 5 mM MgSO4 
was inoculated by cell patches from the overnight plate to OD600 0.4-0.6, and the cultures were 
grown at 37 °C and 280 rpm. Once the cell density reached OD600 0.8-1, xylose was added to the 
cultures at a final concentration of 10 g/L to induce the expression of comK and comS, and the 
induced cultures were incubated for 1.5 h to develop the artificially supercompetent state. 1.5 µg 
of gRNA delivery vector and 1.5 µg of each editing template were used per transformation, and 
transformed cells were incubated for 80 min at 280 rpm and 37 °C, and plated on LBG 
containing 85 µg/mL spectinomycin to select recombinants. The same procedure was used to 
evict gRNA transcription cassettes from the thrC locus after each round of CRISPR-Cas9 
genome editing, except that 1 µg of ScaI-linearized pAW031-5 was used per transformation, and 
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cells were plated on LBA and subsequently tested for spectinomycin sensitivity [263]. Media 
was supplemented with 3 g/L sodium acetate when culturing ΔpdhA mutants. 
 
7.2.4 Cultivation medium and conditions 
B. subtilis strains were plated on non-select LB agar and grown overnight at 37 °C. A 
single colony was used to inoculate 25 mL non-select LB, and the culture was grown for ~12 h at 
37 °C and 280 rpm. The culture was then used to inoculate 20 mL pre-warmed non-select 
cultivation medium (4% v/v) of the following composition (per L): sucrose, 30 g; mannitol, 10 g; 
(NH4)2SO4, 17 g; K2HPO4∙3H2O, 18.3 g; KH2PO4, 6 g; trisodium citrate∙ 2H2O, 1 g; yeast 
extract, 5 g; leucine, 250 mg; isoleucine, 250 mg; MgSO4, 120 mg; CaCl2, 5.5 mg; FeCl2∙ 6H2O, 
13.5 mg; MnCl2∙ 4H2O, 1 mg; ZnCl2, 1.7 mg; CuCl2∙ 2H2O, 0.43 mg; CoCl2∙ 6H2O, 0.6 mg; 
Na2MoO4∙ 2H2O, 0.6 mg. Cultures were grown at 37 °C and 280 rpm, and the medium was 
supplemented with 3 g/L sodium acetate when culturing ΔpdhA mutants. To assess cell growth in 
the presence of L-valine, cells were grown in a minimal medium of the following composition 
(per L): sucrose, 10 g; (NH4)2SO4, 12 g; K2HPO4∙3H2O, 18.3 g; KH2PO4, 6 g; trisodium citrate∙ 
2H2O, 1 g; MgSO4, 120 mg; CaCl2, 5.5 mg; FeCl2∙ 6H2O, 13.5 mg; MnCl2∙ 4H2O, 1 mg; ZnCl2, 
1.7 mg; CuCl2∙ 2H2O, 0.43 mg; CoCl2∙ 6H2O, 0.6 mg; Na2MoO4∙ 2H2O, 0.6 mg. L-valine was 
supplemented at a concentration of 3 g/L, 8 g/L, or 20 g/L as indicated. 
 
7.2.5 L-valine quantification 
L-valine was first converted to its α-hydroxy acid, i.e. 2-hydroxy-3-methylbutyric acid, 
via nitrosation prior to quantification via HPLC as previously described [331] with minor 
modifications. Culture samples were centrifuged at 13000 rpm for 10 min, and the cell-free 
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supernatant was diluted as required. 500 µL of cell-free supernatant was mixed with 100 µL of 1 
M KNO2, and the nitrosation reaction was initiated by adding 20 µL of 3 M HCl. The reaction 
was conducted at 45 °C for 40 min, and was stopped by adding 100 µL of 2 M NaOH. The 
nitrosated samples were then degassed in an ultrasonic water bath at 50 °C for 30 min, and filter-
sterilized prior to HPLC analysis. The HPLC system consists of a Shimadzu LC-10AT solvent 
delivery unit, Shimadzu RID-10A refractive index detector, Shimadzu CTO-20A column oven, 
and an Aminex HPX-87H chromatographic column. The column and detector temperatures were 
maintained at 27 °C and 30 °C, respectively, and the flow rate of the mobile phase (i.e. 5 mM 




7.3.1 Derivation of L-valine-overproducing strains of B. subtilis  
To derive L-valine-overproducing strains of B. subtilis, we employed our recently 
developed CRISPR-Cas9 toolkit [263]. Overexpression of comK, encoding the competence 
transcription factor ComK, and comS, encoding competence protein S (ComS), during 
exponential growth can significantly improve the transformation efficiency of B. subtilis strains, 
compared to transformation via natural competence [65]. Accordingly, we transformed AW001-
2 [263] with SacI-linearized pAW002-5, followed by auto-eviction of the ParaE::mazF-Spc
R 
cassette as previously described [263], resulting in the artificially supercompetent strain AW001-
5 that coexpressed xylose-inducible comK and comS from the bpr locus (Figure 7.2). Given that 
ilvBHC are expressed as part of a single operon and the regulatory elements controlling its 
expression are spatially defined, we chose to replace the 677 bp region upstream of the ilvB RBS, 
176 
 
including the TnrA box, all four CodY binding sites, the CRE, the tRNALeu T-box, and Pilv-leu, 
with the strong constitutive promoter Pgrac. We also sought to mutate bcd to prevent the 
conversion of L-valine to 2-ketoisovalerate. To simultaneously replace Pilv-leu and its regulatory 
elements with Pgrac, and mutate bcd, AW001-5 was transformed with SacI-linearized pAW004-5 
(transcribing gRNAs targeting bp +276 of Pilv-leu and bcd.P585T), and AhdI-linearized pAW017-
5 (the Pgrac::ilvBHC editing template) and pAW018-5 (the mut.bcd.P585T editing template). The 
resulting strain was subsequently transformed with ScaI-linearized pAW031-5 for gRNA 
eviction from the thrC locus, yielding strain AW002-5 (Figure 7.2). AW002-5 was then 
transformed with SacI-linearized pAW006-5 (transcribing a gRNA targeting amyE.P636T) and 
AhdI-linearized pAW020-5 (the Pgrac::ybgE:ywaA ΔamyE editing template), resulting in 
integration of a Pgrac::ybgE:ywaA expression cassette at the amyE locus in strain AW003-5 upon 
gRNA eviction (Figure 7.2). Similarly, AW003-5 was transformed with SacI-linearized 
pAW007-5 (transcribing a gRNA targeting wprA.P1419T) and ScaI-linearized pAW021-5 (the 
Pgrac::ilvD ΔwprA editing template), resulting in integration of a Pgrac::ilvD expression cassette at 
the wprA locus in strain AW004-5 upon gRNA eviction (Figure 7.2).   
 The inhibition of AHAS by BCAAs is well documented and is a common feature of most 
of them [316, 332]. IlvH of B. subtilis is a reportedly valine-sensitive AHAS that is similar in 
structure to AHAS III of E. coli (i.e. IlvHEc), and both enzymes possess several conserved amino 
acid residues that have been replaced to abolish or reduce the valine sensitivity of IlvHEc [332-
334]. Based on the results of cited mutational studies and patents based on IlvHEc, we introduced 
three point mutations to conserved amino acid residues in IlvH, i.e. N11A, G14D, and N29H. A 
fourth point mutation, i.e. N17F, was also introduced as the point mutation S17F reduced the 
valine sensitivity of IlvHEc [333], and N and S are both polar amino acids. The specified point 
177 
 
mutations were introduced into native IlvH in AW004-5 via transformation of SacI-linearized 
pAW013-5 (transcribing a gRNA targeting ilvH.P40T) and AhdI-linearized pAW022-5 (the 
IlvH(N11A,G14D,N17F,N29H) editing template), resulting in the expression of engineered IlvH, 
i.e. IlvH*, in strain AW005-5 upon gRNA eviction (Figure 7.2). To compare the performance of 
strains expressing either IlvH, IlvH*, or AlsS for L-valine overproduction, we initially attempted 
to construct an editing template for the genomic integration of a Pgrac::ilvD:alsS expression 
cassette at the wprA locus of AW003-5, in parallel with the mutation of ilvB. However, this 
plasmid was not stable in E. coli due to the presence of alsS, prompting us to replace the 186 bp 
region between bp 29 of the alsR ORF and bp 2 of the alsS ORF, including promoters PalsR and 
Pals, and the AlsR regulatory and activator binding sites, with the relatively strong constitutive 
promoter Pgrac.UPmod (Note that a consensus RBS, 8 bp spacer region, and T-A substitution in bp 1 
of the alsS ORF was inserted with Pgrac.UPmod). The simultaneous engineering of the als promoter 
and mutation of ilvB was achieved by transforming AW004-5 with SacI-linearized pAW009-5 
(transcribing gRNAs targeting bp +49 of Pals and ilvB.P1101NT), and AhdI-linearized pAW023-
5 (the Pgrac.UPmod::als editing template) and pAW025-5 (the mut.ilvB.P1101NT editing template), 
resulting in strain AW006-5 upon gRNA eviction. 
1A751 (i.e. the wild-type strain), AW004-5, AW005-5, and AW006-5 were evaluated for 
L-valine overproduction in shake flask cultures. The cell density peaked at OD600 4.6 after 12 h 
Figure 7.3A) and the L-valine titer was below the detectable limit of ~0.1 g/L in cultures of 
1A751  (Figure 7.3B). On the other hand, the cell density reached OD600 8.1 after 12 h (Figure 
7.3A) and the final L-valine titer was 1.24 g/L in cultures of AW004-5 (Figure 7.3B), 
representing a >12-fold increase in L-valine production compared to 1A751. A slightly lower 
peak cell density of OD600 7.7 after 12 h (Figure 7.3A) and higher final L-valine titer of 1.44 g/L 
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was observed in cultures of AW005-5, compared to AW004-5, suggesting that L-valine feedback 
inhibition of native IlvH in B. subtilis is modest at this level of L-valine overproduction. 
Interestingly, cell growth and L-valine overproduction were severely delayed in cultures of 
AW006-5, although the cell density was markedly higher (OD600 12.3; Figure 7.3A) and the L-
valine titer was comparable (1.5 g/L; Figure 7.3B) after 24 h, compared to cultures of AW005-5.  
 
7.3.2 Pyruvate availability limits L-valine overproduction in B. subtilis  
We next sought to identify potential bottlenecks limiting L-valine overproduction in B. 
subtilis to improve culture performance. L-leucine and L-valine biosynthesis are in direct 
competition for the intermediate 2-ketoisovalerate (Figure 7.1), while L-isoleucine is also derived 
from pyruvate by the same enzymes that synthesize L-valine (i.e. IlvBHCD, YbgE, and YwaA; 
Figure 7.1). Accordingly, we simultaneously mutated leuA and ilvA in AW005-5 via 
transformation of SacI-linearized pAW010-5 (transcribing gRNAs targeting leuA.P764NT and 
AW007-5 with SacI-linearized pAW008-5 and AhdI-linearized pAW023-5, resulting in strain 
AW008-5 upon gRNA eviction. However, a severe growth defect was observed for AW008-5, 
prompting us to insert a somewhat weaker inducible promoter upstream of alsS, i.e. the 
mannitol-inducible promoter PmtlA [335], via transformation of AW007-5 with SacI-linearized 
pAW008-5 and AhdI-linearized pAW024-5 (the PmtlA::als editing template), resulting in strain 
AW009-5 upon gRNA eviction (Figure 7.2). The peak cell density and final L-valine titer 
decreased to OD600 3.6 after 8 h (Figure 7.4A) and 1.27 g/L (Figure 7.4B), respectively, in 
cultures of AW009-5 compared to AW007-5. We postulated that the enhanced conversion of2-
acetolactate to acetoin due to the increased expression of alsD may have hindered the culture 





Figure 7.2. Genome engineering strategies for L-valine overproduction in B. subtilis. Color 
legend for genes and promoters: light blue, genes serving as integration sites; green, genes to be 
overexpressed from engineered promoters (dark blue); red, genes that are mutation targets (black 
segment indicates mutation); pink, native promoters and corresponding regulatory elements. 
alsD, acetolactate decarboxylase; alsS, acetolactate synthase; amyE, α-amylase; bcaP, BCAA 
permease; bcd, BCAA dehydrogenase; bpr, bacillopeptidase F; comK, competence transcription 
factor; comS, competence protein S; ilvA, L-threonine dehydratase; ilvB, acetohydroxy-acid 
synthase catalytic subunit; ilvC, acetohydroxy-acid isomeroreductase; ilvD, dihydroxy-acid 
dehydratase; ilvH, native acetohydroxy-acid synthase regulatory subunit, ilvH*, engineered 
acetohydroxy-acid synthase regulatory subunit; leuA, 2-isopropylmalate synthase; pdhA, E1α 
subunit of the pyruvate dehydrogenase complex; sigF, sporulation-specific transcription factor 
σF; wprA, cell wall-associated protease; ybgE, BCAA aminotransferase; ywaA; BCAA 
aminotransferase; Pilv-leu, ilvBHC-leuABCD promoter and corresponding regulatory elements; 
Pals, alsSD promoter and corresponding regulatory elements; PbcaP, bcaP promoter and 
corresponding regulatory elements; PxylA,Bm, xylose-inducible xylA promoter (Bacillus 
megaterium); Pgrac, constitutive promoter; PmtlA, mannitol-inducible mtlA promoter; Pgrac.UPmod, 
constitutive promoter. 
 
linearized pAW014-5 (transcribing a gRNA targeting alsD.P99T) and AhdI-linearized pAW027-
5 (the mut.alsD.P99T editing template), resulting in strain AW010-5 upon gRNA eviction 
(Figure 7.2). However, the peak cell density and final L-valine titer marginally increased to 
OD600 4 after 24 h (Figure 7.4A), and 1.35 g/L (Figure 7.4B), respectively, in cultures of 
AW010-5, compared to AW009-5, suggesting that 2-acetolactate availability was not limiting L-
valine overproduction in our strains.  
L-valine overproduction was enhanced by overexpressing the BCAA exporters YgaZH in 
E. coli [305] and BrnFE in C. glutamicum [310], such that L-valine secretion could be a factor 
limiting overproduction in B. subtilis cultures. Accordingly, we replaced the 214 bp region 
upstream of the bcaP start codon, including CodY-I, CodY-II, and PbcaP, with Pgrac.UPmod (Note 
that a consensus RBS and 8 bp spacer region were inserted with Pgrac.UPmod.). Moreover, 
sporogenesis occurs in B. subtilis cultures in response to nutrient depletion and high cell 
densities [336], potentially hampering culture performance and preventing its application in the 




Figure 7.3. Time profiles of A) cell density and B) L-valine titer in cultures of 1A751, AW004-
5, AW005-5, and AW006-5. SD of experiments performed in duplicate are shown in Panels A 
and B. ND indicates that the L-valine titer was below the detectable limit of ~0.1 g/L. 
 
the expression of genes that initiate prespore development [336], as a mutation target to 
potentially improve culture performance and the utility of our strains for industrial application. 
To replace PbcaP with Pgrac.UPmod with or without simultaneously mutating sigF, AW010-5 was 
transformed with SacI-linearized pAW011-5 (transcribing a gRNA targeting bp +7 of PbcaP) and 
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AhdI-linearized pAW028-5 (the Pgrac.UPmod::bcaP editing template), or SacI-linearized pAW012-
5 (transcribing gRNAs targeting bp +7 of PbcaP and sigF.P371T) with AhdI-linearized pAW028-
5 and pAW029-5 (the mut.sigF.P371T editing template), resulting in respective strains AW011-5 
and AW012-5 upon gRNA eviction (Figure 7.2). The peak cell density (OD600 3.5 after 8 h; 
Figure 7.4A) and final L-valine titer (1.24 g/L; Figure 7.4B) declined slightly in cultures of 
AW011-5, compared to AW010-5, suggesting that L-valine secretion was not limiting 
overproduction in our strains. Similarly, the peak cell density (OD600 3.2 after 8 h; Figure 7.4A) 
and final L-valine titer (1.09 g/L; Figure 7.4B) further declined in cultures of AW012-5, 
compared to AW011-5.  
Finally, we attempted to increase pyruvate levels by mutating pdhA via transformation of 
AW012-5 with SacI-linearized pAW015-5 (transcribing a gRNA targeting pdhA.P116T) and 
AhdI-linearized pAW030-5 (the mut.pdhA.P116T editing template), resulting in strain AW013-5 
upon gRNA eviction (Figure 7.2). The peak cell density and final L-valine titer increased by 
128% (OD600 7.3 after 12 h; Figure 7.4A) and 171% (2.95 g/L; Figure 7.4B) in cultures of 
AW013-5, compared to AW012-5. These results suggest that pyruvate availability limits L-
valine overproduction in B. subtilis, which is true, in general, of L-valine overproducing strains 
of C. glutamicum [301].  
 
7.3.3 Inactivating the L-leucine and L-isoleucine pathways significantly enhances L-valine 
overproduction in the ΔpdhA background 
Upon identifying pyruvate availability as the major bottleneck limiting L-valine 
overproduction in B. subtilis, we reexamined previous strain engineering strategies in the ΔpdhA 




Figure 7.4. Time profiles of A) cell density and B) L-valine titer in cultures of AW007-5, 
AW009-5, AW010-5, AW011-5, AW012-5, and AW013-5. SD of experiments performed in 
duplicate are shown in Panels A and B. 
 
transformed with SacI-linearized pAW015-5 and AhdI-linearized pAW030-5, resulting in 
respective strains AW014-5, AW015-5, AW016-5, AW017-5, AW018-5, and AW019-5 upon 
gRNA eviction. As expected, the mutation of pdhA resulted in significant improvements to L-
valine overproduction in all previously derived strains (Figure 7.5). The final L-valine titers in 
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cultures of AW014-5 (2.2 g/L; Figure 7.5B) and AW015-5 (2.4 g/L; Figure 7.5B), i.e. respective 
ΔpdhA mutants that express native ilvH and ilvH*, were similar, further suggesting that L-valine 
feedback inhibition of IlvBH is minimal in B. subtilis. Notably, the L-valine titer reached 4.61 
g/L in cultures of AW016-5 (Figure 7.5B), representing a 92% increase compared to AW015-5. 
These observations suggest that a competition for cellular resources exists between the pathways 
for BCAA biosynthesis, such that leuA and ilvA are critical targets for mutation to significantly 
enhance L-valine overproduction in B. subtilis in spite of the resulting auxotrophy. On other 
hand, the L-valine titer declined to 3.01 g/L in cultures of AW017-5 (Figure 7.5B), suggesting, 
once again, that upregulating the expression of alsS in parallel with ilvBH impedes L-valine 
biosynthesis. In contrast to the alsD mutant AW010-5 that produced a similar L-valine titer to its 
parent strain AW009-5, AW018-5 produced even less L-valine than AW017-5 (i.e. 2.14 g/L 
compared with 3.01 g/L; Figure 7.5B), indicating that alsD is not an appropriate target for 
mutation to enhance L-valine overproduction. Similarly, the L-valine titer reached only 1.86 g/L 
in cultures of AW019-5 (Figure 7.5B), supporting the prior suggestion that increasing the 
expression of bcaP does not improve L-valine overproduction. Finally, the final L-valine titer 
was significantly higher in cultures of AW013-5 (2.95 g/L; Figure 7.4B), compared to AW019-5 
(1.86 g/L; Figure 7.5B), indicating that the prevention of sporogenesis via mutation of sigF in 
AW013-5 improved culture performance. Accordingly, we mutated sigF in AW016-5 via 
transformation of SacI-linearized pAW016-5 (transcribing a gRNA targeting sigF.P371T) and 
AhdI-linearized pAW029-5, resulting in strain AW020-5 upon gRNA eviction. While the cell 
density profiles (Figure 7.6A) and L-valine titers (Figure 7.6B) were quite similar in cultures of 





Figure 7.5. Time profiles of A) cell density and B) L-valine titer in cultures of AW014-5, 
AW015-5, AW016-5, AW017-5, AW018-5, and AW019-5. SD of experiments performed in 
duplicate are shown in Panels A and B. 
 
7.4 Discussion 
Due to its well characterized genetic profile and ease of manipulation, robust growth 
characteristics in simple media, and proven track record as a GRAS biomanufacturing platform, 
B. subtilis is a logical choice as a production host for amino acids. Here, we have demonstrated 
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high-level L-valine overproduction in engineered B. subtilis as a first step toward its development 
into an industrially relevant production host for amino acids. Importantly, our engineered strains 
contain no replicating plasmids and, therefore, do not require antibiotic selection and are 
inherently more stable than previously developed L-valine-overproducing strains of E. coli and 
C. glutamicum. It is anticipated that further strain and bioprocess development can lead to 
improved L-valine overproduction in our engineered strains, and that B. subtilis can be of 
industrial utility for the production of L-valine and potentially other amino acids.  
The feedback inhibition of bacterial AHAS is a conserved feature among many, but not 
all, such enzymes [316]. Presumably due to the presence of the regulatory subunit (i.e. IlvH) that 
bears similarity to valine-sensitive IlvHEc, IlvBH has been identified as a valine-sensitive 
homologue of AHAS III from E. coli [332]. The half maximal inhibitory concentration (IC50) of 
L-valine for the IlvBH homologue of C. glutamicum, i.e. IlvBNCg, is as low as 105 mg/L [337], 
and the minimum inhibitory concentration (MIC) of L-valine in E. coli K-12 and its derivatives, 
which lack functional L-valine-insensitive AHAS II, is as low as 2 mg/L [338]. On other hand, B. 
subtilis 168 can grow in medium containing at least 2.3 g/L L-valine as the sole nitrogen source 
[327], indicating that IlvBH is significantly less sensitive to L-valine compared to IlvBHEc. Our 
data is in agreement with this observation, as the L-valine titer reached 2.2 g/L in cultures of 
AW014-5, and the peak cell density exceeded that observed in cultures of 1A751, i.e. OD600 5.8 
and OD600 4.6 for AW014-5 and 1A751, respectively. We further investigated potential L-valine 
feedback inhibition of IlvBH by simultaneously mutating leuA and ilvA in AW014-5 via 
transformation of SacI-linearized pAW010-5 with AhdI-linearized pAW019-5 and pAW026-5, 
resulting in strain AW021-5 upon gRNA eviction. The peak cell density and final L-valine titer 




Figure 7.6. Time profiles of A) cell density and B) L-valine titer in cultures of AW016-5, 
AW020-5, and AW021-5. SD of experiments performed in duplicate are shown in Panels A and 
B. 
 
AW021-5, representing no significant difference in cell growth and a 22% decrease in the L-
valine titer compared to cultures of AW016-5 (4.61 g/L; Figure 7.6B), i.e. a strain expressing 
ilvH* that is otherwise identical. We also performed growth experiments with AW004-5 and 
AW005-5 in minimal medium containing various concentrations of L-valine to establish if 
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growth inhibition occurred in the presence of excess L-valine. The growth profiles were nearly 
identical in cultures of AW004-5 and AW005-5 for L-valine concentrations up to 20 g/L (Figure 
7.7), indicating that feedback inhibition of IlvBH by L-valine is not significant enough to affect 
cell growth. In fact, the respective final cell densities increased by 37% and 43% in cultures of 
AW004-5 and AW005-5 containing 20 g/L L-valine, compared to the respective controls without 
supplemental L-valine, suggesting that YbgE and/or YwaA could convert L-valine to 2-
ketoisovalerate to initiate L-valine catabolism. These observations are in contrast to those of a 
prior study in which a Δbcd mutant could not grow in minimal medium containing L-valine as 
the sole nitrogen source [327]. However, the expression of native ybgE and ywaA were 
presumably repressed by L-valine-activated CodY in the cited study. The improved L-valine 
overproduction in cultures of AW016-5, compared to AW021-5, may have resulted from a mild 
degree of feedback inhibition of IlvBH that is not sufficient to repress growth. Another 
possibility is that IlvH* modulated the activity of the IlvBH* holoenzyme, resulting in increased 
flux through the L-valine biosynthetic pathway, however, further investigation is required to 
establish the cause of the modest improvements to culture performance in strains expressing 
ilvH*. 
Given that AlsS is a dedicated ALS, one might expect its overexpression to be beneficial   
to L-valine overproduction, compared to IlvBH, which converts pyruvate to 2-acetolactate, and 
pyruvate and 2-ketobutyrate to 2-aceto-2-hydroxybutyrate during L-valine and L-isoleucine 
biosynthesis, respectively. Upregulating the expression of the als operon in the ΔilvB 
background in AW006-5 resulted in severely delayed growth and L-valine overproduction in our 
production medium, while the overnight growth of AW006-5 in LB medium prior to inoculation 




Figure 7.7. Time profiles of the cell density in cultures of A) AW004-5 and B) AW005-5 
containing no supplemental L-valine (control), or 3 g/L, 8 g/L, or 20 g/L L-valine. SD of 
experiments performed in duplicate are shown in Panels A and B. 
 
may be explained by the fact that the activity of dedicated ALS from acetoin-producing bacteria 
is optimal under low pH (~pH 6) [316], and that the expression of alsSD is induced in the 
presence of acetate and a low pH in B. subtilis [325]. In other words, cell growth and L-valine 
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overproduction are initially poor in our production medium that contains excess sucrose, until 
acetate begins to accumulate with a concomitant decrease in the pH of the culture, in turn, 
increasing the activity of AlsS. On the other hand, cell growth, and presumably L-valine 
overproduction, remain low in LB medium, which lacks a dedicated carbon source and can cause 
ammonification due to amino acid metabolism, in turn, increasing the pH of the culture. The 
compromised culture performance of AW018-5, i.e. a strain in which the expression of alsS was 
upregulated and alsD was mutated, suggests that 2-acetolactate levels are sufficient in our 
engineered strains, and that acetoin produced during carbon overflow metabolism in strains with 
intact alsD may serve as a carbon source in the later stages of the culture when sucrose is 
depleted [315].  
 BCAA exporters have been overexpressed in E. coli, i.e. YgaZH [305], and C. 
glutamicum, i.e. BrnFE [310], and their overexpression significantly improved L-valine 
overproduction in both hosts. Of the four aforementioned proteins analyzed via BLAST [339], 
only BrnF shared significant similarity with any B. subtilis proteins. Specifically, BrnF and 
AzlC, a component of the 4-azaleucine transporter AzlCD (encoded by azlCD) from B. subtilis 
[328], are 31% identical (76% coverage; score 83.6). However, mutation of azlCD did not 
significantly affect the expression of CodY-regulated genes in the presence of BCAAs, 
suggesting that it does not play a significant role in the maintenance of cellular L-valine levels 
[328]. On the other hand, bcaP is among the most highly CodY-regulated genes in B. subtilis, 
and CodY activity is modulated in a negative feedback loop by the expression of bcaP in 
minimal medium containing only BCAAs [328]. In spite of the fact that BcaP is the most 
efficient permease for the uptake of L-valine, our attempts to improve L-valine overproduction 
through promoter engineering to enhance bcaP expression were unsuccessful. Perhaps secretion 
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of L-valine is naturally efficient enough in B. subtilis to service the production capacity of our 
engineered strains. CodY should be highly active in L-valine overproducing strains, such that 
bcaP expression from its native promoter should be severely diminished. Accordingly, BcaP 
may not serve as a permease for the facilitated export of L-valine, and a currently unidentified 
exporter(s) of BCAAs may perform this function. Alternatively, based on the hydrophobicity of 
L-valine and its observed water/lipid phase partition coefficients, it is plausible that L-valine can 
passively diffuse across the cell membrane at significant rates [340]. Clearly, further 
investigation is required to clarify the dominant mechanism by which excess L-valine is secreted 
from the cell to potentially enhance overproduction, which may be achieved by overexpressing a 
dedicated BCAA exporter, or through engineering or chemical treatment of the cell membrane to 
enhance permeability.  
 It is evident from our results that pyruvate availability is limiting L-valine overproduction 
in B. subtilis, which is also the case in C. glutamicum [301]. On other hand, pyruvate may not be 
as scarce in E. coli as inactivating the pyruvate dehydrogenase complex did not increase L-valine 
overproduction to the same degree as reported here [304, 305]. The severe pyruvate limitation in 
B. subtilis is not surprising as its metabolism is suboptimal in the presence of preferred carbon 
sources due to regulatory mechanisms designed to carefully control metabolic fluxes at the 
expense of biomass accumulation, enabling a rapid response to environmental changes [240]. To 
circumvent the rigid flux distribution at the glucose-6-P and fructose-6-P nodes, where 
glycolysis, the PPP, and cell wall biosynthesis diverge, we successfully applied CRISPRi to 
reduce the expression of enzymes at the branch points of these central metabolic pathways, in 
turn, significantly enhancing heterologous HA production in B. subtilis. This approach may also 
prove effective in diverting additional pyruvate or 2-ketoisovalerate from competing metabolic 
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pathways toward L-valine overproduction. For example, we were unsuccessful in mutating panB, 
encoding ketopantoate hydroxymethyltransferase (PanB) which converts 2-ketosiovalerate to 2-
dehydropantoate during pantothenate biosynthesis, in our engineered strains, such that it may be 
an appropriate target for transcriptional repression to improve L-valine overproduction. One 
potentially beneficial aspect of the B. subtilis metabolism for L-valine overproduction is the 
general excess of intracellular NADPH that exists due to strict flux partitioning at the glucose-6-
P node [240, 341]. The biosynthesis of one mol L-valine requires two mol NADPH (Figure 7.1), 
such that a natural overabundance of NADPH is potentially a major advantage during L-valine 
overproduction. Finally, the substantial increase in the L-valine titer in cultures of AW016-5, 
compared to AW015-5 (Figure 7.5B), due to the simultaneous mutation of leuA and ilvA is a 
similar phenomenon to that observed upon the mutation of alaT, encoding an aminotransferase 
that converts pyruvate and L-glutamate to L-alanine and 2-ketoglutarate (AlaT), and ilvA in C. 
glutamicum [310]. In our study, mutating leuA is essential as ilvBHC and leuABCD comprise a 
single operon, such that significant L-leucine production is inevitable in strains in which Pilv-leu 
has been replaced to relieve transcriptional regulation. On the other hand, abolished L-isoleucine 
biosynthesis should contribute less to the improved flux into L-valine overproduction as the 
expression of ilvA is repressed by CodY [318], which is likely active under our cultivation 
conditions.  
To generate AW013-5, we successfully replaced three promoters and their corresponding 
transcriptional regulatory elements (i.e. Pilv-leu, Pals, and PbcaP), chromosomally integrated two 
expression cassettes (i.e. Pgrac::ybgE:ywaA ΔamyE and Pgrac::ilvD ΔwprA), mutated six genes 
(i.e. bcd, leuA, ilvA, alsD, sigF, and pdhA), and introduced four point mutations into a single 
ORF to generate the engineered protein IlvH*, over nine successive rounds of editing to generate 
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AW013-5, demonstrating the efficacy of our CRISPR-Cas9 toolkit for advanced strain 
engineering. While we were consistently able to generate two mutations simultaneously, our 
attempt to replace Pilv-leu, and mutate bcd and leuA in a single round of editing was unsuccessful. 
An assessment of the individual editing and transformation efficiencies of all three targets 
revealed that the replacement of Pilv-leu with Pgrac (~70% of 5×10
3 CFU µgDNA
-1) was significantly 
less efficient then the mutation of leuA (~100% of ~104 CFU µgDNA
-1) or bcd (~100% of ~105 
CFU µgDNA
-1) (Note that 50% of ~2×103 CFU µgDNA
-1
 contained both Pgrac in place of Pilv-leu and 
the bcd mutation when generating AW002-5). The editing and transformation efficiencies for 
different genomic targets can vary significantly due to the frequency of recombination events at 
respective loci [263], and the ratio of the sizes of the inserted and replaced DNA fragments 
significantly affects recombination efficiency [86]. These respective observations may explain 
the particularly low transformation efficiency for the simultaneous mutation of leuA and ilvA 
(~2×102 CFU µgDNA
-1), and the generally lower editing and transformation efficiencies observed 
when chromosomally inserting genes, compared to gene mutations, in the present study. 
Accordingly, recombination appears to be the limiting step in applying the CRISPR-Cas9 system 
to genome editing in B. subtilis, and efforts to bolster its natural recombination efficiency are 





Chapter 8  
Original contributions and recommendations 
 
8.1 Original contributions 
8.1.1 A comprehensive CRISPR-Cas9 toolkit 
The most comprehensive and efficient CRISPR-Cas9 toolkit reported to date for B. 
subtilis was developed. At the same time this work was published, CRISPRi [342] and genome 
editing [216, 343] with the CRISPR-Cas9 system were reported in B. subtilis. However, the 
singe plasmid CRISPR-Cas9 systems developed by other groups are not suited to multiplexing or 
CRISPRi, which are two of the most important applications of this technology, such that their 
application to scalable strain engineering will be limited. On the other hand, we have 
demonstrated highly efficient gene mutations and insertions, continuous editing, multiplexing, 
and transcriptional interference with our toolkit, and have successfully applied it to advanced 
strain engineering through various case studies. Since the initial report, components of the toolkit 
have been distributed through Addgene, a nonprofit global plasmid repository. 
 
8.1.2 Novel B. subtilis strains for high-level HA production 
Using our toolkit, in combination with improved cloning methods (i.e. superior auto-
evicting counter-selectable integration cassettes, and high-efficiency natural and artificial 
transformation protocols), we engineered the cell membrane of HA-producing B. subtilis strains 
to enhance the functional expression of heterologously expressed SeHAS, in turn, significantly 
improving HA production. These novel strains may be of industrial utility as microbial HA 
production replaces extraction from animal and avian sources, and our results suggest that 
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membrane engineering may be a broadly effective strategy to enhance the functional expression 
of transmembrane proteins. Moreover, removal of certain lipids from the membrane of HA-
producing B. subtilis has shed new light on the lipid dependence for functional expression of 
SeHAS.  
Similarly, we reduced the expression of zwf and pfkA, whose respective gene products are 
enzymes at the branchpoints of the PPP and glycolysis with cell wall biosynthesis, to divert 
carbon flux from central metabolism into HA biosynthesis. Individual repression of zwf and pfkA 
expression typically improved the HA titer at the expense of the MW. On the other hand, 
multiplexed repression of zwf and pfkA expression further enhanced the HA titer while modestly 
increasing the MW, compared to the control strain, resulting in the generation of potentially 
industrially relevant HA-producing B. subtilis strains. Accordingly, this strain engineering 
strategy is superior to the traditional approach of upregulating genes in the HA biosynthetic 
pathway, such that it can serve as a paradigm for the future development of heterologous and 
natural HA production strains, as well as those engineered to produce other metabolites. 
Moreover, we have provided new insight into the mechanism of HA biosynthesis by SeHAS in 
B. subtilis by artificially altering the supply of the precursors GlcUA and GlcNAc. 
 
8.1.3 Bioprocess development for heterologous HA production in B. subtilis using oxygen 
vectors 
We have identified several hydrocarbons and perfluorocarbons as oxygen vectors to 
enhance culture performance for heterologous HA production in B. subtilis. In particular, the 
addition of n-hexadecane, perfluoro-1,3-dimethylcyclohexane, and perfluoromethyldecalin 
resulted in significant enhancements to cell growth and HA production, albeit without notable 
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changes to the MW. We also observed that, in contrast to cultures of group C streptococci, 
higher shear rates may increase carbon flux through the HA biosynthetic pathway without 
negatively affecting the MW of produced HA, and that certain vectors may alter the functional 
expression of Class I HAS in B. subtilis. Taken together, the results of this study provide valuable 
insight for future bioprocess development in microbial HA production. 
 
8.1.4 Novel B. subtilis strains for L-valine overproduction 
 Using our toolkit, we engineered the natural L-valine biosynthetic pathway to relieve 
transcriptional and allosteric inhibition in the presence of excess amino acids, resulting in a >14-
fold increase in L-valine production relative to the wild-type strain. Further strain engineering 
revealed that pyruvate availability and competing amino acid biosynthetic pathways were 
limiting L-valine overproduction in B. subtilis, and combinatorial gene mutations to relieve these 
bottlenecks resulted in an ~50-fold increase in the L-valine titer, compared to the wild-type 
strain. While bioprocess development is required to reach production levels comparable to those 
obtained with E. coli and C. glutamicum, our strains show promise as biomanufacturing 
platforms for L-valine overproduction. Moreover, this case study has identified recombination 
efficiency as the limiting factor for the application of the CRISPR-Cas9 system in B. subtilis, 
providing us with a full assessment of and future direction to improve toolkit performance. 
 
8.2 Recommendations 
1. The toolkit described herein has proven to be an invaluable resource for advanced strain 
engineering as outlined in this thesis, and should find widespread use in the engineering 
of B. subtilis strains. While the multiplexing efficiency for two targets was consistently 
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high in this work, our success in higher order multiplexing has been limited. Editing three 
or more targets at once would require prior knowledge of the targets as being highly 
recombination-susceptible, which is likely a rare situation in real applications. 
Accordingly, enhancements to the natural recombination system of B. subtilis, or the 
introduction of viral recombination proteins may increase the multiplexing capacity of 
the toolkit. Highly efficient genome editing mediated by the SPP1 phage-derived GP35 
recombinase was demonstrated in B. subtilis using phosphorothioated lagging-strand-
targeting ssDNA as the editing template [344]. Another simple approach may be to 
overexpress proteins of the native B. subtilis recombination machinery (e.g. RecA) to 
enhance recombination efficiency, and both of these strategies are currently under 
investigation in our laboratory.  
2. The major limitation of B. subtilis as a host for heterologous HA production is the 
inherently lower MW of the produced HA, compared to that of group C streptococci, 
which is the case for all non-native producers. We have employed two markedly different 
approaches to improve heterologous HA production in B. subtilis, i.e. cell membrane 
engineering and metabolic engineering to divert carbon flux into HA biosynthesis, in 
addition to the application of oxygen vectors to reduce shear stress without oxygen 
limitation, yet only modest improvements to the MW were obtained in all scenarios. On 
the other hand, supplementing cultures with GlcUA and, in particular, GlcNAc 
dramatically improved the MW of HA produced by AW006-3, such that improving the 
precursor supply ratio should be a primary focus. As previously discussed in Section 5.4, 
initial attempts to improve UDP-GlcNAc levels via repression of tagO or murAA 
expression resulted in growth defects, such that lower levels of CRISPRi-mediated 
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transcriptional repression of tagO and murAA, and potentially murAB and mnaA, should 
be explored as a means to improve the MW of HA produced by AW018-3 and AW019-3.   
Additionally, a better understanding of the adaptations of naturally producing 
streptococcal strains may provide opportunities to improve the MW of HA produced in 
engineered B. subtilis. 
3. Based on our assessment of potential oxygen vectors, it appears that the effects of 
structurally similar compounds on HA production can differ significantly. For example, 
perfluorodecalin and perfluoromethyldecalin differ by only a single methyl group, yet 
perfluoromethyldecalin supplementation dramatically improved HA production 
compared to its unmethylated counterpart. As such, predictions of the performance of a 
given compound as an oxygen vector based on the results obtained with similar 
compounds may be inaccurate, and the assessment of additional hydrocarbons and 
perfluorocarbons as potential oxygen vectors is likely necessary to identify superior 
compounds to further enhance culture performance. Thus, it is recommended that 
additional compounds be evaluated as potential oxygen vectors, including those that have 
been successfully applied elsewhere. For example, enhanced HA production was 
observed in S. zooepidemicus cultures supplemented with n-dodecane [262], and forane 
F66E was shown to significantly improve oxygen transfer in Enterobacter aerogenes 
cultures [141]. Moreover, the evaluation of oxygen vectors in medium-cell-density fed-
batch cultivations for HA production is of interest as oxygen limitation quickly ensues, 
necessitating excessively high agitation rates and oxygen supplementation to maintain 
culture performance.  
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4. To relieve the pyruvate limitation in our engineered L-valine-overproducing strains, we 
inactivated the pyruvate dehydrogenase complex via mutation of pdhA, necessitating the 
supplementation of acetate to maintain growth in cultures of ΔpdhA mutants. A 
preliminary assessment of L-valine overproduction in fed-batch cultures revealed that 
acetate metabolism is poor in our strains, which is not surprising given that B. subtilis 
does not possess an active glyoxylate shunt [345]. Furthermore, both CcpA and CodY 
repress the expression of acsA [318, 346], encoding acetyl-CoA synthetase that converts 
acetate to acetyl-CoA to initiate acetate metabolism, in nutrient-rich medium. 
Accordingly, activation of the glyoxylate shunt via expression of aceB, encoding 
isocitrate lyase, and aceA, encoding malate synthase, from Bacillus licheniformis, which 
was previously demonstrated in B. subtilis [345], and replacement of the acsA promoter 
and its corresponding regulatory elements with a strong constitutive promoter (e.g. 
Pgrac.UPmod) should significantly improve acetate utilization in ΔpdhA mutants. These 
combined strategies may ultimately be necessary to achieve sufficient growth and, in 
turn, high-level L-valine overproduction in engineered B. subtilis, and are currently being 
explored in our laboratory. 
5. The extension of amino acid biosynthetic pathways for the production of non-native 
alcohols has been reported, for example [347-349]. In particular, isobutanol was 
produced in B. subtilis by the conversion of 2-ketoisovalerate to isobutyraldehyde, via 
keto-acid decarboxylase, which is subsequently converted to isobutanol by alcohol 
dehydrogenase. As 2-ketoisovalerate is the direct precursor of L-valine, our engineered L-
valine-overproducing strains should serve as ideal base strains from which to derive 
superior isobutanol-producing B. subtilis strains. In addition, we have identified a novel 
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pathway for the conversion of 2-ketoisovalerate to 1-butanol that exploits the native L-
valine degradation pathway of B. subtilis. Currently, strain engineering for isobutanol and 
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Appendix A. Supplementary tables 








mcrA Δ(mrr-hsdRMS-mcrBC) endA1 recA1 ɸ80dlacZΔM15 
ΔlacX74 araD139 Δ (ara,leu)7697galU galK 
rpsL (StrR) nupG λ− tonA Mini-F lacIq1 (GentR) 
Lucigen 
B. subtilis   
1A751 his nprR2 nprE18 ΔaprA3 ΔeglS102 ΔbglT bglSRV [350] 



















































1A751 lacA::(cas9, tracrRNA, ErmR), thrC::(PxylA.SphI+1::amyE-
gRNA.P636T, PxylA.SphI+1::ugtP-gRNA.P395T, ParaE::mazF, 




















































Plasmids   
pIEFBPR 
Pspac::mazF, lacI, Amp
R, SpcR, B. subtilis auto-evicting counter-
selectable bpr integration vector 
[13] 
pDG1731 B. subtilis thrC integration vector [188] 
pAX01 PxylA, Bm, xylR, Amp
R, ErmR, B. subtilis lacA integration vector [330] 
pCRISPR  E. coli plasmid for CRISPRa transcription [82] 
pCas9 E. coli plasmid for expression of Cas9 [82] 
pgRNA-
bacteria  
E. coli plasmid for gRNA transcription [23] 
pdCas9-
bacteria 
E. coli plasmid for expression of dCas9 [23] 
pAW008 Pgrac::seHas:tuaD, Neo
R, B. subtilis amyE  integration vector 
This 
work 
pAW016 Pgrac::lacZ, lacI, Spc





R, AmpR, B. subtilis auto-evicting counter-





R, ErmR, B. subtilis auto-evicting  counter-





R, ErmR, B. subtilis auto-evicting 





R, ErmR, B. subtilis auto-evicting  




PxylA.SphI+1, ParaE::mazF, araR, Spc
R, ErmR, B. subtilis counter-




PxylA.SphI+1::ugtP-gRNA.P395T , ParaE::mazF, araR, Spc
R, ErmR, 




PxylA.SphI+1::amyE-gRNA.P25NT , ParaE::mazF, araR, Spc
R, 






PxylA.SphI+1::amyE-gRNA.P330T , ParaE::mazF, araR, Spc
R, ErmR, 




PxylA.SphI+1::amyE-gRNA.P636T , ParaE::mazF, araR, Spc
R, ErmR, 




PxylA.SphI+1::amyE-gRNA.P1344T , ParaE::mazF, araR, Spc
R, 




PxylA.SphI+1::seHas-gRNA.P394T , ParaE::mazF, araR, Spc
R, 




CRISPRa, ParaE::mazF, araR, Spc
R, ErmR, B. subtilis counter-




ugtP-CRISPRa.P395T, ParaE::mazF, araR, Spc
R, ErmR, B. 




(BglII) PxylA.SphI+1::ugtP-gRNA.P395T (NcoI), ParaE::mazF, 
araR, SpcR, ErmR, B. subtilis multi-gRNA counter-selectable 





gRNA.P395T (NcoI), ParaE::mazF, araR, Spc
R, ErmR, B. subtilis 









PxylA.SphI+1, ParaE::mazF, araR, Spc
R, ErmR, B. subtilis auto-




PxylA.SphI+1::lacZ-gRNA.P28NT, ParaE::mazF, araR, Spc
R, ErmR, 





PxylA, Bm::dcas9, xylR, Amp






R, ET for insertion of the HA 




seHas-ET-1330bp-P394T, AmpR, editing template for KO of 




amyE-ET-1330bp-P636T, AmpR, editing template for KO of 
amyE at amyE.P636T 
This 
work 
primer sequence (5’-3’)#  
P3.1 tctactttgacctgcaggaagtcatgtaaaagatgaggttggttcattctc   
P3.2 cagattgagctagcgaaggcagcagttttttggcc  
P3.3 gtgactgacccgggggcgcgccctcgaggccttccgaaaatgc   
P3.4 gtcactgaactagtaccggtaattccggcgactgtttctgtttcag  
P3.5 ctctacttgagctctaaagcctggggtgcctaatga  
P3.6 gctaaagaggtccctagaagcgctaaggatctaggtgaagatcctttttgataa  
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P3.7 agcgcttctagggacctctttagctccttg  
P3.8 ctactttgagccggctgaagcatttatcagggttattgtctcatg  
P3.9 catacctgcttcctccttaagatctcatttccccctttgatttttagat  
P3.10 ctctatgacaattggctcctaacttataggggtaacacttaa  
P3.11 cagattgaggatccctacccaatcagtacgttaattttggc  
P3.12 agatcttaaggaggaagcaggtatggtaagc  
P3.13 catacctgcttcctccttaagatctatgttgagtaaagcgttttcatttaaaccttc  
P3.14 cactttgagaattcttattcattcagttttcgtgcggactg  
P3.15 gtcattgagctagccataaaaaactaaaaaaaatattga  
P3.16 gacattggatcctgacatcagttacagcatgcatcttatataacctcgtcagtattt  
P3.17 tatgatgcatgcaaggaaaaactgctggagatgttttagagctagaaatagcaagttaaa  
P3.18 tatgatgcatgcagcgaataacggcagtaaaggttttagagctagaaatagcaagttaaa  
P3.19 tatgatgcatgccagccgacatcgtatcaaatgttttagagctagaaatagcaagttaaa  
P3.20 tatgatgcatgcgcattgaatgacggggcagagttttagagctagaaatagcaagttaaa  
P3.21 tatgatgcatgcggttcatttcaagtgaacgagttttagagctagaaatagcaagttaaa  
P3.22 tatgatgcatgccaagcaatgtcattgttcatgttttagagctagaaatagcaagttaaa  
P3.23 gctcatgaggatccaaaaaaagcaccgactcggt  
P3.24 gagacttggctagctatttcttaataactaaaaatatggtataatactc  
P3.25 cagattgaggatccatgagttcaactcaac  
P3.26 aaacagattacgtgaaggaaaaactgctggagatg  
P3.27 aaaacatctccagcagtttttccttcacgtaatct  
P3.28 ggaactgctagctgaatcatacagatctcataaaaaactaaaaaaaatattgaaaatact  
P3.29 ttaacgtactgattgggtagccatggaaaaaaagcaccgactcggt  
P3.30 ccatggctacccaatcagtacgttaattttgg  
P3.31 gctcatgaggatcctaaggaggaagcaggtatgg  
P3.32 gctattgaccatggaaaaaaagcaccgactcggt  
P3.33 gctcatgaggatccaaaaaaagcaccga  
P3.34 gtgttagatctagataatgcggtagtttatcacagttaaattgc  
P3.35 ctaagatatctagatcagtcacctcctagctgactcaaatc  
P3.36 gctattgacctgcaggtcgtgatgagcagctgagcc  
P3.37 agtattttcaatattttttttagttttttatggctagccaggctcatatttcacatccgc  
P3.38 gctagccataaaaaactaaaaaaaatattgaaaatactg  
P3.39 gtgttaccatggcctaggtagattgagcatgccttattttcatcttatataacctcgtca  
P3.40 gacttagaggcgcgccgtcgcaggcattattgcagc  
P3.41 gtgattgaaccggtttcctctgacagctgtttgagtg  
P3.42 gcattagcatgcgtcacgacgttgtaaaacgagttttagagctagaaatagcaagttaaa  
P3.43 gctattgaactagtaaaggaggtatcaagtatggataagaaatactcaataggcttagct  
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P3.44 gacattgaagatctcctgcaggataaaacgaaaggcccagtctttc  
P3.45 acaagaggtttgacggcatgattatc  
P3.46 gatttttacattgcttggatgtcatgattatcacagcagtttttccttcacgtaatctg  
P3.47 tgataatcatgacatccaagcaatgtaaaaatcacagg  
P3.48 cgcagctatggatgataaagacttg  
P3.49 cctaccttcaacgttatgactg  
P3.50 acttttttgtttggtgaaagattgtac  
P3.51 ctcaatcgggaaacagttttatcg  
P3.52 atcaatgcgctccacatagc  
P3.53 cattgaggtgaatttacttgaatacc  
P3.54 ggaagtgactgactcgaga  
P3.55 cgtttaccaagaaactccttatgaatg  
P3.56 tcaaaagaagggcaagttcc  
P3.57 acattcttaccgcatcaaaggaagc  
P3.58 ccatctccttcgatagctgtgaag  
P3.59 gctagcctgatctcgaccatcgaattcttagtgg  
P3.60 ccaatgattcggattttgatagccgatggt  
P3.61 gtgattgaccatggttgtttggaaagcgagggaagcgttc  
P3.62 ggtctattgctagctgtgtgtttccatgtgtccagtttgg  
P3.63 ggctttttgaacgatagattgcaccag  
P3.64 tcaagcaatgtcattgtttaataagagctcgtcaatcaaggaaagcgtcatgcacag  
P3.65 gagctcttattaaacaatgacattgcttgataggtcacc  
P3.66 caatgattcggattttgatagccgatgg  
P3.67 cgggaggaaggtcatgaataatctgc  
P3.68 ggcggcatcaaatcgaaattaagtactttatcaattcaatgccctgtctaagaaccg  
P3.69 tgataaagtacttaatttcgatttgatgccgccaaacatataga  
P3.70 ggaagagaaccgcttaagcccg  
P3.71 ccatacattcttcgcttggctg  
P3.72 gttacaccatcactgttcgttcc  
P3.73 ttgccgccagcggtattcc  
P3.74 tccagcgaataacggttactcgagttatttgaatcgttttgcaaacattcttgacactc  
P3.75 taactcgagtaaccgttattcgctggatttttattgc   
P3.76 aagaggcgtactgcctgaacg  
P3.77 aaatctggtcggagattgggatgatagc  
P3.78 cttgttcagtacctaagtaacgtcattactcgagatacgatgtcggctgatacagcc  
P3.79 ctcgagtaatgacgttacttaggtactgaacaagaatttaaagaaatg   
P3.80 ttcacttgaaatgaacccgctcca  
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ǂ: amyE: α-amylase; lacA (ganA): β-galactosidase; cas9: CRISPR-associated protein 9 (Cas9; 
Streptococcus pyogenes); mazF: endoribonuclease (Escherichia coli); thrC: threonine synthase; 
ugtP: UDP-glucose diacylglyceroltransferase; seHas: hyaluronan synthase (Streptococcus 
equisimilis); tuaD: UDP-glucose 6-dehydrogenase; xylR: xylose operon repressor (Bacillus 
megaterium); wprA: cell wall-associated protease; dcas9: dead Cas9 (derived from S. pyogenes); 
lacZ: β-galactosidase (E. coli); lacI: lactose operon repressor (E. coli); bpr: bacillopeptidase F; 
araR: repressor of arabinose operons; NeoR: neomycin resistance cassette; ErmR: erythromycin 
resistance cassette; SpcR: spectinomycin resistance cassette; AmpR: ampicillin resistance 
cassette; #: restriction sites used for cloning are underlined; inserted restriction sites are 









P3.81 gcaaccgttacttaggtactgaacaag  
P3.82 gatcgtgcctgtcagtcattaggatcccacttgaaatgaacccgctccag  
P3.83 ggatcctaatgactgacaggcacgatcaatgccag  
P3.84 gatgttttgaccggttgtggcg  
P3.85 cgaagcgaaggaaaatggatgc  
P3.86 ggtcaaagcgtctacttcacaatgag  
P3.87 tgtatgaacggtctggtctttgcc  
P3.88 caggtattcgctggtcacttcgatg  
P3.89 gaaacggcaaaacgttctgg  
P3.90 gtgttgggttcacaatgtcg  
P3.138 ggttcacaacgatggcagctc  
P3.139 actgatctggatccatgagaacattaaaaaacctcataactgttgtg  
P3.140 gattgatctagattagtggtgatgatggtggtgtaataattttttacgtgttccccagtc  
P3.141 acaagcttcctttagcaccaaagagat  
P3.142 agagggatttttgactccgaagtaagtc  
P3.143 acgcaaatgcataactgcttccaaca  
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Editing efficiency between pAW006-2 and pAW013-2 (1330 bp HL 
ugtP ET; ugtP KO) obtained without modified competence protocol 
3.7B NS 
Editing efficiency between HA operon KI (pAW009-2/pAW020-2) and 
seHas KO (pAW011-2/pAW021-2) 
3.7C S 
Editing efficiency between HA operon KI (pAW009-2/pAW020-2) and 
ugtP KO (pAW006-2-2/1330 bp HL ugtP ET) 
3.7C S 
Editing efficiency between seHas KO (pAW011-2/pAW021-2) and 
ugtP KO (pAW006-2-2/1330 bp HL ugtP ET) 
3.7C S 
Editing efficiency between original and modified competence protocols 




Editing efficiency between amyE (pAW009-2/1330 bp HL amyE ET) 
and ugtP (pAW006-2/1330 bp HL ugtP ET) KOs 
3.9A S 
Editing efficiency between PCR product (1330 bp HL amyE editing 
template) and pAW022-2 (pAW009-2; amyE KO) 
3.9B NS 
Transformation efficiency between PCR product (1330 bp HL amyE 
editing template) and pAW022-2 (pAW009-2; amyE KO) 
3.9B S 
Editing efficiency between 300 and 500 bp HL editing templates 
(pAW006-2; ugtP KO) 
3.9C S 
Editing efficiency between 300 and 750 bp HL editing templates 
(pAW006-2; ugtP KO) 
3.9C S 
Editing efficiency between 300 and 1000 bp HL editing templates 
(pAW006-2; ugtP KO) 
3.9C S 
Editing efficiency between 300 and 1330 bp HL editing templates 
(pAW006-2; ugtP KO) 
3.9C S 
Editing efficiency between 500 and 750 bp HL editing templates 
(pAW006-2; ugtP KO) 
3.9C NS 
Editing efficiency between 500 and 1000 bp HL editing templates 
(pAW006-2; ugtP KO) 
3.9C S 
Editing efficiency between 500 and 1330 bp HL editing templates 
(pAW006-2; ugtP KO) 
3.9C NS 
Editing efficiency between 750 and 1000 bp HL editing templates 
(pAW006-2; ugtP KO) 
3.9C S 
Editing efficiency between 750 and 1330 bp HL editing templates 
(pAW006-2; ugtP KO) 
3.9C NS 
Editing efficiency between 1000 and 1330 bp HL editing templates 




Transformation efficiency between 300 and 500 bp HL editing 
templates (pAW006-2; ugtP KO) 
3.9C S 
Transformation efficiency between 300 and 750 bp HL editing 
templates (pAW006-2; ugtP KO) 
3.9C S 
Transformation efficiency between 300 and 1000 bp HL editing 
templates (pAW006-2; ugtP KO) 
3.9C S 
Transformation efficiency between 300 and 1330 bp HL editing 
templates (pAW006-2; ugtP KO) 
3.9C S 
Transformation efficiency between 500 and 750 bp HL editing 
templates (pAW006-2; ugtP KO) 
3.9C S 
Transformation efficiency between 500 and 1000 bp HL editing 
templates (pAW006-2; ugtP KO) 
3.9C S 
Transformation efficiency between 500 and 1330 bp HL editing 
templates (pAW006-2; ugtP KO) 
3.9C S 
Transformation efficiency between 750 and 1000 bp HL editing 
templates (pAW006-2; ugtP KO) 
3.9C S 
Transformation efficiency between 750 and 1330 bp HL editing 
templates (pAW006-2; ugtP KO) 
3.9C NS 
Transformation efficiency between 1000 and 1330 bp HL editing 
templates (pAW006-2; ugtP KO) 
3.9C S 
Editing efficiency between P25NT (pAW007-2) and P330T (pAW008-
2) (1000 bp HL editing templates; amyE KO) 
3.9D NS 
Editing efficiency between P25NT (pAW007-2) and P636T (pAW009-
2) (1000 bp HL editing templates; amyE KO) 
3.9D S 
Editing efficiency between P25NT (pAW007-2) and P1344T 
(pAW0010-2) (1000 bp HL editing templates; amyE KO) 
3.9D S 
Editing efficiency between P330T (pAW008-2) and P636T (pAW009-
2) (1000 bp HL editing templates; amyE KO) 
3.9D S 
Editing efficiency between P330T (pAW008-2) and P1344T 
(pAW0010-2) (1000 bp HL editing templates; amyE KO) 
3.9D S 
Editing efficiency between P636T (pAW009-2) and P1344T 
(pAW0010-2) (1000 bp HL editing templates; amyE KO) 
3.9D S 
Transformation efficiency between P25NT (pAW007-2) and P330T 
(pAW008-2) (1000 bp HL editing templates; amyE KO) 
3.9D NS 
Transformation efficiency between P25NT (pAW007-2) and P636T 
(pAW009-2) (1000 bp HL editing templates; amyE KO) 
3.9D NS 
Transformation efficiency between P25NT (pAW007-2) and P1344T 
(pAW0010-2) (1000 bp HL editing templates; amyE KO) 
3.9D NS 
Transformation efficiency between P330T (pAW008-2) and P636T 




Transformation efficiency between P330T (pAW008-2) and P1344T 
(pAW0010-2) (1000 bp HL editing templates; amyE KO) 
3.9D NS 
Editing efficiency between P636T (pAW009-2) and P1344T 
(pAW0010-2) (1000 bp HL editing templates; amyE KO) 
3.9D NS 
Editing efficiency between amyE (pAW009-2) and ugtP (pAW006-2) 
KOs (editing template combination 1) 
3.9F NS 
Editing efficiency between amyE (pAW009-2) and ugtP (pAW006-2) 
KOs (editing template combination 2) 
3.9G NS 
Editing efficiency between 1330 bp HL editing template and 1000 bp 




Editing efficiency between 1330 bp HL editing template and pAW022-




Editing efficiency between 1000 bp HL editing template and pAW022-




Multiplexing efficiency between initial demonstration (1330 bp HL 
editing templates) and editing template combination 1 (pAW006-2 




Multiplexing efficiency between initial demonstration (1330 bp HL 
editing templates) and editing template combination 2 (pAW006-2 




Multiplexing efficiency between editing template combinations 1 and 2 




Transcription of lacZ mRNA between induced and uninduced cultures 
of AW016-2 
3.10 S 
Expression of β-galactosidase between induced and uninduced cultures 
of AW016-2 
3.10 S 




















mcrA Δ(mrr-hsdRMS-mcrBC) endA1 recA1 ɸ80dlacZΔM15 
ΔlacX74 araD139 Δ (ara,leu)7697galU galK 
rpsL (StrR) nupG λ− tonA Mini-F lacIq1 (GentR) 
Lucigen 
B. subtilis   
168/1A1 trpC2 [351] 
1A786 amyE::cat Cm lacA::spec leuB8 metA4 Sp hsd(RI)R+M- [330] 
1A751 his nprR2 nprE18 ΔaprA3 ΔeglS102 ΔbglT bglSRV [350] 
AW008 1A751 amyE::(Pgrac::seHas:tuaD, Neo







1A751  amyE::(Pgrac::seHas:tuaD, Neo
R), lacA::(PxylA, Bm::dcas9, 
xylR, ErmR ) 
This work 
AW003-4 
1A751  amyE::(Pgrac::seHas:tuaD, Neo
R), lacA::(PxylA, Bm::dcas9, 
xylR, ErmR ), thrC::(Pgrac::pgsA:clsA) 
This work 
AW004-4 
1A751  amyE::(Pgrac::seHas:tuaD, Neo
R), lacA::(PxylA, Bm::dcas9, 




1A751  amyE::(Pgrac::seHas:tuaD, Neo
R), lacA::(PxylA, Bm::dcas9, 
xylR, ErmR ), wprA::(PxylA.SphI+1::ftsZ-gRNA.P79NT(15C-U)) 
This work 
AW006-4 
1A751  amyE::(Pgrac::seHas:tuaD, Neo
R), lacA::(PxylA, Bm::dcas9, 
xylR, ErmR ), wprA::(PxylA.SphI+1::ftsZ-gRNA.P244NT) 
This work 
AW007-4 
1A751  amyE::(Pgrac::seHas:tuaD, Neo
R), lacA::(PxylA, Bm::dcas9, 
xylR, ErmR ),  thrC::(Pgrac.UPmod::pgsA:clsA) 
This work 
AW008-4 
1A751  amyE::(Pgrac::seHas:tuaD, Neo
R), lacA::(PxylA, Bm::dcas9, 




1A751  amyE::(Pgrac::seHas:tuaD, Neo
R), lacA::(PxylA, Bm::dcas9, 






1A751  amyE::(Pgrac::seHas:tuaD, Neo
R), lacA::(PxylA, Bm::dcas9, 




1A751  amyE::(Pgrac::seHas:tuaD, Neo
R), lacA::(PxylA, Bm::dcas9, 
xylR, ErmR ), thrC::(Pgrac.UPmod::pgsA:clsA), 
wprA::(PxylA.SphI+1::ftsZ-gRNA.P533NT) 
This work 
AW012-4 1A751  amyE::(Pgrac::seHas:tuaD, Neo
R), ΔpssA This work 
AW013-4 1A751  amyE::(Pgrac::seHas:tuaD, Neo
R), ΔugtP This work 
Plasmids   
pAW004-2 
ParaE::mazF, araR, Spc
R, ErmR, B. subtilis auto-evicting  
counter-selectable thrC integration vector 
[214] 
pAW017-2 
PxylA.SphI+1, ParaE::mazF, araR, Spc
R, ErmR, B. subtilis auto-
evicting counter-selectable wprA integration vector 
[214] 
pAW019-2 
PxylA, Bm::dcas9, xylR, Amp




lacI, Pgrac, MCS, Cat









lacI, Pgrac::pgsA:clsA, MCS, Cat




Pgrac::pgsA:clsA, ParaE::mazF, araR, Spc
R, ErmR, B. subtilis 
auto-evicting  counter-selectable thrC integration vector 
This work 
pAW003-4 
Pgrac.UPmod::pgsA:clsA, ParaE::mazF, araR, Spc
R, ErmR, B. subtilis 
auto-evicting  counter-selectable thrC integration vector 
This work 
pAW004-4 
PxylA.SphI+1::ftsZ-gRNA.P79NT, ParaE::mazF, araR, Spc
R, ErmR, 




PxylA.SphI+1::ftsZ-gRNA.P79NT(10A-G), ParaE::mazF, araR, Spc
R, 




PxylA.SphI+1::ftsZ-gRNA.P79NT(15C-U), ParaE::mazF, araR, Spc
R, 




PxylA.SphI+1::ftsZ-gRNA.P244NT, ParaE::mazF, araR, Spc
R, ErmR, 






PxylA.SphI+1::ftsZ-gRNA.P244NT(15C-A), ParaE::mazF, araR, 




PxylA.SphI+1::ftsZ-gRNA.P533NT, ParaE::mazF, araR, Spc
R, ErmR, 





R, ErmR, B. subtilis counter-selectable 




R, ErmR, B. subtilis counter-selectable 
ugtP integration vector 
This work 
primer sequence (5’-3’)#  
P4.32 gctattgaccatggaaaaaaagcaccgactcggt  
P4.122 cagattgaggatccatgtttaacttaccaaataaaatcacacta  
P4.123 ctcttatcctccttttgtacagattgcttagttagatgtttttaacgcttccca  
P4.124 gcaatctgtacaaaaggaggataagagaatgagtatttcttccatccttttatcac  
P4.125 agtaactaactagtttataagatcggcgacaacag  
P4.126 ggtcatggatccgcaatatgcactgacgtctattctcc  
P4.127 tggtgcataggtcccgggataa  
P4.128 ggatctatgcaaccgttttttcgg  
P4.129 cacagattgagctagcttctctccatggacgcgtgac  
P4.130 gctattgacctgcaggaattcatgtaaaagatgag  
P4.131 ccttccgaaaaaacggttgcatagatccgaaggcagcagttttttggcc  
P4.132 atcgatggatcactagaaaattttttatcttatcacttgaaattgg  
P4.133 gataagataaaaaattttctagtgatccatcgatgaaggcagcagttttttggcc  
P4.134 tatgatgcatgcattttcaatcattcggttaagttttagagctagaaatagcaagttaaa  
P4.135 cgcgtggcatgcattttcaatcgttcggttaagttttagagctagaaatagcaagttaaa  
P4.136 gcacctgcatgcatttttaatcattcggttaagttttagagctagaaatagcaagttaaa  
P4.137 tatgatgcatgcctgctctttgctttcttcaggttttagagctagaaatagcaagttaaa  
P4.138 tatgatgcatgcctgctatttgctttcttcaggttttagagctagaaatagcaagttaaa  
P4.139 tggaatgcatgctcgcggaatgcttcaagcatgttttagagctagaaatagcaagttaaa  
P4.140 ctctacgacctgcaggatcaagtggatcacaggcgac  
P4.141 cagattgagctagcccccatatcagaaacggcattcag  
P4.142 gtctactgggcgcgccgacgtacagcatttgcggaat  
P4.143 cagacagaaccggtatgaataatccctataacccttccgattgt  
P4.144 ctcactgacctgcaggtttgcaaaaggcagcaacgagc   
P4.145 cagattgagctagccttccagttcggcgtctgtattcc  
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ǂ: amyE: α-amylase; clsA: cardiolipin synthase; ftsZ: cell division initiation protein; lacA (ganA): 
β-galactosidase; mazF: endoribonuclease (Escherichia coli); pgsA: 
phosphatidylglycerophosphate synthase; thrC: threonine synthase; ugtP: UDP-glucose 
diacylglyceroltransferase; seHas: hyaluronan synthase (Streptococcus equisimilis); tuaD: UDP-
glucose-6 dehydrogenase; xylR: xylose operon repressor (Bacillus megaterium); wprA: cell wall-
associated protease; dcas9: dead Cas9 (derived from S. pyogenes); lacI: lactose operon repressor 
(E. coli); araR: repressor of arabinose operons; pssA: phosphatidylserine synthase; NeoR: 
neomycin resistance cassette; ErmR: erythromycin resistance cassette; SpcR: spectinomycin 
resistance cassette; AmpR: ampicillin resistance cassette; #: restriction sites used for cloning are 
underlined; inserted restriction sites are italicized; protospacer sequences are in bold font; 
substitutions in protospacers are in bold font and underlined; Pgrac.max and downstream ribosome 













P4.146 gtgactgaggcgcgccatgtggagcgcattgatgagc  



















mcrA Δ(mrr-hsdRMS-mcrBC) endA1 recA1 ɸ80dlacZΔM15 
ΔlacX74 araD139 Δ (ara,leu)7697galU galK 
rpsL (StrR) nupG λ− tonA Mini-F lacIq1 (GentR) 
Lucigen 
B. subtilis   
1A751 his nprR2 nprE18 ΔaprA3 ΔeglS102 ΔbglT bglSRV [350] 
AW008 1A751 amyE::(Pgrac::seHas:tuaD, Neo
R)  [239] 
AW009 1A751 amyE::(Pgrac.UPmod::seHas:tuaD, Neo






































R) vpr::(Pgrac.ΔUP::araE)  







R) vpr::(Pgrac.ΔUP::araE)  































































R) vpr::(Pgrac.ΔUP::araE)  

























R) vpr::(Pgrac.ΔUP::araE)  

























R) vpr::(Pgrac.ΔUP::araE)  
wprA::(PxylA.SphI+1::zwf-gRNA.P603NT(10U-C), 



























thrC::(Pgrac::pgcA:glmS)   
This work 
Plasmids   
pHT01 lacI, Pgrac, Cat
R, AmpR, B. subtilis replicating shuttle vector [215] 
pAW008 Pgrac::seHas:tuaD, Neo
R, B. subtilis amyE  integration vector [238] 
pAW009 
Pgrac.UPmod::seHas:tuaD, Neo
R, B. subtilis amyE  integration 
vector 
This work 
pAW016 Pgrac::lacZ, lacI, Spc
R, ErmR, B. subtilis ugtP integration vector [238] 
pAW017-2 
PxylA.SphI+1, ParaE::mazF, araR, Spc
R, ErmR, B. subtilis auto-
evicting counter-selectable wprA integration vector 
[238] 
pAW018-2 
PxylA.SphI+1::lacZ-gRNA.P28NT, ParaE::mazF, araR, Spc
R, ErmR, 




PxylA, Bm::dcas9, xylR, Amp




Pgrac::pgsA:clsA, ParaE::mazF, araR, Spc
R, ErmR, B. subtilis 
auto-evicting counter-selectable thrC integration vector 
[239] 
pAW001-3 
Pgrac.UPmod::araE, ParaE::mazF, araR, Spc
R, ErmR, B. subtilis 
auto-evicting counter-selectable vpr integration vector 
This work 
pAW002-3 
Pgrac.ΔUP::araE, ParaE::mazF, araR, Spc
R, ErmR, B. subtilis auto-
evicting counter-selectable vpr integration vector 
This work 
pAW003-3 
PxylA.SphI+1::pfkA-gRNA.P41NT, ParaE::mazF, araR, Spc
R, ErmR, 




PxylA.SphI+1::pfkA-gRNA.P41NT(10C-A), ParaE::mazF, araR, 




PxylA.SphI+1::pfkA-gRNA.P41NT(15U-C), ParaE::mazF, araR, 




PxylA.SphI+1::pfkA-gRNA.P315NT(10G-A), ParaE::mazF, araR, 






PxylA.SphI+1::pfkA-gRNA.P315NT(15U-G), ParaE::mazF, araR, 




PxylA.SphI+1::pfkA-gRNA.P610NT(10G-A), ParaE::mazF, araR, 




PxylA.SphI+1::pfkA-gRNA.P610NT(15U-C), ParaE::mazF, araR, 




PxylA.SphI+1::zwf-gRNA.P92NT, ParaE::mazF, araR, Spc
R, ErmR, 




PxylA.SphI+1::zwf-gRNA.P92NT(10U-G), ParaE::mazF, araR, 




PxylA.SphI+1::zwf-gRNA.P92NT(15C-A), ParaE::mazF, araR, 




PxylA.SphI+1::zwf-gRNA.P603NT , ParaE::mazF, araR, Spc
R, 




PxylA.SphI+1::zwf-gRNA.P603NT(10U-C), ParaE::mazF, araR, 




PxylA.SphI+1::zwf-gRNA.P603NT(15G-U), ParaE::mazF, araR, 




(BglII) PxylA.SphI+1, ParaE::mazF, araR, Spc
R, ErmR, B. subtilis 




PxylA.SphI+1::pfkA-gRNA.P41NT, ParaE::mazF, araR, Spc
R, 





PxylA.SphI+1::pfkA-gRNA.P41NT(10C-A), ParaE::mazF, araR, 




Pgrac::pgcA, ParaE::mazF, araR, Spc
R, ErmR, B. subtilis auto-
evicting counter-selectable thrC integration vector 
This work 
pAW020-3 
Pgrac::glmS, ParaE::mazF, araR, Spc
R, ErmR, B. subtilis auto-
evicting counter-selectable thrC integration vector 
This work 
pAW021-3 
Pgrac::pgcA:glmS, ParaE::mazF, araR, Spc
R, ErmR, B. subtilis 




primer sequence (5’-3’)#  
P5.28 ggaactgctagctgaatcatacagatctcataaaaaactaaaaaaaatattgaaaatact  
P5.31 gctcatgaggatcctaaggaggaagcaggtatgg  
P5.32 gctattgaccatggaaaaaaagcaccgactcggt  
P5.33 gctcatgaggatccaaaaaaagcaccga  
P5.97 cagattgagtcgacggatcactagaaaattttttatcttatcacttgaaattgg  
P5.98 gcacttgaggatccttcctcctttaattggg  
P5.107 tatgatgcatgccgaactgctgcgttcattccgttttagagctagaaatagcaagttaaa  
P5.108 cgcgtggcatgccgaactgctgagttcattccgttttagagctagaaatagcaagttaaa  
P5.109 gatcctgcatgccgaaccgctgcgttcattccgttttagagctagaaatagcaagttaaa  
P5.110 gtgttagcatgctaattttttcacacccatatgttttagagctagaaatagcaagttaaa  
P5.111 tcaatcgcatgctaattgtttcgcacccatatgttttagagctagaaatagcaagttaaa  
P5.112 atgttagcatgcgttcgtggccacgttttaaggttttagagctagaaatagcaagttaaa  
P5.113 atgttcgcatgcgttcgcggccgcgttttaaggttttagagctagaaatagcaagttaaa  
P5.114 cctaggggatcactagaaaattttttatcttatcacttg  
P5.115 ctaattgagttggagtattcttcatgcatgcttcctcctttaattgggaattgttatc  
P5.116 gcatgcatgaagaatactccaactcaattagaacca  
P5.117 gagacaatgcgatcgctcattttatccaaagcttttcaatttc  
P5.118 gctattgacctgcaggcggaaaagtaaaccgggaatatgag  
P5.119 agataaaaaattttctagtgatcccctagggaaagtgacggcgtattcattgag  
P5.120 ctatttgaggcgcgccgccctgaaagctggtgagaca  
P5.121 gagacaatactagtggcttggcctgcgaaatcaag  
P5.150 cagattgacctaggttgaaattggaagggagattctttattat  
P5.151 gtgattgagcatgcttcctcctttaattgggaattgttatc  
P5.152 tggaatgcatgctttgtccgttttgatataaagttttagagctagaaatagcaagttaaa  
P5.153 tggaatgcatgctttgtccgttgtgatataaagttttagagctagaaatagcaagttaaa  
P5.154 agtgtggcatgctttgtacgttttgatataaagttttagagctagaaatagcaagttaaa  
P5.155 tggaatgcatgcatgtagcggtttgtccaaaggttttagagctagaaatagcaagttaaa  
P5.156 gaaattgcatgcatgtagcggtctgtccaaaggttttagagctagaaatagcaagttaaa  
P5.157 tggaatgcatgcatgtatcggtttgtccaaaggttttagagctagaaatagcaagttaaa  
P5.158 ccaaaattaacgtactgattgggtaggcggtttaaactccggaga  
P5.159 ctacccaatcagtacgttaattttgg  
P5.160 gctattgacctgcaggaagtcatgtaaaagatgag  
P5.161 atagctctttctccaagtcatgcatgcttcctcctttaattgggaattgttatc  
P5.162 gcatgcatgacttggagaaagagctatgaacg  
P5.163 gacattgagcgatcgctctactgtcaatcgatttattttgctgttgactcaacaatttc  
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ǂ amyE: α-amylase; araE: transporter of L-arabinose and D-xylose; araR: repressor of arabinose 
operons; dcas9: dead Cas9 (derived from S. pyogenes); glmS: L-glutamine-D-fructose-6-
phosphate amidotransferase; lacA (ganA): β-galactosidase; lacI: lactose operon repressor (E. 
coli); lacZ: β-galactosidase (E. coli); mazF: endoribonuclease (Escherichia coli); pfkA: 6-
phosphofructokinase; pgcA: phosphoglucomutase; thrC: threonine synthase; ugtP: UDP-glucose 
diacylglyceroltransferase; seHas: hyaluronan synthase (Streptococcus equisimilis); tuaD: UDP-
glucose 6-dehydrogenase; xylR: xylose operon repressor (Bacillus megaterium); wprA: cell wall-
associated protease; zwf: glucose-6-phosphate 1-dehydrogenase; NeoR: neomycin resistance 
cassette; ErmR: erythromycin resistance cassette; SpcR: spectinomycin resistance cassette; AmpR: 
ampicillin resistance cassette; #: restriction sites used for cloning are underlined; inserted 
restriction sites are italicized; protospacer sequences are in bold font; substitutions in 
















P5.164 acctacgattccacacatgcatgcttcctcctttaattgggaattgttatc  
P5.165 gcatgcatgtgtggaatcgtaggttatatcggt  
P5.166 gtgattgagcgatcgcttactccacagtaacactcttcgcaag  
P5.167 gctattcaatcgataaaggaggtatcaagtatgtgtggaatcgtaggttatatcggt  
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HA titer in cultures containing various oxygen vectors (4 h) 6.1A S 
HA MW in cultures containing various oxygen vectors (4 h) 6.1B S 
Cell density in cultures containing various oxygen vectors (4 h) 6.1C S 
HA titer in cultures containing various oxygen vectors (6 h) 6.1A S 
HA MW in cultures containing various oxygen vectors (6 h) 6.1B S 
Cell density in cultures containing various oxygen vectors (6 h) 6.1C S 
HA titer in cultures containing various oxygen vectors (8 h) 6.1A S 
HA MW in cultures containing various oxygen vectors (8 h) 6.1B NS 
Cell density in cultures containing various oxygen vectors (8 h) 6.1C S 
HA titer in cultures containing various oxygen vectors (10 h) 6.1A S 
HA MW in cultures containing various oxygen vectors (10 h) 6.1B S 
Cell density in cultures containing various oxygen vectors (10 h) 6.1C S 
HA titer in cultures containing various oxygen vectors (12 h) 6.1A S 
HA MW in cultures containing various oxygen vectors (12 h) 6.1B S 
Cell density in cultures containing various oxygen vectors (12 h) 6.1C S 
HA titer in cultures in which n-hexadecane was added at 0 h or 2 h after inoculation 
(4 h) 
6.2A S 
HA MW in cultures in which n-hexadecane was added at 0 h or 2 h after inoculation 
(4 h) 
6.2B NS 
Cell density in cultures in which n-hexadecane was added at 0 h or 2 h after 
inoculation (4 h) 
6.2C NS 
HA titer in cultures in which n-hexadecane was added at 0 h or 2 h after inoculation 
(6 h) 
6.2A NS 
HA MW in cultures in which n-hexadecane was added at 0 h or 2 h after inoculation 
(6 h) 
6.2B NS 
Cell density in cultures in which n-hexadecane was added at 0 h or 2 h after 
inoculation (6 h) 
6.2C S 
HA titer in cultures in which n-hexadecane was added at 0 h or 2 h after inoculation 
(8 h) 
6.2A NS 
HA MW in cultures in which n-hexadecane was added at 0 h or 2 h after inoculation 
(8 h) 
6.2B S 
Cell density in cultures in which n-hexadecane was added at 0 h or 2 h after 
inoculation (8 h) 
6.2C NS 
HA titer in cultures in which n-hexadecane was added at 0 h or 2 h after inoculation 
(10 h) 
6.2A S 





Cell density in cultures in which n-hexadecane was added at 0 h or 2 h after 
inoculation (10 h) 
6.2C NS 
HA titer in cultures in which n-hexadecane was added at 0 h or 2 h after inoculation 
(12 h) 
6.2A NS 
HA MW in cultures in which n-hexadecane was added at 0 h or 2 h after inoculation 
(12 h) 
6.2B S 
Cell density in cultures in which n-hexadecane was added at 0 h or 2 h after 
inoculation (12 h) 
6.2C S 
HA titer in cultures in which perfluoro-1,3-dimethylcyclohexane was added at 0 h or 
2 h after inoculation (4 h) 
6.2A S 
HA MW in cultures in which perfluoro-1,3-dimethylcyclohexane was added at 0 h or 
2 h after inoculation (4 h) 
6.2B S 
Cell density in cultures in which perfluoro-1,3-dimethylcyclohexane was added at 0 
h or 2 h after inoculation (4 h) 
6.2C NS 
HA titer in cultures in which perfluoro-1,3-dimethylcyclohexane was added at 0 h or 
2 h after inoculation (6 h) 
6.2A NS 
HA MW in cultures in which perfluoro-1,3-dimethylcyclohexane was added at 0 h or 
2 h after inoculation (6 h) 
6.2B S 
Cell density in cultures in which perfluoro-1,3-dimethylcyclohexane was added at 0 
h or 2 h after inoculation (6 h) 
6.2C S 
HA titer in cultures in which perfluoro-1,3-dimethylcyclohexane was added at 0 h or 
2 h after inoculation (8 h) 
6.2A NS 
HA MW in cultures in which perfluoro-1,3-dimethylcyclohexane was added at 0 h or 
2 h after inoculation (8 h) 
6.2B NS 
Cell density in cultures in which perfluoro-1,3-dimethylcyclohexane was added at 0 
h or 2 h after inoculation (8 h) 
6.2C NS 
HA titer in cultures in which perfluoro-1,3-dimethylcyclohexane was added at 0 h or 
2 h after inoculation (10 h) 
6.2A S 
HA MW in cultures in which perfluoro-1,3-dimethylcyclohexane was added at 0 h or 
2 h after inoculation (10 h) 
6.2B NS 
Cell density in cultures in which perfluoro-1,3-dimethylcyclohexane was added at 0 
h or 2 h after inoculation (10 h) 
6.2C NS 
HA titer in cultures in which perfluoro-1,3-dimethylcyclohexane was added at 0 h or 
2 h after inoculation (12 h) 
6.2A NS 
HA MW in cultures in which perfluoro-1,3-dimethylcyclohexane was added at 0 h or 
2 h after inoculation (12 h) 
6.2B NS 
Cell density in cultures in which perfluoro-1,3-dimethylcyclohexane was added at 0 
h or 2 h after inoculation (12 h) 
6.2C S 
HA titer in cultures containing various concentrations of n-hexadecane (4 h) 6.3A S 
HA MW in cultures containing various concentrations of n-hexadecane (4 h) 6.3B S 
Cell density in cultures containing various concentrations of n-hexadecane (4 h) 6.3C S 
HA titer in cultures containing various concentrations of n-hexadecane (6 h) 6.3A S 
HA MW in cultures containing various concentrations of n-hexadecane (6 h) 6.3B NS 
245 
 
Cell density in cultures containing various concentrations of n-hexadecane (6 h) 6.3C S 
HA titer in cultures containing various concentrations of n-hexadecane (8 h) 6.3A S 
HA MW in cultures containing various concentrations of n-hexadecane (8 h) 6.3B S 
Cell density in cultures containing various concentrations of n-hexadecane (8 h) 6.3C S 
HA titer in cultures containing various concentrations of n-hexadecane (10 h) 6.3A S 
HA MW in cultures containing various concentrations of n-hexadecane (10 h) 6.3B S 
Cell density in cultures containing various concentrations of n-hexadecane (10 h) 6.3C S 
HA titer in cultures containing various concentrations of n-hexadecane (12 h) 6.3A S 
HA MW in cultures containing various concentrations of n-hexadecane (12 h) 6.3B NS 
Cell density in cultures containing various concentrations of n-hexadecane (12 h) 6.3C S 
HA titer in cultures containing various concentrations of n-heptane (4 h) 6.4A S 
HA MW in cultures containing various concentrations of n-heptane (4 h) 6.4B S 
Cell density in cultures containing various concentrations of n-heptane (4 h) 6.4C S 
HA titer in cultures containing various concentrations of n-heptane (6 h) 6.4A S 
HA MW in cultures containing various concentrations of n-heptane (6 h) 6.4B NS 
Cell density in cultures containing various concentrations of n-heptane (6 h) 6.4C S 
HA titer in cultures containing various concentrations of n-heptane (8 h) 6.4A S 
HA MW in cultures containing various concentrations of n-heptane (8 h) 6.4B NS 
Cell density in cultures containing various concentrations of n-heptane (8 h) 6.4C S 
HA titer in cultures containing various concentrations of n-heptane (10 h) 6.4A S 
HA MW in cultures containing various concentrations of n-heptane (10 h) 6.4B S 
Cell density in cultures containing various concentrations of n-heptane (10 h) 6.4C S 
HA titer in cultures containing various concentrations of n-heptane (12 h) 6.4A NS 
HA MW in cultures containing various concentrations of n-heptane (12 h) 6.4B NS 
Cell density in cultures containing various concentrations of n-heptane (12 h) 6.4C NS 
HA titer in cultures containing various concentrations of perfluoromethyldecalin (4 
h) 
6.5A S 
HA MW in cultures containing various concentrations of perfluoromethyldecalin (4 
h) 
6.5B S 
Cell density in cultures containing various concentrations of perfluoromethyldecalin 
(4 h) 
6.5C S 
HA titer in cultures containing various concentrations of perfluoromethyldecalin (6 
h) 
6.5A S 
HA MW in cultures containing various concentrations of perfluoromethyldecalin (6 
h) 
6.5B NS 
Cell density in cultures containing various concentrations of perfluoromethyldecalin 
(6 h) 
6.5C S 
HA titer in cultures containing various concentrations of perfluoromethyldecalin (8 
h) 
6.5A S 





Cell density in cultures containing various concentrations of perfluoromethyldecalin 
(8 h) 
6.5C S 
HA titer in cultures containing various concentrations of perfluoromethyldecalin (10 
h) 
6.5A S 
HA MW in cultures containing various concentrations of perfluoromethyldecalin (10 
h) 
6.5B S 
Cell density in cultures containing various concentrations of perfluoromethyldecalin 
(10 h) 
6.5C S 
HA titer in cultures containing various concentrations of perfluoromethyldecalin (12 
h) 
6.5A S 
HA MW in cultures containing various concentrations of perfluoromethyldecalin (12 
h) 
6.5B S 
Cell density in cultures containing various concentrations of perfluoromethyldecalin 
(12 h) 
6.5C S 
kLa in cultures containing various concentrations of n-hexadecane 6.6A S 
kLa in cultures containing various concentrations of n-heptane 6.6B S 
kLa in cultures containing various concentrations of perfluoromethyldecalin 6.6C S 
Lactate titer in cultures with or without 0.5% v/v n-hexadecane operated at an 
agitation rate of 300 rpm (4 h) 
6.7A NS 
Lactate titer in cultures with or without 0.5% v/v n-hexadecane operated at an 
agitation rate of 300 rpm (6 h) 
6.7A S 
Lactate titer in cultures with or without 0.5% v/v n-hexadecane operated at an 
agitation rate of 300 rpm (8 h) 
6.7A NS 
Lactate titer in cultures with or without 0.5% v/v n-hexadecane operated at an 
agitation rate of 300 rpm (10 h) 
6.7A NS 
Lactate titer in cultures with or without 0.5% v/v n-hexadecane operated at an 
agitation rate of 300 rpm (12 h) 
6.7A NS 
Acetate titer in cultures with or without 0.5% v/v n-hexadecane operated at an 
agitation rate of 300 rpm (4 h) 
6.7B NS 
Acetate titer in cultures with or without 0.5% v/v n-hexadecane operated at an 
agitation rate of 300 rpm (6 h) 
6.7B NS 
Acetate titer in cultures with or without 0.5% v/v n-hexadecane operated at an 
agitation rate of 300 rpm (8 h) 
6.7B NS 
Acetate titer in cultures with or without 0.5% v/v n-hexadecane operated at an 
agitation rate of 300 rpm (10 h) 
6.7B NS 
Acetate titer in cultures with or without 0.5% v/v n-hexadecane operated at an 
agitation rate of 300 rpm (12 h) 
6.7B NS 
2,3-BDO titer in cultures with or without 0.5% v/v n-hexadecane operated at an 
agitation rate of 300 rpm (4 h) 
6.7C S 
2,3-BDO titer in cultures with or without 0.5% v/v n-hexadecane operated at an 
agitation rate of 300 rpm (6 h) 
6.7C S 
2,3-BDO titer in cultures with or without 0.5% v/v n-hexadecane operated at an 




2,3-BDO titer in cultures with or without 0.5% v/v n-hexadecane operated at an 
agitation rate of 300 rpm (10 h) 
6.7C S 
2,3-BDO titer in cultures with or without 0.5% v/v n-hexadecane operated at an 
agitation rate of 300 rpm (12 h) 
6.7C S 
HA titer in cultures operated at an agitation rate of 600 rpm without vector, with n-
hexadecane, or with perfluoromethyldecalin, or 300 rpm without vector and with 
supplemental oxygen (4 h) 
6.8A S 
HA MW in cultures operated at an agitation rate of 600 rpm without vector, with n-
hexadecane, or with perfluoromethyldecalin, or 300 rpm without vector and with 
supplemental oxygen (4 h) 
6.8B NS 
Cell density in cultures operated at an agitation rate of 600 rpm without vector, with 
n-hexadecane, or with perfluoromethyldecalin, or 300 rpm without vector and with 
supplemental oxygen (4 h) 
6.8C S 
HA titer in cultures operated at an agitation rate of 600 rpm without vector, with n-
hexadecane, or with perfluoromethyldecalin, or 300 rpm without vector and with 
supplemental oxygen (6 h) 
6.8A S 
HA MW in cultures operated at an agitation rate of 600 rpm without vector, with n-
hexadecane, or with perfluoromethyldecalin, or 300 rpm without vector and with 
supplemental oxygen (6 h) 
6.8B S 
Cell density in cultures operated at an agitation rate of 600 rpm without vector, with 
n-hexadecane, or with perfluoromethyldecalin, or 300 rpm without vector and with 
supplemental oxygen (6 h) 
6.8C S 
HA titer in cultures operated at an agitation rate of 600 rpm without vector, with n-
hexadecane, or with perfluoromethyldecalin, or 300 rpm without vector and with 
supplemental oxygen (8 h) 
6.8A S 
HA MW in cultures operated at an agitation rate of 600 rpm without vector, with n-
hexadecane, or with perfluoromethyldecalin, or 300 rpm without vector and with 
supplemental oxygen (8 h) 
6.8B S 
Cell density in cultures operated at an agitation rate of 600 rpm without vector, with 
n-hexadecane, or with perfluoromethyldecalin, or 300 rpm without vector and with 
supplemental oxygen (8 h) 
6.8C S 
HA titer in cultures operated at an agitation rate of 600 rpm without vector, with n-
hexadecane, or with perfluoromethyldecalin, or 300 rpm without vector and with 
supplemental oxygen (10 h) 
6.8A S 
HA MW in cultures operated at an agitation rate of 600 rpm without vector, with n-
hexadecane, or with perfluoromethyldecalin, or 300 rpm without vector and with 
supplemental oxygen (10 h) 
6.8B S 
Cell density in cultures operated at an agitation rate of 600 rpm without vector, with 
n-hexadecane, or with perfluoromethyldecalin, or 300 rpm without vector and with 
supplemental oxygen (10 h) 
6.8C S 













mcrA Δ(mrr-hsdRMS-mcrBC) endA1 recA1 ɸ80dlacZΔM15 
ΔlacX74 araD139 Δ (ara,leu)7697galU galK 
rpsL (StrR) nupG λ− tonA Mini-F lacIq1 (GentR) 
Lucigen 
B. subtilis   
1A751 his nprR2 nprE18 ΔaprA3 ΔeglS102 ΔbglT bglSRV [350] 
AW001-2 1A751 lacA::(cas9, tracrRNA, ErmR) [263] 
AW001-5 





1A751 lacA::(cas9, tracrRNA, ErmR), bpr::(PxylA, 




1A751 lacA::(cas9, tracrRNA, ErmR), bpr::(PxylA, 





1A751 lacA::(cas9, tracrRNA, ErmR), bpr::(PxylA, 












1A751 lacA::(cas9, tracrRNA, ErmR), bpr::(PxylA, 
Bm::comK:comS, xylR), Pgrac::ilvBHC, Δbcd, 





1A751 lacA::(cas9, tracrRNA, ErmR), bpr::(PxylA, 
Bm::comK:comS, xylR), Pgrac::ilvBH
*C, Δbcd, 




1A751 lacA::(cas9, tracrRNA, ErmR), bpr::(PxylA, 
Bm::comK:comS, xylR), Pgrac::ilvBH
*C, Δbcd, 





1A751 lacA::(cas9, tracrRNA, ErmR), bpr::(PxylA, 
Bm::comK:comS, xylR), Pgrac::ilvBH
*C, Δbcd, 





1A751 lacA::(cas9, tracrRNA, ErmR), bpr::(PxylA, 
Bm::comK:comS, xylR), Pgrac::ilvBH
*C, Δbcd, 












amyE::Pgrac::ybgE:ywaA, wprA::Pgrac::ilvD, ΔleuA, ΔilvA, 
PmtlA::als, ΔalsD, Pgrac.UPmod::bcaP  
AW012-5 
1A751 lacA::(cas9, tracrRNA, ErmR), bpr::(PxylA, 
Bm::comK:comS, xylR), Pgrac::ilvBH
*C, Δbcd, 
amyE::Pgrac::ybgE:ywaA, wprA::Pgrac::ilvD, ΔleuA, ΔilvA, 




1A751 lacA::(cas9, tracrRNA, ErmR), bpr::(PxylA, 
Bm::comK:comS, xylR), Pgrac::ilvBH
*C, Δbcd, 
amyE::Pgrac::ybgE:ywaA, wprA::Pgrac::ilvD, ΔleuA, ΔilvA, 




1A751 lacA::(cas9, tracrRNA, ErmR), bpr::(PxylA, 
Bm::comK:comS, xylR), Pgrac::ilvBHC, Δbcd, 




1A751 lacA::(cas9, tracrRNA, ErmR), bpr::(PxylA, 
Bm::comK:comS, xylR), Pgrac::ilvBH
*C, Δbcd, 




1A751 lacA::(cas9, tracrRNA, ErmR), bpr::(PxylA, 
Bm::comK:comS, xylR), Pgrac::ilvBH
*C, Δbcd, 





1A751 lacA::(cas9, tracrRNA, ErmR), bpr::(PxylA, 
Bm::comK:comS, xylR), Pgrac::ilvBH
*C, Δbcd, 





1A751 lacA::(cas9, tracrRNA, ErmR), bpr::(PxylA, 
Bm::comK:comS, xylR), Pgrac::ilvBH
*C, Δbcd, 
amyE::Pgrac::ybgE:ywaA, wprA::Pgrac::ilvD, ΔleuA, ΔilvA, 




1A751 lacA::(cas9, tracrRNA, ErmR), bpr::(PxylA, 
Bm::comK:comS, xylR), Pgrac::ilvBH
*C, Δbcd, 
amyE::Pgrac::ybgE:ywaA, wprA::Pgrac::ilvD, ΔleuA, ΔilvA, 




1A751 lacA::(cas9, tracrRNA, ErmR), bpr::(PxylA, 
Bm::comK:comS, xylR), Pgrac::ilvBH
*C, Δbcd, 
amyE::Pgrac::ybgE:ywaA, wprA::Pgrac::ilvD, ΔleuA, ΔilvA, 




1A751 lacA::(cas9, tracrRNA, ErmR), bpr::(PxylA, 
Bm::comK:comS, xylR), Pgrac::ilvBHC, Δbcd, 




Plasmids   
pAX01 PxylA, Bm, xylR, Amp
R, ErmR, B. subtilis lacA integration vector [330] 
pgRNA-
bacteria  
E. coli plasmid for gRNA transcription [23] 
pAW008 Pgrac::seHas:tuaD, Neo





R, ErmR, B. subtilis auto-evicting  
counter-selectable thrC integration vector 
[263] 
pAW014-2 
(BglII) PxylA.SphI+1::ugtP-gRNA.P395T (NcoI), ParaE::mazF, 
araR, SpcR, ErmR, B. subtilis multi-gRNA counter-selectable 




R, ET for insertion of the HA 
biosynthetic operon into the amyE locus at amyE.P636T 
[263] 
pAW001-5 
PxylA, Bm::comK, xylR, ParaE::mazF, araR, Spc
R, ErmR, B. subtilis 




PxylA, Bm::comK:comS, xylR, ParaE::mazF, araR, Spc
R, ErmR, B. 




PxylA.SphI+1::Pgrac::ilvBHC-gRNA, ParaE::mazF, araR, Spc
R, ErmR, 






R, ErmR, B. subtilis counter-selectable 





PxylA.SphI+1::Pgrac::ilvBHC-gRNA, ParaE::mazF, araR, Spc
R, 




PxylA.SphI+1::amyE-gRNA.P636T, ParaE::mazF, araR, Spc
R, ErmR, 





gRNA.P636T, ParaE::mazF, araR, Spc
R, ErmR, B. subtilis 




PxylA.SphI+1::Pgrac.UPmod::als-gRNA, ParaE::mazF, araR, Spc
R, 





gRNA, ParaE::mazF, araR, Spc
R, ErmR, B. subtilis counter-






PxylA.SphI+1::Pgrac::ilvBHC-gRNA, ParaE::mazF, araR, Spc
R, 




PxylA.SphI+1::Pgrac.UPmod::bcaP-gRNA, ParaE::mazF, araR, Spc
R, 





gRNA, ParaE::mazF, araR, Spc
R, ErmR, B. subtilis counter-




PxylA.SphI+1::ilvH-gRNA.P40T, ParaE::mazF, araR, Spc
R, ErmR, B. 




PxylA.SphI+1::alsD-gRNA.P99T, ParaE::mazF, araR, Spc
R, ErmR, B. 




PxylA.SphI+1::pdhA-gRNA.P116T, ParaE::mazF, araR, Spc
R, ErmR, 




PxylA.SphI+1::sigF-gRNA.P371T, ParaE::mazF, araR, Spc
R, ErmR, 









pAW018-5 mut.bcd.P585T editing template, AmpR 
This 
work 








R, B. subtilis wprA integration vector 
This 
work 
pAW022-5 IlvH(N11A,G14D,N17F,N29H) editing template, AmpR  
This 
work 








pAW025-5 mut.ilvB.P1101NT editing template, AmpR  
This 
work 
pAW026-5 mut.ilvA.P581NT editing template, AmpR  
This 
work 
pAW027-5 mut.alsD.P99T editing template, AmpR  
This 
work 




pAW029-5 mut.sigF.P371T editing template, AmpR  
This 
work 
pAW030-5 mut.pdhA.P116T editing template, AmpR  
This 
work 
pAW031-5 editing template to restore thrC, AmpR 
This 
work 
primers sequence (5’-3’)#  
P7.1 gcatgcctaacttataggggtaacacttaaaaaaga  
P7.2 gttttctgactcatatcgatttcctcctttcatttccccctttgatttttagat  
P7.3 aaaggaggaaatcgatatgagtcagaaaacagacgcacct  
P7.4 gcagatgagctagcctaataccgttccccaagctcacg  
P7.5 gctattgacctgcaggacaagagaaggacgtgacgaag  
P7.6 ttaagtgttacccctataagttaggcatgcttaaatttaatcagaaaagtcgttttttct  
P7.7 ctacttgaggcgcgcccaactggcagtatatagatggaaagtggc  
P7.8 cagattgaaccggtatctaaatcctcagcgcttgagaaagc  
P7.9 gcgtatcagctagcaaaggaggtatcaagtatgaaccgatcaggcaagcatc  
P7.10 cgtgaccagcggccgcttacttctccctccagcagaagtacagc  
P7.11 ggtcatgcatgctgattcactcgttactaaaggttttagagctagaaatagcaagttaaa  
P7.12 gctattgaccatggaaaaaaagcaccgactcggt  
P7.13 ggaactgctagctgaatcatacagatctcataaaaaactaaaaaaaatattgaaaatact  
P7.14 ctaaaactcttcatgcaggtggcggcagcatgcatcttatataacctcgtc  
P7.15 tgccgccacctgcatgaagagttttagagctagaaatagcaagttaaa  
252 
 
P7.16 gctcatgaggatccaaaaaaagcaccgactcggt  
P7.17 gctctaaaacagtcgaaacaggtattacgcgcatgcatcttatataacctcgtc  
P7.18 gcgtaatacctgtttcgactgttttagagctagaaatagcaagttaaa  
P7.19 tatgatgcatgcgcattgaatgacggggcagagttttagagctagaaatagcaagttaaa  
P7.20 taaaactttaaatcggcaagcgtgctgcatgcatcttatataacctcgtc  
P7.21 agcacgcttgccgatttaaagttttagagctagaaatagcaagttaaa  
P7.22 taaaaccactccttattatgcattttgcatgcatcttatataacctcgtc  
P7.23 aaaatgcataataaggagtggttttagagctagaaatagcaagttaaa  
P7.24 gctctaaaacctctggtatgtagataatgagcatgcatcttatataacctcgtc  
P7.25 tcattatctacataccagaggttttagagctagaaatagcaagttaaa  
P7.26 taaaactctctctggggtaggtacatgcatgcatcttatataacctcgtc  
P7.27 atgtacctaccccagagagagttttagagctagaaatagcaagttaaa  
P7.28 gctctaaaacttctcctactcaatattatagcatgcatcttatataacctcgtc  
P7.29 tataatattgagtaggagaagttttagagctagaaatagcaagttaaa  
P7.30 aaaactcgcgcgccggattttgtttgcatgcatcttatataacctcgtc  
P7.31 aaacaaaatccggcgcgcgagttttagagctagaaatagcaagttaaa  
P7.32 ggtcatgcatgctgactgtggtgaaccgctccgttttagagctagaaatagcaagttaaa  
P7.33 gctctaaaactctaatagagaagtcattgtgcatgcatcttatataacctcgtc  
P7.34 acaatgacttctctattagagttttagagctagaaatagcaagttaaa  
P7.35 aaaaccttcattcacgacttctcccgcatgcatcttatataacctcgtc  
P7.36 gggagaagtcgtgaatgaaggttttagagctagaaatagcaagttaaa  
P7.37 cgcagccagctagttcatcacc  
P7.38 gcatgctgtaactgatgtcaggatccgatatggttcgtatatggattgagtctgac  
P7.39 aaaggaggaactaaaatggggactaatg  
P7.40 gtgtgccacagggatttgctg  
P7.41 ggatcctgacatcagttacagcatgccagctattgtaacataatcggtacgg  
P7.42 cattagtccccattttagttcctcctttaattgggaattgttatccgctcac  
P7.43 gctgaacagcagcaaatccctgtggcacacgaaccgttgtaggtggcgtg  
P7.44 catgggaaggtgatgaactagctggctgcgctcgagccatccggaagatc  
P7.45 cttctcgtcccaacaattgaggc  
P7.46 cgtaacgattaagtttcattagcgcgcatgcaggtggcggcaaagg  
P7.45 gcgcgctaatgaaacttaatcgttacggatatcaacaaacaatctg  
P7.48 cctcttgcgcagactgcatc  
P7.49 ttcaaagtttgatgcagtctgcgcaagagggaaccgttgtaggtggcgtg  
P7.50 attgccggcctcaattgttgggacgagaagctcgagccatccggaagatc  
P7.51 caatccgctcatattcgactgg  
P7.52 cataccagaaaagatgcgcgctgataagaaacaggtattacgctgaacgag  
P7.53 ttatcagcgcgcatcttttctggtatggagggctacg  
P7.54 tttcgatacgacgcttcgtgatgg  
P7.55 tgttcaccatcacgaagcgtcgtatcgaaagaaccgttgtaggtggcgtg  
P7.56 ttggttttccagtcgaatatgagcggattgctcgagccatccggaagatc  
P7.57 gcagcccgcctaatgagcgggcttttttgctagctgtgtgtttccatgtg  
P7.58 cgttcaataagcttattcattctagattcctcctttaattgggaattgttatcc  
P7.59 taacaattcccaattaaaggaggaatctagaatgaataagcttattgaacgagaaaaaac  
P7.60 cattatcttatcctcctttgagctctcacacttccactgtccagttaaac  
P7.61 gagctcaaaggaggataagataatgactaaacaaacaattcgcgttg  
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P7.62 aaaaaagcccgctcattaggcgggctgcaccggtttacttgctttcagtcagcgctg  
P7.63 cgccagatcttccggatggctcgagtcgtgatgagcagctgagcc  
P7.64 cccgtaccgattatgttacaatagctggctagccaggctcatatttcacatc  
P7.65 gcagcccgcctaatgagcgggcttttttgtcgcaggcattattgcagc  
P7.66 gagaataaaagaagaacatcgattttcttcctctgacagctgtttgagtg  
P7.67 gcggatgtgaaatatgagcctggctagccagctattgtaacataatcggtacgg  
P7.68 cctcctttaattgttatccgctcacaattccac  
P7.69 aattgtgagcggataacaattaaaggaggaaagataatggcagaattacgcagtaatatg  
P7.70 aaaagcccgctcattaggcgggctgcggatccttagattttcataataccgccgg  
P7.71 caaacagctgtcagaggaagaaaatcgatgttcttcttttattctctcaag  
P7.72 tgtttggctcagctgctcatcacgactcgagccatccggaagatc  
P7.73 acagattcctgtagtcggagacag  
P7.74 atagaccggtgatccggaataacacatcggagcgcgccaccacagtcaatgtgataattc  
P7.75 tgtgttattccggatcaccggtctattcacaaaaaggcattaccacattgaaagcattac  
P7.76 cctgctgtcaattcatctttgatttcag  
P7.77 cgccagatcttccggatggctcgagcattctgcattaagctgtatttggtcc  
P7.78 aagataaaaaattttctagtgatccctcgagtcgcagtagccgaagagcttc  
P7.79 taacaattcccaattaaaggaggaaactaaaatgacaaaagcaacaaaagaaca  
P7.80 gaaaacccacgccacctacaacggttcggaacaaaccgatacggc  
P7.81 gaagctcttcggctactgcgactcgagggatcactagaaaattttttatcttatcacttg  
P7.82 tttgttcttttgttgcttttgtcattttagtttcctcctttaattgggaattgttatcc  
P7.83 atattttggccgtatcggtttgttccgaaccgttgtaggtggcgtg  
P7.84 gaccaaatacagcttaatgcagaatgctcgagccatccggaagatc  
P7.85 gaagcatcattctctgaacatatttcccaattaaaggaggaaactaaaatgac  
P7.86 gtttcaggagccttttctctttcctcctcgagtcgcagtagccgaag  
P7.87 gaagctcttcggctactgcgactcgaggaggaaagagaaaaggctcctg  
P7.88 cattttagtttcctcctttaattgggaaatatgttcagagaatgatgcttcc  
P7.89 gccagatcttccggatggctcgagcgtctttacagggcaggtagc  
P7.90 ttcattatctacgctagcttattaatactcttctttccattctgcgagc  
P7.91 aaagaagagtattaataagctagcgtagataatgaagaagaaggttttaaacc  
P7.92 aacccacgccacctacaacggttcaccttcaacatgaacgacg  
P7.93 accttcgtcgttcatgttgaaggtgaaccgttgtaggtggcgtg  
P7.94 gttgctacctgccctgtaaagacgctcgagccatccggaagatc  
P7.95 cgccagatcttccggatggctcgagtcttggctctgcaggataatgg  
P7.96 ttcaaatatgtacctaccccgcgcgcttattagccgcctccgacacttgc  
P7.97 ttgcaagtgtcggaggcggctaataagcgcgcggggtaggtacatatttgaaaaacg  
P7.98 aaacccacgccacctacaacggttcctctaggcttttgagtaacaagctatc  
P7.99 tagcttgttactcaaaagcctagaggaaccgttgtaggtggcgtg  
P7.100 caaccattatcctgcagagccaagactcgagccatccggaagatc  
P7.101 cgccagatcttccggatggctcgagcagattggaaatcagacagagc  
P7.102 tcaaaatctccgtcttagctgggtcataatagagaagtcattgttgatacttgataaatc  
P7.103 caacaatgacttctctattatgacccagctaagacggagattttgaactgtcag  
P7.104 aaacccacgccacctacaacggttcttcatcagaccacacctttactg  
P7.105 aacagtaaaggtgtggtctgatgaagaaccgttgtaggtggcgtg  
P7.106 tgcgctctgtctgatttccaatctgctcgagccatccggaagatc  
P7.107 cgccagatcttccggatggctcgagcgatcattactggaggcgacag  
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ǂ: alsD, acetolactate decarboxylase; alsS, acetolactate synthase; amyE, α-amylase; araR, 
repressor of arabinose operons; bcaP, BCAA permease; bcd, BCAA dehydrogenase; bpr, 
bacillopeptidase F; cas9, CRISPR-associated protein 9 (Cas9; Streptococcus pyogenes); comK, 
master competence regulator; comS, competence protein S; ilvA, L-threonine dehydratase; ilvB, 
acetohydroxy-acid synthase catalytic subunit; ilvC, acetohydroxy-acid isomeroreductase; ilvD, 
dihydroxy-acid dehydratase; ilvH, native acetohydroxy-acid synthase regulatory subunit, ilvH*, 
engineered acetohydroxy-acid synthase regulatory subunit; lacA, β-galactosidase; leuA, 2-
isopropylmalate synthase; mazF, endoribonuclease (Escherichia coli); pdhA, E1α subunit of the 
pyruvate dehydrogenase complex; sigF, sporulation-specific transcription factor σF; thrC, 
threonine synthase; tracrRNA, trans-activating CRISPR RNA; wprA, cell wall-associated 
protease; xylR, xylose operon repressor (Bacillus megaterium); ybgE, BCAA aminotransferase; 
ywaA; BCAA aminotransferase; NeoR, neomycin resistance cassette; ErmR, erythromycin 







P7.108 gataaaaaattttctagtgatccctcgagacaaaaaaccagctcttgagctgg  
P7.109 aacaattcccaattaaaggaggaaactaaaatgaaagggagcgtttttaggaag  
P7.110 gaaaacccacgccacctacaacggttcatgcctttaggcagatccttcg  
P7.111 gctcaagagctggttttttgtctcgagggatcactagaaaattttttatcttatcacttg  
P7.112 cttcctaaaaacgctccctttcattttagtttcctcctttaattgggaattgttatcc  
P7.113 ccgcgaaggatctgcctaaaggcatgaaccgttgtaggtggcgtg  
P7.114 ccgctgtcgcctccagtaatgatcgctcgagccatccggaagatc  
P7.115 cgccagatcttccggatggctcgaggaatcgttcgcccgtgtgac  
P7.116 ctgcccagtgttttcgaaagtcacctaggttagcgccggattttgtttccaag  
P7.117 cttggaaacaaaatccggcgctaacctaggtgactttcgaaaacactgggcagag  
P7.118 gaaaacccacgccacctacaacggttcggtttctgctccgcctacg  
P7.119 caaaccgtaggcggagcagaaaccgaaccgttgtaggtggcgtg  
P7.120 caactgtcacacgggcgaacgattcctcgagccatccggaagatc  
P7.121 cgccagatcttccggatggctcgagccgcagcaaaccatatgg  
P7.122 tgatcatcagttaaatcaggtcattatctagaattcacgacttctcccttttc  
P7.123 aaagggagaagtcgtgaattctagataatgacctgatttaactgatgatcaattaaaag  
P7.124 gaaaacccacgccacctacaacggttcaaggaacgcacggaaacg  
P7.125 gcttgtacgtttccgtgcgttccttgaaccgttgtaggtggcgtg  
P7.126 cttttctccatatggtttgctgcggctcgagccatccggaagatc  
P7.127 cgaagcgaaggaaaatggatgc  
P7.128 ggtcaaagcgtctacttcacaatgag  
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Figure S6.1. The derivation of an improved strain of B. subtilis for heterologous HA production. 
Genomic integration vector pAW009 was constructed by amplifying promoter Pgrac.UPmod from 
pHT01, followed by insertion into SalI/BamHI-digested pAW008. Pgrac.UPmod is a weaker 
derivative of promoter Pgrac that has a modified upstream promoter element (UP) that reduces the 
relative promoter strength by approximately half. AW009 was constructed via transformation by 
natural competence of 1A751 with NdeI-linearized pAW009, resulting in the integration of a 
Pgrac.UPmod::seHas:tuaD expression cassette and neomycin resistance marker (i.e. npt, encoding 
neomycin phosphotransferase) at the amyE locus. AW009 constitutively expresses seHas and 
tuaD, respectively encoding hyaluronan synthase from S. zooepidemicus (SeHAS) and native 
UDP-glucose-6 dehydrogenase (TuaD), resulting in the production of high MW HA and, in turn, 
encapsulation of AW009. AW009 produced approximately twice as much HA as our previous 
production strain, i.e. AW008, which was constructed via transformation of 1A751 with NdeI-
linearized pAW008. Other genes and abbreviations: bla encodes β-lactamase for selection of E. 
coli on ampicillin; amyE encodes native α-amylase; origin of replication (ori); genomic DNA 
(gDNA) 
 
 
